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Background and context: Pharmaceutical care describes a range of patient-
focussed activities delivered by pharmacists. The activities aim to optimise 
medicines use for patients, and reduce harm from adverse events with 
medicines.   
This study was conducted in an NHS Scotland organisation, where the clinical 
pharmacy service has an established quality management system.  It was 
evident that some gaps existed in the quality assurance parameters for clinical 
pharmacy services and pharmaceutical care, with there being no clearly defined 
route to report adverse events or near misses that arose from within the service. 
In quality management terms this meant it was difficult to determine whether 
optimal pharmaceutical care was being delivered, or to establish how accurate 
clinical pharmacists were in their pharmaceutical care activities; additionally, this 
meant it was difficult to evidence areas for quality improvement. 
Aim: This study aimed to explore the perceptions, experiences and behavioural 
determinants of the hospital clinical pharmacists in relation to optimal and 
suboptimal pharmaceutical care within an NHS organisation in Scotland using a 
theoretical framework.   
The research used the concept of suboptimal pharmaceutical care to describe the 
gap between pharmaceutical care as intended, and pharmaceutical care as 
delivered.  
Design and methods: This research used qualitative study design and a 
phenomenological approach and was conducted in two phases, the first phase 
influencing the design of the second phase.  
In Phase 1, focus group methodology was used to determine perceptions of 
hospital clinical pharmacists to optimal and suboptimal pharmaceutical care. 
Study participant (n=20) were hospital clinical pharmacists recruited from 
hospitals across the NHS Scotland health board. A topic guide focussed the 
discussions on the activities related to medicines reconciliation and 
Kardex/medicines review. Data generated from focus groups was in the form of 
written statements and audio recorded narrative to describe participants’ 
perceptions of barriers and enablers to providing optimal pharmaceutical care. 
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The Theoretical Domains Framework (TDF), an integrative theoretical framework 
that describes behavioural determinants, was used to analyse the findings.  
Phase 2 used in depth interviews to explore participants’ (n=10) experiences of 
optimal and suboptimal pharmaceutical care.  A semi-structured interview 
schedule was developed using TDF to facilitate identification of behavioural 
determinants to the provision of optimal and suboptimal pharmaceutical care.   
Results: Within Phase 1, participants perceived that there were barriers to the 
delivery of optimal pharmaceutical care, citing time factors, lack of policy and 
procedure, conflicting priorities (including uncertainty over efficiency versus 
thoroughness), poor underpinning knowledge of medicines by doctors, and 
inadequate skills in completing and documenting activities as contributory 
factors. In Phase 2, key determinants were elicited and included knowledge (of 
trainees), time, policy, procedure or guidance on suboptimal pharmaceutical 
care, and personal and professional barriers and enablers, including professional 
embarrassment and hierarchy.  
Conclusions: The study has allowed an exploration of an underacknowledged 
topic in clinical pharmacy practice, and identified behaviours, including role 
uncertainty and embarrassment, that may contribute to lack of reporting on 
suboptimal pharmaceutical care.   Recommendations have been made using 
behavioural change technique interventions, and include educational 
interventions, skills training, modelling, enablement, persuasion, incentivisation, 
coercion, restriction and environmental restructuring. Implementation of these 
interventions, and evaluation of their effectiveness, will enable the organisation 
to have more robust quality assurance parameters within the clinical pharmacy 
service, and ensure continued conformance with the quality management 
system. Across the wider clinical pharmacy community, lessons may be learned 
about perceptions and experiences relating to suboptimal pharmaceutical care, 
and consideration made to capturing the learning opportunities that can arise 
when considering suboptimal pharmaceutical care in practice.  
Key words: hospital clinical pharmacists; pharmaceutical care; suboptimal 
pharmaceutical care; Theoretical Domains Framework; behaviour change 




In undertaking the Doctorate of Professional Practice programme, there were a 
number of people who believed in me and helped me along the way and I take 
the opportunity to thank them here:  
My work colleague and friend: Heather Grant, you always knew when to inspire, 
encourage and persuade, when to just listen to my waffle and occasional whine, 
and gently set me back on the path again.  Thank you. 
My children: I hope that watching me tackling an academic endurance task will 
remind you that tough things are worth taking on, even when you’re old. You 
don’t always know what hurdles and hiccups there will be, but you work around 
them and keep moving on.  You have each tackled your own hurdles, and 
endured your own hiccups during the time I was undertaking these studies, and 
I am immensely proud of the way you have done so. You are an inspiration, and 
the stars I navigate home by. Thank you. 
My long-suffering husband: you put up with me throughout, and supported me 
in pursuit of a personal goal. I wouldn’t have made it without you. Thank you. 
My academic supervisors: you have helped me navigate the academic world, 
encouraged me, given me feedback and kept me on the path (or somewhere 
near it anyway). Dr Vibhu Paudyal, Professor Derek Stewart and Professor Scott 
Cunningham, thank you. 
The research participants, work colleagues and my facilitator: without you this 
would not have been possible.  Busy people who were willing to take part in my 
research. Without your openness and candour this would have been a very 
different project.  Thank you. 
My friends: you have put up with me being grumpy and tetchy, listened to my 
frustrated rants and given me time, kindnesses and the occasional distraction. 
You know who you are.  Thank you. 
The thesis is dedicated to my mum.  She has been an inspiration to me all my 
life, and has great reserves of strength and tenacity. She has shown me 
unswerving love and support throughout, and I wouldn’t have got to this point 




NHS Scotland Organisation R&D videoconferences, Edinburgh, May 2017 and 
April 2018; September 2019. Oral presentations on research background, 
recruitment, initial findings. 
Health Sciences Research and Pharmacy Practice (HSRPP) Symposium, 
Newcastle. April 2018. Oral presentation: How do hospital clinical pharmacists 
perceive and experience optimal and suboptimal pharmaceutical care? 
Robert Gordon University Life Sciences research conference, Aberdeen. May 
2018. Poster presentation: Perceptions and experiences of hospital clinical 
pharmacists relating to suboptimal pharmaceutical care: qualitative studies using 
the Theoretical Domains Framework. Appendix I Poster 1 
NHS Scotland Event, Glasgow. June 2018. Poster presentation: Perceptions and 
experiences of hospital clinical pharmacists relating to suboptimal 
pharmaceutical care: qualitative studies using the Theoretical Domains 
Framework. Appendix I Poster 1 
UK Association of Hospital Chief Pharmacists seminar, Edinburgh. June 2018 
(invited speaker). Oral presentation: How do hospital clinical pharmacists 
perceive and experience optimal and suboptimal pharmaceutical care? 
European Society of Clinical Pharmacy (ESCP) conference, Belfast. October 
2018. Poster presentation: Perceptions and experiences of hospital clinical 
pharmacists relating to suboptimal pharmaceutical care: qualitative studies using 
the Theoretical Domains Framework. Appendix II Poster 2  
Clinical Pharmacy Congress, London. June 2019. Poster presentation:  
Perceptions and experiences of hospital clinical pharmacists relating to 
suboptimal pharmaceutical care: qualitative studies using the Theoretical 
Domains Framework. Appendix II Poster 2 
NHS Scotland Organisation Nursing, Midwifery, and Allied Health Professions 
Doctoral Researchers Group, Edinburgh.  September 2019. Oral presentation: 
Methodology and research philosophy: How to translate a research idea 
(curiosity) into a research question 
RPS/University of Strathclyde Research and Development event, Glasgow. 
September 2019. Poster presentation. Perceptions and experiences of hospital 
clinical pharmacists relating to suboptimal pharmaceutical care: qualitative 
studies using the Theoretical Domains Framework.  Appendix III Poster 3 
UKCPA Autumn symposium, London. November 2019. Poster presentation. 
Perceptions and experiences of hospital clinical pharmacists relating to 
suboptimal pharmaceutical care: qualitative studies using the Theoretical 
Domains Framework.   Abstract available at: https://ukclinicalpharmacy.org/wp-
content/uploads/2019/11/PM-UKCPA-Conference-2019-abstract-booklet-





ABBREVIATIONS and GLOSSARY 
 
ACCP American College of Clinical Pharmacy 
BCT Behaviour change technique 
BSi British Standards Institute 
CAQDAS computer assisted qualitative data analysis software 
CD Controlled drug 
COM-B Capability, opportunity, motivation – behaviour – a 
model for behaviour change 
COS Core outcome standards 
CPD Continuing professional development 
DATIX Electronic risk management system 
ECS Emergency care summary 
EPMA Electronic prescribing and medicines administration 
ERDS Education research and development services 
ESCP European Society of Clinical Pharmacy 
ETTO Efficiency thoroughness trade-off 
FMEA Failure modes and effects analysis 
FY1 Foundation year 1 doctor in postgraduate training 
programme 
GP General Practitioner 
GPhC
  
The General Pharmaceutical Council - the regulatory 
body for pharmacists and pharmacy technicians in 
the UK.  
HIS Healthcare Improvement Scotland 
IDL Immediate discharge letter 
ISO International organisation for standardisation 
IT Information technology 
IV Intravenous  
KARDEX Prescription and administration record used in 
hospitals 
KPI Key performance indicator 
MDS Monitored dose system 
MI Medicines Information 
MMT Medicines management team 
MPharm Masters in Pharmacy degree 
MRC Medical Research Council 
MSc Master of Science degree 
NES NHS Education Scotland 
NG Naso-gastric 
NHS National Health Service 
NHSSO NHS Scotland Organisation (research setting) 
NPSA National Patient Safety Agency (for England and 
Wales) 
NPT Normalisation Process Technique 
PARiHS Promoting Action on Research Implementation in 
Health Services 
PCNE Pharmaceutical Care Network Europe 
PICO Population, intervention, comparison, intervention  
viii 
 
PIP Pharmacist independent prescriber 
QRGS Quality Risk and Governance Services 
RESEARCHER The professional doctorate student 
R&D Research and development 
RGU Robert Gordon University 
RPS Royal Pharmaceutical Society (since 2010) 
RPSGB Royal Pharmaceutical Society of Great Britain (until 
2010) 
SACT  Systemic anti-cancer therapy 
SCAN South East Scotland Cancer Network 
SEA Significant Event Analysis 
SOPC Suboptimal pharmaceutical care 
SPIDER Sample, phenomenon of interest, design, 
evaluation, research type 
TDF Theoretical Domains Framework 
TRAK or TRAKcare TRAKcare electronic patient management system 
WHO World Health Organisation 
UK United Kingdom 
UKCPA United Kingdom Clinical Pharmacy Association 




For the past 25 years, I have worked as a specialist pharmacist within pharmacy 
quality risk and governance services in an NHS Scotland Organisation.  The role 
of our team is to provide support services and specialist advice across pharmacy 
services in primary and secondary care.  My own specialist support and advisory 
roles include medicines governance, the safe use of medicines, managing 
adverse events and some aspects of quality management. 
In my quality management advisory role, I have worked with clinical pharmacy 
services across my organisations’ hospital pharmacies to establish processes 
that comply with the quality management system (ISO 9001) that we are 
accredited to. I have also worked with the organisations’ pharmacy teams to 
establish processes for reporting adverse events. This work has included 
developing structures and processes for reporting on adverse events with 
medicines, as well as developing processes for reporting and learning from 
adverse events. The reporting, review, measuring and monitoring, and learning 
from adverse events provides a key function within the quality management 
system. 
There were, however, some anomalies in the adverse event reporting process 
for clinical pharmacy. Although, as a group, clinical pharmacists were actively 
reporting on medication adverse events, for example prescribing errors, there 
was no clear route for them to report on issues or errors arising from within the 
clinical pharmacy service.  In other words, it was difficult to establish how 
accurate clinical pharmacists were in their clinical pharmacy and pharmaceutical 
care roles, and this left a gap in the quality management system arrangements 
for clinical pharmacy. I had noted that there was a paucity of research in the 
quality management of clinical pharmacy services, and had reviewed published 
as well as grey literature to find measuring and monitoring methods that had 
been used elsewhere.  I had found little that was of practical help. 
At the same time, clinical pharmacy services were changing and adapting to 
pressures on services.  I had conversations with clinical pharmacists who were 
trying to improve the quality, efficiency and effectiveness of the services, and 
those who were struggling with workload and capacity to provide the services 
they wanted to the patients who needed them.  Anecdotally clinical pharmacists 
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were able to describe occasions when something had not gone as planned, 
where they had not provided the pharmaceutical care they had intended, or had 
used or given incorrect information, for example. 
The opportunity to carry out research in this area arose from a chance 
conversation at a qualitative methods workshop at a conference.  From that, I 
understood that research could help me understand how to develop a quality 
assurance process for clinical pharmacy, or at least understand why it was 
proving difficult to establish and implement a process.  A professional practice 
doctorate would allow me to develop my professional practice, contribute to 
professional knowledge and build research skills.  Building research capability 
had been a gap in my professional practice, and an area I wished to develop.  
At the start of the research journey, I naively thought I would be able to identify 
areas where pharmacists had not delivered optimal pharmaceutical care, and 
use that data to develop a taxonomy to describe suboptimal pharmaceutical 
care, and therefore a reporting process.  There were some potential barriers to 
this approach.  Firstly, asking someone to disclose where things have not gone 
well, or where there has been an error or incident can be emotive and 
challenging.  Secondly, there was no a priori definition of what optimal 
pharmaceutical care is, as a standard against which the service could be 
measured.  The term suboptimal pharmaceutical care was devised, therefore, as 
a means of addressing both of these: suboptimal describes the point of interest, 
between optimal care and error or harm, and avoids the associated emotive 
language of error or incident. The lack of a definition of optimal or suboptimal 
pharmaceutical care influenced the design of the research. 
The research aimed to help me understand what barriers, if any, there were to 
reporting suboptimal pharmaceutical care.  I wanted to know what experiences 
clinical pharmacists had of what they perceived to be suboptimal when delivering 
pharmaceutical care.  Furthermore, I wanted to understand whether the delivery 
of suboptimal pharmaceutical care was having emotional impact on the 
pharmacists who are my work colleagues, perhaps causing moral distress.  I 
knew that burnout and moral distress amongst healthcare professionals was an 
emerging challenge to healthcare delivery, and was of interest to me in 
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CHAPTER 1 BACKGROUND AND INTRODUCTION 
 
1.1 Introduction to Chapter 1 
This chapter will give background, setting and context to the research. The 
setting for the research was a National Health Service (NHS) Organisation in 
Scotland, and the focus will therefore be on pharmacy practice within Scotland 
and, where relevant, the United Kingdom (UK). The chapter will outline 
descriptions of clinical pharmacy and pharmaceutical care, and introduce the 
concept of suboptimal pharmaceutical care. This introductory chapter will cover 
how clinical pharmacists practice, the structures they work in, how they are 
trained and how they, and the pharmacy profession, are guided and supported.  
The chapter will then proceed to describe quality management systems, and 
specifically how quality management principles have been applied in this NHS 
Scotland organisation, and within the clinical pharmacy service.  The chapter will 
conclude with discussion on medicines safety and the role of the clinical 
pharmacist, and how involvement in adverse events within medicines can lead to 
moral distress and burnout amongst healthcare professionals. 
 
1.2 Clinical pharmacy and pharmaceutical care 
The focus of this thesis is clinical pharmacy and pharmaceutical care and these 
terms are introduced and described here: 
 
1.2.1 Clinical pharmacy 
Clinical pharmacy is both a scientific discipline and a branch of pharmacy 
practice, which aims to ‘optimise the therapeutic use of medicines by patients 
and professionals in order to maximise the likelihood that an optimal balance of 
clinical, humanistic and economic outcomes is achieved’ (European Society of 
Clinical Pharmacy 2005).  Clinical pharmacy services arose from a societal need 
to improve the use of medicines, initially in the hospital setting, and thereafter 
across all healthcare settings (Hudson, McAnaw and Johnson 2007), and clinical 
pharmacists are described as practitioners who provide medicines management 
and the relating care for patients.  For the purposes of this thesis, with the 
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research being conducted in the hospital setting, the definitions and applications 
will be focussed on hospital clinical pharmacy. 
Clinical pharmacy practice is an established discipline across the world. The 
American College of Clinical Pharmacy (ACCP) defines clinical pharmacy as 
‘embodying the application by pharmacists of the scientific principles of 
pharmacology, toxicology, pharmacokinetics and therapeutics to the care of 
patients’ or in an abridged form as ’the area of pharmacy concerned with the 
science and practice of rational medicine use’ (American College of Clinical 
Pharmacists, 2008). The European Society of Clinical Pharmacy (ESCP) defines 
clinical pharmacy as ‘a health specialty that describes the activities and services 
of a clinical pharmacist in developing and promoting the rational and appropriate 
use of medicines’ (European Society of Clinical Pharmacy 2005). Clinical 
pharmacy has been defined in the UK by the United Kingdom Clinical Pharmacy 
Association (UKCPA) as ‘encompassing the knowledge, skills and attitudes 
required by pharmacists to contribute to patient care’ (United Kingdom Clinical 
Pharmacy Association 2005). 
Clinical pharmacy practice can therefore be said to be a practice where skilled 
pharmacists promote the rational and effective use of medicines with the aim of 
improving health and wellbeing, and preventing disease, and through these 
actions improve the quality of life of patients.  
In the UK, clinical pharmacy developed initially in secondary care (the term used 
to describe NHS hospitals that provide urgent and planned care) in the 1980’s, 
as a means of putting the pharmacist nearer to the patient and to the healthcare 
team that are caring for the patient.  The term clinical pharmacy was first 
formally acknowledged in the UK in the 1986 Nuffield Report (Nuffield 
Foundation 1986), which welcomed the changes in practice that clinical 
pharmacists could bring to hospital pharmacy services.  Clinical pharmacy 
practice marked a move away from the product supply and prescription check 
functions of the pharmacist to one where the pharmacist was an integral part of 
the healthcare team.  A rapid development of clinical pharmacy services followed 
and by the early 1990’s the majority of NHS hospitals in the UK provided clinical 
pharmacy services.  The range of clinical pharmacy services varied significantly 
when surveyed in the 1990’s (Calvert 1999), and continues to do so, with little 
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agreement as to which components of a clinical pharmacy service are the most 
important (Rotta et al 2015; Onatade et al 2018), and effective (Gallagher et al 
2014), making measurement and comparison of clinical pharmacy services 
difficult.  Activities undertaken by clinical pharmacists to achieve the rational and 
effective use of medicines, include in broad terms (Onatade, Miller and Sanghera 
2016; Rotta et al 2015):  
• Medicines review, where the purpose is to review medicines prescription 
and administration charts, (referred to as a Kardex in this thesis) for 
accuracy, and to identify any prescribing or administration errors. 
• Modifying drug doses or drug choices, in accordance with standards of 
practice, and with the individual patient’s characteristics central to 
decision making. 
• Review of the appropriateness of medicines at all stages of the patient 
journey with the purpose of ensuring medicine safety at transitions of 
care; this process is described as medicines reconciliation. 
• Patient medicine counselling, putting the patient first, and providing 
information to the patient to enable effective use of medicines. 
• Prescribing/deprescribing where the purpose is to ensure that medicine 
use is safe and effective and appropriate for each individual patient 
• Authorising discharge, where the purpose is the safe transition of care 
which is patient focussed. 
This list is not exhaustive: The components of a clinical pharmacy service will 
depend on the specialty, and on the availability of a competent clinical 
pharmacist to provide the service. This research programme will describe a 
number of key activities and functions within clinical pharmacy practice, and 
these are described here. 
 
1.2.1.1 Medicines review 
The review of medicines and administration charts for accuracy to identify 
prescribing or administration errors and discrepancies is an established and 
recognised component of a clinical pharmacists’ role, and pharmacists have been 
described as a ‘safety net’ by doctors, (Dean et al 2002; Dornan et al 2009).  
Dean et al (2002) conducted a multi-centred qualitative study with 41 doctors in 
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secondary care and identified that new doctors in particular relied on 
pharmacists to notice and explain their mistakes.   This was reinforced by the 
findings of the EQUIP study (Dornan et al 2009). The study demonstrated that 
doctors relied on pharmacists and nurses to identify and correct errors.  In the 
systematic review section of the EQUIP study, the prescribing error detection 
rate was shown to be highest when data was collected by pharmacists. A similar 
finding on error detection was made by Phansalker et al (2007), who concluded 
that pharmacists were the most thorough compared with other healthcare 
professionals when conducting a review of prescribed medicines, but pointed out 
that some errors may remain undetected. 
The aforementioned studies highlight the skill that pharmacists have in detecting 
prescribing mistakes and errors, however Donyai et al (2008) identified that 
there was a risk that overworked and stressed pharmacists could miss errors or 
incorrectly identify errors.  This was supported by the findings of a small local 
study in the UK by Tully and Buchan (2009) who examined prescription errors 
during hospital inpatient care, and the factors that influenced their identification 
by pharmacists. They reported that workload predicted error identification rate 
and reported that 40% fewer prescribing errors were identified on the busiest 
days. They also reported that senior pharmacists were more likely to identify 
errors than junior pharmacists, suggesting an area for ongoing education. 
As a service provided by clinical pharmacists, medicines review is frequently 
described as a key activity (Onatade, Miller and Sanghera 2016), and is 
described as a task that increases the safety and effectiveness of medicines use 
Dean et al 2002).  There is, however, a paucity of recent research into medicines 
review as a process. 
 
1.2.1.2 Medicines reconciliation 
Medicines reconciliation is a complex activity, with responsibility shared across 
the multidisciplinary team, and with implications for the safety of the patient 
(Scottish Government 2013; National Institute for Health and Care Excellence 
2015; Royal Pharmaceutical Society 2013). The purpose of medicines 
reconciliation, within the hospital setting, is to obtain the most accurate list 
possible of all the medicines a patient is taking, at all stages of the patient 
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journey – that is, at admission, transfer and discharge.  Medicines reconciliation 
should result in an accurate list of medicines, including both prescribed and non-
prescribed (over the counter, herbal or illicit) medicines.  The documented list 
should include name, dose, frequency and route, with any discrepancies or 
differences noted, along with reasons for any changes. The role of the clinical 
pharmacist may be to conduct medicines reconciliation, or to verify that it has 
taken place, and identify any resultant pharmaceutical care issues, depending on 
organisational policies. 
Systematic reviews of medicines reconciliation have shown mixed results: a 
systematic review in 2016, examining 17 studies found that pharmacist-led 
medicines reconciliation improved post hospitalisation healthcare utilisation 
(Mekonnen, McLachlan and Brien 2016).  However, this was not the findings of a 
systematic review in 2018. Cheema et al restricted the review to 18 randomised 
controlled trials with medicines reconciliation, and found that whilst there was a 
reduction in medicine discrepancies, this did not lead to a significant reduction in 
adverse drug events, nor to a decreased level of healthcare utilisation (Cheema 
et al 2018).  Variability in the quality of the included studies prompted the 
authors of this systematic review to advise caution in the interpretation of the 
findings, and a call for improved outcome measures to be established (Cheema 
et al 2018). 
 
1.2.1.3 Pharmacist independent prescribing 
Pharmacists have been able to prescribe in the UK since 2006, and this has 
facilitated some changes to practice for clinical pharmacy teams. Pharmacist 
independent prescribers (PIPs) prescribe autonomously, whilst working within 
their area of competency, across different clinical conditions. It is important that 
pharmacist independent prescribers learn from errors and near misses, and to 
do this, that they record and report prescribing errors and near misses (Royal 
Pharmaceutical Society 2016).  The In-practice Guidance for Pharmacists 
(General Pharmaceutical Council 2019) states that pharmacists must reflect on 
feedback or concerns that come from others, and act to prevent the same thing 
recurring.   
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There are a number of studies that have examined the accuracy of pharmacist’s 
prescribing by looking at error rate (Baqir et al 2015) and at appropriateness of 
prescribing (Latter et al 2012).  Baqir et al (2015) explored the nature, extent 
and prevalence of pharmacist prescribing errors by using data from pharmacists 
in a NE England Trust. As the number of errors were low, it was not possible to 
categorise them by their nature, but prevalence of error was reported at 0.3% 
for pharmacists.  There have been other UK studies that have attempted to 
compare pharmacist prescribing error rates with those of doctors. Taylor and 
Davies (2019), found that 6% of pharmacist independent prescribers’ discharge 
prescriptions had errors (N= 395), compared with 46% of those from doctors 
(N=706).  A similar UK study conducted found that pharmacist independent 
prescribers had an accuracy of 99.8% (0.2% error rate; N=532)) and doctors 
89.5% (10.5% error rate; N=2416) for discharge prescriptions (Phillips et al 
2019).  The variation is perhaps due to the different data collection methods.  
The reported studies did not describe how prescribing errors for pharmacists are 
normally collected and collated. 
 
1.2.1.4 Prioritising the delivery of clinical pharmacy services 
With increasing pressures on services, clinical pharmacy services have looked at 
mechanisms for targeting resource to where it is most needed.  One of the ways 
of doing this has been to prioritise the clinical pharmacy services, or target 
pharmaceutical care, using prioritisation tools; these tools are called by a variety 
of names, as described in a systematic review (Alshakrah, Steinke and Lewis 
2019).  The systematic review of prioritisation tools identified 17 different tools 
from the literature.  Terms for the tools included priority coding, pharmacy risk 
screening tool (Cottrell, Caldwell and Jardine 2013) and pharmaceutical 
assessment screening tool (Hickson et al 2017).  There were some common 
features of the prioritisation tools: the majority aimed to identify patients most 
at risk from adverse drug reactions, adverse events or medication errors.  None 
of the included studies showed a measurable impact on prescription errors or 
adverse drug events. However, key themes identified from the studies were the 
positive impact of risk assessment tools on both patient care and provision of 
pharmacy services.  The review also highlighted the limitations of risk 
prioritisation tools.  The systematic review concluded that because of the 
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heterogeneity of the different tools being used, it was not possible to measure 
objectively the impact of tools on patient outcomes and on workforce efficiency, 
and concluded that further research is needed in this area (Alshakrah, Steinke 
and Lewis 2019).   
Other studies of risk prioritisation tools have examined the accuracy of priority 
coding of patients by pharmacists. Hickson et al (2017) noted when attempting 
to validate a tool that they had developed, that accuracy in coding was limited, 
with just under half of patients not being scored according to the tool (Hickson 
et al 2017). A qualitative study exploring decision making in priority coding 
processes (Saxby et al 2017), found that clinical judgement often overrode the 
scoring tool. This is supported by an unpublished mixed methods study in the 
NHS Scotland organisation clinical pharmacy service (NHS Scotland Organisation 
Pharmacy 2019). The study compared the priority coding decisions of 
pharmacists with those of the research team, with the research team following 
the priority coding tool precisely as written. The study concluded that there were 
variations between individuals in the way the tool was used.  In addition, the 
local study also found that clinical judgement often overrode the scoring tool, 
and that the priority coding tool was used more for work planning than 
prioritising patients, and this reflected the findings of both Hickson et al and of 
Saxby et al (Hickson et al 2017; Saxby et al 2017).  
 
1.2.1.5 Establishing quality assurance in clinical pharmacy 
Quality assurance is defined as ’the maintenance of a desired level of quality in a 
service or product, especially by means of attention to every stage of the 
process of delivery or production’ (Oxford Dictionary 2020).  Establishing the 
‘desired level of quality’ can be difficult when there is a lack of a uniform or 
consistent description of clinical pharmacy, and this has been previously 
described, (Calvert 1999, Cotter, Barber and McKee 1994). Calvert (1999) 
identified that the lack of a uniform description or definition of a clinical 
pharmacy service, and a paucity of research into service effectiveness, had 
resulted in clinical pharmacy services that had developed based on opinion 
rather than evidence. Onatade et al (2018), more recently, described the lack of 
agreed priorities, measures or defined outcomes for hospital clinical pharmacy as 
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a barrier to services being delivered effectively and consistently (Onatade et al 
2018).   
The lack of a standard description or definition of clinical pharmacy services, or 
of standards for clinical pharmacy services (Agnew and Friel 2014) makes quality 
assurance programmes difficult to implement.  Instead, because of the difficult 
nature of measuring the direct impact of a clinical pharmacy service on patient 
outcomes, the tendency has been to collect activity data – the number and 
uptake of interventions made, or the number of patients visited, for example. 
Activity measures of the frequency of ward visits have been described for 
England (Onatade, Miller and Sanghera 2016; McLeod et al 2014).  However, a 
measure of activity or ward visits does not assess the quality of the service 
provided on those visits. 
Other research has investigated the theoretical application of quality risk 
management to clinical pharmacy processes in an Austrian hospital, using failure 
modes and effects analysis (FMEA) (Wunder et al 2013).  The theoretical 
description in this study identified a range of clinical pharmacy processes and 
their associated potential failure points.  For example, it was identified that there 
could be a patient hazard due to a missing intervention that a pharmacist either 
overlooked or did not know.  The study gave suggestions for prevention, such as 
gaining knowledge, and standardising work practices but did not provide any 
mechanisms for detecting failures.  Although described as quality risk 
management, the outlined description was theory based, and limited to a select 
few clinical pharmacy processes. 
In summary, extant literature shows that there is a gap in knowledge in 
demonstrating quality assurance within clinical pharmacy services, and that the 
focus of measurement is often on activity rather than outcomes.   Clinical 
pharmacy practice can take place across different healthcare settings, however 
in this study the focus was on hospital clinical pharmacy and as such the focus of 
this introductory chapter will predominantly be in that setting. 
 
1.2.2 Pharmaceutical care 
Clinical pharmacy activities can be described under the philosophical umbrella of 
pharmaceutical care.  Pharmaceutical care was described in the USA by Heplar 
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and Strand (1990) as: ‘the responsible provision of drug therapy for the purpose 
of achieving definite outcomes which improve the patient’s quality of life’ and 
this definition has been widely accepted worldwide as a description for the 
philosophy by which clinical pharmacists’ practice.  The Pharmaceutical Care 
Network Europe (PCNE) consensus definition offers the following definition: 
‘Pharmaceutical care is the pharmacist’s contribution to the care of individuals in 
order to optimize medicine use and improve health outcomes’ (Allemann et al 
2014). 
An adaptation of the original Hepler and Strand definition was coined by the 
Scottish Government in the document Prescription for Excellence (Scottish 
Government 2013a) to include emphasis on partnership working, and to 
incorporate reference to minimising adverse events with medicines; the revised 
definition of pharmaceutical care being:  ‘a model of pharmacy practice which 
requires pharmacists to work in partnership with patients and other health and 
social care professionals to obtain optimal outcomes with medicines and 
eliminate adverse events where possible’. 
The above definitions describe having the patient as the focus of the care, 
working collaboratively both with patients and other healthcare professionals, 
maximising the benefits of medicines, optimising outcomes, and reducing 
adverse events. However, similarly to discussions on the assessment and 
evaluation of clinical pharmacy previously described, there is little agreement 
about which components of pharmaceutical care are the most important- i.e. 
make the most difference to the patient (Onatade et al 2018).  Definitions for 
pharmaceutical care refer to outcomes – ‘definite outcomes’ (Hepler and Strand 
1990), ‘health outcomes’ (PCNE), ‘optimal outcomes with medicines’ (Scottish 
Government 2013a) - and there is therefore a latent expectation that the 
outcomes are measurable.  However, there is little consensus on what outcome 
measures to use in pharmaceutical care, and this creates a barrier to comparing 
practice and to developing interventions.  A systematic review by Beuscart et al 
(2017), exploring the outcome reporting of medicines review as a 
pharmaceutical care intervention in older patients, for example, found it difficult 
to compare effectiveness of interventions because of the lack of a core set of 
outcome measures.  That is not to say interventions were not effective, but that 
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measuring the effectiveness had not been guided, and studies therefore could 
not be compared. The lack of core outcome measures continues to be 
problematic when looking for evidence for pharmaceutical care interventions, 
and whilst core outcome sets (COS) are a valuable addition when assessing 
interventions, even the developers of COS highlight that they will only state 
WHAT should be measured and not HOW (Millar et al 2017).    
Without outcomes driving it, or a set of established procedures, pharmaceutical 
care will vary depending on who is delivering it, as well as being by its nature 
individual to the patient in receipt of it, and a definition of optimal 
pharmaceutical care remains elusive. 
 
1.2.2.1 Suboptimal pharmaceutical care 
When planning the research, it became apparent that there was a need to clarify 
and describe what was not ‘optimal’ in terms of pharmaceutical care, and this 
led to the establishment of the novel term suboptimal pharmaceutical care. 
Suboptimal means ‘not at the best possible level or standard’ (Merriam-Webster 
dictionary 2019).  Suboptimal is a term familiar to those working in healthcare 
through the term ‘suboptimal dosing’ for example as a descriptor for failing to 
achieve therapeutic levels when it comes to medicines.   
The term suboptimal has been applied in nursing, with the description of 
suboptimal care, which has been used when describing the suboptimal care of 
the acutely unwell patient.  Quirke, Coombs and McEldowney (2011) carried out 
a systematic review and concept analysis on the topic, and found that although 
suboptimal care was commonly used as a phrase in nursing, there was no clearly 
defined concept.  The authors concluded that suboptimal care was a patient 
safety issue and needed objective measures.  Attributes of suboptimal care were 
described as delays, poor assessment and inadequate patient management, and 
antecedents to suboptimal care were identified as being patient complexity, 
workforce, and organisational and educational factors (Quirke, Coombs and 
McEldowney 2011).  In nursing of the acutely unwell patient, the term 
suboptimal has been selected as a preferred term, being less judgemental than 
‘poor care’, and is proactive, with an intended desire to improve rather than 
criticise (Price et al 2015).  
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A similar approach was taken when adopting terminology for this study, with 
suboptimal pharmaceutical care being deemed less judgemental than poor or 
substandard pharmaceutical care.  There is an associated inference that 
suboptimal pharmaceutical care can be improved, and that understanding the 
attributes and factors that enable suboptimal pharmaceutical care to be 
delivered will facilitate service improvement. 
In attempting to describe the point at which pharmaceutical care becomes 
suboptimal, a schematic was designed and used throughout the research.  The 
schematic is positional and not directional, with optimal being the intentional 
action (Figure 1.1)  
 
Figure 1.1 Schematic for suboptimal pharmaceutical care 
 
It was not anticipated that there was harm to the patient through the delivery of 
suboptimal pharmaceutical care.  The hypothesis was rather that optimal 
pharmaceutical care, with its philosophy of improving outcomes with medicines, 
was not being achieved 100% of the time.  A literature search could not find any 
reference to suboptimal pharmaceutical care, and this therefore became a novel 




1.3 Hospital Clinical Pharmacy practice in Scotland and the UK  
This section will outline hospital clinical pharmacy practice in the UK, with a 
contextual focus on Scotland, since the programme of research was carried out 
in Scotland.  The section will describe how pharmacists are educated and 
trained, and the professional and practical educational and training support that 
exists once they are qualified.  Further, this section will describe the regulatory 
and ethical frameworks hospital clinical pharmacists operate within in Scotland 
and the UK. 
 
1.3.1 The training and professional development of hospital clinical pharmacists 
in the UK 
Pharmacists start their training as an undergraduate, and progress through pre-
registration and foundation years.  They will then have the opportunity to 
undertake post-graduate level education and training.  In addition, pharmacists 
must undergo continuing professional development (CPD) throughout their 
career, and this professional development forms an important component of the 
regulatory framework that pharmacists operate within. Understanding the 
training and the professional development that clinical pharmacists undertake, 
and the regulatory framework within which they operate is important when 
looking at the way attitudes, perceptions and behaviours form in relation to 
professional roles at work. The different stages of training will be briefly 
described, before describing professional development, and professional and 
ethical guidance. 
 
1.3.1.1 Undergraduate training in the UK 
Pharmacist training in the UK starts with the four year MPharm degree course.  
The course is intended to give students a grounding in theoretical knowledge, 
professional behaviours and the clinical skills needed to become a pharmacist 
(General Pharmaceutical Council 2011).  All pharmacy undergraduate courses 
must be accredited by the General Pharmaceutical Council (GPhC), and to enable 
this the GPhC has outlined ten standards for the initial education and training of 




1. Patient and public safety  
2. Monitoring, review and evaluation of initial education and training  
3. Equality, diversity and fairness  
4. Selection of students and trainees  
5. Curriculum delivery and the student experience  
6. Support and development for students and trainees  
7. Support and development for academic staff and pre-registration tutors 
8. Management of initial education and training  
9. Resources and capacity  
10. Outcomes 
During the undergraduate course, trainees must gather evidence of compliance 
with each standard, and are expected to follow a curriculum that covers five 
broad areas of syllabus (General Pharmaceutical Council 2011): 
1. How medicines work (including therapeutics and applied sciences) 
2. How people work (including health conditions and social sciences) 
3. How systems work (including management, regulation and governance) 
4. Core and transferable skills (including research and appraisal skills) 
5. Attitudes and values (including professionalism) 
A pharmacy degree allows pharmacists to enter different branches of practice, 
including hospital pharmacy. 
 
1.3.1.2 Pre-registration training in the UK 
On successful completion of the four year course, the pharmacist trainee enters 
a 52 week pre-registration training period, where they are under the supervision 
of a tutor.  The training will take place predominantly in one sector of pharmacy 
practice, with opportunities to experience other sectors. Pre-registration training 
may change in the future (Rudkin et at 2020), with reforms planned to better 
equip pharmacists for increasingly clinical roles across multiple sectors .   
During the pre-registration period, the trainee is expected to develop and to 
demonstrate knowledge and competence against 76 performance standards that 
are assessed by the individual’s tutor (General Pharmaceutical Council 2019a).  
The performance standards operate within the three units of personal 
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effectiveness, interpersonal skills and medicines and health, and include 
standards that the trainee must demonstrate compliance with (Figure 1.2). 
  
Figure 1.2. Performance standards for pre-registration training (adapted from 
General Pharmaceutical Council 2019a) 
 
In addition, the trainee will be expected to demonstrate competence in nine 
professional attributes: 
1 Person centred care 
2 Communication and consultation skills 
3 Problem solving, clinical analysis and decision making 
4 Self directed learning and motivation 
5 Multi-professional working and leadership 
6 Quality management and organisation 
7 Professional integrity and ethics 
8 Resilience and adaptability 
9 Pharmacy in practice 
The trainee is required to keep a portfolio of evidence that will demonstrate their 
achievement of these nine professional attributes, as well as the performance 
standards, and the portfolio is examined as part of their overall assessment.  
The trainee will also start to keep a record of their ongoing CPD (continuous 
professional development) during their pre-registration year.  The period of pre-
registration training ends with a registration assessment. This period of training 




•demonstrating a commitment to quality
•demonstrating ongoing learning and development
Personal effectiveness
•working effectively with others
•communicating effectively
Interpersonal  skills
•providing additional clinical and pharmaceutical services




prerequisite to a future role in hospital pharmacy. By the time the trainee has 
become a pharmacist they will have gained therapeutic knowledge, as well as a 
grounding in quality, governance and professionalism. 
 
1.3.1.3 Early years and foundation training for hospital pharmacists in Scotland 
Newly registered pharmacists enter a period of foundation training, within the 
sector they are first employed.  During this period, they will learn to apply the 
clinical knowledge they have gained during undergraduate and pre-registration 
training to the workplace, whilst under the supervision of more senior 
colleagues, and with support from a work-based tutor. In Scotland, foundation 
training is delivered through use of the NES Pharmacy competency-based 
training programme, which is accredited by the Royal Pharmaceutical Society 
(RPS).  Foundation training generally takes two years to complete. The aim of 
the foundation training period is to allow pharmacists to develop a range of 
skills, build on their knowledge using a framework for learning, and gain 
experience that will equip them in their future roles (Royal Pharmaceutical 
Society 2018; NHS Education Scotland 2019). The foundation framework aims to 
develop the attributes of a pharmacist across nine areas: 
1. Professional accountability 
2. Evidence-informed decision making 
3. Person-centred care 
4. Communication and consultation skills 
5. Collaborative working 
6. Leadership and management 
7. Education  
8. Research and evaluation 
9. Resilience and adaptability 
During the foundation training period, pharmacists are expected to carry out an 








1.3.1.4 Post-graduate training for hospital clinical pharmacists in Scotland 
Once a hospital clinical pharmacist has completed foundation level training, they 
have the opportunity to progress their career through post-graduate training. An 
MSc in advanced clinical pharmacy is a formal training route that many hospital 
clinical pharmacists will opt to take to progress their career, and learning will 
include, for example, advanced therapeutics, quality improvement and research 
skills.   
 
1.3.1.5 Pharmacist independent prescribing for hospital clinical pharmacists in 
Scotland 
NHS Education Scotland supports pharmacists in training for independent 
prescribing, and in implementing those skills into practice. The training consists 
of University based training, supported by clinical skills training, and patient-
centred consultation skills. Once pharmacist independent prescribers have been 
assessed as being competent they must register with the GPhC, as the 
regulatory body for pharmacists. The core competencies for pharmacist 
prescribers have been described (Royal Pharmaceutical Society 2016), and are 
incorporated into the knowledge and skills training, and include prescribing 
governance and consultation competencies.  Standards have been established 
for pharmacist independent prescribers, and include taking responsibility for 
prescribing, prescribing within level of competency, using clinical judgement, 
and raising concerns (General Pharmaceutical Council 2019). Once a pharmacist 
independent prescriber has been assessed as competent, their on-going 
competence is assured through CPD and professional revalidation. 
 
1.3.1.6 Continuing professional development (CPD) and professional revalidation 
of pharmacists in the UK 
All pharmacists must keep a record of CPD as part of their registration as a 
pharmacist with the General Pharmaceutical Council (GPhC).  In 2018, CPD 
recording became aligned with the newly introduced revalidation process in the 
revalidation framework (General Pharmaceutical Council 2018).  For revalidation, 
pharmacists are required to submit four CPD records, a peer discussion record 
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and a reflective account statement.  However, professionally, pharmacists are 
expected to undertake as much learning activity as necessary to support safe 
and effective practice, and the submission of records for revalidation would be 
expected to be part of a wider range of CPD activities.  
Pharmacy professionals must follow the nine standards that have been issued by 
the GPhC, (Figure 1.3), and the process of revalidation aligns to these standards 
by asking that the reflective account refers back to the standards, with three 
different standards being proposed for each year.  The nine standards are: 
1 Person centred 
2 Partnership working 
3 Effective communication 
4 Professional knowledge and skills 
5 Effective leadership 
6 Speaking up about concerns 
7 Respect for personal privacy and confidentiality 
8 Professional behaviour 
9 Professional judgement 
 
Figure 1.3. GPhC Standards for Pharmacy Professionals (use approved; picture source: GPhC) 
 
In summary, pharmacist training in the UK is grounded in theory, skills and 
professional behaviours, which is maintained and built on through further 
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training, CPD and ongoing development, and is assessed at revalidation 
annually. Pharmacists are trained to understand their role in the medicine 
journey, and to reflect on their opportunities for learning.   
 
1.3.2 Professional regulation and professional development for pharmacists in 
the UK 
Pharmacists are regulated as a profession to assure standards of practice.  All 
pharmacists in the UK are regulated by the independent regulator, the General 
Pharmaceutical Council (GPhC), as required by the Pharmacy Order (UK 
Government 2010). The GPhC are responsible for professional standards for all 
pharmacists, including fitness to practice, continuing professional development 
(CPD) and premises standards.    
Individual pharmacists may take professional guidance and support from a range 
of organisations, as appropriate to their speciality and to their level of 
experience, and are held accountable for maintaining appropriate levels of 
professional practice.  In addition, pharmacists have the option to register with 
their professional body, the Royal Pharmaceutical Society (RPS).  The RPS aims 
to develop the professionalism of pharmacists through the provision of guidance, 
educational support, information about medicines and pharmacy practice.  
 
1.3.3 Specialist professional guidance for hospital pharmacists in the UK 
As hospital clinical pharmacists progress through their careers, they are likely to 
specialise in a clinical area.  At this stage, they may opt to join one or more 
specialist interest groups pertinent to their specialty. Specialist interest groups 
all offer support and guidance relevant to their specialty, and can be a source of 
practical advice for a specialty, as well a network that can be accessed to share 
information.  Special interest groups often have a range of educational 
materials, peer to peer networks and competency frameworks to facilitate 
professional development within a specialty. Some special interest groups offer 
study days and conferences, and will have different means of communicating out 





1.3.4 Ethical Guidance for Pharmacists in Scotland and the UK  
Ethical and moral guidance for pharmacists may come from the GPhC, as the 
regulator, or the RPS, as the professional body, and additionally from 
Government, in the form of reports, standards, statements or ethical 
frameworks. The research study took place in Scotland, and policy context was 
considered in relation to Scotland, and to the UK.  As part of devolution, health 
is devolved to the Scottish Government; primary legislation, however, relating to 
medicines, and to the pharmacy profession are not devolved.  When considering 
the planned research study, the researcher reflected on the key professional 
drivers that were in place when the research was planned in 2014, updated in 
2017 when the research was taking place and reviewed in 2019.  The researcher 
identified those drivers that were influential in their own professional 
development, and that prompted interest in the research topic (Table 1.1). 
Pharmacists in the UK have been developing services that enable the principles 
of ethical guidance to be implemented, in their professional conduct and 
behaviours (General Pharmaceutical Council 2017; Scottish Government 2013a; 
Lord Carter 2016), in openness, honesty and candour including the reporting of 
errors (General Pharmaceutical Council 2014; Royal Pharmaceutical Society 
2014; Royal Pharmaceutical Society 2016a) and in sharing lessons learned 
(Royal Pharmaceutical Society 2014; Healthcare Improvement Scotland 2016; 
Royal Pharmaceutical Society 2016a; Royal Pharmaceutical Society 2019).  
However, whilst these guidance documents provide the ethical framework for 
pharmacists to work within, they do not describe, for example, how to report 
pharmacist prescribing errors, or how to share learning from errors, and that 
leaves a gap in practice and variation across the profession. 
Table 1.1 therefore summarises the key statements made in the grey literature 
that are significant in relation to this research, relating to professionalism, duty 
of candour and reporting and learning from errors.  Many of these statements 
apply across different sectors of pharmacy, but are selected here as being 
pertinent to hospital pharmacy, and to clinical pharmacy in particular.  The 
statements and quotes are those that influenced the researcher, and that raised 
the question of how the principles of professionalism, duty of candour and 
learning from error were being applied to hospital clinical pharmacy practice.   
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Table 1.1 Key statements relating to professionalism, duty of candour, error reporting and learning from error 
Source Year Title of document Exemplar quotes relating to professionalism, duty 
of candour, error reporting and learning from error 
Department of 
Health 
2008 Pharmacy in England –Building on strengths 
– delivering the future 
‘with greater clinical responsibilities come greater 







Standards of conduct, ethics and 
performance, 
Seven principles for behaviour 
1. Make patients your first concern 
2. Use your professional judgement in the interest of 
patients and the public 
3. Show respect for others 
4. Encourage patients and the public to participate in 
decisions about their care 
5. Develop your professional knowledge and 
competence 
6. Be honest and trustworthy 








2014 Openness and honesty - the professional duty 
of candour 
‘Be open and honest with patients when something goes 
wrong with their treatment or care which has caused, or 
has the potential to cause, harm or distress’. 
‘Be open and honest with colleagues and employers’ 




2014 Medicines Ethics and Practice Just Culture: ‘pharmacists are encouraged to learn from 
mistakes or incidents, and to share lessons learnt 
throughout the profession. They are further urged to use 
this shared learning to reduce the likelihood of similar 
mistakes and incidents from happening again’. 
Scottish 
Government 
2013a Prescription for Excellence Professionalism: 
‘a set of values behaviours and relationships’ 
It includes such components as integrity, honesty, duty, 







Source Year Title of document Exemplar quotes relating to professionalism, duty 




2016 Governance and Assurance: Learning from 
Adverse Events 
 
Learning and Improvement summary: 





2016a Professional standards for the reporting, 
learning, sharing, taking action, and review 
of incidents 
‘Reporting sharing and learning from incidents is a key 




2017  Achieving excellence in Pharmaceutical Care Transformation of pharmacy roles: ‘increasing capacity 
and offering the best person-centred care in the best 
setting’. 
Lord Carter’s 
Report for the 
Department of 
Health & Social 
care 
2016 Operational productivity and performance in 
NHS Hospitals: unwarranted variations 
Report identified ‘unwarranted variation, and 
inefficiencies in hospitals’, including pharmacy.  Proposed 
an increase in access to pharmacy services, with 80% of 





2019 In-practice guidance for pharmacist 
prescribers 
 
‘Pharmacist prescribers must record, report, and learn 
from errors and near misses to manage the risk of 
making and repeating mistakes’. 
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To summarise this section, pharmacists are guided throughout their careers by a 
framework of governance, underpinned by knowledge and skills gained through 
education and training. Principle values that pharmacists are expected to adhere 
to include integrity, honesty, openness and accountability.  Pharmacists are 
required to make patients their first concern, and are encouraged to learn from 
mistakes, errors and near misses, and to share learning with other pharmacy 




1.4 The NHS Scotland organisation research setting 
This section will firstly describe the NHS Scotland organisation where the 
research was conducted, and then the hospital pharmacy services. The section 
will go on to describe how the hospital clinical pharmacy services are organised 
and delivered within the organisation. 
1.4.1 The NHS Scotland organisation 
The organisation is a health board located in Scotland. The organisation has four 
acute hospital sites and one hospital delivering acute psychiatric services, and 
serves a population of around nearly 890,000, set to rise to 925,000 by 2025.   
The organisation’s Strategic Plan 2014-2024: Our Health, Our Care, Our Future, 
(NHS Scotland Organisation 2014) outlines the challenges facing the health 
service in the current decade.  The document outlines a vision for services that 
will require changes in practices and in mind set. This strategic plan aligns with 
the Scottish Government vision set out in ‘2020 Vision for health a social care – 
a route map’ – with its triad of quality ambitions of ‘Quality of Care, Health of 
the Population, and Value and Financial Sustainability’ (Scottish Government 
2013b). 
 
1.4.2 NHS Scotland organisation pharmacy strategy 
The pharmacy strategy 2018-2020 (NHS Scotland Organisation 2018) describes 
the intended direction for all pharmacy services in the NHS Scotland 
organisation. The strategic vision is for a pharmacy service that will ‘work 
proactively with others in healthcare to deliver first class pharmaceutical 
services, with the patient at the centre of care’. The primary aim from this vision 
is ‘to work collaboratively with patients and providers to provide safe supplies of 
medicines, in the best setting for the patient’.  The strategy describes how this 
will be done, by having a workforce that is skilled, competent and 
compassionate, and by making the best use of resources available, particularly 
in terms of workforce.  The pharmacy strategy is adopted by all pharmacy 
services, including clinical pharmacy, and the ethos and principles of the 




1.4.3 Organisation and management of hospital pharmacy services in the 
organisation 
Hospital pharmacy services are delivered across five main hospital sites, with 
some pharmacy services provided across smaller satellite locations.  The five 
main sites are managed by a site lead pharmacist.  The line management of 
clinical pharmacy services differs across each hospital site, with the site lead 
having overall responsibility for all staff and service on their site.  In addition, 
there are two clinical pharmacy leads, for acute and for primary care.  The 
organisational structure of the pharmacy service is described in Figure 1.4.   
 
 
Figure 1.4 Organisational structure for organisations’ hospital pharmacy services  
 
Clinical pharmacy leads are responsible for the strategic direction of clinical 
pharmacy services and chair the clinical pharmacy operations group. 
The clinical pharmacy operational group has representatives from all five 
hospital sites, and has as its remit the provision of operational guidance and 
direction to clinical pharmacy services, and to act as a conduit for 
communication and information to and from other sources.  The groups’ 
SCAN South East Scotland Cancer Network  
CHP Community health partnership 
ERDS – Education research and development services 
QRGS – Quality risk and governance services 
MMT - Medicines management team 
MI- Medicines information 
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workstreams include efficiency and effectiveness, performance, education and 
training, and quality improvement across the clinical pharmacy services.   
In addition to the clinical pharmacy operational group, there are clinical 
pharmacist groups at each of the five sites for cascade of information.  These 
differ across the sites in their meeting frequency, and in their structure and 
organisation. Clinical pharmacy is an integral part of the hospital pharmacy 
service in the organisation, and employs the major proportion of pharmacists 
within its service. 
 
1.4.4 Roles and responsibilities of clinical pharmacists in the organisation. 
The roles and responsibilities of clinical pharmacists are described in several 
ways including:  
a) in a job description,  
b) in a process map as part of the quality management system, and  
c) on the organisations’ intranet pages for clinical pharmacy services. 
 
1.4.4.1 Job Description   
Clinical pharmacists in the organisation have a job description describing their 
core roles and responsibilities.  The job description for a clinical pharmacist 
describes areas of responsibility, and includes the tasks and activities to be 
undertaken by the post holder in order to meet those responsibilities. The tasks 
and activities are described under the core headings ‘clinical’, ‘resource 
management’ and ‘education and research’. The job description is reviewed 
every two years as part of ongoing personal development processes. 
 
1.4.4.2 Process Map for Clinical Pharmacy   
The process map for clinical pharmacy (Figure 1.5) describes the relationship 
between key clinical pharmacy processes and their controls and measurements, 
and these will be expanded on later in this chapter. Process maps form an 
integral part of the quality management system for the organisations’ pharmacy 
services, as will be described later in this chapter. 
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Figure 1.5 Process map for clinical pharmacy service (use approved:  Pharmacy Quality Risk and Governance Services) 
 





KEY ACTIVITIES CONTROL MEASURE (MONITORING) 
Systematic approach to individual patient care, 
including where relevant non-medical prescribing 
Pharmacist/pharmacy staff competency 
Prioritisation of patients via triage and/or 
referral tools; division procedures 
Defined screening criteria – national/local 
screening criteria 
Documentation of activity 
Competency assessment 
Key performance indicators 
Peer review/appraisal/case-based 
discussion  
Nonconformity reporting  
Discharge and transition planning (including 
medicine reconciliation) 
Division policy and local procedures 
Documentation of activity 
complaints/adverse events via DATIX 
adverse event reporting system 
Workload statistics (numbers only) 
Optimisation of medication regimen (targeted 




Documentation of medicines information/advice 
provided 
National/Division/Local policies and procedures  
Competency assessment 
Peer review/case-based discussion 
Ad hoc audit 
Key Performance Indicators 
Medicines Supply Procedures: safe, effective and 
economical  
 
Stock sheet review 
Pharmacy Staff competency  
Division/Local policies and 
procedures/formulary 
Operating procedures, Medicine supply and 
usage data 
Competency assessment 
Complaints & customer feedback 
Key performance indicator (joint with 
Stores) 




Implementation of national contracts 
Education and training of multidisciplinary team 
Division/Local policies and procedures 
Documentation of activity/medicines 
information/financial reports & advice supplied 
Legal requirement 
Operating procedures/ checklist   








TRIGGERS               













Safe effective & economic 
use of medicines 
 
Optimal pharmaceutical 




















1.4.4.3 Intranet description of clinical pharmacy service  
The role and purpose of the clinical pharmacy service has been described by the 
organisation’s clinical pharmacy operations group, and is made available to all 
clinical pharmacists via the organisation’s intranet. The following core roles and 
responsibilities of clinical pharmacists are taken from the intranet pages. 
• To provide information on medicines to the multidisciplinary team (MDT) 
• To review medicines and advise on changes to medicine treatment when 
appropriate 
• To check the accuracy and appropriateness of medicines prescribed in 
immediate discharge letters (IDL) 
• To review medicines prescription and administration charts for accuracy 
and identify prescribing or administration errors 
• To arrange for the supply of medicines that require preparation in the 
pharmacy aseptic unit 
• To facilitate the supply of medicines for patients 
• To provide advice on medicines policy/governance/safety 
• To report adverse events with medicines including adverse drug reactions, 
medication errors, near misses 
• To train and educate other MDT members on medicines especially when 
new medicines are being introduced 
In addition to these core roles there are multiple roles that are shared with other 
members of the MDT.  Some of these are administrative roles –for example, 
facilitating the completion of unlicensed medicines request forms, formulary and 
non-formulary medicines request forms and individual patient treatment request 
forms to ensure these medicines can be obtained for patients; supporting the 
writing of protocols and guidelines to guide practice with medicines.  There are 
roles that fulfil legal or professional requirements - checks on controlled drugs, 
stock list review, antimicrobial stewardship.  In addition, there are roles that 
support patient education, counselling, compliance, the transition to other care 
settings or discharge, and monitoring patients for side effects and toxicity and 
efficacy.  Finally, there are multidisciplinary team support roles through 
participating in meetings, providing specialist feedback on formulary adherence 
28 
 
and medicines expenditure, and collaborating in quality improvement projects 
and audit. 
In summary, the roles, responsibilities and functions described for the clinical 
pharmacy services  within the organisation reflect those described for clinical 
pharmacy and pharmaceutical care earlier in this chapter.  That is, to rationalise 
and improve the use of medicines, with the aim of improving health outcomes, 
and by working with patients and other healthcare practitioners, ultimately 
improve the quality of life of patients. There are clear descriptions of these roles 
and responsibilities available to clinical pharmacists. In addition, description of 
specific tasks and activities are described through operating procedures. 
Having discussed in this section how clinical pharmacy operates in the 
organisation, the following section will discuss quality management, and quality 
management systems and how they are of relevance and importance to clinical 
pharmacy practice within the organisation.
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1.5 Quality Management 
This section will describe the general principles of a quality management system, 
and how quality management has become an integral part of the organisation’s 
hospital pharmacy service and, of relevance to this thesis, to the clinical 
pharmacy service. In the context of this professional doctorate, understanding 
the principles of a quality management system is important, since the 
researcher’s role in quality management was a trigger for the research. 
 
1.5.1 General principles of quality management  
Quality management is ‘a style of management focussing on the principles of 
quality, especially in the development and implementation of working practices’ 
and that ‘guides a business, organisation or department towards delivering the 
best product or service it can’  (Oxford Dictionary 2020a). 
A quality management system is ‘a collection of standards and practices 
established within an organisation to ensure consistent quality of products or 
services’ (Oxford Dictionary 2020b).  The standardised system for quality 
management is described in the international standard, ISO 9001:2015. 
ISO, or the International Organisation for Standardisation, is a non-government 
organisation made up of the standards organisations of its member countries. 
The aim of the ISO is to establish standards that aim to facilitate the creation of 
products and services that are safe, reliable and of good quality. The British 
Standards Institute (BSi) is one of the member bodies, and publishes standards 
in the UK.  Organisations that adopt a quality management system will generally 
pursue certification to the standard, via an accredited body, such as BSi. 
Accreditation and certification give an organisation credentials, and 
demonstrates to their customers that they have systems in place that meet the 
requirements of the standard.   
The seven fundamental principles of quality management, as per the 
International Organisation for Standardisation, are (International Organisation 
for Standardisation 2015): 
• Customer focus – to meet and exceed customer requirements 
• Leadership – to establish unity of purpose and direction 
• Engagement of people – to create a competent and empowered workforce 
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• Process approach – to achieve consistent and predictable results  
• Improvement – focussing on improvement for success 
• Evidence based decision making – using data and information to make 
decisions 
• Relationship management – managing relationships with all interesting 
parties including suppliers 
Each principle of quality management must be demonstrated by an accredited 
organisation, as part of the ongoing assessment process. 
 
1.5.1.1 The International standard for quality management systems (ISO 9001) 
The international standard for quality management systems (ISO 9001) consists 
of a set of requirements that organisations must meet, demonstrating an ability 
to provide services that consistently meet customer and relevant statutory and 
regulatory requirements. Further, the standard describes how the organisation 
should aim to enhance customer satisfaction, through improvement, and 
through the assurance of conformity to customer and applicable statutory and 
regulatory requirements (British Standards Institute 2015). In the context of this 
research, the need to meet ISO 9001 standards within the clinical pharmacy 
service were important considerations, and will be discussed later in this 
chapter. 
The international standard for quality management consists of a number of 
clauses that the organisation must demonstrate compliance with, the broad 
headings of which are (British Standards Institute 2015): 
• Context of the organisation 
• Leadership 
• Planning 
• Support and resources 
• Operations 
• Performance evaluation 
• Improvement 
Each clause contains a series of subclauses, and the remainder of this section 
will describe the seven subclauses that are most pertinent to this research and 
this thesis: customer focus; monitoring and measuring; competence; 
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determining and reviewing the requirements for services; control of service 
provision; monitoring, measuring, analysis and evaluation; nonconformity and 
corrective action.  Table 1.2 describes the requirements of the organisation for 





Table 1.2 Requirements of organisation related to key ISO 9001 subclauses 
(adapted from British Standards Institute 2015) 
ISO 9001 Clause Key Subclause Requirements of organisation 
Leadership Customer 
focus 
To demonstrate leadership and commitment by ensuring 
that requirements for delivering the service are 
determined, understood and consistently met, and that 
any risks or opportunities to enhance customer focus are 






To verify that services conform to requirements using 
valid and reliable measures and monitors.  To ensure, 
through measurement and monitoring, that services 
continue to be fit for purpose. 
Support and 
Resources 
Competence To ensure personnel are competent on the basis of their 
education, on-going training and experience, and that 
they continue to be competent for the tasks they are 




To ensure that statutory and regulatory requirements, as 
well as those requirements deemed necessary by the 




To ensure requirements are continually reviewed to 
ensure services can continue to be provided consistently.   
Operations Control of 
service 
provision 
To describe the characteristics of services provided, the 
anticipated results, the monitoring and measuring 
resources, the environment and infrastructure, the 
employment of competent persons, the validation of 
review processes, and the implementation of actions to 







To determine what needs to be measured and monitored, 
the methods to be used and the frequency of the 




To describe the actions to be taken when a 
nonconformity arises in order to control and correct, and 
to deal with the consequence of the nonconformity. 
 
1.5.1.2 Nonconformity and corrective action 
The subclause nonconformity and corrective action will now be further detailed 
since it was pertinent to the research, as will be described later in this chapter. 
33 
 
The definition of nonconformity used in the quality management standard is ‘any 
failure to meet a requirement, where that requirement is defined by the 
organisation. A requirement can be that of a customer, of a statutory or 
regulatory body, of ISO 9001 or of the organisation’ (British Standards Institute 
2015). When a nonconformity arises, actions should be taken firstly to control 
and correct the nonconformity (correcting actions), and secondly to deal with the 
consequences of the nonconformity. In addressing the consequence of a 
nonconformity, there should be an evaluation of the need for action to eliminate 
root causes.  This is achieved by reviewing and analysing the nonconformity, 
determining the causes of the nonconformity and determining if similar 
nonconformities exist or could potentially occur; this is corrective action.  Finally, 
any corrective action taken to address the nonconformity should be assessed for 
effectiveness.   
Organisations that have an accredited quality management system need to 
demonstrate that they comply with the required arrangements, and must 
continually review their processes for collecting information that provides 
evidence for compliance, which is then assessed at internal and external audit.  
 
1.5.2 Quality management in the organisations’ pharmacy departments 
The NHS Scotland organisation’s hospital pharmacy service has had accreditation 
to the ISO 9001 quality management system for over 25 years. The decision to 
pursue accreditation came from a desire to establish core standards of practice 
across pharmacy services, under a quality management system. The scope of 
registration of the quality management system includes clinical pharmacy 
services.   
The maintenance of accreditation requires systematic evaluation by external 
audit of the quality management system for all pharmacy processes. The 
external audits are conducted by BSi auditors, and are complemented by 
internal quality audits carried out by the organisations’ pharmacy quality risk 
and governance services.  All pharmacy services that are within the scope of 
registration must comply with the ISO 9001 quality management standard 
(British Standards Institute 2015) in all aspects of service provision. As 
described, the requirements include the legal, regulatory, professional and 
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ethical frameworks that apply, and for clinical pharmacy services some of the 
legal, regulatory, professional and ethical frameworks that apply have been 
described earlier in this chapter.   
 
When the current version of the ISO 9001 standard was issued in 2015, (British 
Standards Institute 2015), all accredited organisations were required to 
transition to the new standard to continue accreditation. There were significant 
changes in the 2015 iteration of the standard:  there was more emphasis on 
risk-based thinking, customer focus, performance evaluation and aligning with 
the organisation’s strategy; it also built on the previous standard’s emphasis on 
continuous and systemic improvement of processes.   
For clinical pharmacy, as well as for all other pharmacy services in the 
organisation, the specific arrangements in place to comply with the quality 
management standards are described in a process map (Figure 1.5).  Any 
changes in process or activity must be reflected in the process map.  The 
process map shows key clinical pharmacy activities, and the monitors or controls 
and the measures for these key activities are described.  One of the challenges 
in establishing and updating the process map was the paucity of measures that 
can be applied to the clinical pharmacy process, from a quality management 
perspective.  This has been described earlier in this chapter in relation to the 
paucity of quality assurance measures that are established in practice for clinical 
pharmacy, and for pharmaceutical care in the UK. The next section will describe 
and evaluate those elements of measuring, monitoring and control that have so 
far been introduced into the hospital clinical pharmacy services, and highlight 
the gaps that exist. 
 
1.5.3 Quality management for organisations’ hospital clinical pharmacy services  
This section will describe the current quality management measures and controls 
for the hospital clinical pharmacy services within the organisation, and how 
service performance is assessed. The measures and controls are described in the 
clinical pharmacy process map (Figure 1.5).  Controls include the competency of 
the workforce, prioritisation and screening, the documentation of activity; 
measures or monitors include key performance indicators (KPI’s), peer review, 
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nonconformity reporting and DATIX reporting of adverse events, and these are 
described here: 
  
1.5.3.1 Competency of workforce 
The competency requirement of clinical pharmacists is described in job plans and 
job descriptions.  Staff selection will include assessment of current competency, 
and once employed, staff will be trained in local work practices. Line 
management and personal development are recorded through the TURAS 
platform (the NHS Education for Scotland training and learning platform).  
Demonstration of ongoing control is assessed through audit, and through 
ongoing internal reporting processes. Descriptions of the training, on-going 
professional development and CPD requirements for pharmacists were described 
earlier in this chapter.  
 
1.5.3.2 Prioritisation and screening 
In the organisation, in common with other hospital pharmacy services across the 
UK, there has been a necessary move towards maximising the efficiency and 
effectiveness of the clinical pharmacy service over the past five to ten years in 
order to meet targets.  One of the ways of doing this has been to help clinical 
pharmacists to prioritise their workload or target their pharmaceutical care to 
patients who will most benefit, using a form of triage or screening, and this has 
been described (1.2.1.4).  Within the organisation, the process for prioritising 
patients uses the term priority coding. 
The priority coding process used in the organisation starts when a patient is 
admitted.  Pharmaceutical care issues are identified from a knowledge of their 
medicines on admission, then checked and recorded during medicines 
reconciliation processes. Further care issues may be identified for any new 
medicines that are added during patient stay. From information about patient, 
disease and medicines, pharmacists allocate a prioritisation code to patients that 
determines the frequency with which the patient will be reviewed during their 
stay (Table 1.3), with codes of Phar 1 to Phar 4 denoting frequency of review.  
Additionally, all patients are prioritised for review at the point of discharge, 
denoted by the code Phar D.  The prioritisation coding can change during the 
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patient’s stay if there is change to patient or to medicines, however that will only 
occur if the pharmacist becomes aware of the change. 
 
Table 1.3 Agreed frequency of patient visits: priority coding  
















Monitoring of the priority coding process is achieved through reportage as a key 
performance indicator (1.5.4.5).  The key performance indicator for this process 
assesses the proportion of high priority patients seen, i.e. those coded as ‘Phar  
1’, according to predetermined screening criteria, with the target being 100%. 
 
1.5.3.3 Screening criteria 
Screening criteria are incorporated into the priority coding tool that has been 
designed for prioritisation of patients within the organisation.  Screening criteria 
have been established under broad headings of medicine factors, patient factors 
and disease factors (Appendix 1.1). The core set of screening criteria were 
established and approved by lead clinical pharmacists, with additional speciality-
specific criteria developed locally by specialist clinical pharmacy teams.  The 
screening criteria acts as a control of the clinical pharmacy activity of taking a 
systematic approach to individual patient care. 
 
1.5.3.4 Documentation of activity 
All information relating to the pharmaceutical care issues should be recorded 
onto the TRAKcare system, which is the electronic patient record system in use 
within the organisation.  Documentation on TRAK provides a permanent record 
of the pharmaceutical care issues, from admission to discharge. TRAKcare can 
be accessed by pharmacy staff in secondary and primary care at any point in the 
patient’s journey. Documentation recorded by clinical pharmacists includes the 
priority code, details of medicines reconciliation, ongoing pharmaceutical care 
issues and discharge planning information.  In addition, the pharmacist will 
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document on the patient’s Kardex/medicine chart to indicate that they have 
reviewed the medicines prescribed. 
 
The controls described in 1.5.3.1 to 1.5.3.4 that are in place for clinical 
pharmacy activities give levels of assurance that are assessed by the following 
monitors: 
 
1.5.3.5 Key performance indicators (KPIs)  
All the organisations’ pharmacy services define and report on their KPIs to the 
senior management team: this is how the service has decided to measure the 
performance and effectiveness of the quality management service.  The two key 
performance indicators for the clinical pharmacy service are:  
1. Proportion of Priority 1 code patients seen, according to referral criteria 
(target 100%) 
2. Proportion of independent prescribers who have used their qualification in 
the last 28 days (target 100%) 
 
KPI 1 is an indicator of the ability of clinical pharmacists to see patients that 
have been assessed as requiring a daily visit, and is therefore an activity 
indicator rather than a quality indicator. KPI 2 is an indicator of those pharmacist 
prescribers that are able to use their prescribing in their current role, and is 
therefore an organisational indicator rather than a quality indicator.  
KPI data has been collected from clinical pharmacy services at all sites to comply 
with the performance measurement element of the quality management system 
(British Standards Institute 2015). For example, during 2018/2019 the 
proportion of Priority code 1 patients seen within target time ranged from 5% for 
one site for one month, to 80% for another site, for one month’s worth of data.  
 
1.5.3.6 Peer review  
Within the organisation, clinical pharmacists take part in informal peer review. 
Peer review is a process often used in healthcare, with the aim of improving 
quality of care (Al-Lamki, 2009). Peer review, when conducted as intended, 
allows participants to reflect on their practice compared with that of others. It 
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requires a skill set, depends on the openness and transparency of participants, 
and relies on the presentation of a case that can be thoroughly examined. 
The current process described as peer review varies across the organisations’ 
hospital sites both in frequency and in content.  The programme varies and 
occasionally includes case presentations, inviting discussion and feedback by 
attendees, but also may include educational sessions on, for example, updates 
and training, new drugs, current practice in a clinical area.   
In summary, informal peer review has some elements of the intended purpose of 
allowing peer discussion of a case, but lacks the formality of process that could 
enable wider shared learning, and is not used consistently.  
 
1.5.3.7 Nonconformity reporting 
Within the quality management system (British Standards Institute, 2015) there 
is a requirement to report on deficiencies in service or product provision, and 
these are called nonconformities, described earlier in this chapter.  The principle 
purpose of nonconformity reporting is to identify areas for quality improvement.  
For the organisations’ pharmacy services, nonconformity reporting has become 
well established across most of the technical services – dispensary, aseptic and 
distribution. Nonconformity reporting can work successfully where there is a 
defined process, with built in checks:  the medicine is selected, it is checked and 
is either right or wrong.  Nonconformity reports are used to reflect on what has 
happened, to share with the team and to address any areas that can be 
improved.  Within the technical and medicine supply services in the pharmacy 
service, nonconformity reporting is the established process used when an error 
or failure occurs, and the error is identified before the ‘product’ leaves the 
department. This is sometimes referred to in other pharmacy disciplines 
(community pharmacy, for example) as a near miss. However, if the error or 
failure has left the department, or has been through multiple checks which 
should have detected the error or failure, then that event is classed as an 
adverse event across NHS Scotland, and this will be discussed further later in 
this section.    
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Within clinical pharmacy services it has been difficult to establish nonconformity 
reporting:  the process for identifying pharmaceutical care issues is 
predominantly cognitive.  There are however some clinical pharmacy tasks and 
activities that lend themselves to nonconformity reporting – regulatory roles like 
controlled drug checks and the review of stock lists for wards, that are 
timetabled, and a failure to carry out these tasks could constitute a 
nonconformity, and be reportable.  That said, the lack of definition of what 
constitutes a nonconformity for pharmaceutical care activities undertaken by 
clinical pharmacists leaves a gap in meeting quality management system 
requirements, and was the focus of this research. 
 
1.5.3.8 Adverse event reporting on DATIX 
Adverse event reporting has been established within the quality management 
system for the organisations’ pharmacy services as the process for reporting 
errors and incidents.  Adverse event as a term to describe errors and incidents 
was adopted by Healthcare Improvement Scotland, and NHS Scotland has used 
this terminology since 2012.  The Healthcare Improvement Scotland definition of 
an adverse event is: ‘an event that could have caused, or did result in, harm to 
people or groups of people’ (Healthcare Improvement Scotland 2019).  Across 
NHS Scotland all health boards have adverse event reporting systems, and all 
but one utilises the DATIX electronic risk management system. The DATIX 
system functions both for reporting of adverse events, and for their subsequent 
management, including investigation and feedback. 
Across the organisations’ pharmacy services, serious near misses, adverse 
events and informal complaints (for example when a ‘customer’ contacts the 
department to report an error) are reported using the DATIX risk management 
system.  This has been defined locally in procedures to cover the requirements 
of the accredited quality management system. 
A detailed search of the DATIX risk management system database was 
conducted by the researcher during planning of the research study. The search 
concluded that for the period 2015-2018 clinical pharmacists were rarely 
reporting incidents that arose from within the clinical pharmacy service, even 
though adverse event reporting is included in the process map (Figure 1.5) as a 
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monitor.  In addition, the DATIX risk management system database was 
examined by the researcher to establish what pharmacist independent 
prescribing errors were being recorded on the DATIX system; no examples were 
found in the period 2015 to 2018, either self-reported or reported by another 
individual.  
There was, however, substantial evidence that clinical pharmacists were using 
the reporting system to record adverse events with medicines, as part of a 
medicine safety role. Examination of the DATIX risk management system 
database provided evidence that pharmacists report approximately 17% of all 
medication adverse events in the organisation, across multiple reporting 
categories (Figure 1.6). 
 
 
Figure 1.6 Graph showing % of all medication adverse event reports by 
organisations’ pharmacists 2015-2018 [From DATIX risk management system, 
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In summary, the controls and monitors described within this section act as a 
means of managing quality and performance within the clinical pharmacy 
service.  Formal performance review of clinical pharmacy within the quality 
management system includes a review of KPIs, and reporting on nonconformities 
and adverse events (‘error reporting’) at a six-monthly performance review 
meeting. However, as described previously, the data collected for the clinical 
pharmacy service for KPI’s are not reflective of performance quality, and there 
are very few nonconformities or adverse events formally recorded that relate to 
clinical pharmacy activities. This leaves a gap in meeting the requirements of the 
quality management system, a gap in how clinical pharmacists meet their 
professional requirements to ‘report errors and share learning’ (Royal 
Pharmaceutical Society 2016a; Royal Pharmaceutical Society 2019), and a gap 
in how clinical pharmacy services can use the quality management system to 
drive improvement.   
The thesis will now continue with a general overview of medicine safety, 
outlining the role of the pharmacist, and exploring possible reasons why clinical 
pharmacists have found it difficult to identify nonconformities and adverse 




1.6 Medicine safety and the role of the pharmacist 
Medicine safety is a global challenge, and in 2017 the World Health Organisation 
(WHO) made it a priority, with the publication of their third Patient Safety 
Challenge, Medication without Harm (World Health Organisation, 2017).  The 
challenge, to reduce severe avoidable medication-related harm by 50%, has 
been a reminder to healthcare professionals of the risks associated with 
medicines, particularly on the risks of harm at transitions of care, in high risk 
situations and with polypharmacy.  Medicine safety systems rely on the reporting 
of adverse events with medicines, in order to understand, assess and analyse 
the issues and challenges (National Patient Safety Agency 2007; National Patient 
Safety Agency 2014; World Health Organisation 2017).  In the UK, the WHO 
challenge built on previous targets to reduce harm with medicines, which were 
initiated with ‘An Organisation with a Memory’ (Donaldson 2000) and the 
subsequent development of systems and processes that were designed to help 
healthcare organisations to improve their reporting and learning from adverse 
events. (National Patient Safety Agency 2007).  Studies continue to be carried 
out on barriers to the reporting of adverse events, since underreporting is an 
acknowledged issue (Keers et al 2013; Vrbnjak et al 2016; Alshehri, Keers and 
Ashcroft 2017). 
Pharmacists in the UK have a key role in medicine safety, and it is a role 
expected of them as professionals (Royal Pharmaceutical Society 2014; Royal 
Pharmaceutical Society 2016a; Royal Pharmaceutical Society 2019). Hospital 
clinical pharmacists have opportunities to review patient medication at 
transitions of care, and within the activities of Kardex/medicines review (1.2.1.1) 
and medicine reconciliation (1.2.1.2) will identify and correct any discrepancies 
and errors. 
However, as described in 1.2.1.1 there are factors (workload and stress for 
example), that influence the ability of pharmacists to detect prescribing errors, 
and there is some evidence that although pharmacists may act on and correct 
identified prescribing errors, reporting is less likely (National Patient Safety 
Agency 2014; Williams, Phipps and Ashcroft 2013).  A qualitative study on the 
attitudes of UK hospital pharmacists to reporting medication incident (Williams, 
Phipps and Ashcroft 2013) concluded that whilst hospital pharmacists recognised 
43 
 
the importance of reporting prescribing errors, underreporting was prevalent. 
The study described the cognitive process by which the decision to report was 
made.  Barriers to reporting medication incidents were identified, and included 
anxieties relating to interprofessional relationships, perceptions about the 
reporting process, time taken to report; reporting likelihood was influenced by 
the severity of patient harm.   
Identifying, responding to and reporting on adverse events with medicines is a 
key skill that hospital clinical pharmacists have.  It requires vigilance and 
attention to detail and it requires clinical pharmacists to review and assess the 
actions of others. As Daniel Kahneman states in ‘Thinking Fast and Slow’: ‘it is 
easier to recognise other people’s mistakes than our own’ (Kahneman 2011). In 
considering how clinical pharmacists would report on their own suboptimal 
pharmaceutical care, this statement was pertinent, given that their training and 
skill frequently focusses on identifying adverse events made by others, and may 
be less focussed on identifying adverse events made by themselves. 
Having explored the role of the hospital clinical pharmacist in reporting 
medication incidents, and discussed the lack of self-reporting of adverse events 
within the clinical pharmacy service, the following section will explore how the 
reporting of adverse events has been shown to affect the behaviour of people 
involved. Reporting of adverse events is interpreted here as including where  an 
individual self-reports, as well as where an adverse event has been identified by 




1.7 Moral distress and burnout amongst healthcare professionals 
This section will start by describing the impact that dealing with an adverse 
event has on healthcare staff, then discuss moral distress and burnout, how they 
develop and manifest in healthcare workers, and conclude with what this may 
mean to the healthcare workforce. 
 
1.7.1 Impact of an adverse event with a medicine on healthcare professionals 
It is known that being involved in an adverse event with a medicine has an 
impact on the member of staff involved, and those involved have been called 
“the second victim’ of an adverse event (Wu 2000).  Support for those involved 
in a medication error is now established within medical and nursing practice, and 
the support process is part of the governance processes of NHS health boards.  
However, there are studies that demonstrate that the reporting of adverse 
events holds stigma or ‘professional embarrassment’ for doctors (Wu 2000; Seys 
et al 2013; Bowie et al 2005), and there is a suggestion that stigma has an 
influence on the likelihood of adverse event reporting (Williams, Phipps and 
Ashcroft 2013). There is also some evidence that moral distress and burnout can 
arise as a consequence to involvement in adverse events (Wilkinson 1987).  
 
1.7.2 Moral distress amongst healthcare professionals 
Moral distress describes the emotional impact invoked when things do not go 
according to intention, whether this is because they do not go according to plan 
(adverse event), or cannot go according to plan (latent or environmental 
conditions).  Moral distress was first described in nursing, to describe the gap 
between what nurses want to do, and what they are able to do, particularly in 
relation to moral conflict and ethical challenges.  Jameton (1984) described 
moral distress as ‘the distress felt when one knows the right thing to do, but 
institutional constraints make it nearly impossible to pursue the right course of 
action’.  Wilkinson (1987) further added the dimension of a sensory experience 
of distress, and the negative feeling that leaves the person with.  Wilkinson also, 
through his studies of nurse experiences, differentiated between the initial 
distress (characterised by frustration, anger and anxiety) and the reactive 
distress that occurs later (characterised by guilt, low self- esteem and feeling 
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powerless).  Studies conducted with nurses in Australia have identified negative 
consequences for patients as well as the nurse (Burston and Tuckett 2013): 
physical symptoms of nausea, insomnia and fatigue were reported by nurses, 
and the resultant coping mechanisms of distancing and passivity can have an 
impact on patient care. 
As the concept of moral distress has become more widely discussed, so has 
research in other healthcare professionals to explore this, as each profession has 
its own code of ethics and sets of legal and professional guidelines. The concept 
of moral distress as applied to community pharmacy in the UK has been 
explored by Astbury et al (2015), in a study examining the research agenda for 
moral distress in community pharmacy practice.  In the mixed methods study, 
the authors used three focus groups, which were analysed using grounded 
theory principles. Four categories relating to moral distress were identified, 
namely: legislative constraints, commercial pressures, challenges to 
professionalism and risk taking and resilience. Fifteen individual themes were 
then identified and this was followed by a pilot questionnaire which was sent to 
fifty pharmacists to assess the validity of the tool. In the study the authors 
discuss how the expanding role of pharmacists to include pharmaceutical care 
gives rise to more opportunities for moral and ethical issues to be a factor in 
decision making processes.  The main focus of the study was on community 
pharmacy, where professional isolation and commercial conflict have additional 
impact (Astbury et al 2015).   
Moral distress in hospital clinical pharmacists has been studied in Sweden 
(Kälvemark et al 2004). Although Sweden has a different healthcare system 
from the UK, there are similarities in terms of clinical pharmacy practice. Ethical 
dilemmas arising from the variance between the needs of the patient and the 
interests of the organisations were cited as being key influences on moral 
distress.  This mixed methods study of participant interviews followed by 
questionnaires, rated patient prioritisation systems and time constraints as 
causing the highest levels of distress. This description of clinical pharmacy 
service provision, where not all prioritised patients can be seen due to time 
constraints is familiar in UK hospitals. Even with prioritisation and screening, 
pharmacists may not be able see all the patients that they want to, and this had 
implications for this study, when contemplating the emotional impact of 
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suboptimal pharmaceutical care.  The consequences of extended episodes of 
moral distress are known to have impact on healthcare professionals (Wilkinson 
1987). 
 
1.7.3 Burnout in healthcare professionals 
Burnout, or occupational stress, amongst healthcare professionals is an 
emerging challenge to healthcare delivery (Brindley et al 2019), and one of the 
factors identified as being causative in burnout is a feeling of not having control 
over one’s work, frequently described as moral distress.  Burnout is now thought 
to be responsible for high levels of absenteeism, as well as with healthcare 
professionals leaving their chosen profession or changing sectors.  (Austin et al 
2017; Wilson and Simpkin 2019).  There is a paucity of research into burnout 
amongst pharmacists in the UK, but emerging research from the US indicates 
that burnout is having an impact both on the wellbeing of pharmacists and on 
their retention within the profession (Hagemann et al 2020). 
Sections 1.6 on medicine safety and 1.7 on moral distress and burnout in this 
chapter have touched on some of the psycho-social implications of being 
involved in adverse events in healthcare: of guilt and professional 
embarrassment, and of working in a stressful environment, where organisational 
constraints may lead to a feeling of underperforming, with associated feelings of 
guilt and anxiety.  This was relevant to this research study, with its focus on 
exploring suboptimal pharmaceutical care as a concept, and the desire to 
understand the impact the disclosure of suboptimal pharmaceutical care may 
have on clinical pharmacists. 
 
1.8 Summary of Chapter 1 
This chapter has outlined the background to the research, attempted to define 
and describe the concept of clinical pharmacy and pharmaceutical care, and how 
hospital clinical pharmacists undergo training and professional development over 
the course of their career.  Quality management principles and quality 
management system as relevant to the clinical pharmacy service within the 
organisation were described. There were descriptions of the gaps that exist in 
the quality management arrangements for the clinical pharmacy service, and 
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these were reflected by a paucity of literature on the topic of quality assurance 
arrangements for clinical pharmacy and pharmaceutical care. Of note there was 
a gap around the identification, reporting and sharing of adverse events 
associated with pharmaceutical care, and this has been described for the 
purpose of this research as suboptimal pharmaceutical care.  The chapter 
concluded with discussion on medicine safety, and the role of the pharmacist, 
and an overview of the topics of moral distress and burnout in healthcare 
professionals, topics that is was perceived may be of relevance when considering 
suboptimal pharmaceutical care. 
In setting out in this chapter the context of the organisation, the researcher’s 
role, and with the introduction of the key concepts of clinical pharmacy and 
pharmaceutical care, as well as quality management, the thesis will now go on 
to describe the research that was designed, which aimed to explore what 
hospital clinical pharmacists perceived and understood to be optimal and 
suboptimal pharmaceutical care, whether and how suboptimal pharmaceutical 
care manifested in practice and what effect this had on those delivering the 





CHAPTER 2 METHODOLOGY 
 
2.1 Introduction to Chapter 2 
This chapter will give an outline of key philosophical paradigms and methodology 
in the context of the proposed research.  It will provide an overview of 
qualitative methodology, and describe different types of qualitative methods that 
have been applied in healthcare research.  It will conclude with describing the 
rationale and justification by which the methodology for the planned professional 
doctorate research was adopted. 
 
2.2 Approaches to research 
Research is the rigorous, systematic process of enquiry into a phenomenon of 
interest (Creswell 2014). It can use different methods, but is based on 
observation, measurement and comparison to rules or theories, in order to 
understand the phenomenon in a new way.  The Merriam-Webster dictionary 
defines research as ‘investigation or experimentation aimed at the discovery and 
interpretation of facts, revision of accepted theories or laws in the light of new 
facts, or practical application of such new or revised theories or laws’ (Merriam-
Webster 2018). 
Research starts with a question. At the initial stage, the question can appear in 
the form of a thought, or series of thoughts questioning why a phenomenon 
occurs, or occurs in a certain way, or whether it exists at all. From these initial 
thoughts, research requires a plan being put into place as to how these 
questions can be answered. The plan will need to include elements of research 
design, and to identify appropriate research methods for collecting, analysing 
and interpreting data.  
Underpinning research are the beliefs and the approach of the researcher in 
relation to the world as they see it, and this philosophy has been referred to in 
the literature in two ways.  The term worldview (Creswell 2014), where 
worldview is defined following the explanation of Guba, (1990), as ‘a basic set of 
beliefs that guide action’ (Creswell, 2014); and the term paradigm (Bowling 
2014; Lincoln, Lynham and Guba 2011), where paradigm is defined as ‘a set of 
ideas (hypotheses) about the phenomena under inquiry’ (Bowling 2014). Both of 
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these terms acknowledge the involvement of the researcher with their topic of 
inquiry, and acknowledge that their worldview will influence how they take the 
research forward through design, planning and execution. 
 
2.2.1 Research philosophy  
Understanding the philosophy behind research helps the researcher in the 
design, planning and execution of research.  Research philosophy describes the 
concepts underpinning how data should be collected, analysed and used. 
Creswell (2014) states that worldviews are better described in terms of their 
ontology, epistemology, axiology and methodology, and that by understanding 
and declaring these, the researcher is giving transparency and honesty to their 
research (Table 2.1). 
 
Table 2.1 Research philosophy definitions (adapted from Creswell 2014) 
Research term Simplistic definition 
Ontology The reality that research aims to understand by investigation 
(what it means to be human, or the nature if reality) 
Epistemology The relationship between the stated reality and the person 
carrying out the research (how we know what we know or 
what counts as knowledge) 
Axiology The role of the researcher’s own values on the research 
process (how we bring influence, and how we know that) 
Methodology The technique(s) used by the person carrying out the 
research to investigate the reality (how we decide how to add 












Donyai (2012) describes how these worldviews interconnect, and how they 
interact with methodology, methods and data in the research process (Figure 
2.1). 
 
Figure 2.1 Interactions between ontology, epistemology, axiology, methodology, 
methods and data in the research process (Adapted from Donyai 2012)  
 
Creswell (2014) states that research paradigms should be linked to the research 
methodology (strategies of inquiry) and to research methods. Behind research 
methodology lies the philosophical underpinning paradigm (typical model) or 
‘worldview’.  According to Creswell (2014), there are four paradigms or 
worldviews: post-positivism, constructivism, transformativism and pragmatism.  
Table 2.2 shows how each paradigm relates to a research approach, a strategy 
of inquiry, the methods for achieving the strategy of inquiry, and what key 
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2.3 Research design 
This section on research design will introduce, define and describe quantitative 
and qualitative research.  It will describe some of the different types of 
qualitative research designs, and give examples from pharmacy practice 
research to illustrate the differences between them.  It will go on to summarise 
some of the strengths and weaknesses of the different qualitative research 
designs. 
 
2.3.1 Quantitative research 
Quantitative research is the measurement and analysis of observations in a 
numerical way (Bowling 2014).  In quantitative experimental research the 
researcher assesses if there is a cause and effect model, by varying the inputs 
and measuring the outputs, generally using statistics, mathematics or 
computational techniques.  There are four types of quantitative research: 
descriptive, correlational, quasi-experimental and experimental. Randomised 
control trials are an example of experimental quantitative research design.  
Another example is survey research, which can be correlational, descriptive or 
quasi-experimental. Survey research may for example quantify or score a 
description of opinions or attitudes from a population by studying a sample, 
using questionnaires or structured interviews with the aim of generalising about 
the population from the sample studied (Creswell 2014). 
 
2.3.2 Qualitative research  
Qualitative research is social research which is carried out in the field (natural 
setting), and analysed largely in non-statistical ways (Bowling 2014). Qualitative 
research helps researchers access the feelings and thoughts of the participants, 
which can lead to better understanding of the meaning those participants ascribe 
to their experiences (Sutton and Austin 2015).  Lincoln and Guba (1985) note 
that the natural setting is essential because the phenomena of study take their 
meaning not just from themselves but from their context and setting (Lincoln 
and Guba 1985). 
There are five different types of qualitative research methodology: narrative, 
grounded theory, ethnographic, case study and phenomenological research 
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(Bowling 2014) and these are described here, using examples from pharmacy 
practice research for each type of research, to enhance understanding in a 
setting that was relevant and familiar to the researcher. 
 
2.3.2.1 Narrative research   
The term narrative research comes from the humanities, where the lives of 
individuals are studied and then extracted into stories by the researcher, but 
which are primarily derived from the participants. Krujitbosch et al (2018) for 
example, used a narrative research method in a study exploring the moral 
dilemma of community pharmacists.  In this study, an undisclosed number of 
early year pharmacists working in community pharmacies in the Netherlands 
were asked to give a written narrative review of a situation where they had 
experienced a moral dilemma; this was defined as being a situation where there 
is a choice of at least two actions that can be taken, with neither being the 
obvious preferred option morally. A total of 128 narratives met the criteria, and 
inductive content analysis gave rise to three categories (patient, doctor and 
involved parties) and 22 subcategories to describe the type of moral dilemma 
that community pharmacists face on a daily basis (Krujitbosch et al 2018).  
 
2.3.2.2 Grounded theory research  
The term grounded theory comes from sociology, where a generalised abstract 
theory is produced, grounded in the views of the participants and includes a 
detailed description of the setting and of the individuals to provide context 
(Robson 2011).   
A qualitative study exploring how patients with gout become engaged with their 
disease management and medicine compliance used grounded theory research 
(Howren et al 2018).  The Canadian study used the patient perspective of twelve 
participants, using interviews, to develop an explanatory framework to 
understand the process by which patients become engaged in their own disease 
management.  
Grounded theory as an approach works well to gain insight into the perception 
and experiences of others.  Grounded theory, where the investigator develops 
conceptual categories from the data and makes new observations to develop 
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these categories further, or into subcategories (Bowling 2014), derives its 
hypotheses directly from the data, with the rich description of the context, 
setting and participants being part of the narrative.   
 
2.3.2.3 Ethnographic research 
The term ethnographic research comes from anthropology and sociology, and 
describes the shared patterns of behaviours of an intact cultural group in their 
natural setting over a prolonged period of time. Ethnographic studies give a 
descriptive account of social life and culture in a defined social system, based on 
qualitative methods like observation, unstructured interviews over a period of 
time, and analysis of documents (Robson 2011; Bowling 2014).   
Ethnographic research in pharmacy practice can be used to look at the patterns 
of behaviour of pharmacists as a cultural group, or at a group of patients, and 
through the in-depth method of collecting data, provide a rich narrative 
description.  For example, Lea, Corlett and Rodgers (2015) describe how 
interruptions, multi-tasking and task-switching in community pharmacy can be 
factors associated with dispensing errors.  In a qualitative study in England, 
eleven pharmacists participated in research using unstructured observations 
which recorded all their activities, including interruptions, along with case study 
notes containing pharmacist details, workflow and staffing information.  The 
resultant analysis used directional work maps as a technique to show how the 
pharmacists worked amongst the interruptions, and concluded that pharmacists 
did not appear to have insight of the consequences of interruptions, multi-
tasking and task switching on their performance (Lea, Corlett and Rodgers 
2015).  In this study, the ethnographic methodology allowed the researcher to 
use multiple sources of data to build a picture of the way the pharmacists were 
working, and the problems they encountered, and used this to describe patterns 
of behaviours of the participants.   
 
2.3.2.4 Case study research 
Case study research is where the researcher develops an in-depth analysis of a 
case by collecting detailed information using a variety of data collection 
procedures over a sustained period of time (Robson 2011; Bowling 2014).  
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An example of case study research in pharmacy was described by MacLure and 
Stewart (2018), where they explored the e-health and digital literacy 
experiences of pharmacy staff in North East Scotland. The case study approach 
used both observations and interviews in community and hospital pharmacies 
with both sets of data (observation and interview) being collated and analysed 
using a framework approach.  Four themes were inducted, namely technology, 
training, usability and processes. The case study approach here enabled the 
researchers to gain insight into the beliefs and experiences of pharmacy staff in 
different sectors (MacLure and Stewart 2018). 
 
2.3.2.5 Phenomenological research  
The term phenomenological research comes from fields of philosophy and 
psychology, and describes the study of the lived experiences of individuals 
(Creswell 2014).  The description distils the essence of the experiences of 
several individuals who have all experienced the phenomena and the researcher 
then, invoking a constructivist paradigm, constructs meaning. Phenomenological 
research typically involves in-depth interviews (Bowling 2014; Creswell 2014). 
An example of a phenomenological pharmacy practice research study examined 
pharmacist behaviour in dispensing opioids, specifically the decision-making 
process, incorporating ethical judgements (Russ et al 2019).  The study, in the 
USA, used purposive and snowballing sampling to recruit seven pharmacists, 
who were interviewed by telephone, using a semi-structured technique.  The 
researcher then interpreted participant experiences, which is a feature of 
phenomenological research: multiple people experience similar events, but when 
probed give different points of view.  In the study, a theoretical framework, 
based on factors impacting ethical behaviours was used to interpret the data, 
and the accumulated information unified to explain the phenomena.  The study 
described how pharmacist behaviours were influenced by patient, doctor and 
community knowledge, and how decision-making processes during opioid 
dispensing used a combination of ethical education, moral teaching and 
leadership experience.  By using a phenomenological approach, the study was 
designed to interpret the interview data, using a framework, and aggregate the 
views of all participants (Russ et al 2019). 
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The strengths and weaknesses of the five different types of qualitative research 
design (narrative, grounded theory, ethnographic, case study and 
phenomenological) are summarised in Table 2.3.   
 
Table 2.3. Strengths and weaknesses of different qualitative research designs 
(adapted from Creswell 2014) 




Uses the voice of the 
participants, given at the 
time they experience the 
phenomenon 
Using written narrative 
excludes some participants.  
Grounded theory 
research 
Develops a theory that can 
be further tested 





perspectives can be 
captured using observation 
interview and documents 
Requires prolonged time 
period, and being part of the 




In-depth study, can bring 
together the views of 
different sectors 
Dependant on selection of 
cases, and on the interaction 
of the researcher with each 




perspectives, seeks out 
different view points 





2.4 Qualitative research – designing robust, quality-driven research. 
This section will outline the parameters that need to be considered when 
designing qualitative research.  The section will define and describe 
trustworthiness and reflexivity, and demonstrate how these elements can be 
incorporated into research design. In addition, this section will outline the 
different methods of sampling, sample size, question type, interview method and 
data analysis and presentation, and how they all need to be considered in the 
design of research. 
 
2.4.1 Ensuring trustworthiness and reflexivity in qualitative research 
This section will outline the ways in which trustworthiness and reflexivity should 
be considered during research design and planning, and further, how 
trustworthiness and reflexivity should be described for qualitative research 
studies, as a means of establishing confidence in the truth of the findings.  
 
2.4.1.1 Trustworthiness 
Processes that increase the trustworthiness of research can be embedded at the 
planning stage by careful consideration of the four parameters that are 
described as being key to trustworthiness: credibility, transferability, 
dependability and confirmability (Shenton 2004; Lincoln and Guba 1985); 
actions that can be planned to address this in research are described in Table 
2.4 for each parameter. 
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Table 2.4 Research approaches to build in trustworthiness (adapted from 
Shenton 2004) 
Parameter Approach to increase 
trustworthiness in methodology 
Credibility (whether the 
phenomena have been accurately 
represented by the study- 
confidence in the truth of the 
findings) 
Choice of appropriate research method 
Being familiar with cohort of study 
/using ”natural setting” 
Robust sampling plan 
Triangulation 
Integrity and honesty 
Reflective commentary 
Peer and supervisory support 
Transferability (whether the study 
could be “transferred” to other 
situations or contexts) 
Full description of the study context 
Dependability (whether the study 
is consistent and could be repeated 
and get similar results) 
Use of overlapping methods  
Confirmability (whether the study 
has been carried out as objectively 
as possible – the results are shaped 
by participants and not researcher) 
Triangulation  
 
Reflective commentary  
 
Acknowledgment of predisposition or 




The inclusion of details of actions and approaches taken to ensure 
trustworthiness should be incorporated into descriptions of the method used in 
research, and in the findings, and will be incorporated throughout this thesis. 
 
2.4.1.2 Reflexivity 
Reflexivity is an important consideration when undertaking qualitative methods 
of research, when conducting interviews to generate data, and when analysing 
data.  Reflexivity requires the researcher to reflect on their ability to be truly 
unbiased when conducting the research, and to consider the effects of their bias 
on the study, as well as considering any subjective bias that may be present.  
Austin and Sutton (2014) refer to the process of reflexivity as the filters through 
which the research process – the way questions are asked, and data is gathered 
and analysed – is carried out, and emphasise the need to clearly articulate 
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reflexivity throughout communications (reports, presentations etc.) about the 
research (Austin and Sutton 2014). 
However, there are also established ways to minimise bias.  Reflexivity includes 
trustworthiness, as described above, but also includes techniques that 
encourage reflection, consistency of approach, equity, and fairness. Techniques 
and tools designed to minimise bias can be incorporated into research design.  
The use of topics guides and interview schedules, for example, can help 
consistency and can be checked for subjective bias in advance (Creswell 2014).  
Tools and techniques that have been used in a study should be clearly described 
(Austin and Sutton 2014).  Reference to reflexivity, and steps taken to address 
this, will be included throughout this thesis. 
 
2.4.2 Sampling strategies in qualitative research 
When designing research, the strategy by which the sample is selected should 
be considered, and reported on.  Within qualitative research, there are three 









Convenience  Purposive Snowballing 




population with a 
particular goal or 
purpose in mind 
Uses original small 
sample to 
propose/connect to 
others that meet 
criteria 


















response.  Limits 
transferability 
 
2.4.3 Sample size in qualitative research 
Whilst statistical models are not generally applied in qualitative research, there 
must be a process by which a suitable sample size is determined. The sample 
size must be adequate for the research to have meaning, but not be inhibitory in 
terms of workload, nor of researcher and participant time.   
The subject of sample size has been much discussed in the literature, with 
debate about whether sample size can be determined a priori or whether it is 
better to be adaptive, for example, using the data saturation approach (Baker, 
Edwards and Doidge 2012; Rosenthal 2016; Sim et al 2018).  
Sim et al (2018) propose four approaches to determining sample size in 
qualitative research – rule of thumb, conceptual, numerical and statistical.  If 
considering rule of thumb, then the sample size in qualitative research will 
depend to a certain extent on the type of research design selected (Sim et al 
2018). Narrative or case studies would be expected to have an intensive study 
of one to five participants. Phenomenological studies involving focus groups or 
interviews typically three to ten. (Creswell 2014).   
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In phenomenological studies, where semi-structured interviews are utilised, 
reference is often made to reaching ‘data saturation’.  This is a conceptual 
model, and is the point at which there are no new emerging themes, findings, or 
concepts.  So, in deciding sample size, an estimate is made of the sample size 
that would be expected to give an adequate sample, using ‘rule of thumb’ (Sim 
et al 2018).  To assure data saturation, an estimate is then made of how many 
further participants will be interviewed if new themes emerge at that point. This 
is referred to as stopping criterion (Francis et al 2010), and can be represented 
as N+n sampling, where N is the initial analysis sample, obtained using the a 
priori ‘rule of thumb’ estimate for the sample size, and n indicates the stopping 
criterion.   
Francis et al (2010) recommend that the initial analysis sample is set at ten for 
research that involves two or three stratification variables (e.g. age, gender), 
and states that it is necessary to describe stopping criterion in advance, by 
stating the number of further interviews that will take place after the initial ten 
(Francis et al 2010).  To achieve data saturation therefore, sampling requires 
oversubscription of participants at recruitment, or keeping reserve participants, 
to avoid a time lag in recruitment of additional participants, and the potential the 
lag has for introducing bias. For example, there may be offline discussion about 
the topic, or practice or processes may have changed in the interim.   
With conceptual models, there is a suggestion that the sample size should also 
consider the scope of the research and the quality of the data.  For example, 
where the research has a less developed theory, the sample size may need to be 
larger to produce robust data (Guest, Namey and McKenna 2017; Sim et al 
2108).  
Reference to how sample size was determined, and the rationale for 
determination will be included in description of the research design for this 
study. 
 
2.4.4 Data generation in qualitative research 
Qualitative research involves collecting information from participants to generate 
data (Robson 2011).  This information can be verbal or written, and is a form of 
inquiry using questioning. Focus groups and interviews when used as methods 
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will both require that the type of question used to generate data be considered 
in advance.   
2.4.4.1 Question types used in qualitative research 
There are three basic types of question used in qualitative interviews: main 
questions, probes, and follow up questions (Bowling 2014).  A main question will 
begin and guide the conversation, and ask questions like ‘describe how...?’ or 
‘what happened when..?’.  Probe questions then aim to clarify answers given to 
a main question, and seek further detail or clarity, and use questions like ‘can 
you tell me more about…?’, or use pauses, or a simple enquiring ‘yes…?’.  A 
follow up question is used to pursue the implication and meaning of a main or 
probe question, and might ask ‘what do you mean by…?’ or ‘can you tell me 
more about...?’  
The different question types, particularly main and follow up, frequently employ 
open ended questions, and then utilise follow up prompts. There are six types of 
open-ended question (Table 2.6); experience or behaviour, sensory, opinion or 
value, knowledge, feeling and background and demographic.  
 




Explanation and example 
Experience or 
behaviour 
Should reflect a direct observation that could have been 
made by watching interviewee 
‘How would you approach this task?’ 
Sensory Focusses on things physically experienced (and may 
prompt other memories) 
‘When that happened, did you experience a physical 
reaction?’ 
Opinion or value Checks participants understanding of a phenomena or 
experience and provides insight into their goals and 
intentions 
‘Would you say that x has had a positive or negative 
impact on your situation?’ 
Knowledge 
 
Provides factual information 
‘Do you know what the policy for x is?’ 
Feeling Describes an emotion  
‘What emotion did that situation evoke?’ 
Background or 
demographic 
Characterisation of participants 




Each type of open-ended question has a different function in an interview or 
focus group discussion, and understanding this is important when designing the 
topic guide or interview guide.  Where a theory is used to design the topic guide 
or theory, there may be pre-existing interview guides or adaptable 
questionnaires, or the theory may lend itself to using certain types of open- 
ended question to obtain information. 
 
2.4.4.2 Interviews and focus groups in qualitative research 
Interviews may be conducted with an individual or with a group, for example in 
a focus group discussion.  There are three different interview methods: 
structured, semi-structured, unstructured (sometimes called open).   
A structured interview has the ability to incorporate a theoretical framework, but 
is less likely to be inductive and may be subject to framing bias.  The structured 
interview will often use fixed wording and be delivered in a predetermined order. 
Structured interviews may use some open-ended questions during the interview, 
which distinguishes it from a quantitative survey questionnaire (Robson 2011; 
Bowling 2014).   
Semi-structured interviews will use an interview guide, which will detail the 
topics that the interviewer wants to cover, and may have standardised wording.  
However, there will be a flexibility in approach to question order, depending on 
responses from the interviewee, and probe and follow up questions are asked 
where necessary, but may not necessarily form part of the interview guide. A 
semi-structured interview can incorporate a theory or theoretical framework in 
the design of the interview guide, allowing certain topics to be explored in some 
depth (Creswell 2014).  A semi-structured interview will take longer to conduct 
than a structured interview, which may be a barrier if the sample size is large 
(Robson 2011; Bowling 2014).  There are disadvantages to having an interview 
guide: if kept to rigidly it could direct and steer interviews around those topics 
the researcher had preconceived views on, rather than being flexible, and thus 
introduce bias (Robson 2011). 
Unstructured interviews are generally employed when an inductive approach is 
desirable, and are more likely to be used in focus group discussions than 
structured or semi-structured interviews. An unstructured interview has the 
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potential to explore topics and give personal insight, and will often have a topic 
guide outlining the general area of interest rather than a predetermined set of 
questions.  Unstructured interviews have been described as ‘guided 
conversations’ (Robson 2011), and have the potential to obtain in-depth and 
sensitive information, and, when used in one to one interviews, of uncovering an 
interviewee’s private account of their feelings, attitudes and behaviours (Bowling 
2014).  
The interview process has been described as having six stages: the arrival, 
introduction, commencement, during, ending and afterwards stages (Ritchie and 
Lewis 2006). In addition, it is known that the personal attributes of the 
interviewer will have an impact on the conduct of the interview and the findings. 
Some of the attributes that make a good interviewer include being a good 
listener, having a logical mind, having curiosity, creating rapport, being calm and 
being credible. (Ritchie and Lewis 2006).  In addition, there are a number of 
techniques that the interviewer should be cognisant of when conducting 
interviews in qualitative research that can help to reduce bias (Ritchie and Lewis 
2006; Bowling 2014):  
• Careful wording (avoiding leading questions, or influencing the response) 
• Avoiding assumptions (not assuming answers will be the same to different 
questions) 
• Avoiding misunderstandings and uncertainty (adjusting wording rather 
than suggesting a response) 
• Using probing techniques (repeating question, pausing and expressing 
neutrality to allow the interviewee to reflect) 
• Redirecting (bringing the interview back to topic) 
Techniques used in interviews can be learned as skills, and personal attributes 
enhanced through consideration and reflection, in order to ensure that the 
interview process proceeds as intended and gives optimal data. 
 
2.4.5 Data collection and analysis in qualitative research 
This section will describe the method and purpose of data analysis. In qualitative 
research, the purpose of data analysis is to make sense out of text.  To achieve 
this, data is taken apart, dissected and examined in detail. With the quantity of 
data collected from qualitative interviews with multiple participants, or from 
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focus groups, there must be some form of narrowing or ‘winnowing’ of the data, 
and a process of selecting some data and disregarding other (Creswell 2014).  In 
this phase, the researcher must be particularly mindful of reflexivity.   
Different types of qualitative research by their nature will have different outputs 
and this will lead to different styles of data collection, data analysis and data 
presentation. Table 2.7 revisits the different types of qualitative research, as 
described in Section 2.3, and describes the anticipated data output, which in 
turn dictates the way the data is presented: 
 
Table 2.7 Anticipated data output for different types of qualitative research 
(adapted from Robson 2011; Bowling 2014) 
Research type Anticipated data output 
Narrative research 
 
re-tell participants’ stories using structural 
devices (plot, setting, activities, 
denouement).  Often includes long sections 
of narrative 
Grounded theory research Generates categories of information by open 
coding, selecting a category and positioning 




Describes the setting and/or individuals and 
then analyses the data for themes or issues 
Case study research 
 
Describes the setting and individuals and 
then analyses the data for themes and 
issues 
Phenomenological research Analyses significant statements, generates 
‘meaning’ units and creates ‘essence’ 
description 
 
For qualitative research, the process of data collection and analysis has five 
phases: firstly, collecting the data, next becoming familiar with the data, sorting 
or coding the data, interpreting the data and finally representing the themes; 
these five phases are described here: 
 
2.4.5.1 Data organisation: collecting, organising and transcribing data  
Data is generally collected in qualitative research by interviews, either individual 
or group, and is collected by taking notes, audio recording or video recording, or 
a combination of these means (Ritchie and Lewis 2006; Robson 2011). However, 
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the most frequently used method is audio recording using an audio recording 
device to generate audio files. 
The large amount of data generated by qualitative interviews needs to be 
organised, in order to facilitate analysis, and the first step is to transcribe audio 
output to the written form.  There are three types of transcription – verbatim, 
intelligent verbatim and clean.  Verbatim transcription includes hesitations, 
pauses, and other details of interaction, either with the interviewer or with other 
participants in a group setting.  Alternatives to verbatim transcription include 
intelligent verbatim, where only relevant pauses or details like interruptions are 
recorded, or ‘clean’ transcript, which is merely a recording of the spoken words 
(Robson 2011).  Transcription from a group setting interview like a focus group 
is complex, since there are multiple voices.  In addition, the interaction between 
participants is an important feature of a focus group, and should therefore be 
noted and recorded (Robson 2011), so verbatim transcriptions are deemed most 
appropriate, and a clean transcript is not considered adequate. The time taken 
to transcribe verbatim focus group discussions can take eight to ten hours per 
hour of audio (Sutton and Austin 2015), depending on the skill of the 
transcriber, and this is a consideration when planning qualitative research. 
After data transcription, data must be organised in a way that facilitates analysis 
and interpretation.  There are different means of doing this: using Microsoft 
word documents or tables, using excel documents, and creating individual or 
linked files, or by using computer assisted qualitative data analysis software 
(CAQDAS), of which NVivo™ is an example.  
 
2.4.5.2 Data analysis: initial familiarisation 
Familiarisation with the data is a key stage in data analysis, and starts with 
accessing audio files to listen back to the interviews or focus groups discussions 
prior to carrying out transcription.  Familiarisation continues throughout the 
analysis process, with reading and re-reading of transcripts to become 
embedded in the data, and to become familiar with key illustrative quotes and 





2.4.5.3 Data analysis: coding data into themes 
The process of coding data into themes will vary depending on what mode of 
analysis is being used. Bowling describes three possible methods of data analysis 
from gathered data: thematic, content or framework analysis (Bowling 2014). 
Thematic analysis: thematic analysis focuses on examining themes or patterns 
of meaning within data.  Thematic analysis emphasises both the organisation 
and the rich description of the data set, and has theoretically informed 
interpretation of meaning.  In thematic analysis, inductive coding occurs, and 
the researcher will, through familiarisation, establish emerging codes and 
themes through examination of the transcripts, will document these codes and 
themes and look for relationships between them. 
Content analysis:  in content analysis, data are collected, coded by theme or 
category and the coded data analysed or presented.  Content analysis is often 
seen as simplistic analysis. 
Framework analysis: in framework analysis, a thematic framework is 
identified which reflects study aims as well as key themes from the data. 
Where a framework is used, the codes are predetermined, and sections of text 
can be bracketed against a code.  This can be done in Microsoft word or excel 
documents, or using CAQDAS.  Framework analysis is a useful tool to use where 
there are multiple researchers, where there are large data sets, and as a space 
where new researchers can learn and develop their skills (Gale et al 2013; 
Bowling 2014).  Bowling claims that framework analysis is more informed by the 
reasoning of existing knowledge than thematic or content analysis (Bowling 
2014). 
 
2.4.5.4 Data analysis: interpreting themes 
Interpretation is the process whereby broader themes are identified from the 
data.  Interpretation may be made in relation to the framework categories, 
where framework analysis is used.  At this stage in the data analysis process the 
researcher must be particularly mindful of trustworthiness and reflexivity in their 
interpretation of the data set, as described earlier, and seek to represent the 




2.4.5.5.  Data presentation: representing themes 
The process of gathering data which represents the findings starts with 
familiarisation, and the identification of key quotes, and continues throughout 
the coding process.  The researcher will establish concordant and recurring 
themes, and represent these with representative exemplar quotes.  In addition, 
the researcher may, depending on the findings, represent discordant themes, as 
a means of demonstrating the breadth of the findings, and the variation of the 
views of participants.  In qualitative research, themes are generally represented 




2.5 The use of theory in research 
A theory, in research terms, has been described by Creswell (2013) as a 
scientific prediction or explanation for what the researcher expects to find 
(Creswell 2013). Stewart and Klein (2016) assert that researchers should 
consider the theoretical basis for their studies at planning: they state that the 
use of theory enhances robustness and rigour, as well as the relevance and the 
impact of the findings, when applied correctly. In addition, it is acknowledged 
that using theory can connect pieces of research data to other studies, and thus 
build impact academically, in terms of understanding, by using a common 
language across disciplines (Stewart and Klein 2016). However, there are 
challenges when selecting a theory.  There are many theories to choose from, 
and the array can be confusing with little consensus on which theories are fit for 
purpose (Stewart and Klein 2016).   Theory selection should be reliably informed 
and justified, and that requires some knowledge and awareness of the different 
types of theory, and how they can be used in research in different fields of 
science. 
Nilsen (2015), within the field of implementation science, states that theory can 
help guide the process of translating research into practice (process models), in 
evaluating implementation (evaluation frameworks), or can be used to 
understand what influences implementation, for example of a change of practice.   
Determinant frameworks, classic theories or implementation theories can be 
used to understand factors that influence implementation (Nilsen 2015). 
Changes to existing practices or new practices require changes in both individual 
and collective behaviour (Atkins et al 2017; Cane et al 2012) and the application 
of theory can be used, either to guide the change, to evaluate the change or to 
better understand factors influencing the implementation of the change. 
Within the literature, theories can be referred to using a variety of terms: 
theoretical lens; theoretical perspective; theoretical framework; conceptual 
framework; and conceptual model (Osanloo and Grant 2016; Creswell 2014; 
Maxwell 2012).  Nilsen (2015) attempts to explain the difference between 
theory, models and frameworks, with reference to implementation science, as 




Table 2.8 Differences between theory, model and framework  (adapted from 
Nilsen 2015) 
Construct  Description 
Theory Aims to explain how and why specific relationships (or 
variables) lead to specific outcomes. 
They aim to structure our understanding and explanation of 
the world 
Model Often described as a theory with a narrower definition of 
explanation.  It is descriptive rather than explanatory 
Framework Consists of various constructs, concepts or variables, with the 
relationship between them being assumed to account for the 
phenomenon. Frameworks describe phenomena by fitting them 
into a set of categories.  They do not provide explanation.  
 
2.5.1 Theory selection 
Selection of the appropriate theory, model or framework will depend on the 
ontological and epistemological stance of the researcher and the context and 
purpose of the research. It is acknowledged that in selecting a theory, model or 
framework, certain assumptions about the likely findings will be made that will 
influence the outcome of the research.  For example, does the research aim to 
understand the behaviour of individuals, or is it the organisational climate and 
culture which will determine outcomes? The process of selection will start with 
an understanding of the research purpose: is it to understand process (process 
model), evaluation (evaluation framework) or understand influences 
(determinant frameworks)? (Nilsen 2015).  Taking account of, and declaring 
these assumptions and considering the context and setting ensures that the 
theory, model or framework selected will enhance the research findings. 
A theory, model or framework can be used at different stages within a research 
study, and Birken et al (2017) describe twelve points at which theory can be 




Table 2.9 The use of theory by researchers (adapted from Birken et al 2017) 
 Theory can be used: 
1 To identify key constructs that may be barriers or facilitators 
2 To enhance concept clarity 
3 To clarify terminology 
4 To convey the wider context of the study 
5 To inform data collection 
6 To inform data analysis 
7 To specify outcomes 
8 To frame an evaluation 
9 To guide an implementation plan 
10 To guide the selection of implementation strategies 
11 To specify the process of implementation 
12 To specify hypothesised relationships between constructs 
 
In addition to describing when a researcher might use theory, Birken et al 
(2017) cite various criteria used by researchers when selecting which theory to 
use.  The criteria were developed by conducting a survey of 223 implementation 




Table 2.10 Criteria used by researchers when selecting theory (adapted from 
Birken et al 2017) 
 Criteria used by researchers 
1 Analytical level 
2 Logical consistency/plausibility 
3 Description of change process 
4 Empirical support 
5 Generalisability 
6 Application to specific setting 
7 Inclusion of change strategies/techniques 
8 Outcome of interest 
9 Diagrammatic representation 
10 Associated research methods 
11 Process guidance 
12 Disciplinary approval 
13 Explanatory power/testability 
14 Simplicity/parsimony 
15 Specificity of causal relationships among constructs 
16 Familiarity 
17 Degree of specificity 
18 Accessibility 
 
Understanding implementation, and the barriers and enablers or facilitators to 
implementation is important when designing research that is to be applied in the 
real world. Frameworks, specifically determinant frameworks, aim to understand 
and explain some of the influences on implementation, either by predicting 
outcomes, or by interpreting outcomes retrospectively.  Barriers and enablers 
are independent variables; implementation outcomes are dependant variables.   
Examples of determinant frameworks that aid in the understanding of 
implementation include Diffusion of Innovation Theory, (Rogers, 2003), 
Promoting Action on Research Implementation in Health Services (PARiHS) 
(Rycroft-Malone 2010) and the Theoretical Domains Framework (TDF) (Cane et 
al 2012).  The TDF will be discussed in detail later in this chapter. 
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Determinant frameworks, for example Normalisation Process Theory (NPT) 
(McEvoy et al 2014), TDF and the COM-B model (Michie, Van Stralen and West 
2011), have been widely used as evaluation frameworks.  The ability of the TDF 
to be used both to understand influences and to evaluate implementation makes 
it a good candidate to use in health service research. 
 
2.5.2. Applications of theory in pharmacy practice 
Theories used in pharmacy practice research may come from the fields of 
psychology, sociology, anthropology, organisational theory, implementation 
science and biomedical sciences (Stewart & Klein 2016; Donyai 2012, Nilsen 
2015).  Implementation science is concerned with the challenges associated with 
the translation of research into practice in healthcare.  Implementation science 
recognises the benefits of using theoretical models and frameworks to help 
understand implementation, and to make interventions more likely to succeed, 
and uses behaviour change theories as underpinning. 
Guidance from the Medical Research Council (MRC) (Craig et al 2008) on 
designing complex interventions has provided further support for the use of 
theory.  The MRC guidance stresses the importance of using behaviour change 
theories to underpin intervention development, in order to strengthen the 
intervention and to enable proper evaluation of the success of implementation. 
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2.6 The Theoretical Domains Framework (TDF) 
With the availability of many social and psycho-social theories it can be difficult 
for researchers to decide which would be optimal, when the data is not yet 
available.  TDF has the advantage of being suitable for use both in design and in 
analysis, and having the ability to help understand behaviours and behavioural 
determinants, which can then be mapped to behavioural change and 
implementation. Additionally, TDF has been extensively validated as a research 
tool in healthcare research (Cane et al 2012; Phillips et al 2015 ).  Several of the 
criteria cited by Birken (Table 2.10) apply to the use of the TDF, including but 
not limited to: description of the change process and the inclusion of change 
strategy techniques, accessibility, and familiarity. 
 
2.6.1 Theoretical Domains Framework (TDF) background and applications 
The Theoretical Domains Framework (TDF) is not a single theory as such, but an 
integrative theoretical framework developed in the fields of implementation and 
behaviour change research by psychology theorists (Cane et al 2012).  The 
framework was developed from 33 different theories of behavioural change, 
which comprised 128 different constructs.  The TDF consists of 14 domains, 





Table 2.11 The 14 Domains of the TDF (adapted from Cane et al 2012) 
 Domain Expansion Example or construct 
1 Knowledge Awareness of existence of 
something 
Procedural knowledge, 
process or task 
knowledge 
2 Skills Ability or proficiency 





role and identity 
Behaviours at work Professional confidence, 
professional boundaries, 
group identity 
4 Beliefs about 
capabilities 
Acceptance of truth, reality 
or validity of an ability 




5 Optimism Confidence in system Optimism or pessimism 
6 Beliefs about 
consequences 
Acceptance of truth, reality 
or validity about outcome 
of an action or behaviour 




7 Reinforcement Increasing probability of 
response by planning 
Rewards, incentives, 
sanctions, punishments 
8 Intentions Conscious decision to act a 
certain way 
Stability of intentions, 
stages of change 
9 Goals Mental image of outcome Goal or target setting, 
action planning 
10 Memory attention 
and decision-
making 
Retain information and 







Anything that influences 
positively or negatively 





12 Social influences Anything that influences 
changes in behaviours and 
actions 
Social pressures, social 
norms, power conflict, 
group identity 


















The aim of the theorists when creating an integrative theoretical framework was 
to simplify the process by which behavioural change theory could be applied, 
and make it accessible to a wider range of disciplines across healthcare, as a 
means of understanding the behavioural changes that can act as barriers or 
facilitators when planning or implementing changes in practice.  The TDF has 
also been used in qualitative studies to guide the development and design of, for 
example, interview guides (Duncan et al 2012), and has been used extensively 
in the analysis of qualitative data, for example audio recordings from interviews 
(Phillips et al 2015). 
The framework has been used to identify barriers and enablers to the 
implementation of evidence-based interventions that require a change in 
behaviour since the framework identifies behavioural determinants. From this 
understanding of barriers and enablers, theory-based interventions can be 
developed that may help to achieve the desired behaviour change.  In the UK, 
the TDF it has been used to evaluate campaigns for hand hygiene (Dyson et al 
2013) and in antibiotic governance to examine the influences on the prescribing 
of antibiotics in general practice (Fleming et al 2012). TDF has also been applied 
to investigating behaviours that influence prescribing errors (Duncan et al 2012).  
In pharmacy practice research, TDF has been used to explore the barriers to 
reporting adverse drug events by nurses and pharmacists (Mirbaha et al 2015), 
and to explore the beliefs’ of pharmacists on their research capabilities (Stewart 
et al 2019); the latter study used TDF in questionnaire design, as well as in 
analysing free text responses.  The electronic cross-sectional survey of 
pharmacists explored the experiences and confidence of pharmacists with 
research, and at the conduct, dissemination and translation of research.  It 
found few pharmacists were involved in research conduct, nor dissemination 
(published research) and, using TDF during qualitative analysis, found that the 
domains of environmental context, and of knowledge featured dominantly in 
responses.  TDF was then used to suggest what interventions might be 
successful in addressing barriers uncovered by the research. The study therefore 
used TDF both in design and in analysis.  
As TDF is a framework, not every domain will necessarily be relevant in all 
research.  For example, in a study on antibiotic prescribing (Fleming et al 2012) 
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using TDF, researchers opted to apply five pre-selected domains (environmental 
context and resources, knowledge, social influences, beliefs about consequences 
and memory attention and decision-making), to their topic of study, from the 
stage of development of the topic guide.  In a study on prescribing errors 
amongst trainee doctors, Duncan et al (2012) described how they had omitted 
optimism, goals, emotion and reinforcement in their analysis, as there were 
either insufficient references made to these domains by participants or where 
present, the domain reference did not add to the body of knowledge (Duncan et 
al 2012).  There is therefore the potential for the domains that are dominant to 
emerge from the data when using TDF, and whilst these cannot be allocated a 
weight or statistical significance, it can allow different populations, settings or 
participants to be simplistically compared.   
 
2.6.2 Theoretical Domains Framework and behaviour change 
The link between TDF and behaviour change is well documented (Cane et al 
2015, Michie, Atkins and West 2014): the benefit of using TDF is that it can help 
guide individuals or organisations towards an optimum suite of techniques to 
apply to changing behaviours or making improvement.  To this end, researchers 
in behavioural change have designed a consultative tool, the behavioural change 
wheel, shown as a schematic (Figure 2.2), which links theoretical aspects of 
behaviour change with the components needed to make sustained change.  The 
behaviour change wheel is based on the understanding that the framework for 
comprehending behaviour consists of three elements – capability, opportunity 
and motivation. These three elements interact collectively to influence the 
likelihood of behaviour change, and the model is known as the COM-B model 
(Michie, Van Stralen and West 2011).  This model of behaviour recognises that 
changing one or more elements puts the system or process under investigation 






Figure 2.2. The behaviour change wheel COM-B model of behaviour change (creative commons, 
Michie et al 2011) 
 
Using the schematic (Figure 2.2), the elements of behaviour change - capability, 
opportunity and motivation - can be evaluated and assessed, consideration 
made of which element (capability, opportunity or motivation) may need to 
change, and a suitable intervention identified.  The intervention can be identified 
from the behaviour change wheel, using an intervention function from one of the 
nine interventions outlined in the red sections in the behaviour change wheel 
(Figure 2.2).  Michie, Van Stralen and West (2011) provide definitions for the 
nine different behaviour change interventions (Table 2.12): 
 
Table 2.12 Behaviour change interventions (adapted from Michie, Van Stralen and West 2011) 
Intervention Definition 
Education Increasing knowledge or understanding 
Persuasion Communicating to induce positive or negative emotions, 
and resultant action 
Incentivisation Creating an expectation of reward 
Coercion Creating an expectation of punishment 
Training Passing on skills 
Restriction Creating rules to decrease or increase behaviour 
Environmental 
restructuring  
Change of the physical and/or social context 
Modelling Providing examples to imitate or aim for 




The outer (grey) wheel of the behaviour change wheel (Figure 2.2) consists of 
policy and fiscal changes which can be established, or amended, to support the 
interventions. 
A corresponding behaviour change technique (BCT) taxonomy has been 
developed in order to standardise the content and reporting of intervention 
studies, and to assign BCTs to the TDF domains (Michie, Atkins and West 2014; 
Cane et al 2015).  This taxonomy, shown in Figure 2.3, can be used to identify 
behavioural changes that will map to the TDF domains, to provide the most 
effective interventions, with the best likelihood of success when implemented.   
 
 
    
 
 
Figure 2.3 How TDF domains relate to COM-B components (Creative commons; 




Figure 2.3 also shows how each of the components of the COM-B model – 
capability, motivation and opportunity- can be further divided.  Capability can be 
physical or psychological, opportunity can be physical or social; motivation can 
be reflective or automatic; opportunity can be social or physical.  Not all of the 
sub-components will be relevant in all situations and contexts; physical skill and 
cognitive and interpersonal skills are grouped together as ‘skills’ in TDF, for 
example. 
Using the behaviour change wheel, and with an understanding of how COM-B 
and TDF are related allows behaviour change interventions that are likely to be 
effective to be suggested for each of the TDF domains (Michie, Atkins and West 
2014).  The nine intervention functions are defined, and the behaviour 
technique(s) or policy intervention(s) that are most likely to be appropriate and 




Table 2.13 Behavioural change intervention definitions and behaviour change techniques (adapted from Michie, Atkins and West 2014) 
Intervention Definition Suggested behaviour change technique Policy categories for change 
Education Increasing knowledge or 
understanding 
Information and awareness; Feedback on 
behaviour/outcome of the behaviour; prompts 




Persuasion Communicating to induce 
positive or negative 
emotions, and resultant 
action 
Credible source; information about social and 
environmental consequences; feedback on 





Incentivisation Creating an expectation of 
reward 
Feedback on behaviour; feedback on outcome of 
behaviour; monitoring of behaviour by others 





Coercion Creating an expectation of 
punishment 
Feedback on behaviour; monitoring of behaviour 
of others without evidence of feedback; 
feedback on outcome of behaviour; monitoring 
outcome of behaviour by others without 





Training Passing on skills Demonstration/instruction of the behaviour; 
feedback on behaviour; behavioural rehearsal or 
practice; self-monitoring 
Guidelines; fiscal measures; 
regulation  
Restriction Creating rules to decrease 
or increase behaviour 
No BCT are linked because this intervention 
function is focussed on changing the way that 




Change of the physical 
and/or social context 
Adding objects to the environment; prompts and 
cues; restructuring the physical environment 
Guidelines, fiscal measures, 
regulation; environmental 
planning 
Modelling Providing examples to 
imitate or aim for 
Demonstration of the behaviour Communication/marketing 
Enablement Reducing barriers to 
increase opportunity or 
capability 
Goal setting; adding objects to the environment 
or restructuring; problem solving; action 
planning; self-monitoring of behaviour; review 






The behaviour change intervention types described in Tables 2.12 and 2.13 can 
be related to the 14 TDF Domains, as summarised in Table 2.14 (Michie , Atkins 
and West 2014). This table is a useful tool to use when making 
recommendations for interventions, where study findings have been mapped to 
the TDF domains. 
 
Table 2.14 TDF domain and associated behaviour change techniques (adapted 
from Michie, Atkins and West 2014) 




role and identity 
Education; persuasion; modelling 
Beliefs about 
capabilities 
Education; persuasion; modelling; 
enablement 




Education; persuasion; modelling 
Reinforcement Training; incentivisation; coercion; 
environmental restructuring 
Intentions Education; persuasion; modelling; 
incentivisation; coercion 
Goals Education; persuasion; incentivisation; 









Training; restriction; environmental 
restructuring; enablement 
Social influences Restriction; environmental restructuring; 
modelling; enablement 




Education; training; modelling; enablement 
 
Being able to link the findings of qualitative research to an implementation plan 
that has been verified and validated is advantageous.  In professional practice 
research, with its emphasis on local implementation and impact, the behaviour 




Selection of methods to be used in research require careful consideration to 
ensure that they meet study requirements, are robust and are deliverable.   
The researcher reflected on the underpinning philosophy behind research, and 
considered aspects of different methods, theories and techniques when 
considering the development of the research study.  As a novice researcher, this 




2.7 Alignment of research methods to research methodology for this professional 
practice research 
This section will outline how the philosophy of research methodology was used 
to develop the protocol, research question and objectives for the research 
undertaken. 
 
2.7.1 Linking methodology to the aims and objectives of this research 
In selecting an appropriate research methodology when conducting research (in 
this instance professional practice research), the philosophical viewpoint of the 
researcher, the required research outcomes and the research question and 
objectives should all be considered. 
This research study is described by the title ‘A theoretical exploration of hospital 
clinical pharmacists’ perceptions, experiences and behavioural determinants in 
relation to provision of optimal and suboptimal pharmaceutical care’.  The study 
has taken as its research question: 
How do hospital clinical pharmacists perceive and experience suboptimal 
pharmaceutical care? 
The research question elicited aims, and for Phase 1 the study aim was: 
1. To explore, using focus groups, the perceptions of hospital clinical 
pharmacists to optimal and suboptimal pharmaceutical care. 
The objectives designed to support this aim are outlined in Chapter 3. 
The aims for Phase 2 were  
1. To explore pharmacists’ experiences of the provision of optimal and 
suboptimal pharmaceutical care within their practice 
2. To explore the behavioural determinants relating to the provision of 
optimal and suboptimal pharmaceutical care using the Theoretical 
Domains Framework. 
The objectives designed to support these aims are outlined in Chapter 4. 
Considering these aims, and taking, as a researcher, an external viewpoint on 
the experiences of hospital clinical pharmacists, and with a constructivist stance, 
a phenomenological inquiry, using a theoretical framework to understand the 
behaviours of hospital clinical pharmacists was selected.  Phenomenological 
85 
 
inquiry is described as:  ‘A design of inquiry…in which the researcher describes 
the lived experiences of individuals about a phenomenon as described by 
participants’ (Creswell, 2014) 
Reflecting on the philosophical worldview of the researcher, and adapting Table 
2.1. to include researcher worldview helped the researcher to understand and 
communicate the purpose of this research and its philosophical stance, and this 
is described in Table 2.15: 
 
Table 2.15 Research philosophy and researcher worldview (adapted from 
Creswell 2014) 
Research term Simplistic definition Researcher worldview 
Ontology The reality that research 
aims to understand by 
investigation 
Clinical pharmacists are not 
recording ‘errors’ within 
pharmaceutical care delivery 
Epistemology The relationship between the 
stated reality and the person 
carrying out the research 
Researcher as an outsider but 
‘interested party’ wanting to 
understand the phenomenon 
Axiology The role of the researcher’s 
own value on the research 
process 
Researcher believes learning from 
error and reflective thinking 
important for quality management, 
quality improvement and 
professionalism 
Methodology The technique(s) used by the 
person carrying out the 
research to investigate the 
reality 
Asking those who ‘live that life’ for 
their perspectives and experiences 
to better understand their world 
 
The researcher should consider the description and communication of their 
research from the outset. The PICO tool (population, intervention, comparison, 
outcome) is useful when developing and describing quantitative research 
protocols (Richardson et al 1995). However, this research is qualitative and the 
acronym SPIDER has been suggested as a descriptive tool for qualitative 
research (SPIDER=Sample, phenomenon of interest, design, evaluation, 
research type) (Cooke, Smith and Boothe 2012).  These descriptive tools have 
been developed to assist in literature searches or systematic reviews. It is 
beneficial therefore to ensure the descriptive information is easily accessible 
when designing or describing qualitative research, and therefore either included 
in the title or used as key words. The application of the SPIDER tool to this 




Table 2.16 SPIDER tool application to the professional practice research study 
(adapted from Cooke, Smith and Boothe 2012) 
   
S Sample Hospital clinical pharmacists within organisation 
PI Phenomenon 
of interest 
Suboptimal pharmaceutical care, and why it is not 
being reported or shared 
D Design Qualitative by focus group and interview 
E Evaluation Inductive, mapping to TDF, looking for emerging 





2.7.2 Justification of research method choice for the professional practice 
research undertaken 
As a professional practice doctorate student, the desire to understand the 
behaviour of hospital clinical pharmacists emerged from the researcher’s role 
within the workplace.  During early literature reviews it became apparent that 
there was paucity of description of the specific phenomena of interest, that 
being, as described in Chapter 1, the delivery of suboptimal pharmaceutical 
care.  It was also apparent that this terminology was novel, and this influenced 
research design. 
Firstly, there was a need to consider whether hospital clinical pharmacists would 
perceive and understand the term suboptimal pharmaceutical care in the way 
that the researcher intended.  Methodologies for garnering understanding of 
perception include qualitative interviews (Bowling 2014), and options for the 
type of qualitative interview are outlined in section 2.2.2.  Semi-structured or 
open questions support the desire to understand perceptions of a concept 
(Bowling 2014; Kitzinger 1995), and a group setting would enable collusion and 
input from others in building understanding (Bowling 2014).  Therefore, for 
Phase 1 of the study, focus group discussions was selected as the method.  
Since the research was embedded within the researcher’s organisation, sampling 
was convenience and purposive, within the NHS Scotland organisation. The 
description of the methods used and the subsequent findings are described in 
Chapter 3.  
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A topic guide was designed, using the input of local clinical pharmacy experts. 
The proposed framework for analysis was chosen as the Theoretical Domains 
Framework (TDF), being a suitable framework for describing the understanding 
of the participants in relation to a concept.   
Secondly, once understanding of suboptimal pharmaceutical care was obtained, 
the researcher wanted to explore the experiences of the hospital clinical 
pharmacists in relation to suboptimal pharmaceutical care, and understand more 
about their behaviours in relation to this.  To achieve this, qualitative interviews 
were selected as a method for Phase 2, using in-depth individual interviews to 
allow disclosure of experiences in a safe setting, (Bowling, 2014). Since 
individuals are known to have both a ‘public account’ and a ‘private account’ of 
their views (Bowling 2014; Robson 2011), this provided further support to the 
use of individual interviews in this phase of the research. 
Using a theoretical framework to construct a semi-structured interview schedule 
gives more robust data (Stewart and Klein 2016; Duncan  et al 2012; Phillips et 
al 2015).  The theoretical framework chosen as being optimal to understand 
behavioural determinants was the Theoretical Domains Framework (TDF), and 
was selected for its ability for use both in design and analysis. The description of 




2.8 Research governance and approval 
This section will briefly outline research governance principles and demonstrate 
how these were applied to the planned research study. Further, this section will 
outline the research approval processes that were required to be met, and 
demonstrate how approval was sought and granted. 
2.8.1 Research governance principles 
NHS Research Scotland (2017) describes research governance as ’the setting of 
standards to improve research quality and to safeguard the public’. Enhancing 
ethical and scientific quality, preventing poor performance and misconduct, 
promoting good practice, reducing adverse incidents, and ensuring lessons are 
learned all contribute to research governance (NHS Research Scotland 2017). 
Within the policy framework for health and social care research, the NHS Health 
Research Authority (HRA) outline principles that apply to all health and social 
care research, and outline the responsibilities of those involved (NHS Health 
Research Authority 2017).  In outlining the methodology, and by the rich 
descriptions of the methods used in the research in Chapters 3 and 4, the 
researcher aimed to demonstrate that research governance principles were 
adhered to. 
 
2.8.2 Research approval processes 
Research approval processes act as part of the research governance 
arrangements for a professional practice doctorate.  The researcher was required 
to meet the requirements both of the host university, Robert Gordon University, 
and their NHS Scotland organisation’s workplace, within which the study took 
place, and the processes and requirements are described separately here: 
2.8.2.1 Research approval- Robert Gordon University 
Research approval is described for Robert Gordon University in the Research 
Governance and Integrity Policy (Robert Gordon University 2014), and includes 
the requirement to prepare and submit a written protocol outlining the planned 
research with sections relating to: 
• Research team, including researcher expertise, and any training required 
• Research question, aims and objectives 
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• Background to study 
• Setting, sampling plan and inclusion and exclusion criteria 
• Proposed methods 
• Data collection and data analysis strategies 
• Data management strategies 
The preparation of the protocol assisted the researcher in structuring the study 
design and formed an integral part of research planning. Approval of the 
protocol by Robert Gordon University research ethics committee was sought.   
Approval was granted from the university (Ref S62; Appendix 2.1). 
 
2.8.2.2 Research approval – NHS Scotland organisation 
Approval was sought from the Caldicott guardian for the NHS Scotland 
organisation, and from the organisation’s Research and Development 
department, who confirmed that ethical approval was not required for this study, 
as it did not involve patients. (Ref NR/2003AB6; Appendix 2.2). 
To comply with the NHS Scotland organisations’ requirements, the protocol, 
along with the consent form (Appendix 3.2) and the participant information pack 
(Appendix 3.1), was submitted to the organisation’s Pharmacy Quality 
Improvement Team and approval was granted from this group (Ref QIT83: 
Appendix 2.3). 
 
2.9 Summary of Chapter 2 
This chapter has outlined research approaches from a theoretical perspective, 
and described techniques and tools used in research to generate and analyse 
data.  Furthermore, this chapter has described in detail the purpose, selection 
and use of theory in research, with specific reference to the Theoretical Domains 
Framework (TDF).  Next, the researcher reflected on the planned research and 
described and justified the methods that were adopted, and finally, considered 
research governance, and outlined how research approval was sought prior to 
research study commencement. 
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CHAPTER 3 Phase 1: Perceptions of hospital clinical 
pharmacists to optimal and suboptimal pharmaceutical 
care 
 
3.1. Introduction to Chapter 3 
This chapter will justify and describe the methods used for Phase 1 of the 
research, and will then present the findings from the Phase 1 study.  Phase 1 
was designed to explore hospital clinical pharmacists’ perceptions and 
understanding of the concepts of optimal and suboptimal pharmaceutical care.  
The Phase 1 study used focus groups to generate data relating to the 
perceptions of participants. The findings from the focus group were mapped to 
the Theoretical Domains Frameworks (TDF) to identify how hospital clinical 
pharmacists perceived barriers and enablers that influenced behaviour in the 
delivery of optimal pharmaceutical care. 
 
3.2 Research question, aims and objectives 
The overarching research question for this research was: 
How do hospital clinical pharmacists perceive and experience suboptimal 
pharmaceutical care? 
The aim of this Phase 1 study was: 
To explore, using focus groups, the perceptions of hospital clinical pharmacists 
to optimal and suboptimal pharmaceutical care. 
The supporting objectives were: 
1. To determine the perceptions of focus group participants to optimal and 
suboptimal pharmaceutical care using a topic guide to direct discussion. 
2. To determine whether the term suboptimal pharmaceutical care would be 
understood by participants, and represented by the findings. 
3. To map the findings from the focus groups to the Theoretical Domains 
Framework to understand the perceptions of participants. 
4. To use the theoretically mapped findings of the focus group to inform the 
next phase of the research. 
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3.2.1. Justification for use of focus groups discussions in study 
Focus group discussions as a method was selected as this phase of the research 
was exploratory, looking to understand in particular how clinical pharmacists 
would perceive the term suboptimal in relation to pharmaceutical care.   
The description of focus group discussions as a method was outlined in Chapter 
2, and describes the advantages and disadvantages of conducting qualitative 
interviews with a group of participants, rather than with individuals.   
The participants of a focus group are encouraged to interact with each other 
during discussion, and this interpersonal interaction is a feature of focus groups. 
Participants present their views, then listen to the contributions of others, reflect 
on their own views and may reframe their views in response to what they hear 
(Ritchie and Lewis 2006). As a group, discussions may lead to the stimulation of 
new ideas, and the refining of these ideas through discussion. Participants may 
thus identify shared concerns more rapidly than the use of the individual 
interview, and gain a better collective understanding of complex issues (Bowling 
2014).  The focus group setting allows a more naturalistic way through dialogue 
and conversation than an interview, and provides a way of understanding how 
the participants perceive, understand and experience the world around them 
(Ritchie and Lewis 2006). Focus group discussions can be used to examine ‘not 
only what people think, but how they think and why they think that way, as well 
as what their understanding is, and what priorities they have’ (Bowling 2014). 
Focus groups have been used to understand perceptions of the barriers and 
facilitators to implementation: a Canadian study used focus groups to determine 
barriers and facilitators to the implementation of clinical pharmacy key 
performance indicators (Minard et al 2016).  In the study, three focus groups 
were held, with twenty-six pharmacists.  Participants identified both barriers and 
facilitators and the findings were used to inform the wider implementation of the 
key performance indicators.  The study authors concluded that the focus group 
method was successful as ‘attitudes and perceptions are not developed in 
isolation, but through interaction with other people’.   
In the current study, the novel concept of suboptimal pharmaceutical care was 
being tested, to ascertain what hospital clinical pharmacists perceived the 
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concept to mean, when given the opportunity to discuss interactively in a focus 
group setting.  Taking part in focus group discussions can make participants feel 
that they are part of the research, which can enhance the impact of the research 
when the purpose is to establish new practices (Robson 2011).  This was an 
advantage in this study, as focus group discussions enabled a wider group of 
participants to engage with the research, who would then be aware of the 
research work when implementation was being proposed. 
A disadvantage of focus group discussions is that there is limited in-group 
confidentiality, with other participants being present, and this may inhibit some 
responses that relate to personal feelings or actions (Robson 2011). That was 
not considered a barrier in this Phase 1 study, as there would be an opportunity 
for individual input from participants in Phase 2. It has been reported that there 
may also be a reluctance by participants to express a dissenting opinion in a 
focus group (Kitzinger 1995), but that was not considered to be a barrier, since, 
as above, participants would have an opportunity for individual input in Phase 2.  
A practical disadvantage of the focus group discussion is that the data generated 
are difficult and time consuming to collect, process and analyse (Ritchie and 
Lewis 2006), as described in Chapter 2, and this will be discussed further on in 
this chapter, when consideration was made to adapting the method to suit the 
research purpose. 
The research team considered the advantages and disadvantages of focus group 
discussions as a method and concluded that focus group discussions were 
appropriate for this phase of the study. 
 
3.2.2 Justification for use of TDF in analysis of study data 
The use of a theory in the analysis of generated data was described in Chapter 
2, and included description of the benefits of theory when analysing qualitative 
data. Additionally, framework analysis was described as a means to manage and 
organise the data.  The process by which the data is analysed using a framework 
requires the researcher to obtain familiarisation with the data, coding or 
mapping to a thematic framework, and interpreting the data, all of which are 
required in qualitative data analysis; the use of framework analysis is a skill that 
the novice qualitative researcher should develop (Bowling et al 2014) .   
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The Theoretical Domains Framework (TDF), the chosen theoretical framework for 
this study, was described in Chapter 2.  The intention of this phase of the study 
was not to determine individual behavioural determinants, which is the 
conventional use of TDF (Cane et al 2012).  However, mapping of the data to 
TDF during analysis allows themes and subthemes to be extracted that help the 
researcher to understand the perceptions of participants, including barriers or 
enablers.  Perceptions are an antecedent of, and influence behaviours, and 
therefore use of the TDF is justified. In Phase 1, TDF was used in data analysis. 
The output from this phase of the research was intended to inform the design of 
the Phase 2 study. The Phase 2 study design incorporated TDF as the theoretical 
framework, and the research team therefore agreed that the use of TDF in Phase 
1 would be beneficial to the researcher as skill development, and for mapping 
and interpretation of the data generated, and the use of TDF is therefore 





Having outlined the justification for the use of focus groups as a qualitative 
method, and of use of TDF in the analysis of the generated data, this section will 
describe in detail how the study was designed, and executed, to meet the key 
aims of this phase of the research.   
 
3.3.1 Design of study 
This phase of the study, known as Phase 1, was underpinned by a qualitative 
research design, since the nature of the research question and objectives 
necessitated the collection of rich and meaningful data.  The research was 
grounded in constructivism, and used a phenomenological approach (see 
Chapter 2).  The study was designed to provide data that would be used in 
Phase 2 of the study. 
When designing focus group discussions, principles relating to group size, 
numbers, composition and balance of participants should be considered: 
(Bowling 2014; Kitzinger 1995; Côte-Arsenault & Morrison-Reedy 2005; Robson 
2011): 
• A focus group should not be too small or too large, 6-12 participants being 
deemed best.  
• There should be between 5 and 20 focus group discussions in total, with 
separate groups, rather than serial discussions with the same group, to 
avoid ‘groupthink’. 
• There should be balance within the group in terms of age/sex/experience, 
with the aim being to provide a safe and comfortable environment.   
• Consideration should be made whether homogenous or heterogenous 
groups best suit the research requirements. 
 
3.3.1.1 Research setting 
The research setting for this study was an NHS Scotland organisation pharmacy 
department, where the researcher and facilitator work.  The researcher is a 
member of the pharmacy quality, risk and governance department, and the 
facilitator a member of the pharmacy education, research and development 
department.  The researcher and the facilitator work closely with the clinical 
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pharmacy services, from which the participants were recruited, but neither work 
within the clinical pharmacy team.  The relationship of the researcher and 
facilitator to the research setting has the potential to bring bias (Bowling 2014): 
in this research, the researcher is seeking understanding of the concept of 
suboptimal pharmaceutical care and a solution to a problem; the facilitator to 
ensuring the research has impact within the workplace. Both researcher and 
facilitator reflected on their biases, acted to minimise impact of bias, and this 
reflection formed part of an ongoing reflexive process. 
 
3.3.1.2 Content validity: Field work 
Prior to undertaking the research study, the researcher carried out preliminary 
field work by shadowing five experienced clinical pharmacists from acute 
medicine, general medicine, oncology and palliative care, at three different 
hospital sites between January and March 2017.  The field work covered: the use 
of TRAK (electronic health record); the priority coding process (patient acuity or 
prioritisation) and the medicines reconciliation and Kardex/medicines review 
processes and documentation.  Variation was noted across the different hospital 
sites and their clinical pharmacy services, and this became a consideration when 
planning the study.  Familiarisation of the field in which the participants worked 
was important to build initial rapport with the participants, and understand the 
language they used in conversations about their work experiences. 
 
3.3.1.3 Population and recruitment 
The study was carried out using a convenience, purposive and homogenous 
sample of the 128 clinical pharmacists working in the five acute hospitals that 
are part of the NHS Scotland organisation. Participants were recruited using 
email sent to all clinical pharmacists, which included an information pack 
(Appendix 3.1).  Pre-registration pharmacists were excluded as having 
insufficient experience of working systems to be able to participate fully in the 
discussions.  Respondents who expressed interest in taking part in the study 
were sent a consent form (Appendix 3.2), and a demographic data collection 
form (Appendix 3.3) to complete, and a supplementary information pack 
introducing the topic for discussion in the focus group. (Appendix 3.4) 
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When planning the consent process, research governance was considered, and a 
statement was included on the consent form: ‘I understand that any event 
where patient safety may have been compromised will be followed up following 
normal governance procedures for adverse event reporting’. This recognised that 
there could be disclosure during the research of otherwise unreported adverse 
events.  The consent form design (Appendix 3.2) would be improved by having a 
box to initial for each consent statement, rather than a tick box (NHS Health 
Research Agency 2019). 
Initial recruitment resulted in 27 pharmacists expressing interest in taking part 
in the focus group discussions at the five hospital sites.  Once the date had been 
established there was some attrition, with six pharmacists being on leave or not 
working on the date arranged for the focus group discussion at their site.   
Recruitment therefore resulted in 21 participants, spread across the five hospital 
sites. 
 
3.3.1.4 Sampling plan 
The sampling plan was to conduct five focus groups, one at each of the five 
acute hospital sites in the organisation, with five to seven participants at each 
site, with differing levels of experience.  Conducting the focus groups at each 
site was deliberate, in part to capture variation in practice across the different 
sites, and in part to provide a safe and familiar environment for participants, 
with known colleagues. Due to attrition, the final sampling plan had four to five 
participants at each site, with differing levels of experience, and a total of 21 
participants.  One participant failed to attend on the day, resulting in 20 actual 
participants.  The demographics of participants is described in section 3.4.1. 
 
3.3.2 Data collection methods 
Focus groups generate data in the form of discourse between participants, and 
traditionally this data is captured by audio recording, followed by the 
transcription of the audio recording into written word. 
The focus group method was adapted in this study to suit the design 
requirements of this phase of the research.  These were:  
• to facilitate a rapid analysis of data to enable Phase 2 to follow.  
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• to obtain member checking of the output in real time.  
• to engage the participants during the focus group. 
To achieve this, the study design was adapted to enable participants to record 
written statements describing their perceptions of optimal and suboptimal 
pharmaceutical care during the focus group, and form a key part of the data 
generated. The physical activity of recording participant contributions in writing 
would engage participants, and provide a visual output that could be member 
checked.  
The discussion was audio recorded to act as auditable verification, and to enable 
key illustrative verbal quotes to be extracted as supplementary data to support 
the written statements. 
The data collection was therefore twofold: 1) written statements made by 
participants, and 2) supporting illustrative quotes extracted from audio 
recordings. In addition, reflective field notes were made by the researcher and 
the facilitator to describe the focus group setting, interactions, and level of 
engagement. 
Using the adapted and abridged focus group method to save time, and to meet 
the study requirements was agreed in advance with the research team, and is a 
novel method of conducting focus group discussions. A review of method 
adaptation of focus group discussion in the literature found a single qualitative 
focus group study that had used written statements on post-it notes as a means 
of generating data (Peterson and Barron 2007).  However, in that study the 
adaptation had a different purpose: to encourage reluctant participants rather 
than as a method to more efficiently capture focus group data (Peterson and 
Barron 2007). 
The adapted study design for the focus groups is summarised in Table 3.1, 
showing the process for designing, conducting and analysing a typical focus 
group, and for the adapted focus group method. 
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Table 3.1 Comparison of typical focus group and adapted focus group 
Typical focus group Adapted focus group 
5-10 participants 5-10 participants 
Discuss topic, guided by topic guide Discuss topic, guided by topic guide; 
record written statements onto post-it 
notes that exemplify discussion 
Audio record and transcribe Audio record; listen back & identify 
and extract illustrative quotes  
Analysis of data from transcriptions 
and researcher/facilitator field notes 
Analysis of data from written 
statements, illustrative quotes and 
researcher/facilitator field notes 
Send to participants to member check Participants member check during and 
at the end of the session  
 
The adapted method will be discussed further throughout the chapter. 
 
3.3.3 Data collection instruments and techniques 
A focus group topic guide was established based on discussions with the 
research team and around clinical pharmacy processes.  The topic guide was 
simplistic, and not theory based, relying solely on the analysis to apply the 
theoretical framework, and this may be perceived as a weakness in study 
design.  The intention was for discussions to focus on patient facing aspects of 
pharmaceutical care, and two topics for discussion were selected.  The two 
topics were medicines reconciliation and Kardex or medicines review, and these 
were described in Chapter 1.   
Medicines reconciliation, in this context and setting, is the process of ensuring 
that a hospital patient’s medication list is current and accurate.  Within the 
organisation, this task is initiated out by the admitting doctor, with the 
pharmacist confirming that the process has been carried out and documented 
accurately.  
Kardex/medicines review, in this context and setting, is the process of assessing 
prescribed inpatient medication by clinical pharmacists to identify and document 
pharmaceutical care issues, and to ensure patients receive medicines as 
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intended by the prescriber.  The process for Kardex/medicines review is 
described in a procedure. Kardex is the paper based inpatient medicines 
prescription and administration record used in the organisation. 
In preparation for the focus groups, data collection instruments were assembled 
and included an Olympus digital audio recorder model DS-3500 to capture the 
audio output, and A1 paper, pens and post-it notes to capture the written 
output.    
Additionally, documentation was prepared to assist in the conduct of the focus 
groups, including reflective field notes template (Appendix 3.6), operating 
procedure (Appendix 3.7), an on-the-day checklist (Appendix 3.8), and focus 
group ground rules (Appendix 3.5).   
 
3.3.4 Conduct of focus groups and data generation 
Elements of good and of poor practice when conducting focus group discussions 
have been described (Bowling 2014), and these elements are summarised in 
Table 3.2, describing the factors that influence the likelihood of success or 



















Having a clear objective 
Being well managed/facilitated 
Having a safe environment 
Having clarity of purpose 
Being time banded 
Being accurately recorded 
Having a defined endpoint 














Amateur or inexperienced facilitators 
Facilitator who has vested interest (may lead to bias) 
Failure to adequately brief facilitator 
Lack of focus 
Too small or too large a group 
Scope is too ambitious for one setting 
Lack of flexibility as issues emerge 
 
The researcher reflected on elements of focus group conduct during the planning 
of the Phase 1 study, conducted some self-directed study and formal training 
(Appendix IV).  Good practice was assured by rigorous planning. The objective 
and purpose of the research, and the role of the focus group discussion were 
stated in the information pack for participants (Appendix 3.1).  An experienced 
facilitator was recruited from the research team, their role was clarified through 
ongoing discussion and briefing in advance of the focus groups.  The physical 
environment was known to participants, being on their own hospital site, and the 
emotional environment was made safe by assuring confidentiality in the 
information pack (Appendix 3.1), reinforcing at the start of the focus group, and 
reiterating in the focus group ground rules (Appendix 3.5). The focus group 
duration was stated in the information pack, and in confirmatory emails sent in 
advance, and time keeping was part of the planned process.   
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Each focus group started with an introduction by the researcher, where the plan 
for the focus group was described, detailing how the participants were to 
introduce and record their ideas using post-it notes placed onto a flipchart. 
Discussion was focussed on two topics as outlined in the topic guide. 
Focus group participants were asked to discuss suboptimal pharmaceutical care 
in relation to the first topic of discussion, and write examples onto GREEN post-it 
notes.  After 10-15 minutes on this task participants were asked to discuss 
influencing factors in relation to suboptimal pharmaceutical care for one or two 
of the examples they had described.  For this participant-led stage of the task 
they were asked to record written statements onto two different coloured post-it 
notes. PINK post-it notes were to record positive influencing factors (enablers), 
and ORANGE post-it notes to record negative influencing factors 
(barriers)(Figure 3.1). This task was conducted for approximately 20 minutes, 
and then repeated for the second topic of discussion. The use of the different 
colours was deliberate, to enable participants to visualise their responses at the 







       
Figure 3.1 Participant information for recording written statements 
 
Participants were advised that audio recording would take place to enable 
illustrative quotes to be extracted.  It was confirmed by the researcher that all 
participants had completed and signed the consent form prior to commencement 
of each focus group. Each focus group was then read a standard introduction 
giving the definition of pharmaceutical care (Appendix 3.9). The focus group 
ground rules (Appendix 3.5) were circulated and displayed throughout the focus 
















After discussing the two topics of medicines reconciliation and Kardex/medicines 
review, the researcher verbally summarised the content of the written 
statements, asking participants to confirm that their intention was recorded 
accurately. This step acted as member checking of the written record. The 
researcher kept time, and drew the discussion to a close after 45 minutes, 
thanking the participants for taking part.  After each focus group, the researcher 
and facilitator met to share reflective field notes, and to discuss practical aspects 
of the conduct of the focus group.   
 
3.3.5 Data processing 
For Phase 1 focus groups, the data included demographics about participants, 
and the data generated related to individual hospital sites.  Focus group and 
individual data were processed and stored in a manner that ensured 
confidentiality. 
For the data generated, the written statements were transcribed verbatim into 
Microsoft word documents by the researcher, for each focus group, in order for 
extraction and analysis to take place (Appendix 3.12).  The data was not 
merged, but treated separately for each focus group, and for each topic 
(medicines reconciliation and medicines review).  Treating each focus group 
separately at the stage of transcription and data presentation was considered to 
be applicable and appropriate for a professional doctorate, where each focus 
group represented a separate hospital site, with different practices and 
processes, with data synthesised at a later stage to allow common themes to be 
determined for interpretation and discussion. 
The digital audio recordings were transferred from the Olympus digital recorder 
to secure computer files using Olympus data management software.  There was 
no transcription, but illustrative quotes were extracted (3.3.7). 
 
3.3.6 Data management and storage 
Data management processes were followed to ensure that individuals’ and focus 





3.3.6.1 Protecting confidentiality 
Focus group data, the output from each focus group, the audio files and the 
transcripts were kept securely to protect the confidentiality of participants. The 
written statements on post-it notes were photographed, then their content 
transcribed into Microsoft Word documents by the researcher. A sample was 
checked by the facilitator. Field notes were reviewed at the end of each focus 
group, any additional comments added to the form, which were then kept 
securely until accessed for data processing and analysis.  
 
3.3.6.2 Anonymity 
Each focus group was assigned a number, rather than using the hospital site 
name, when anonymising the data.  The risk of individuals being identified by 
their handwriting on written statements was considered low, and whilst the 
written statements were transcribed, the photographic image of the focus group 
output was also deemed to be part of the data generated for the purpose of the 
thesis.  Illustrative quotes were not assigned to individuals to assure anonymity.  
Identifiable information, such as the audio recording, was deleted from the audit 
recorder immediately after the file had been transferred to a secure computer 
file using Olympus data management software. Each audio file had a unique 
reference and a secure master file was created that matched the audio file to 
focus group as a numeric representation (one to five) to ensure that the data 
was anonymised, but could be traced back for audit or data integrity purposes. 
 
3.3.6.3 Privacy of participants 
Demographic information about participants was collected as necessary for the 
research and kept securely.  Once transcribed, the demographic data collection 
that linked data to individual participants was destroyed.   
 
3.3.7 Data extraction method 
The data extraction method was agreed in advance by the research team.   
Firstly, the transcribed written statements from each of the five focus groups 
were mapped to the Theoretical Domains Framework by the researcher and a 
member of the research team.  Interrater checking of the mapping of the 
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generated data between coders was ongoing, and any variance discussed and 
resolved.  This presented a learning opportunity for the researcher.   
 
Secondly, the audio files were accessed by the researcher for the purpose of 
extracting illustrative quotes to support the written statements that described 
participants’ perceptions of optimal and suboptimal pharmaceutical care.  In 
addition, listening to the audio output enabled the researcher to familiarise 
themselves with the audio recording of the focus group discussions.  Input from 
a member of the research team verified that the illustrative quotes represented 
the written statements. Tables were then prepared in Microsoft word to present 
the data, consisting of written statement and illustrative quotes, and these are 
presented in Appendix 3.12. 
 
3.3.8 Data analysis method 
The data was analysed using TDF.  Data analysis started after the conduct of the 
first focus group when the researcher and facilitator met to discuss the reflective 
field notes, which were collected using a template (Appendix 3.6).  Abridged 
notes from each focus group summarised the practical aspects of each focus 
group (Appendix 3.11).  The process of reviewing field notes with the facilitator 
after each focus group was beneficial as it allowed for reflection on how the 
conduct of the focus groups had been carried out, and enabled initial thoughts 
about the output from the focus groups to be captured.  
Data analysis continued with the examination of the data transcribed from 
written statements as presented in Microsoft word tables (Appendix 3.12) to 
cross check the TDF coding process, to verifiy the domains represented, and to 
commence the process of analyis by identifying initial themes and subthemes.  
Familiarisation and immersion in the data at this early stage was an important 
part of the data analysis.  
Data reduction – the process of filtering the data to reduce it to a manageable 
size - was not required at this stage of the adapted focus group method.  The 
reduction occurred during the focus group, by the group forming consensus on 
the written statements. The selection of written statements for further discussion 
was led by participants.   
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The data processing and extraction are described in detail here, since the 
method used in this study created a novel way of data generation (written 
statements), data extraction (transcribing written statements and accessing 
audio files), and the data presentation, using captured images from the focus 
groups, reflects this process. 
 
3.3.9 Data processing and extraction: medicines reconciliation and 
Kardex/medicines review 
This section will outline the data processing and extraction processes for each 
focus group discussion. The two topics were treated separately during the focus 
group discussion in accordance with study design, and therefore ten sets of data 
extraction are described: 
 
• Medicines reconciliation data extraction (3.3.9.1 to 3.3.9.5) for Focus 
groups 1 to 5. 
• Figures 3.2 to 3.6 showing the images from discussions on medicines 
reconciliation for Focus groups 1 to 5, followed by explanatory notes, 
relating to the written statements selected by participants for further 
discussion. 
• Summary of data processing and extraction for topic of medicines 
reconciliation 
 
• Kardex/medicines review data extraction (3.3.9.7 to 3.3.9.11 for Focus 
groups 1 to 5. 
• Figures 3.7 to 3.11 showing the images from discussions on 
Kardex/medicines review for Focus groups 1 to 5, followed by explanatory 
notes, relating to the written statements selected by participants for 
further discussion.  
• Summary of data processing and extraction for topic of Kardex/medicines 
review 
Full transcripts from the written statements are presented in Appendix 3.12. 
[Note: the written statements made by participants relate to the clinical 
pharmacy service in the organisation, as described in Chapter 1; the statements 
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were written by participants and certain abbreviations and shorthands were used 
which are explained here: 
IDL = intermediate discharge letter; ECS = emergency care summary; TRAK = 
TRAKcare, the electronic patient record used; Paperlite = a programme to 
reduce paper records in the organisation; med rec = medicine reconciliation, 
(described in Chapter 1); Kardex = a prescription and administration record; 





3.3.9.1 Focus group 1: medicines reconciliation 
The output of the discussion on medicines reconciliation was captured as a 
photographic image on completion of the focus group (Figure 3.2). Focus group 
1 generated seven examples of suboptimal pharmaceutical care delivery in 
medicines reconciliation (green post-its), with seven influencing factors 
emerging when discussed in more depth, for the two selected examples: four 
negative influencing factors or barriers to provision of optimal pharmaceutical 
care (orange), three positive influencing factors or enablers to provision of 
optimal pharmaceutical care (pink) in relation to the two selected examples.  
 
Figure 3.2 Focus group 1 output: medicines reconciliation 
 
Focus group 1 explanatory notes for participant-selected examples: 
The group opted to have additional discussion on the statement: 




The negative influencing factor, or barrier to optimal pharmaceutical care being 
delivered, related to the paper record of medicines reconciliation not being 
available: 
 ‘loose paper being lost’.   
The enabler for this barrier was to have an agreed location to keep a medicines 
reconciliation record, and to have an agreed format for completion: 
 ‘Agreed location and format’ 
Since the research took place, paper documentation has been replaced by an 
electronic record. 
The second statement that was selected by participants to be discussed was:  
‘incomplete medicines reconciliation’.    
A barrier to optimal pharmaceutical care was perceived to be the lack of 
motivation of the junior doctors to whom this task generally falls: 
‘motivation to see benefit’ 
A second barrier was identified as being a tendency for the medicines 
reconciliation to focus only on those medicines that are applicable to the 
specialty: 
 ‘Only focussing on area of specialty rather than all medicines’ 
This barrier describes how medicines reconciliation sometimes focussed only on 
respiratory medicines on a respiratory ward, or only rheumatology medicines on 
a rheumatology ward for example, and this behaviour included both doctors and 
pharmacists.  
An enabler for this barrier was perceived to be a maintenance of a generalist 
knowledge of medicines by pharmacists and doctors: 
‘maintaining generalist knowledge’ 
A second enabler was using appropriate sources of information for carrying out 
medicines reconciliation: 
 ‘Using ECS as primary source’ 
The ECS referred to is the emergency care summary, and is recognised as being 




3.3.9.2 Focus group 2: medicines reconciliation 
The output of the discussion on medicines reconciliation was captured as a 
photographic image on completion of the focus group (Figure 3.3). Focus group 
2 generated eleven examples of suboptimal pharmaceutical care delivery in 
medicines reconciliation (green post-its), with nine influencing factors emerging 
when discussed in more depth, for the two selected examples: five negative 
influencing factors or barriers to provision of optimal pharmaceutical care 
(orange), four positive influencing factors or enablers to provision of optimal 
pharmaceutical care (pink) in relation to the two selected examples.  
 
Figure 3.3 Focus group 2 output: medicines reconciliation 
 
Focus group 2 explanatory notes for participant-selected examples: 
Focus group 2 opted to have additional discussion on the statement: 
‘Too many resources to access – ECS, renal vital data, GP letter, patient’ 
This statement describes some of the sources used to carry out a thorough 
medicines reconciliation, and how it is not always clear which sources to use 
when this is not defined. 
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The participants perceived barriers to optimal pharmaceutical care being 
delivered in medicines reconciliation as relating to a lack of time, and to high 
patient volume, and the presence of out of date emergency care summaries in 
the patient record: 
‘Out of date ECS; lack of time; patient volume’ 
The suggested enabler for these perceived barriers was the availability of clinical 
technicians on more wards, with the technician using a referral tool available in 
the service, to highlight high risk patients, and with the technician having input 
into the management of patients: 
 ‘Clinical technician referral tool/input’ 
A second statement discussed in more detail by the group was: 
 ‘Asking closed questions of patient’ 
This referred to the practice of asking patients for information about their 
medicines during medicines reconciliation, and a perceived negative behaviour of 
using an inadequate questioning style. An enabler to asking closed questions 
was proposed by participants as being: 
‘training in open questioning skills’ 
This demonstrates that participants perceive that skills used in medicines 
reconciliation can be taught and reinforced. 
Barriers to provision of optimal pharmaceutical care were perceived as being: 
‘Patient expectations’ 
‘overemphasis on medicines and not seeing other factors e.g. medical 
history’ 
‘time consuming task’ 
‘Patient expectations’ referred to the lack of understanding by the patient of the 
purpose of medicines reconciliation and the role of the pharmacist in clarifying or 
expanding on information already collected by the admitting doctor.  The enabler 
to this barrier was: 
 ‘Health literacy’ 
Health literacy is a generic term to describe the ability of patients to understand 
and process health information, and here is used to describe the perceived gap 
between what patients currently understand about processes that pharmacists 
are involved in, for example, medicines reconciliation. 
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In describing an ‘overemphasis on medicines’, the participants refer to the 
knowledge and awareness that a complete medicines reconciliation will take 
account of the medical history of a patient, not just the presenting history, and 
current medicines.  The enabler: 
‘holistic approach’  
reflects this. 
The description of medicines reconciliation as: 
  ‘time consuming task’ 
relates to how carrying out a complete and accurate medicines reconciliation is 
time consuming, and participants suggested that asking closed questions of a 




3.3.9.3 Focus group 3: medicines reconciliation 
The output of the discussion on medicines reconciliation was captured as a 
photographic image on completion of the focus group (Figure 3.4). Focus group 
3 generated eight examples of suboptimal pharmaceutical care delivery in 
medicines reconciliation (green post-its), with four influencing factors emerging 
when discussed in more depth, for the one selected example: one negative 
influencing factor or barrier to provision of optimal pharmaceutical care 
(orange), three positive influencing factors or enablers to provision of optimal 
pharmaceutical care (pink) in relation to the one selected example.  
 
Figure 3.4 Focus group 3 output: medicines reconciliation 
 
Focus group 3 explanatory notes for participant-selected example: 
Focus group 3 opted to have additional discussion on the statement: 
 ‘Lack of access to relevant information’ 
The statement refers to the process of accessing information that is necessary to 
carry out medicines reconciliation.  A barrier to provision of optimal 
pharmaceutical care was perceived as: 
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 ‘Structure of IT makes information retrieval difficult’ 
This statement refers to the incompatibility of IT medical information systems in 
primary and secondary care making it difficult to obtain up to date information 
on a patients’ medicines.  The enablers to the incompatibility were seen as:  
 ‘Joined up IT system’ and 
 ‘Better access to information from outwith [NHS Scotland organisation]’ 
 ‘Access to adequate IT devices [computers]’ 
The latter statement relates to a shortage of computer availability, and since the 
research took place, this has been addressed. 
A further enabler described by participants relating to IT systems was: 
 ‘Better Trak training; standardisation of paperlite system’ 
Better TRAK training was perceived as being needed by both pharmacists and 
doctors to ensure that information was recorded appropriately within TRAK.  
Standardisation of the paperlite system refers to perceived differences both 
within each hospital and across the different hospitals in the way the paperlite 
process was being implemented across the organisation.   
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3.3.9.4 Focus group 4: medicines reconciliation 
The output of the discussion on medicines reconciliation was captured as a 
photographic image on completion of the focus group (Figure 3.5). Focus group 
4 generated eight examples of suboptimal pharmaceutical care delivery in 
medicines reconciliation (green post-its), with six influencing factors emerging 
when discussed in more depth, for the two selected examples: three negative 
influencing factors or barriers to provision of optimal pharmaceutical care 
(orange), three positive influencing factors or enablers to provision of optimal 
pharmaceutical care (pink) in relation to the two selected examples.  
 
 
Figure 3.5 Focus group 4 output: medicines reconciliation 
 
Focus group 4 explanatory notes for participant-selected examples: 
Focus group 4 opted to have additional discussion on the statement: 
‘Communication/handover between staff e.g. Dr to Dr, pharmacist to Dr. 
pharmacist to pharmacist/pharmacy staff’ 
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as an example of why suboptimal pharmaceutical care may be delivered, and 
outlining that multiple parties are involved in the process of medicines 
reconciliation, and that communication between parties is important to optimise 
the process. The barriers discussed included: 
‘Differences across different sites yet all sites access TRAK’ 
which refers to intra-site differences which became apparent when patients 
move between sites for different episodes of care.  An additional barrier was 
described which related to perceptions of other members of the multidisciplinary 
team, and describes the negative perception by the team of pharmacists having 
a policing role: 
‘Lack of understanding of pharmacist/pharmacy staff role by Drs and 
nurses –e.g. sometimes seen as policing role’ 
Enablers to the discussion on communication were identified: 
‘Robust system in place with same terminology’ 
‘Clear documentation on what has been done/still to do’ 
Clear documentation was described as the optimal method of communicating 
what the process status was for medicines reconciliation, both for pharmacists 
and doctors. 
A second statement was selected for further discussion by the group, and this 
related to medicines reconciliation issued not being followed up by others (other 
pharmacists or admitting doctor): 
‘Medicines reconciliation issues not followed up’ 
However, it was acknowledged that the barriers to medicines reconciliation 
issues being followed up and acted on were complex and included time 
constraints of those involved: 
‘Staff time constraints’ 
as well as the complexity of patients’ medicines and concurrent medical issues: 
‘Complexity of patient’ 
and further compounded by the lack of clarity over the pharmaceutical care 
issues being recorded: 
‘Poor documentation –unable to identify and understand issues’ 
Enablers to the poor practice of not following medicines reconciliation issues up 




‘Culture and attitude’ 
as well as better training in the process of medicines reconciliation: 
‘Training (pharmacist and doctor)’ 
and a clearer, standardised description of the optimal way of carrying out the 
process of medicines reconciliation: 
‘Clear processes(standardisation)’ 
There was a perception by participants that the barriers identified relating to IT 
systems were not restricted to the organisation, and that a single IT system 
across NHS Scotland would be beneficial, enabling sharing of patient information 
across health boards: 
 ‘One national single computer system through NHS’ 
Participants described the poor engagement of staff with the process of 
medicines reconciliation, and this referred both to doctors and to pharmacists: 
‘Staff engagement with medicines reconciliation’ 
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3.3.9.5 Focus group 5: medicines reconciliation 
The output of the discussion on medicines reconciliation was captured as a 
photographic image on completion of the focus group (Figure 3.6). Focus group 
5 generated nine examples of suboptimal pharmaceutical care delivery in 
medicines reconciliation (green post-its), with eight influencing factors emerging 
when discussed in more depth, for the two selected examples: four negative 
influencing factors or barriers to provision of optimal pharmaceutical care 
(orange), four positive influencing factors or enablers to provision of optimal 
pharmaceutical care (pink) in relation to the two selected examples.  
 
 
Figure 3.6 Focus group 5 output: medicines reconciliation 
 
Focus group 5 explanatory notes for participant-selected examples: 
Focus group 5 opted to have additional discussion on the statement 
 ‘Non-stock medicines – omitted doses or incorrect alternatives’ 
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This statement describes how participants perceived that the frequent use of 
non-stock medicines on their wards was resulting in missed or omitted doses. 
Further barriers to the provision of optimal pharmaceutical care were cited, 
including that: 
‘Unlicensed medicines need ordering specially’ 
And that pharmacists had limited time to access the medicines supply process: 
‘Access to medicines/supply process’ 
These statements refer to additional pharmacist time being needed to source 
non-stock or unlicensed medicines, and to recommend substitute or replacement 
medicines, and therefore less time was available for pharmacists to address 
pharmaceutical care issues. 
Two enablers were perceived for this barrier, the first being better awareness by 
staff, referring to the multidisciplinary team, on the role of the pharmacist: 
‘Staff training /awareness session’ 
The second enabler suggested by participants was additional resource to support 
in the supply of medicines, and in particular non-stock and unlicensed 
medicines, suggested this role could be taken on by pharmacy technicians: 
‘Technician support e.g. with non-stock medicines’ 
A second statement that the focus group opted to discuss was: 
 ‘Not being documented adequately’ 
This statement referred to poor practice in documenting medicines reconciliation 
in the patient record, and this created a barrier to provision of optimal 
pharmaceutical care.  Specific contributory factors to this barrier were: 
‘Access to computer’ 
This statement describes how the current process requires access to a computer 
to access the electronic medical record, while concurrently needing access to 
paper records where medicines reconciliation was recorded.  Access to 
computers on a ward is shared with other users. 
In addition, participants referred to difficulty navigating electronic case notes: 
‘Electronic case notes difficult to navigate’ 
Participants discussed enablers for this difficulty and suggested: 
‘Writing notes straight onto TRAK’ 
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This statement referred to the perception that the process of medicines 
reconciliation was not being documented adequately, participants suggested that 
standardised documentation would be an enabler: 
‘Standardised medicines reconciliation form’ 
 
3.3.9.6 Summary of data processing and extraction: medicines reconciliation 
In summary, written statements of examples of suboptimal pharmaceutical care 
were generated from the five focus groups for the topic of medicines 
reconciliation (N=43). Participants then described negative influencing factors or 
barriers as well as positive influences or enablers to the provision of optimal 
pharmaceutical care for participant-selected statements.  The written 
statements, with barriers and enablers, formed the generated data.  TDF was 
used to analyse the generated data, and this is described within study findings. 
Having described data processing and extraction for the medicines reconciliation 
process, sections 3.3.9.7 to 3.3.9.12 will now describe data processing and 






3.3.9.7 Focus group 1: Kardex/medicines review 
The output of the discussion on Kardex/medicines review was captured as a 
photographic image on completion of the focus group (Figure 3.7). Focus group 
1 generated seven examples of suboptimal pharmaceutical care delivery in 
Kardex/medicines review (green post-its), with four influencing factors emerging 
when discussed in more depth, for the one selected example: two negative 
influencing factors or barriers to provision of optimal pharmaceutical care 
(orange), two positive influencing factors or enablers to provision of optimal 
pharmaceutical care (pink) in relation to the one selected example.  
 
 







Focus group 1 explanatory notes for participant-selected example: 
Focus group 1 opted to have additional discussion on the statement: 
‘No medicines reconciliation done on admission’ 
This statement highlighted that there was a perceived barrier to providing 
optimal pharmaceutical care when there was no medicines reconciliation carried 
out when a patient was admitted: an example was cited of a patient not being 
reviewed for three weeks during an admission, as the Kardex/medicines review 
process would normally trigger the patient prioritisation process. 
The group then identified contributory factors and discussed that high numbers 
of new admissions could prevent a thorough medicines review being carried out: 
‘Too many new patients to see to achieve proper medicines reconciliation’ 
A second contributory factor identified described how sometimes the balance 
between being thorough and being efficient resulted in inadequacies: 
‘Trying to do ‘swoop’ of kardexes to identify high risks but getting stuck 
(e.g. due to too much knowledge/unable to prioritise)’ 
Participants then discussed enablers for the issue of having too many new 
patients, and identified that changes would require a change of culture in how 
the Kardex/medicines review process is carried out, and would require 
management support: 
‘Culture and management support’ 
A further enabler was proposed, with pharmacy technician support suggested as 
a means to being able to identify and prioritise at risk patients and to support in 
the medicines reconciliation process: 
‘Pharmacy technician support’ 
However, additional technician support may not necessarily resolve inherent or 
latent problems that exist within the organisation. 
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3.3.9.8 Focus group 2: Kardex/medicines review 
The output of the discussion on Kardex/medicines review was captured as a 
photographic image on completion of the focus group (Figure 3.8). Focus group 
2 generated five examples of suboptimal pharmaceutical care delivery in 
Kardex/medicines review (green post-its), with six influencing factors emerging 
when discussed in more depth, for the two selected examples: three negative 
influencing factors or barriers to provision of optimal pharmaceutical care 
(orange), three positive influencing factors or enablers to provision of optimal 
pharmaceutical care (pink) in relation to the two selected examples.  
 
 
Figure 3.8 Focus group 2 output: Kardex/medicines review 
 
 
Focus group 2 explanatory notes for participant-selected examples: 
Focus group 2 opted to have additional discussion on the statement: 
‘Pharmacy/clinical team’s expectations’ 
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Participants suggested that certain contributory factors created barriers, 
including other staff members making assumptions about how processes are 
carried out: 
‘Making assumptions’ 
and that there was not always consistency between the way processes are 
carried out between different clinical pharmacy team members; 
 ‘Mixed messages within one team’ 
The participants suggested enablers to these including a consistent approach to 
training: 
‘Rotation packs for team’ [a pack that includes specific training relevant 
for service area, available in some areas but not all] 
And an improved initial induction process for each service area to ensure clarity 
in roles and responsibilities: 
‘Team specific induction to make expectations clear’ 
Finally, participants concluded that there was a need to improve leadership in 
setting clear criteria for pharmacy: 
‘Clear criteria for pharmacy as a whole’ 
A second statement was discussed by participants that referred to the wider 
expectations of the multidisciplinary team in relation to the purpose of the 
medicines review process: 
‘Multidisciplinary team’s expectations’ 
Participants identified that a contributory factor for this, and a barrier to the 
provision of optimal pharmaceutical care was: 
 ‘Ongoing need for team specific criteria’ 
Indicating that communication was required to clarify roles within the 




3.3.9.9 Focus group 3: Kardex/medicines review 
The output of the discussion on Kardex/medicines review was captured as a 
photographic image on completion of the focus group (Figure 3.9). Focus group 
3 generated eight examples of suboptimal pharmaceutical care delivery in 
Kardex/medicines review (green post-its), with six influencing factors emerging 
when discussed in more depth, for the two selected examples: one negative 
influencing factors or barriers to provision of optimal pharmaceutical care 
(orange), five positive influencing factors or enablers to provision of optimal 
pharmaceutical care (pink) in relation to the two selected examples.  
 
 
Figure 3.9 Focus group 3 output: Kardex/medicines review 
 
Focus group 3 explanatory notes for participant-selected examples: 
Focus group 3 opted to have additional discussion on the statement: 
‘Lack of technician resource’ 
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This statement reflected perception by participants that a technician resource 
would enable at risk patients to be identified, and that some other competing 
tasks like supply could be managed by suitably trained technicians: 
‘Skill mix, use of technician referral tool’ 
A second statement was selected for further discussion, relating to the need for 
specialist knowledge to provide an adequate medicines review: 
‘Lack of specialist knowledge and training’ 
This was felt by some participants to be in part due to a lack of journal articles 
available in an easy to access format: 
‘Online only access to journals limits reading’ 
Participants discussed enablers to ensure specialist knowledge was shared, using 
local expertise: 
‘Regular MI updates and training’ 
In addition, participants discussed enablers as skills that could be developed to 
assist in developing specialist knowledge: 
‘Critical appraisal skills’ 
And further discussed how the skills could be acquired, by providing protected 
learning time and availability of resources: 
‘Protected learning time and resource’ 
Finally, participants described as an enabler, the introduction or reintroduction of 
a process where learning can be shared across the team: 
‘Journal club’ 
A journal club is a meeting where participants take turns to share the latest 
evidence within their field.
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3.3.9.10 Focus group 4: Kardex/medicines review 
The output of the discussion on Kardex/medicines review was captured as a 
photographic image on completion of the focus group (Figure 3.10). Focus group 
4 generated five examples of suboptimal pharmaceutical care delivery in 
Kardex/medicines review (green post-its), with eight influencing factors 
emerging when discussed in more depth, for the two selected examples: four 
negative influencing factors or barriers to provision of optimal pharmaceutical 
care (orange), four positive influencing factors or enablers to provision of 
optimal pharmaceutical care (pink) in relation to the two selected examples.  
 
 
Figure 3.10 Focus group 4 output: Kardex/medicines review 
 
Focus group 4 explanatory notes for participant-selected examples: 
Focus group 4 opted to have additional discussion on the statement: 
 ‘Timely review – staff availability, competing priorities’ 
This reflected the perception by participants that availability of staff was 
sometimes a barrier to the timely review of medicines, especially where there 
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are competing priorities on pharmacist’s time.  A contributory factor was 
identified as a lack of resource, both of Doctors and of pharmacists: 
‘Lack of pharmacist resource; lack of Dr’s to follow up’ 
Without access to a doctor to follow up on issues, there can be a delay in 
changes being made to the Kardex. 
A further factor identified referred to missing and incomplete documentation that 
could make the process of medicines review difficult: 
  ‘Lack of documentation to support review’ 
And 
 ‘Incomplete TRAK notes, time added unknown’ 
Enablers to the process were perceived be participants as additional resource: 
 ‘More staff would help, variety of staff grades and clinical technicians’ 
A second statement was discussed by participants which described how building 
of skills and experience, through training and supervision is required to provide 
optimal pharmaceutical care in the medicines review process: 
‘Experience of pharmacists to know what should be followed up-
competence/experience/training’. 
Further discussion identified barriers to gaining skills, with infrastructure of the 
intranet, and availability of accurate information identified as barriers: 
‘Access to modify available information on e.g. clinical intranet, intranet 
not user friendly, e.g. out of date policy, guidelines.’ 
A further barrier was identified that refers to understanding when additional 
support may be needed: 
‘Knowing when have reached limit of knowledge’ 
Participants suggested enabler for these barriers, including: 
‘Training/education (ongoing and on the job)’ 
And suggested peer review sessions on relevant topics to expand knowledge and 
understanding: 
‘Peer review on how we work-topics of interest’ 
Finally, participants reflected on how better use of IT could help to access 
relevant and pertinent information to make the process of medicines review 
optimal. 
‘Good IT resources would help – access to evidence- based information 
and up to date guidelines’ 
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3.3.9.11 Focus group 5: Kardex/medicines review 
The output of the discussion on Kardex/medicines review was captured as a 
photographic image on completion of the focus group (Figure 3.11). Focus group 
5 generated seven examples of suboptimal pharmaceutical care delivery in 
Kardex/medicines review (green post-its), with five influencing factors emerging 
when discussed in more depth, for the one selected example: one negative 
influencing factor or barrier to provision of optimal pharmaceutical care 
(orange), four positive influencing factors or enablers to provision of optimal 




Figure 3.11 Focus group 5 output: Kardex/medicines review 
 
Focus group explanatory notes for participant-selected example: 




This reflected the participants discussion on the limited number of pharmacists 
available to carry out thorough medicines review.  Participants went on the 
discuss the factors that influenced capacity, and cited occasions where other 
tasks take priority, with technical issues referring to medicines supply:  
‘Get drawn into technical issues’ 
Suggestions by participants of enablers to address the limited capacity included 
reviewing skill mix and better availability of pharmacy technicians: 
‘Review of skill mix, use of pharmacy technicians/upskilling’ 
In addition, an enabler was identified to clarify the roles that the pharmacist has 
within the multidisciplinary team: 
‘Defined role within multidisciplinary team’ 
A further enabler which was on a similar theme of clearer roles and 
responsibilities was suggested, indicating that participants did not feel that their 
role and purpose was always clear: 
‘Clinical pharmacy service aims clarified’ 
And finally, an enabler was suggested of improved team work and sharing 
learning: 
‘Team working –learning from each other and supporting each other’ 
 
3.3.9.12 Summary of data processing and extraction: Kardex/medicines review 
In summary, written statements of examples of suboptimal pharmaceutical care 
were generated from the five focus groups for the topic of Kardex/medicines 
review (N=32). Participants then described negative influencing factors or 
barriers as well as positive influences or enablers to the provision of optimal 
pharmaceutical care for participant-selected statements. The written statements, 
with barriers and enablers, formed the generated data.  TDF was used to 
analyse the generated data, and this is described within study findings. 
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3.3.10 Situational and environmental data 
Situational and environmental data was recorded during the study. The duration 
of each focus group was available from the digital recorder, and the day and 
time of day noted in the field notes.   
The duration of focus groups ranged from 45 minutes 21 seconds to 53 minutes 
9 seconds, and were all completed witin the planned time of one hour.  Three 
focus groups took place in the morning and two in the afternoon.  Rooms were 
all booked on the hospital site that the participants worked at.  This meant that 
participants did not have to spend time travelling, and additonally increased 
their level of environmental comfort.  Distraction and interruption was minimised 
by using rooms other than their normal office environment.  The focus group 
discussions took part during June and July 2017, on working days for the 
participants. 
By describing in detail the situational and environmental data from the study, 
the readership can assess the generalisability and transferability of the study,  
as is described below.
131 
 
3.3.11. Techniques to enhance trustworthiness 
 
Chapter 2 described how to build trustworthiness in qualitative research.  The 
principles for building trustworthiness of credibility, transferability, dependability 
and conformability apply to focus group discussions.   
Credibility can be assured by the way the study design is described, and when 
the description includes detail of setting and context, transferability can be 
assessed by the readership.  The dependability of the study can be assessed 
through knowledge and awareness of the conduct of the study.  Finally, 
confirmability can be built into design to ensure the participants voices are being 
heard, and this can be assessed by looking at the way data is generated, and by 
reviewing data, data interpretation and discussion.   
The way a study design is described varies between studies, and Orvik et al 
(2013) have argued that the description of situational factors is important in 
strengthening credibility, confirmability, dependability and transferability of the 
findings from focus group research (Orvik et al 2013). The work of Orvik et al 
developed further a quality framework described by Vicsek (2010) to be used for 
the evaluation of focus group results (Vicsek 2010).  Orvik et al suggested the 
addition of three further situational factors to Vicsek’s original six part 
framework, leading to a suggested nine point quality framework (Table 3.3).  
This quality framework will enhance trustworthiness when considering the design 
of focus group methodology, and the nine points, and the action taken in this 




Table 3.3 Quality framework of situational factors for focus group discussions 
(adapted from Vicsek 2010; Orvik et al 2013) 
Situational Factor Reasoning examples Action taken in study 
Interactional factors Social influences, conflict 
avoidance, ‘groupthink’, 
conformity 
Recorded in field notes. Homogenous 
groups, all pharmacists from same site, 
of mixed levels of experience. Aware 
that juniors may be less inclined to 
participate and encouraged throughout 





knowledge of topic 
Demographics collected with consent.  
Study was on pharmaceutical care and 
the participants were practitioners and 
had prior knowledge of topic. 
Moderator/facilitator 
influence 
Style, control, prior 
knowledge of topic 
Facilitator well known to participants, 
and had previous experience, and was 
also a practitioner having prior 
knowledge of topic. 
Environment Room set up and location, 
interruptions, level of 
formality 
Room details recorded in field notes, as 
were interruptions.  Style discussed in 
advance. 
Time factors Time of day and duration Recorded on field notes. 
Content Style of question, prior 
knowledge sent out or 
imparted during session 
Topic guide, discussion between 
researcher and facilitator. 
Psychological safety Familiar setting, trust in 
investigator 
Took place at known location, with 
researcher and facilitator known. 
Ethical issues Informed voluntary 
participation and consent, 
difficult topics 
Consent obtained, reference made to 
patient safety issues at consent. 
Organisational 
factors 
Constraints, support from 
employer 
Support obtained from organisation. 
Planned around work schedules. 
 
In describing the situational factors that the study incorporated, using the 
quality framework (Vicsek 2010; Orvik et al 2013) the readership can ascertain 
the trustworthiness of the research, and assess how transferable the findings will 
be to their own setting. 
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3.4 Findings from Phase 1 focus groups 
Having described in detail the study design and the methods used for the focus 
group discussions, this section will describe the findings of the study, including 
participant demographics, key findings, and the synthesis and interpretation of 
the findings.  
 
3.4.1 Demographics of participants 
The demographics of the participants for each of the five focus groups were 
collected using the demographic collection form (Appendix 3.3) and are 
described in Table 3.4. In the context of hospital clinical pharmacy, staff band 
describes the level of experience of the participants, with Band 6 being more 
junior pharmacists, and Band 8 more senior. 
 
Table 3.4 Focus group participant demographics 
Focus 
group 
1 2 3 4 5 TOTAL 
No of 
participants 
3  5  4 4 4 20 
M/F 
 
3 F 5 F 1M 3F 2M 2F 1M 3F 16F 4M 
Staff Band  3 x Band 8 3 x Band 8 
1 x Band 7 
1 x Band 6 
2 x Band 8 
2 x Band 7 
1 x Band 8 
2 x Band 7 
1 x Band 6 
1 x Band 8 
2 x Band 7 
1 x Band 6 
10 x Band 8 
7 x Band 7 
3 x Band 6 
 
The sample was drawn from the population of hospital clinical pharmacists in the 
NHS Scotland organisation. The sampling intention was for there to be a range 
of levels of experience in each focus group, to ensure that all experience levels 
of pharmacist were represented, and this was achieved. From the twenty 
pharmacists in the sample, eight were independent prescribers at the time of the 
focus groups, and this was representative.  The ratio of male to female 






3.4.2. Data presentation: Framework analysis to TDF 
Thus far, the data from each focus group and for each topic has been considered 
separately, to capture the input and the voice of participants; the reasons for 
this were outlined in 3.3.5. The generated data is presented as transcribed in 
Appendix 3.12, for each topic, and for each focus group, including written and 
verbal output.  
The next two sections will present the findings from framework analysis to TDF, 
where themes and subthemes were generated from the data, firstly for 





3.4.3 Findings: Framework analysis to TDF - medicines reconciliation 
As described in 3.3.7, the transcribed written statements from each of the five 
focus groups were mapped to the TDF by the researcher and a member of the 
research team. For medicines reconciliation there were five dominant TDF 
domains representing recurrent participant comments across all five focus 
groups (Table 3.5).  These were environmental context and resources, 
knowledge, social/professional role and responsibility, skills and memory, 
attention and decision-making.   





















































































































































































































Total 13 9 10 1 0 0 0 1 0 6 34 0 0 0 
 
The key recurring themes (TDF domains) and subthemes identified during 
framework analysis for medicines reconciliation are now presented, followed by 




3.4.3.1 Environmental context and resources domain – medicines reconciliations 
 
 
Subthemes to emerge from the environmental context and resources domain 
included time factors, lack of policy or procedure, lack of resources including 
poor IT access, and insufficient staff resource combined with conflicting 
priorities, and these are each described and represented by illustrative quotes: 
Time factors 
Focus groups discussed time factors as a barrier to providing optimal 
pharmaceutical care with medicines reconciliation, and this became a subtheme. 
There were references to difficulty in completing the task of medicines 
reconciliation in a timely manner: 
‘Timeliness’ [completing within appropriate timescale] [Focus Group 3 – 
written statement] 
Focus group 2 discussed the continual need to obtain a balance between 
efficiency and thoroughness, with one group participant describing their 
individual approach of thoroughness over efficiency: 
‘I always think it’s better to see less patients and try and finish what 
you’re doing with each patient’ [Focus Group 2 – verbal quote] 
Other participants within the same focus group, however, took a different 
approach of seeing more patients less thoroughly. Discussion did not find a 
consensus and this variation was summarised as:  
‘time issues-more patients less intensely or less patients done well?’ 
[Focus Group 2 – written statement] 
It was perceived by participants that there was variation across different teams, 
and at different sites, and that there was a lack of guidance as to what the 
approach should be. 
Lack of policy or procedure 
Focus groups described the implications of a lack of formal policy or procedure .  
Focus group 1 described how on occasion inappropriate sources of information 
were used: 
 ‘inappropriate source’ [Focus Group 1; written statement] 
 
Environmental context and resources 
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Participants described how there was no policy or procedure to clarify, for 
example which sources of information are optimal for carrying out medicines. 
There was tacit acknowledgement that two sources were best practice:  
‘There’s not a policy that says which sources, it* just says two sources’ 
[Focus Group - verbal quote] *refers to Scottish Government chief executive letter 
outlining requirements for medicines reconciliation (Scottish Government 2013)  
 
On the same theme, there were several references to the ECS (emergency care 
summary) throughout the focus groups, either being out of date:  
‘Out of date ECS’ [Focus Group 2 – written statement] 
or being incomplete or incorrect:       
‘incomplete or wrong ECS’ [Focus Group 1 – written statement] 
Since the ECS is one of the primary sources that is used for medicines 
reconciliation, if the incorrect information is used at the outset, this will have 
compounding effects on the process.  There was further discussion by 
participants from Focus Group 1 on the lack of definition of how and where 
medicines reconciliation should be documented. A statement was made as an 
exclamation by one individual, and was met with indications of approval by other 
participants: 
‘I mean, where do you keep a med rec?-, there’s just no consensus!’ 
[Focus Group 1; verbal quote] 
The inconsistency on the location of information will manifest when patients 
move between healthcare settings, and between different hospitals, and will 
have implications for the efficiency of the process if time is required to locate 
documentation.  [Since the research took place, paper records of medicines 
reconciliation have been superseded by electronic recording of the task.] 
Poor IT access 
Focus group participants highlighted that there were issues carrying out the 
medicine reconciliation task when there was a lack of access to computers. 
‘Access to computers’ [Focus Group 5 – written statement] 
There was an understanding and awareness amongst participants that other 
members of the multidisciplinary team would also want to access the system, 
and this affected their behaviour: 
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‘I can’t sit there and do that like for every patient and hog the computer’ 
[Focus Group 3 – verbal quote] 
The lack of access to a computer would mean that documentation of the task 
could not be completed at the time, but would need to be completed back in the 
pharmacy department: 
‘you can’t record in real time due to lack of access’ [Focus Group 3 – 
verbal quote] 
Lack of in the moment access to a computer was described as being a factor in 
individuals not remembering to complete the electronic record retrospectively, 
and this is discussed further within the memory attention and decision-making 
domain. [Since the research took place, additional IT resource has been 
provided]. 
Insufficient staff resource and conflicting priorities 
Focus group discussions included references to insufficient staff resource to be 
able to conduct medicines reconciliation.  Sometimes lack of resources was 
perceived to be due to staff numbers or skill mix, and sometimes due to 
conflicting priorities on the resources: 
‘Pharmacy staffing – priorities’ [competing priorities on time] [Focus 
Group 3 – written statement] 
Focus group participants discussed how perceived conflicting priorities 
contributed to them not completing tasks: 
‘so, you don’t actually finish the process, not through lack of following the 
process, or lack of skill, but because of other priorities pulling you away’ 
[Focus Group 3 – verbal quote] 
 
3.4.3.2 Knowledge domain – medicines reconciliation 
 
 
Subthemes to emerge from the theme of knowledge included knowledge of 
medicines, and patient health literacy.  
Knowledge of medicines 
When discussing the medicines reconciliation process, participants highlighted 




medicines reconciliation, due to lack of recognition (knowledge) of their status as 
medicines:  
‘Health care professionals and patients not recognising medicines as 
medicines – e.g. patch, pill, inhaler, ointment’ [Focus Group 1 – written 
statement] 
There was further discussion between focus group participants as to why there 
may be incomplete or inadequate reconciliation of certain groups of medicines, 
particularly medicines that were less familiar within a specialty:  
‘maybe they don’t feel as confident when it’s general medical things or 
maybe they are happy doing their specialist area but can’t be bothered 
with anything outwith that’ [Focus Group 1 – verbal quote] 
Participants indicated that taking time to correct and complete medicines 
reconciliation impeded delivery of optimal pharmaceutical care. 
 
Patient health literacy 
The lack of recognition of certain items being medicines was also reported for 
patients, and a participant described how a specialist prescribed medicine was 
omitted from the medicines reconciliation process as it was not included in the 
usual sources access for medicines reconciliation:  
‘the patient forgot to mention one that wasn’t listed, -and it was specialist 
prescribed SACT!’ [systemic anti-cancer therapy] [Focus Group 1- verbal 
quote] 
Another example was given where patients needed prompted to recall non oral 
medicines, for example, inhalers:  
‘the patient was clearly on an inhaler, it was right by them, but it wasn’t 
recorded anywhere’ [Focus group 4 – verbal quote] 
 
3.4.3.3 Social/professional role and identity domain – medicines reconciliation 
 
 
The theme of social/professional role and identity adequately described the 
findings and there were no subthemes.  Participants described a lack of clarity 
over roles and responsibilities of different healthcare professionals involved in 
the medicines reconciliation process:  
Social/professional role and identity 
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‘Lack of understanding of medicines reconciliation and why doing it within 
multidisciplinary team’ [Focus Group 3 – written statement] 
Discussion included how ownership and responsibility for the process are not 
shared: 
 ‘Lack of shared ownership/responsibility’ [for medicines reconciliation] 
[Focus Group 1 - written statement] 
This was described further in relation to the pharmacist’s role: 
‘Technically the pharmacist’s role should be a verification process, but it’s 
not.’ [Focus Group 1 - verbal quote] 
The lack of clarity over roles and responsibilities included discussion on variation 
in how the process of medicines reconciliation is carried out by the admitting 
doctor, how medicines reconciliation issues are not always adequately followed 
up and how these factors impact on the ability to provide optimal pharmaceutical 
care: 
‘some doctors do a great job and others just don’t seem to think it’s 
important and then, you know, you’ll have to put in more effort and time’ 
[Focus Group 4 - verbal quote] 
Discussion also included reference to nursing staff not always understanding the 
role and purpose of medicines reconciliation, and not being part of the process: 
‘nursing staff are maybe not as involved with it, maybe see it as a doctor 
and pharmacist thing to sort out’ [Focus Group 4 - verbal quote] 
 
3.4.3.4 Skills domain – medicine reconciliation 
 
 
Subthemes within the theme of skills included skills to conduct and to document 
an accurate and thorough medicines reconciliation.  
 
Conducting  
Participants described deficiencies in the skills required to conduct medicines 
reconciliation, including where the task was incomplete: 
‘Incomplete medicines reconciliation’ [Focus Group 1 – written statement] 
Focus group 4 described specific problems that can arise when the process is not 
completed due to skills deficiency: 




Where the medicines reconciliation process has not been undertaken adequately, 
additional time is spent by the pharmacists resolving and documenting the issue. 
In this situation the lack of skill was interpreted as being by the admitting 
doctor. 
Documenting 
Participants further described how poor skills in documenting the medicines 
reconciliation process could be a barrier. 
‘Not being documented adequately’ [Focus Group 5 – written statement] 
This statement was expanded on during the discussion, with participants 
describing how they may be uncertain whether medicines reconciliation has been 
carried out, when it is not apparent from the patient’s current record on TRAK: 
‘the process might have happened but it’s not clear that it has’ [Focus 
Group 5 – verbal quote] 
This may then lead to duplication of effort, or spending time trying to establish 
the status of the patient’s record, and there are resource implications for this.  
 




From the theme of memory attention and decision-making, subthemes emerged 
of distraction, and paying attention: 
Distraction 
Participants discussed the type of distractions that may occur when they are on 
the ward: 
‘distractions, bleeped/called away from ward’ [Focus Group 1 – written 
statement] 
In this description, participants state that they may be called away from the 
ward, and how this would mean they may forget to go back and complete the 
task, and this was also discussed in Focus group 4: 
‘you can be half way through a task and then another priority comes up 
and you’re called away, and not handed over’ [Focus Group 4 – verbal 
quote] 
Memory, attention and decision-making 
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Being called away may leave the task, or the documentation of the task, 
incomplete: 
‘Inability to complete medicines reconciliation’ [Focus group 1 – written 
statement] 
Paying attention 
Focus group participants described how sometimes the admitting doctor did not 
complete medicines reconciliation adequately when they did not follow a process 
that ensured they covered all aspects of a patient’s medicines: 
‘the focus can be on what they get from the GP rather than everything’ 
[Focus Group 5 – verbal quote] 
 
3.4.3.6 Discordant and absent themes: medicine reconciliation 
During analysis of the generated data, one discordant theme emerged.  This 
included an illustrative quote from a single focus group: a perception of being 
judged by other pharmacists: 
‘I must have all this documented before he goes to the next ward 
otherwise that pharmacist will think I’m terrible’ [Focus Group 2 – verbal 
quote] 
This illustrative quote was selected to illustrate a behavioural response (fear), 
that may influence how individuals respond to the perception of being harshly 
judged. 
Across the five focus group discussions on medicines reconciliation, there was no 
mapping to TDF domains of optimism, beliefs about consequences, 





3.4.4. Findings: Framework analysis to TDF - Kardex/medicines review 
As described in 3.3.7, the transcribed written statements from each of the five 
focus groups were mapped to the TDF by the researcher and a member of the 
research team. 
For Kardex/medicines review there were six dominant TDF domains representing 
recurrent participant comments across all five focus groups, and these were 
environmental context and resources, skills, intentions, social professional role 
and identity, knowledge and memory attention and decision-making (Table 3.6). 
 





















































































































































































































Total 9 12 10 2 0 2 2 10 5 9 26 1 0 0 
 
 
The key recurring themes (TDF domains) and subthemes identified during 
framework analysis for Kardex/medicines review are now presented, followed by 









Within the environmental context and resources domain, subthemes emerged 
relating to time factors, (describing a lack of time to do the task thoroughly); 
conflicting priorities (describing distractions on the ward, being called away to 
other tasks); capacity (describing the high turnover of patients relative to the 
staff resource available) and these subthemes are described here:  
Time factors 
Focus group participants cited time factors as being a barrier to conducting 
Kardex/medicines review: 
‘Time pressures’ [Focus group 5 – written statement] 
Also, time to complete the process thoroughly: 
‘You don’t have time to check, like say non-formulary prescribing, there’s 
just not time, you have to just make sure it’s safe’ [Focus Group 5 – 
verbal quote] 
There were certain tasks that formed part of Kardex/medicines review that were 
perceived to take additional time, and impede the completion of reviews: 
‘sorting out unlicensed medicines and non-formulary- that all takes time’ 
[Focus Group 4 – verbal quote] 
Conflicting priorities 
Focus group participants described conflicting and competing priorities for 
pharmacist involved in Kardex/medicines review:  
‘staff availability, competing priorities’ [Focus Group 4 – written 
statement] 
Other groups discussed the challenges of balancing how they spend time on 
medicines related activities, and whether to prioritise medicines reconciliation or 
Kardex/medicines review: 
‘depends on whether you think it is suboptimal. Say you’ve got half an 
hour to whip round, what is better use of your time – to ‘med rec’ two 
patients or to nip round 16 kardexes and make sure there are no 
Environmental context and resources 
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overdoses, drug interactions, anything that is going to cause harm’ [Focus 
Group 2 – verbal quote] 
Capacity 
Participants described how capacity (the ability to carry out tasks within 
available resource) was a factor in being able to conduct medicines 
reconciliation: 
‘Too many new patients to see to achieve proper medicines reconciliation’ 
[Focus Group 1 -written statement] 
Other participants described how high patient turnover had an influence on task 
prioritisation, with high patient turnover leading to less thorough reviews: 
‘due to patient turnover in xx, it’s maybe more risk reduction: look at 
Kardex, everything’s fine, move on’ [Focus Group 2 – verbal quote] 
There is reference here to how capacity, and shortage of time leads to conflicts 
for participants, in knowing how and where to prioritise their time. 
There was discussion within the focus groups of staffing resource shortages, 
influencing capacity and affecting ability to complete Kardex/medicines review, 
and this was described both for pharmacists: 
‘Lack of pharmacist resource’ [Focus Group 4 – written statement 
And for technicians: 
‘Lack of technician resource’ [to identify at risk patients] [Focus Group 3 – 
written statement 
 
3.4.4.2 Skills domain - Kardex/medicines review 
 
 
Within the skills domain, subthemes emerged relating to skills in conducting 
Kardex/medicines review, communication skills in communicating the process, 
and time management skills. 
Conducting 
Focus group participants described some of the skills required to conduct 
accurate and complete Kardex/medicines review: 





Participants also described how the skills they used in Kardex/medicines review 
had evolved organically, rather than following a protocol or guideline, despite 
priority coding having been introduced: 
 ‘I aim to see every Kardex every day and then kind of prioritise with my 
own internal system’ [Focus Group 5 – verbal quote] 
Other participants described how there would be variation in the competence of 
pharmacists carrying out the task of Kardex/medicines review: 
‘Experience of pharmacists to know what should be followed up-
competence/experience/training’ [Focus Group 4 – written statement] 
In this situation, it would be expected that pharmacists will bring different levels 
of experience and competence to the task, and clear guidance would be needed 
to ensure that the task could be completed adequately. 
Focus group participants also described how the ability to prescribe would 
facilitate the Kardex/medicines review process, through the ability to resolve 
minor issues in the moment: 
‘there are issues you’d be able to sort out yourself if you were a 
prescriber’ [Focus Group 4 – verbal quote] 
Communication 
Focus group participants described how communication of the process of 
Kardex/medicines review had challenges: 
‘I can’t get access to a computer and I think, I’ll do it later, and maybe 
don’t, or I think I’ll do it tomorrow, or half complete and then not go back’ 
[Focus Group 4 – verbal quote] 
Participants also discussed how the convention of signing a Kardex to 
communicate that it had been reviewed was sometimes not done, but 
acknowledged that the action of not signing was not as described in procedures: 
‘I might not be inclined to sign off a Kardex in a situation where I have 20 
minutes to see 20 patients…like as a communication tool – I haven’t 
signed off because I haven’t been able to do all the checks I want to do.  
But this is just something I have set up for myself’ [Focus Group 2 – 
verbal quote] 
Failing to communicate what has been reviewed, and to what extent, may lead 
to duplication in work by other pharmacists when they encounter the Kardex.  It 
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was perceived by participants that doctors may not comprehend the use of a 
signature to indicate that a review had taken place. 
Time management 
Participants in some groups had discussion around time management: 
‘Time management’ [as a barrier to conducting medicine review] [Focus 
Group 3 – written statement] 
and the discussion included challenges in finding the balance between being 
efficient and thorough, and this has some overlap with ‘conflicting priorities’ 
above: 
‘Priority review vs comprehensive’ [Focus Group 5 – written statement] 
And: 
‘as a pharmacist I find it very difficult not to get bogged down in the first 
Kardex’ [Focus Group 1 -verbal quote] 
This theme, indicating uncertainty on how to balance time and effort continued, 
with participants discussing their dilemmas: 
‘maybe sometimes I am trying to go into too much depth; I’ve got too 
much knowledge and not enough time’ [Focus Group 1 – verbal quote] 
Although time factors and constraints, and conflicting priorities are an 
organisational issue, as described above under environmental context and 
resources, time management is a skill, and participants describe both lacking the 
skills, and not knowing how the organisation wants them to manage their time in 
relation to tasks. 
 
3.4.4.3 Intentions domain - Kardex/medicines review 
 
 
The theme of intentions adequately described the findings, particularly around 
participants expressing their intention to review Kardexes at the frequency 
defined by the priority coding:  
‘I may plan to see a patient but then don’t’ [Focus Group 5 – verbal 
quote] 
Participants discussed how complying with the patient prioritisation process 





‘suboptimal is not reviewing the patient in the timescale that you think is 
right’ [Focus Group 1 – verbal quote] 
The priority coding system (described in Chapter 1) acts both as a means of 
prioritising activity, and prioritising patients at risk.  Participants expressed that 
whilst the intention to comply with priority coding exists, other barriers, as 
described, may get in the way of meeting the target. 
 
3.4.4.4 Social professional roles and identity domain - Kardex/medicines review 
 
Two subthemes emerged from the social/professional role and identity domain: 
roles and responsibilities and access to healthcare professionals. 
Roles and responsibilities 
Focus group participants highlighted the poor definition of the role of the 
pharmacist within the multidisciplinary team:  
‘Defined role within multidisciplinary team’ [Focus Group 5 -written 
statement] 
and a perceived expectation by the MDT that certain roles would be undertaken: 
‘Multidisciplinary team’s expectations’ [Focus Group 2 – written 
statement] 
Participants however described how the nature of those expectations was not 
always clear: 
‘I want to know what is expected of ME!’ [Focus Group 2 – verbal quote] 
Discussion continued, with specific reference to the aims of the clinical pharmacy 
service requiring clarification, to ensure pharmacists and other members of the 
multidisciplinary team were aware of specific roles falling within the clinical 
pharmacy service. 
‘Clinical pharmacy service aims clarified’ [Focus Group 5 – written 
statement] 
Access to healthcare professionals 
Participants described how inability to discuss issues with the prescribing doctor 
could lead to delays: 
‘lack of Dr’s to follow up’ [Focus group 4 – written statement] 
Social/professional roles and identity 
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This could mean duplication of effort, and an inability to resolve problems 
identified during the Kardex/medicines review process: 
‘sometimes you’re waiting for a decision to be made, you’ve flagged up 
issues but they haven’t been acted on and there’s no one around’ [Focus 
Group 4 – verbal quote] 
Delays in resolving pharmaceutical care issues could lead to patients continuing 
to receive inappropriate medicines. 
 
3.4.4.5 Knowledge domain - Kardex/medicines review 
 
 
The theme of knowledge adequately described the findings, particularly in 
relation to lack of knowledge due to limited experience. 
Participants of focus groups described how they did not always feel prepared 
when starting in a new speciality, lacking knowledge of how to prioritise patients 
who needed reviewing: 
‘when I started in (x ward) I kind of just had to go, had to decide what 
were the priorities’ [Focus Group 2 – verbal quote] 
One participant described this further: 
‘there is an assumption made that you will know what to do, maybe of 
your skill set and competence’ [Focus Group 2 – verbal quote] 
Whilst this may be expected of a less experienced pharmacist, there was also 
indication that more senior pharmacists were not always confident in their 
knowledge, especially as they started to specialised in an area. 
‘Lack of specialist knowledge and training’ [Focus Group 3 – written 
statement] 
‘we may be better at voicing our thoughts and our knowledge with the 
multidisciplinary team but we maybe don’t have the level of expert 
knowledge we’d like’ [ Focus Group 3 – verbal quote] 
Participants indicated that the lack of knowledge affected their ability to conduct 











Within the memory attention and decision-making domain, two subthemes 
emerged: decision making, and paying attention 
Decision making 
Participants described some of the stages of decision making that were 
sometimes omitted when carrying out Kardex/medicines review: 
‘Not checking blood results where appropriate [for medicines the patient is 
on]; Not checking route of administration is appropriate; Not actually 
seeing patient to assess risk factors e.g. NG tube, weight (high or low) IV 
cannula’ [where review carried out remotely] [Focus Group 1 – written 
statement] 
Paying attention 
Focus group 3 participants described how the process of Kardex/medicines 
review could sometimes become overfamiliar with longer stay patients, leading 
to less thorough review, and how this can lead to missing errors: 
‘so, you know the patient really well, and you look at a Kardex and you 
see what you expect to see, and you miss the glaringly obvious 
transcription error‘ [Focus Group 3 – verbal quote] 
Participants also described some of the challenges in remembering to go back 
and complete an interrupted task: 
‘I can’t get access to a computer and I think, I’ll do it later, and maybe 
don’t, or I think I’ll do it tomorrow, or half complete and then not go back’ 
[Focus Group 4 – verbal quote] 
 
3.4.4.7 Discordant and absent themes – Kardex/medicines review 
During analysis of the generated data, one discordant theme from a single focus 
group discussion was identified, relating to perceived criticism from other 
pharmacists if the Kardex/medicines review task not completed thoroughly: 
Memory attention and decision-making 
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‘I was told – you saw this patient and you missed this – and it might have 
been for a million different reasons and I found that very difficult’ [taken 
as criticism] [Focus Group 1 – verbal quote] 
Although this theme was not discussed in other focus groups, it mirrors the 
discordant theme identified in a different focus group for medicines reconciliation 
– a fear of being negatively judged by colleagues.   
Across the five focus group discussions on Kardex/medicines review there was 






Having outlined the findings of the study, the discussion section will outline the 
key findings for each topic discussed: medicines reconciliation and 
Kardex/medicines review, and start to interpret those key findings in relation to 
the literature.  
 
3.5.1 Key findings 
This qualitative study aimed to explore how pharmacists perceive optimal and 
suboptimal pharmaceutical care. Not all TDF domains were mapped to, for either 
topic, and this was appropriate.  It would be possible to artificially assign quotes 
to domains, as it is an iterative and interpretive process, but there is a possibility 
of introducing bias if the mapping process focuses on the process and not on the 




3.5.1.1 Key findings: medicines reconciliation 
Focus groups participants identified behaviours that they perceived impeded the 
delivery of optimal pharmaceutical care for medicines reconciliation.  The 
findings from the five focus groups were synthesised to determine key findings. 
The five dominant domains, or themes, and the emerging subthemes are 
described here: 
Within the strongly represented environmental context and resources domain, 
subthemes emerged relating to time factors (lack of time to carry out medicines 
reconciliation thoroughly); lack of policy and procedures (to accurately describe 
the process); poor IT access (lack of access to computers), insufficient staff 
resource and conflicting priorities (including uncertainty over how the 
organisation wants resource to be directed). 
Within the knowledge domain, a subtheme emerged relating to poor knowledge 
of medicines by admitting doctors when documenting medicines reconciliation, 




Within the social/professional role and identity domain, a theme emerged 
relating to lack of clarity of roles of different members of the multidisciplinary 
team, and of other pharmacists. 
Within the skills domain, a subtheme emerged relating to a lack of skills required 
to conduct medicines reconciliation thoroughly, including skills in accessing all 
the appropriate information relating to the patient and their medicines; a second 
subtheme related to documenting the activity appropriately. There was 
perceived variation in competency in these skills across both doctors and 
pharmacists. 
Within the memory, attention and decision-making domain, subthemes emerged 
relating to distractions (forgetting to complete the task if distracted or pulled 





3.5.1.2 Key findings: Kardex/medicines review 
Focus groups participants identified behaviours that they perceived impeded the 
delivery of optimal pharmaceutical care for Kardex/medicines review.  The 
findings from the five focus groups were synthesised to determine key findings. 
The six dominant domains or themes and the emerging subthemes are described 
here: 
Within the environmental context and resources domain, subthemes emerged 
relating to time factors, (describing a lack of time to do the task thoroughly); 
conflicting priorities (describing distractions on the ward, being called away to 
other tasks); capacity (describing the high turnover of patients relative to the 
staff resource available).  
Within the skills domain, subthemes emerged relating to lack of competency (in 
carrying out and documenting the process), communication skills (of 
communicating the outcome of the process in an understandable way), and time 




Within the intentions domain, a theme emerged relating to having intention to 
see patients but failing (intention prompted by priority coding process, but 
failing due to environmental factors of time, capacity, and other priorities). 
For the social/professional role and responsibility domain, subthemes emerged 
relating to lack of clarity of roles and responsibilities relating to the activity, and 
a lack of access to other healthcare professionals to resolve issues relating to the 
task. 
Within the knowledge domain, a theme emerged relating to lack of knowledge of 
other pharmacists, or of self (due to lack of experience), and how this could 
mean inadequate Kardex/medicines review. 
Within the memory, attention and decision-making domain, subthemes emerged 
relating to the decision making of others (when waiting for a decision on 
pharmaceutical care issues by prescribers); and of paying attention, to multiple 





Interpretation of the data will be related to the objective for this phase of the 
study, namely how hospital clinical pharmacists perceive optimal and suboptimal 
pharmaceutical care. 
The intention of this phase of the study was to understand perceptions of 
optimal and suboptimal pharmaceutical care within the group setting. Mapping of 
the data to TDF allowed themes to be extracted that help to understand the 
perceptions that clinical pharmacists had when discussing the focus groups 
topics of medicines reconciliation and Kardex/medicines review, and the 
interpretation of these topics are described separately. 
   
 
 
3.5.2.1. Interpretation: optimal and suboptimal medicines reconciliation 
Medicines reconciliation, as described in Chapter 1, is a complex activity, with 
responsibility shared across the multidisciplinary team, and with implications for 
the safety of the patient (Scottish Government 2013; National Institute for 
Health and Care Excellence 2015; Royal Pharmaceutical Society 2013). The 
complexity of medicines reconciliation, and the multidisciplinary input was 
reflected by discussions in the focus groups in this study around the delivery of 
suboptimal pharmaceutical care in medicines reconciliation.  The paucity of 
qualitative research in medicines reconciliation in the UK is reflected by the low 
number of comparator studies. 
Frequent references were made by study participants to a lack of staff resource 
and to insufficient time to conduct medicines reconciliation. The complexity of 
the task, including accessing multiple sources of information required to conduct 
a thorough medicines reconciliation can mean that the process of medicines 
reconciliation can be time-consuming, and be a resource-intensive task.  Al-
Hashar et al reported that 47% of pharmacists in their qualitative study in 
Kuwait perceived that time and staff resource would be a barrier to the 
implementation of medicines reconciliation (Al-Hashar et al 2017), and this is 
supported by the findings in this study.  Whilst in the current study, in contrast 




the organisation, participants of focus groups identified time and resource as 
barriers that impede the delivery of optimal pharmaceutical care within the 
medicines reconciliation process. 
The findings of the current study are similar to those identified in a study on 
barriers to medicine reconciliation in Ireland (Redmond et al 2020), where lack 
of description of process, and poor IT systems to support the process were 
described as barriers. In addition, studies in the USA have shown that the 
complexity of the medicines reconciliation process, and the multiple steps 
involved, can be a barrier to its implementation (Van Sluisveld et al 2012). This 
was reflected by the findings in this study, with participants describing lack of 
consistency of approach within teams, and shortcomings in the documentation 
supporting the multi-step process as barriers to optimal medicines reconciliation.   
The absence of policy or comprehensive process description was cited by 
participants as creating uncertainty in roles and responsibilities both for 
participants as pharmacists, and for other healthcare professionals. Although 
high level policy direction on medicines reconciliation exists in Scotland in the 
form of a Chief Executive Letter (CEL) (Scottish Government 2013), local policies 
and procedures that describe roles, responsibilities and local arrangements 
across all disciplines were perceived as being absent within the organisation. 
Participants in the current study referred to unclear professional role definition 
as causing barriers to the delivery of optimal pharmaceutical care with medicines 
reconciliation.  Poor definition or agreement on roles of different member of the 
multidisciplinary team has been cited as a barrier for the implementation of 
medicines reconciliation in other studies (Al-Hashar et al 2017; Lee et al 2015).   
Study participants described how lack of knowledge about medicines by some 
doctors created a challenge for pharmacists when conducting medicines 
reconciliation. Lack of knowledge of medicines by doctors, and particularly junior 
doctors, has often been cited in literature about the causes of prescribing errors 
(Ross et al 2013; Avery et al 2012).  Poor health literacy of patients was also 
cited in this study as being a barrier to optimal medicines reconciliation, and 
health literacy has previously been reported as a barrier in relation to medicines 
reconciliation (Persell et al 2007). 
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Poor knowledge and low self-reported self-efficacy in the medicines reconciliation 
process were described in a US qualitative study of doctors and pharmacists 
(Boockvar et al 2011), and the findings of this current study also reflect a 
perceived lack of knowledge and awareness in relation to the medicines 
reconciliation process.  The current study did not find examine self-efficacy, as 
self-reporting is not a feature of a focus group discussion. 
During the focus group discussions, it became apparent that there were different 
approaches between pharmacists, and between clinical pharmacy teams, in how 
medicines reconciliation was conducted.  Some opted for efficiency, and seeing 
more patients less thoroughly, and others opted for thoroughness, seeing fewer 
patients more thoroughly.  Striking a balance between efficiency and 
thoroughness has been described for the process of medication reviews in GP 
practices (Duncan et al 2019).  The qualitative study in three practices, with GPs 
and GP practice pharmacists, described how both GPs and pharmacists perceived 
that pharmacists were more thorough but less time efficient than GPs when 
conducting medicine reviews. The current study reflects a similar theme of 
efficiency vs thoroughness, albeit in a different setting, and with a different 
process (medicines reconciliation); in the current study there was discrepancy 
between participants, and a lack of agreement as which approach was 
preferable.  The balance between thoroughness and efficiency is often discussed 
in relation to safety (Hollnagel 2009). Hollnagel describes how, in accordance 
with the efficiency thoroughness trade off (ETTO) principle, demands for 
productivity tend to reduce thoroughness while demands for safety reduce 
efficiency.  Organisational clarification for pharmacists, within their teams or 
across the service, on how the balance should be achieved could ensure less 
variation in how medicines reconciliation is delivered. 
In summary, there is little in the literature, particularly from the UK, regarding 
clinical pharmacists’ perceptions of the barriers and enablers to delivering 
optimal pharmaceutical care in medicines reconciliation in the UK, and the 





3.5.2.2. Interpretation: optimal and suboptimal Kardex/Medicines review 
The process of Kardex/medicines review, in contrast to medicines reconciliation, 
is entirely carried out by clinical pharmacists in the organisation, but relies on 
accurate medicines reconciliation, and accurate prescribing by the admitting 
doctor. The aim of the Kardex/medicines review is to reduce harm with 
medicines and improve the effectiveness of medicines. Within the clinical 
pharmacy service the process for conducting a review is described in a standard 
operating procedure.  As with medicines reconciliation, there was a paucity of 
qualitative research on the topic of Kardex/medicines review, particularly in the 
UK, to use as comparator studies.   
In the current study there were frequent participant references to organisational 
and environmental factors, as barriers to the delivery of optimal pharmaceutical 
care with Kardex/medicines review.  These factors included a lack of time to 
conduct a thorough Kardex/medicines review, conflicting priorities and capacity.  
The lack of time to conduct thorough Kardex/medicines review identified in the 
current study concurs with the findings of a Swedish study:  the study, using 
semi-structured interviews with sixteen hospital doctors and seven hospital 
pharmacists in Sweden, identified similar themes of a lack of resources 
(including time), and of unclear roles and responsibilities as being barriers to 
conducting thorough medicines review (Kempen et al 2020).   
Participants described the conflict between carrying out a thorough 
Kardex/medicines review and being able to see multiple patients, or carry out 
other tasks. This dilemma was described for the topic of medicine reconciliation 
above as the efficiency thoroughness trade off (ETTO) (Hollnagel 2009). The 
findings of the current study in part reflect those of Duncan et al, described 
above, where pharmacists were more thorough but less time efficient when 
conducting medication reviews in GP practices. In the current study there was 
variation identified across participants, with some participants expressing a 
favour for efficiency, and others for thoroughness, and there did not appear to 




A lack of skills was identified by participants in the current study, describing poor 
competency in completing, documenting and communicating the activity.  Poor 
competency in completing and documenting Kardex/medicines review, and of 
communicating the activity, will be detected when the patient moves 
downstream to another ward and a second pharmacist may observe 
discrepancies in the process. Within the organisation the process is currently 
described in operating procedures, and these may benefit from review. 
It was recognised during focus group discussion that variation in knowledge 
impacts on ability to conduct Kardex/medicines review. In particular, discussions 
identified that inexperienced pharmacists will have less knowledge and fewer 
skills relating to the task, and may therefore be less effective.  Studies that 
explored effectiveness of pharmacy interventions from medicines review 
(Graabaek and Kjeldsen 2013) and cost-effectiveness of medicines review 
(Gallagher et at 2014) did not report on qualitative aspects of pharmacist input, 
and cannot be used as comparators to this study.  
Participants in the focus group discussions on Kardex/medicines review 
described how the priority coding system in use provided a framework that gave 
them an intention to see priority patients.  However, environmental factors, like 
time constraints, and conflicting priorities, meant that they did not always get to 
see those patients prioritised by themselves or by other pharmacists. The 
findings in this study echo those of Falconer, Barras and Cottrell, in their two-
phase study using focus groups (N=20) and a cross sectional survey (N=231) 
with Australian hospital pharmacists.  The study explored attitudes and 
perceptions to methods for prioritising patients for pharmacist review.  
Participants in the study identified barriers to meeting the requirements of the 
prioritisation process, including organisational demands, for example patient 
discharge and medicines supply (Falconer, Barras and Cottrell 2019), and this 
was reflected by the findings of the current study, where conflicting priorities 
was cited as a barrier.   
In summary, there is little in the literature, particularly from the UK, regarding 
clinical pharmacists’ perceptions of the barriers and enablers to delivering 
optimal pharmaceutical care in Kardex/medicines review in the UK, and the 




Recommendations are now made for each topic discussed in the focus groups: 
medicines reconciliation and Kardex/medicines review. In the context of the 
organisation, the two topics are treated independently: medicines reconciliation 
is a shared task, and recommendations are not restricted to the pharmacy 
service. 
Recommendations are made based on established behaviour change techniques, 
described in Chapter 2. Chapter 2 also described the link between TDF domains 
and behaviour change techniques (Table 2.14). The behaviour change wheel and 
the COM-B model (Michie Van Stralen and West 2011) can be used to identify 
behaviour change techniques to address barriers which are identified when using 
TDF as a framework (Michie, Atkins and West 2014). Definitions and descriptions 
of behaviour change techniques, as interventions, were described in Table 2.12 





3.6.1 Recommendations – medicines reconciliation 
For the topic of medicines reconciliation there were five dominant behavioural 
domains, and participants expressed their thoughts through discussion of roles 
and responsibilities, competence related to the task, and time constraints and 
staff capacity and availability.  The recommended behaviour change technique 
for each of the dominant domains is described in Table 3.7 
Table 3.7 Suggested behavioural change techniques: medicines reconciliation 
(adapted from Michie, Atkins and West 2014) 
Key domains identified  Suggested behavioural change 
techniques 
Environmental context and 
resources 
Training; restriction, environmental 
restructuring; enablement 
Knowledge  Education 
Social/professional role and 
identity 
Education; persuasion; modelling 
Skills Training 
Memory attention and decision- 
making 
Training; environmental restructuring; 
enablement 
 
The findings of this part of the study, along with the suggested behaviour 
change techniques can be used by the organisation to generate improvements to 
the process of medicines reconciliation. Due to the complex nature of the 
medicines reconciliation process, some of the barriers identified are outwith the 
control of the clinical pharmacy service, and this may create challenges. The 
findings were available for each hospital site, as a result of the way the data was 







3.6.2 Recommendations – Kardex/medicines review 
There were six predominant TDF domains identified for the topic of 
Kardex/medicines review, and participants expressed their thoughts through 
discussions on a lack of time to carry out the task properly, conflicting priorities, 
capacity, staff resource and experience, skills, and clarity around roles and 
responsibilities. 
The suggested behaviour change techniques that articulate with the six 
predominant TDF domains are described in Table 3.8.  
   
Table 3.8 Suggested behavioural change techniques: Kardex/medicines review 
(adapted from Michie, Atkins and West 2014) 
Key domains identified  Suggested behavioural change 
techniques 
Environmental context and 
resources 
Training; restriction; environmental 
restructuring; enablement 
Skills Training 
Intentions Education; persuasion; modelling; 
incentivisation; coercion 
Social/professional role and 
identity 
Education; persuasion; modelling 
Knowledge Education 
Memory attention and decision- 
making 
Training; environmental restructuring; 
enablement 
 
The findings from this part of the study, along with the suggested behaviour 
change techniques, can be used by the organisation to generate improvements 
to the process of Kardex/medicines reconciliation. The findings were available for 
each hospital, due to the way the data was processed and analysed and this was 





3.7 Strengths and limitations of Phase 1  
This section will discuss the strengths and limitations of the Phase 1 study, in 
relation to the study design and conduct, and the analysis of study findings and 
interpretation. 
This qualitative initial phase of the research has addressed the paucity of 
literature relating to suboptimal pharmaceutical care.  The novel approach taken 
in the study ensures the content is original, providing a unique exploration of 
pharmacists’ understanding of the concept of suboptimal pharmaceutical care.  
In addition, the theoretical foundation used enhances the evidence, and provides 
the knowledge required to move forward with developing interventions. 
 
3.7.1 Study design and conduct 
The flexibility of the focus group discussions, by using a topic guide and allowing 
participants to identify for themselves the aspects of suboptimal pharmaceutical 
care they wanted to discuss, means the discussions had breadth and depth. The 
use of a skilled facilitator ensured that all participants took part, and that all 
participants voices were part of the data generated.  The adapted method, 
whereby written statements formed part of data generation, meant that 
participants had the opportunity to ‘member check’ the output, and this was a 
strength of the method design. 
By conducting focus group discussions at five separate hospital sites, 
participants were able to discuss the novel topic of suboptimal pharmaceutical 
care in a safe environment with colleagues, and with trust in the researcher and 
facilitator created during the recruitment stage.  Participants were thus able to 
share concerns openly, as was evidenced by the findings, and this was a 
strength of the study design.   
The setting for the study was a single health board in Scotland, and clinical 
pharmacy practices in other settings may vary.  In describing in detail these 
practices, the readership can consider whether findings will be transferable to 
their own setting. 
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When planning the focus groups, the researcher was conscious of participants 
taking time away from their work. The focus groups were therefore booked for 
one hour. Participants were advised of this in the information pack, and focus 
group discussions were terminated within this time frame. The limited duration 
of the focus group discussions, however, meant that not all written statements 
had negative influencing factors and positive influencing factors identified, and 
this was a weakness of the method.  Additionally, it was not possible to extract 
illustrative quotes for all written statements in the adapted focus group method. 
Whilst this did not affect the analysis, as the written statements generated the 
data that mapped to the TDF, the presentation of the findings is not uniform, 
and is not consistent with typical qualitative data presentation that use 
exclusively illustrative quotes, and this could be perceived as a limitation of the 
study.  Had the focus groups been video recorded, the process for matching the 
verbal illustrative quote to the written statement would have been easier.   
The focus groups varied in the quality of their output, and some group 
participants were better at articulating their collective thoughts and ideas onto 
post-it notes.  This was not an anticipated outcome, and could have been 
improved by better facilitation or clearer instructions at the outset.   
It was difficult to assess if data saturation was achieved, and this was a 
limitation of the study design.  Although there was a topic guide for the 
overarching topics of medicines reconciliation and Kardex/medicines review, 
individual focus groups varied in the topics they wanted to discuss in more 
depth, and this meant that data saturation could not be easily assessed.  A more 
detailed topic guide, better facilitation, and ongoing discussion with the research 
team after each focus group may have mitigated this.  
The study utilised an adapted focus group method as described. The brief written 
statements on post-it notes were adequate for participants, facilitator and 
researcher to understand, as they understood the context and setting for the 
study.  However, in the context of a research study, extensive explanation was 
needed for many of the written statements to create generally understandable 
data, and the time required for this was not considered in the study design. As a 
method of rapidly assimilating the data however, the transcription of written 
statements, and the subsequent extraction of illustrative quotes was successful.  
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The time taken for transcription was reduced from 50 hours to 20, with 
approximately half of the time being used to transcribe the written statements 
and half to extract the illustrative quotes.  The extraction of illustrative quotes 
from the audio recordings enabled the researcher to immerse in the data in a 
way that the straightforward transcription of written statements did not.  
Overall, the adapted focus group method was beneficial to the study, and is a 
novel adaptation.  
 
3.7.2 Data analysis 
The study used deductive methods to analyse data using a set framework. There 
are known weaknesses associated with using deductive methods to analyse 
data, such as mapping to TDF.  Coding may be restrictive and there is 
considerable overlap between some of the domains in the TDF (Atkins et al 
2017). In addition, individual domains may be perceived differently by coders. 
Efforts were made to minimise this variation by the frequent comparison of 
coding between coders during the process. In this study the purpose was not to 
examine the individual behavioural determinants of participants with the aim of 
changing behaviour, but rather to gain insight into participant’s understanding of 
the concept, and to explore their perceptions of suboptimal pharmaceutical care.  
 
3.7.3 Trustworthiness and reflexivity 
Research trustworthiness was assured via a number of strategies, as described 
within this chapter, and is considered a strength of the study. Steps were taken 
to promote credibility, transferability, dependability and confirmability. 
Strategies included: utilising methods with a favourable evidence base and 
deemed fit for purpose; previous experience of the researcher in audit 
interviews, and additional self-guided training in conducting focus groups. The 
detailed and accurate reporting and recording of research procedures allows 
these actions to be appraised by the readership. Reflexivity was enhanced 
through the presence of a facilitator, and the review process that took place 
after each focus group, where researcher and facilitator identified opportunities 
to improve future focus group discussions ensured that the voice of participants 
was represented in the generated data. In addition, reflexivity was assured 
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through reflective processes the researcher undertook to be aware of the effects 




Evidence from this Phase 1 study demonstrated that focus groups were an 
appropriate method to use to understand the perceptions of hospital clinical 
pharmacists to optimal and suboptimal pharmaceutical care.  Use of a topic 
guide that directed discussion to two patient facing pharmaceutical care tasks of 
medicines reconciliation and Kardex/medicines review meant that the five focus 
groups could have their findings explored separately, to reflect minor differences 
in process. This was helpful to the organisation, and highlighted differences in 
approach across the five hospital sites. In addition, the findings could be 
synthesised across the five focus groups, for each topic, to identify recurring 
themes. 
Participants of the focus groups were able to identify aspects of medicines 
reconciliation and of Kardex/medicines that they perceived as being suboptimal 
pharmaceutical care.  Participants used the phrase suboptimal in relation to 
pharmaceutical care, and this was perceived by the research team to be an 
expression of understanding and accepting the terminology, and met one key 
objective of this study. 
With medicines reconciliation, which is a shared task, relying on the input of the 
admitting doctor, participants in all five focus groups identified barriers to the 
delivery of optimal pharmaceutical care, described within key findings. 
Interventions to address the barrier of a lack of clarity of roles and 
responsibilities between professions include education, persuasion and modelling 
to encourage motivation. 
With Kardex/medicines review, where the pharmacist’s role is clearer, 
participants in all five focus groups identified barriers to the delivery of optimal 
pharmaceutical care, described within key findings. The barrier of poor skills in 
documenting and communicating Kardex/medicines review can be addressed 
through skills training to increase capability.  Time management and resource 
barrier can be addressed through environmental restructuring, enablement and 




In addition, for both topics, participants described personal conflict in achieving 
the balance between efficiency and time, and a lack of resources - of time, of 
people and of access to computers - as being barriers to providing optimal 
pharmaceutical care.  These barriers can be addressed using environmental 
restructuring, enablement and training, to create opportunity. 
The findings from Phase 1 were intended to inform the study design for Phase 2, 
and in preparation, an information pack for Phase 2 was prepared using key 
examples from the Phase 1 study (Appendix 3.10). The use of the theoretically 
mapped findings of the focus group to inform the next phase of the research was 






Chapter 4 Phase 2: Experiences of hospital clinical 
pharmacists of suboptimal pharmaceutical care 
 
4.1 Introduction to Chapter 4 
This chapter will justify and describe the methods used in Phase 2 of this 
research, and will then present the findings from the Phase 2 study. The Phase 2 
study was designed to understand hospital clinical pharmacists’ experiences of 
suboptimal pharmaceutical care.  The Phase 2 study used one to one, in-depth 
interviews using a semi-structured interview guide designed using the 
Theoretical Domains Framework (TDF).  The generated data was mapped to 
(TDF) during analysis to identify the behavioural determinants that affect how 
hospital clinical pharmacists experienced barriers and enablers to delivery of 
optimal pharmaceutical care.  Throughout this chapter, the one to one, in depth 
interviews conducted will be referred to generically as interviews. 
 
4.2 Research question, aims and objectives 
The overarching research question for this research was: 
How do hospital clinical pharmacists perceive and experience suboptimal 
pharmaceutical care?  
Aims: The specific aims for this phase of the research were: 
1. To explore pharmacists’ experiences of the provision of optimal and 
suboptimal pharmaceutical care within their practice. 
2. To explore the behavioural determinants relating to the provision of 
optimal and suboptimal pharmaceutical care using the Theoretical 
Domains Framework. 
The supporting objectives for this phase of the research were: 
1. To determine the experiences of participants with suboptimal 
pharmaceutical care using semi-structured interviews designed around the 
Theoretical Domains Framework. 
2. To map the findings from the interviews to the Theoretical Domains 
Framework to determine behavioural determinants of participants. 
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3. To interpret the findings and draw conclusions of participants experiences 
with suboptimal pharmaceutical care. 
4. To interpret the findings in relation to quality management principles, and 
draw conclusions relevant to the organisation. 
 
4.2.1 Justification for use of in-depth interviews in study 
The Phase 2 study built on the findings of the focus groups.  In-depth interviews 
were selected as a method for Phase 2. The interview method has been 
extensively described in Chapter 2, and included interview styles, question 
types, and data processing and analysis methods. The use of interviews as a 
qualitative method in this phase of the research provided the opportunity for 
participants to discuss experiences that they did not feel able to in a group 
setting (Dejonckheere and Vaughn 2019; Bowling 2014). Participants are more 
likely to relate personal feelings or actions in one-to-one interviews (Robson 
2011), and this was relevant to this study.  It was anticipated that there would 
be disclosure of personal experiences with suboptimal pharmaceutical care that 
participants were reluctant to discuss in the focus group setting. The opportunity 
to obtain rich data from in-depth interviews, without the constraint that a group 
setting might introduce, was key to understanding the experiences of 
participants with relation to the provision of suboptimal pharmaceutical care and 
was therefore justified in this study.   
 
4.2.2 Justification for use of Big 5 personality test in study 
The personality test used in this phase of the research was intended to act as an 
ice-breaker, a suggested mechanism for use in interviews (Kitzinger 1995), and 
additionally to give insight into participant’s personality.  Personality type has an 
influence on an individual’s perceptions and this was of interest in this study. 
Ferguson and Lievens (2017) describe how personality tests pick up on typical 
behaviour tendencies, particularly for those who score high on a particular 
personality trait.  Since this research was looking at behavioural determinants, it 
was considered appropriate to include this step in the research at this stage. 
There are many personality tests available, but for the purpose of this research, 
with the requirements of an easy to administer, easy to analyse, self-reporting, 
short personality test that would give descriptive elements of personality, the 
171 
 
Big 5 Inventory personality test was selected by the research team (Goldberg 
1990; John and Srivastava 1999).  
 
4.2.3 Justification for use of Theoretical Domains Framework (TDF) in analysis of 
study data 
The use of a theory in the analysis of generated data was described in Chapter 
2, and again in Chapter 3 and included description of the benefits of theory when 
analysing qualitative data.  There are additional benefits when using a 
theoretical framework to manage and organise the data, and when designing 
research tools and instruments, such as interview schedules.   
Given that the focus of this phase of the study was to explore participants’ 
experiences relating to suboptimal pharmaceutical care, it is appropriate that the 
underpinning for the research comes from a theoretical framework that 
encompasses a number of validated domains influential in behaviour and 
behaviour change at an individual level. The theoretical framework selected was 
the Theoretical Domains Framework (TDF).  The application of TDF was 
described in Chapter 2 and again in Chapter 3.  TDF is designed to determine 
individual behavioural determinants (Cane et al 2012), and, through the 
findings, to support the development of appropriate interventions (Michie et al 
2014).  It was the intention to use the TDF to inform the design of the semi-
structured interview schedule, to create an initial framework for data analysis, 
and for the reporting and discussion of findings.  The use of TDF was therefore 





4.3.1 Design of study  
Phase 2 was underpinned by a qualitative research design, since the nature of 
the research question and aims necessitated the collection of rich and 
meaningful data.  The research was grounded in constructivism, and used a 
phenomenological approach, as described in see Chapter 2.   
 
4.3.1.1 Setting 
The setting for the research study was the clinical pharmacy service in an NHS 
Scotland organisation, as described in Chapter 1. 
 
4.3.1.2 Participant identification 
Interviews were conducted with participants who had previously participated in 
the focus group discussion phase of the study, who had consented, and who had 
shown interest in participating in the interview phase (Figure 4.1).  Phase 1 
focus group discussions had explored the term suboptimal pharmaceutical care.   
 
 
Figure 4.1 Participant sampling 
 
4.3.1.3 Sampling plan 
All participants (n= 20) from phase 1 (focus groups) were contacted by email to 
invite them to take part in the interviews.  The sampling plan was designed 
around a ‘rule of thumb’ initial sampling plan, with data saturation, as described 
in Chapter 2.  The initial sampling plan aimed to recruit ten participants, with a 
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stopping criterion of three.  This is in accordance with known methods of 
reaching data saturation in qualitative research (Francis et al 2010). Data 
saturation would be determined by the interviewer and the stopping criterion 
identified through a review of the collected data on an ongoing basis. 
There was an unplanned delay between Phase 1 and Phase 2. Two participants 
had left, and six participants did not respond to the first or to follow up email, 
leaving 12 potential participants.  One potential participant then  
became unavailable for interview for health reasons.  One participant was 
selected (by dates of availability) to be the stopping criterion, to be interviewed 
if data saturation was not achieved after ten interviews. The remaining ten 
participants formed the study sample (Figure 4.1) 
 
4.3.1.4 Participant information  
Interview participants were sent information in advance of the planned interview 
by email (Appendix 3.10).  The participant information consisted of examples of 
suboptimal pharmaceutical care from Phase 1 focus group discussions, which 
had been mapped to TDF domains, as described in Chapter 3.  The purpose of 
the advance information was to remind participants of the previous phase of the 
research, and to provide them with an abbreviated synthesis of the findings from 
across the five focus groups, in preparation for the interview phase. The extracts 
given in the information for participants were selected by the researcher, and 
confirmed by the research team as being representative of the focus group 
output.   
 
4.3.2 Data collection methods 
The data collection in this phase of the research was from in-depth, one to one 
interviews. Interviews generate data in the form of a discussion between 
interviewer, in this case, the researcher, and the interviewee.  The data was 
collected using audio recording, supported by reflective field notes made by the 






4.3.3. Data collection instruments and techniques  
A semi-structured interview schedule was designed, using the TDF, and informed 
by the findings of Phase 1.  In Phase 1, participant discussion on perceptions 
was predominantly within the environmental context and resources domain, and 
the interview schedule for Phase 2 was intended to expand discussion across 
multiple TDF domains to capture the true experiences of participants. The 
interview schedule was tested on a pharmacist colleague and minor changes 
made to wording (Appendix 4.2) 
It was not known at the planning stage if all fourteen TDF domains would be 
relevant to the target output as 1) there was no prior research looking at 
pharmacist’s experiences of suboptimal pharmaceutical care and 2) there was no  
target output in the semi structured interview guide.  Although the interview 
schedule (Appendix 4.2) included suggested questions for each domain, it was 
the aim of the interviews to enable a free-flowing dialogue, with a neutral stance 
by the interviewer, generating a richness of data, and thus asking all the guide 
questions, and covering all the TDF domains in doing so, was not seen as a 
priority.   
In addition to the interview schedule, a personality test was prepared, which was 
to be administered prior to the interviews.  The personality test used was the Big 
5 Inventory (Appendix 4.3)   
An operating procedure was prepared, to ensure all good practice elements were 
included for the researcher, to ensure consistency and to provide transparency 
in the procedure (Appendix 4.4).  
A template was prepared for collecting field notes (Appendix 4.1), and included 
demographic information about participants, as well as space for reflective notes 
to be collected by the researcher during and after the interview.   
 
4.3.4. Conduct of interviews and data generation 
Having prepared the instruments for use, the researcher reflected on their 
personal attributes and skills in relation to conducting interviews, and carried out 
some self-directed learning and formal training (Appendix IV). 
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Communication between interviewer and interviewee was maintained via email 
and telephone to create rapport, and to ensure the interview would go according 
to plan, at the date, time and place arranged.  Interviews were booked with 
participants at a time and place convenient for them, in locations with adequate 
privacy to assure confidentiality.  
A standardised introduction was prepared (Appendix 4.5), intended to reduce 
variation, and to ensure all necessary information would be provided to 
participants; this stage also included confirming that consent had been given. 
Interviews were conducted as planned and according to the operating procedure 
(Appendix 4.4): The interviewees were greeted at arrival. During the 
standardised introduction (Appendix 4.5) interviewees were handed a Big 5 
inventory personality test to complete (Appendix 4.3).  Although written consent 
was not specifically obtained for the personality test, participants were given the 
opportunity to decline. On completion of the personality test, the audio recording 
of the interview commenced.  
The interviews were audio recorded using an Olympus digital voice recorder 
model DS-3500, with Olympus dictation management software to transfer the 
files to a computer.   
Interviews were conducted according to the sampling plan of 10+1 (ten 
interviews booked and one held as reserve), as described in 4.3.1.3. In 
accordance with the plan, the researcher reviewed emerging themes after 





Figure 4.2 Sampling plan for interviews 
 
The ongoing recording of field notes after each interview was conducted to allow 
data saturation to be determined, by enabling reflection on emerging themes, 
and was included as generated data (Appendix 4.8). 
 
4.3.5 Data processing  
The primary data was generated in the form of digital audio files, and these were 
transferred to a secure computer location using the Olympus dictation 
management software (ODMS), and then deleted from the digital audio recorder.  
The interviews ranged in duration from 19 minutes 14 seconds to 35 minutes 26 
seconds: this information was available from the digital audio files.  Stored audio 
files were accessed for transcription.  Seven audio files were transcribed, using 
intelligent verbatim method, by the researcher and three by an external agency. 
The transcripts from the three externally transcribed interviews were checked 
against the audio file for accuracy once received and any corrections, 
amendments or gaps (for example, the names of drugs) completed.   
Data in the form of personality test scores was generated by the completion of 
the Big 5 inventory personality test (Appendix 4.3) by individuals at the start of 
the interview.  The forms were stored securely until accessed to calculate the 
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the participant cohort.  For the Big 5 personality test, scores were calculated 
using the Big 5 inventory scale scoring schedule (Appendix 4.6)    
 
4.3.6 Data management and storage 
This section will describe how data management procedures were followed to 
ensure that individuals’ details and data remained confidential, and how 
participant privacy and anonymity were protected. 
  
4.3.6.1 Protecting confidentiality 
Interview data, the audio files, the personality test forms and the transcripts 
were kept securely to protect the confidentiality of participants.   
 
4.3.6.2 Anonymity 
The data was anonymised by referring to the interviewee by numbers one to 
ten. Identifiable information, such as the audio recording, was deleted from the 
audio recorder immediately after the file had been saved to a secure location. 
Three of the audio-recorded interviews were transcribed by an external agency, 
and these were sent as encrypted password protected files.  
Each audio file had a unique reference and a secure master file was created that 
matched the audio file to the interviewee as a numeric representation (1-10) to 
ensure that the data was anonymised but could be traced back for audit or data 
integrity purposes. 
Each personality test result was matched with the transcript for the interviewee 
and numbered one to ten. Names of participants were not recorded on the 
personality test forms. 
 
4.3.6.3 Privacy of participants 
Demographic information about participants was collected as necessary for the 
research, and kept securely.  Once transcribed, the demographic data collection 
that linked data to individual participants was destroyed.  Personality test 
information was collected for the research, the personality test score calculated 
for each interviewee, and the forms were then destroyed. 
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4.3.7 Data extraction 
The data extraction method was protocol driven and agreed in advance by the 
research team.   
 
4.3.7.1 Data extraction – interviews 
Firstly, the transcribed interviews were mapped to TDF by the researcher and 
two members of the research team. To ensure consistency and objectivity in 
coding to the TDF, transcripts were coded, as shown in Table 4.1. The 
researcher coded ten interview transcripts, one team member coded five 
transcripts and the other team member coded six to allow a three person 
interrater reliability and verification process for interview 6 (4.4.2). There was 
agreement within the team that an illustrative quote could be mapped to 
multiple TDF domains. 
 
Table 4.1 Coding schedule for mapping of interviews to TDF 
Interviewee 1 2 3 4 5 6 7 8 9 10 
Researcher √ √ √ √ √ √ √ √ √ √ 
Coder 1      √ √ √ √ √ 
Coder 2 √ √ √ √ √ √     
 
4.3.7.2 Data Extraction -personality test data 
Secondly, the personality test scores were calculated and recorded as described 
in 4.3.6 using the Big 5 inventory scale scoring schedule (Appendix 4.6).  The 
scoring was carried out by the researcher, and a sample checked by a colleague. 
 
4.3.8 Data analysis 
Data analysis was conducted, commencing with familiarisation of data and 
mapping to TDF for interviews, and with calculation of personality test data and 
these steps are now described. 
 
4.3.8.1. Data analysis - interviews 
The interview transcripts were analysed using a framework approach, using TDF 
as the main theoretical underpinning framework. In addition, the whole 
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transcript was checked frequently to determine if further data extraction to the 
TDF domains, themes or subthemes could be made.  This ‘checking back’ was 
done repeatedly as the findings were analysed, and ensured that participants’ 
voices were adequately represented.   
After mapping to TDF, the process of data extraction continued, grouping 
themes and subthemes together from within and across the TDF Domains.  This 
step was done by the researcher, with ongoing verification by the research team 
that the themes and subthemes were clear and appropriate.  This step is 
conventional when using a theoretical framework.  The data extraction and initial 
analysis method is summarised in Figure 4.3. 
 
 
Figure 4.3 Schematic of data extraction and analysis process 
4.3.8.2 Data analysis: personality tests  
As described (4.3.5), personality test scores were calculated for each 
interviewee (Table 4.2).  For purposes of this study, the scores were compared 
across the cohort to ascertain personality types for participants (Figure 4.4), and 
the scores and the comparison were used in creating individual profiles for 
participants (4.4.1). A report of individual personality test scores was sent to 
each participant using a template (Appendix 4.7). 
Listening
• Researcher listened to audio files multiple times and made field notes.
Transcribing
• Researcher transcribed audio files (or checked transcription where 
externally transcribed).  
Mapping to 
TDF
• Researcher mapped ten transcripts to TDF, all were independantly 




• Researcher checked back all transcripts once initially mapped, and as 




Table 4.2: Big 5 inventory personality test scores for interview participants. 
 
 
    
 
Figure 4.4 Personality test scores for interviewees 
 










































1 2 3 4 5 6 7 8 9 10 11
Scores for Interviewees 1-10. 
Column 11 shows average for cohort
Series1 Series2 Series3 Series4 Series5
Interviewee / Score 1 2 3 4 5 6 7 8 9 10 Ave Max Min 
Extroversion 33 27 24 21 29 37 28 38 30 26 29.3 38 21 
Agreeableness 42 32 43 37 39 39 37 37 39 31 37.6 43 31 
Conscientiousness 25 33 33 24 41 41 29 30 43 35 33.4 43 24 
Neuroticism 13 31 19 21 20 25 29 23 16 33 23 33 13 
Openness 41 27 35 24 31 45 31 33 33 42 34.2 45 24 
Extroversion Openness Neuroticism Conscientiousness Agreeableness 
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4.3.9 Situational and environmental data 
Situational and environmental data was recorded during the study. The duration 
of each interview was available from the digital recorder, and the day and time 
of day noted in the field notes.  The interview duration ranged from 19 minutes 
13 seconds to 35 minutes 9 seconds, with up to ten minutes spent on 
introduction and carrying out the personality test, and were all therefore 
completed within the planned time of 45 minutes.  Five interviews took place in 
the morning and five in the afternoon.  Rooms were all booked on the hospital 
site that the participants worked at.  This meant that participants did not have to 
spend time travelling, and additonally increased their level of environmental 
comfort.  Distraction and interruption was minimised by using rooms other than 
their normal office environment.  The interviews took place during March and 
April 2018, on working days for the participants. 
 
4.3.10 Techniques to enhance trustworthiness 
The four key components of trustworthiness are credibility, transferability, 
dependability and confirmability (Shenton 2004), as discussed in Chapter 2.  
Each component should be considered during study design to maximise 
trustworthiness. 
Credibility describes whether the phenomena have been accurately represented 
by the study, giving confidence in the truth or credibility of the findings.  
Credibility can be increased during planning of interviews by defining and 
explaining the method and sampling.  In this study, the method and sampling 
plan have been described. This study used a theoretical framework (TDF) in the 
design of the interview schedule, and in data analysis; the use of theory adds to 
the credibility of the findings. 
Transferability describes whether the study could be “transferred” to other 
situations or contexts.  Describing the study in sufficient detail to facilitate 
transferability, or to allow adequate understanding of the context and setting, 
will increase transferability.  In this study, detailed descriptions of the method 




Dependability describes whether the study is consistent, and could be 
repeated, getting similar results in a dependable manner. The conduct of the 
interviews has been described, and detail provided on data generation and 
analysis. These details have allowed dependability to be assessed by the 
readership, to evaluate whether the study could be repeated in another setting.   
Confirmability describes whether the study has been carried out as objectively 
as possible, so the results are shaped by participants and not researcher. Details 
have been provided of the conduct of the interviews, and generated data has 
been presented to allow readership to assess how well the voice of the 
participant has been represented.  By describing reflexivity and biases at all 
stages of the research, the researcher can maximise confirmability.  Reflexivity 




4.4 Findings of Phase 2 interview study  
This section will describe the findings of the Phase 2 study. The findings included 
information about participants as demographic information, and as personality 
test scores. Data was generated from mapping of interview transcripts to the 
Theoretical Domains Framework, which was then analysed.  
This section will first describe participant demographics, then interrater 
reliability, next, the findings from content and framework analysis of the 
generated date and finally the findings from the personality tests. 
 
4.4.1. Demographics of participants  
The demographics of all participants in Phase 2 in-depth interview are shown in 
Table 4.3, and additionally by individual personality profiles for each participant 
(Figures 4.5-4.14). Demographic and descriptive information is relevant when 
considering the transferability and dependability of the study.  The site 
numbering reflects the numbering used in Chapter 3 focus groups. 
Table 4.3 Demographics of participants for Phase 2 interviews 
Interviewee 1 2 3 4 5 6 7 8 9 10 





















Grade/Band  8 8 6 8 8 7 8 8 7 7 
Gender F F F F F F F F M F 
 
The study was conducted across the five acute hospital sites. In Phase 1, one 
focus group discussion was held at each of the five sites, and this was 
considered an important part of the sampling plan.  For the Phase 2 interviews, 
none of the focus group participants from site 3 responded to the request to 
participate in interviews, at initial or follow up request.  Therefore, there was no 
representation from site 3, which was the single site that did not participate in 
the interview phase of the study, and this could have introduced bias. 
Participants for interviews were selected from the initial cohort of 20 pharmacists 
that had taken place in Phase 1 focus group discussions, where the male/female 
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ratio was four males to sixteen females. This is reflective of the ratio across the 
organisation.  Having only one male participant for Phase 2 interviews is less 
than this 1:4 ratio, and may have had an influence on the results. 
 
4.4.1.1 Demographics of participants – personality test results 
Individual profiles of participants were created to describe the demographics of 
participants, incorporating the information from the Big 5 inventory personality 
test results (Figures 4.5-4.14).  The use of the personality test scores in the 
individual profiles is believed to be a novel form of presenting demographic 
information about participants taking part in qualitative research. 
Each personality trait used in the Big 5 inventory is described here (Benet-
Martinez and John 1998; John and Scrivastava 1999): 
Extroversion as a personality descriptor describes the spectrum from 
extroversion to introversion. Extroversion manifests in how an individual 
interacts with others: in general, extroverts draw energy from interacting with 
others, while introverts get tired from interacting with others and replenish their 
energy from being alone.  In the Big 5 personality test, the higher the score the 
more extrovert the person. People high in extroversion tend to seek out 
opportunities for social interaction. They are comfortable with others, 
gregarious, and prone to ‘doing’ and being active rather than being 
contemplative. People low in extroversion, or introverts, are more likely to be 
quieter, introspective, reserved, and thoughtful. 
Agreeableness describes how well people get along with others. While 
extroversion concerns sources of energy and the pursuit of interactions with 
others, agreeableness concerns orientation to others. It is a descriptor of how 
well individuals interact with others. People high in agreeableness tend to be 
well-liked, respected, and sensitive to the needs of others. They have few 
enemies, are sympathetic, and affectionate to their friends and loved ones, as 
well as sympathetic to the plights of strangers. People on the lower end of the 
agreeableness spectrum are less likely to be trusted and liked by others. They 
tend to be more callous, perhaps blunt or rude, ill-tempered, antagonistic, and 
sarcastic. People who are low in agreeableness are not likely to leave others with 
a feeling of warmth. 
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Conscientiousness is a trait that can be described as the tendency to control 
impulses and act in socially acceptable ways, displaying tendencies that facilitate 
goal-directed behaviour.  Conscientious people excel in their ability to delay 
gratification, work within the rules, and plan and organize effectively. Someone 
who is high in conscientiousness is likely to be successful in school and in their 
career, to excel in leadership positions and to doggedly pursue their goals with 
determination and forethought. A person who is low in conscientiousness is 
much more likely to procrastinate, to be flighty, impetuous, and impulsive. 
Neuroticism is a factor of confidence and being comfortable in one’s own skin. 
It encompasses emotional stability and general temper. Those with high scores 
in neuroticism are generally given to anxiety, sadness, worry, and low self-
esteem. They may be temperamental or easily angered, and they tend to be 
self-conscious and unsure of themselves. Individuals who score on the low end 
of neuroticism are more likely to feel confident, sure of themselves, and 
adventurous. They may also be brave and appear unencumbered by worry or 
self-doubt. 
Openness to experience has been described as the depth and complexity of an 
individual’s mental life and experiences. It is also sometimes called intellect or 
imagination. Openness to experience concerns an individual’s willingness to try 
new things, to be vulnerable, and the ability to think outside the box.  An 
individual who scores high in openness to experience is likely to be someone 
who has a love of learning, enjoys the arts, engages in a creative career or 
hobby, and likes meeting new people. An individual who is low in openness to 
experience probably prefers routine over variety, sticks to what they know, and 








Greater than average in agreeableness and openness; lower than average in 
neuroticism and conscientiousness 





Greater than average in neuroticism; lower than average in openness 





Greater than average in agreeableness; lower than average in extroversion and 
neuroticism 





Lower than average in extroversion, conscientiousness and openness 
Figure 4.8 Interviewee 4 profile 
 
Agreeableness Conscientiousness Neuroticism Openness
Extroversion Agreeableness Conscientiousness Neuroticism Openness
Extroversion Agreeableness Conscientiousness Neuroticism Openness 







Greater than average in conscientiousness; lower than average in neuroticism and 
openness 





Greater than average in extroversion, agreeableness. conscientiousness and openness, 
lower than average in neuroticism 





Greater than average in neuroticism; lower than average in conscientiousness 








Extroverrsion Agreeableness Conscientiousness Neuroticism Openness
Extroversion Agreeableness Conscientiousness Neuroticism Openness






Greater than average in extroversion; lower than average in conscientiousness 





Greater than average in conscientiousness; lower in average in neuroticism 





Greater than average in neuroticism and openness; lower than average in extroversion 
and agreeableness 
Figure 4.14 Interviewee 10 profile 
 
4.4.2. Interrater reliability  
An interrater exercise was conducted using the interview transcript that all three 
coders had coded to TDF, (interview 6), as described. A total of 54 quotes were 
extracted from the interview transcript of interview 6 by the three coders: 19 
had a three from three match at first mapping; 21 had a two from three match 
at first mapping and the remaining 14 quotes were discussed and TDF domain(s) 
agreed following discussion.  On discussion between the coders, it was agreed 
that the variation came from inexperience with the TDF (researcher), or 
Extroversion Agreeableness Conscientiousness Neuroticism Openness 
Extroversion Agreeableness Conscientiousness Neuroticism Openness 
Extroversion Agreeableness Conscientiousness Neuroticism Openness
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unfamiliarity with the process that was being described in the transcript 
(research team). The interrater exercise was of benefit to the researcher, and 
adds to the trustworthiness of the study. 
 
4.4.3. Findings – content analysis 
Content analysis of the data generated by mapping the interviews to the TDF 
demonstrated that there was a range in the frequency with which each domain 
occurred, from two instances for the domain ‘reinforcement’ to 75 instances for 
the domain ‘social/ professional role and identity’ (Table 4.4).   
There was also variation in how many quotes were extracted for individual 
participants, from twenty for interviewee 3 to sixty for interviewee 6.  All TDF 
domains were represented in the data extraction phase, although this had not 
been a prior requirement. 
Although there is no significance attached to the frequency with which a domain 
is represented, content analysis may indicate which domains have provided the 
richest data.  However, it is noted that this may be influenced by the 
interviewer, by the interview schedule or by the participants.   
The process of coding data and extracting meaning is subjective. As a naïve 
researcher, starting with the TDF as an a priori framework was beneficial as it 
gave the process an initial structure and allowed TDF domains to be established 





 Table 4.4: Frequency TDF domain mapped to for each interviewee 





























































































































































































































1 Count 1 9 11 5 1 4 0 3 1 3 3 2 6 1 50 
2  4 8 5 1 0 2 1 1 0 2 1 1 5 1 32 
3  1 3 0 1 0 4 0 0 0 2 3 1 5 0 20 
4  1 3 6 5 1 1 1 2 1 4 1 1 2 3 32 
5  4 4 6 4 3 2 0 2 1 1 3 2 2 5 39 
6  1 6 15 6 0 2 0 3 1 2 7 2 9 6 60 
7  3 4 6 1 0 4 0 0 0 1 3 7 5 6 40 
8  3 4 9 1 0 3 0 0 0 1 1 4 6 11 45 
9  7 2 9 0 0 1 0 0 0 2 3 7 1 3 35 
10  1 1 8 2 1 0 0 0 0 3 8 3 2 9 38 
 Totals 26 44 75 26 6 23 2 11 4 23 33 30 43 45 391 




4.4.4 Findings – framework analysis 
As described, the transcripts were individually mapped to the TDF, as the 
underpinning theoretical framework for Phase 2, using framework analysis 
techniques.  During this exercise, the research team conferred on the process for 
mapping, and agreed that the purpose of the data extraction was to identify key 
statements that related to how clinical pharmacist experienced suboptimal 
pharmaceutical.  It was noted that there were four areas where suboptimal 
pharmaceutical care could be experienced, and these are described here: 
1) Identifying suboptimal pharmaceutical care is used as a description of the 
process that may happen with an individual realising that a clinical 
decision they have made, or a prescription they have written has an error; 
or where an individual observes an error in the clinical decision making or 
prescription writing that another pharmacist has done. 
2) Responding to suboptimal pharmaceutical care describes the process that 
follows the detection of suboptimal pharmaceutical care in self or others, 
and may take the form of ‘fixing’ the identified error.  
3) Reporting suboptimal pharmaceutical care is used as a description that 
covers: informal feedback between colleagues who are peers, informal 
feedback from a senior to a more junior colleague, or reporting or self-
reporting using formal means (for example DATIX reporting system).  
4) Reflecting on suboptimal pharmaceutical care describes the process by 
which individuals reflect on their own experiences of suboptimal 
pharmaceutical care.  This may be within their own or other’s practice   
The findings from the data are presented initially using the TDF as a framework, 
and with any emerging subthemes described within each domain. All 14 TDF 
domains were represented by the gathered data (Table 4.4), and are presented.  
Specific examples of suboptimal pharmaceutical care as described by 
interviewees were extracted from the transcripts and anonymised and are 
presented in Appendix 4.9 as supplementary data. 
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4.4.4.1 Knowledge domain 
 
 
There were 26 quotes from participants in the knowledge domain. The quotes 
were captured within the theme of ‘knowledge’ and two subthemes:  
1) Lack of knowledge of what constitutes suboptimal pharmaceutical care 
2) Lack of knowledge – expected as in training 
 
Lack of knowledge of what constitutes suboptimal pharmaceutical care 
The first subtheme emerged from recurring reference to individuals’ knowledge 
and understanding of what would be classified as suboptimal pharmaceutical 
care: 
‘what you're providing is the, the best pharmaceutical care provision you 
can but, it could be suboptimal in others experience or views and that, 
potentially, could be due to limited experience you have or that, or could 
be due to lack of knowledge’ [Interviewee 9 Band 7 Pharmacist]  
This participant referred to lack of knowledge or experience as being an 
influence on whether something would be perceived as suboptimal.  Other 
participants reiterated that it was difficult to define what was suboptimal in 
terms of pharmaceutical care: 
‘I guess it’s quite difficult sometimes to define suboptimal pharmaceutical 
practice’ [Interviewee 9 Band 7 Pharmacist] 
An exception to this uncertainty appeared to be for pharmacist independent 
prescribers, where there was more certainty that making a prescribing error 
would be classed as suboptimal pharmaceutical care: 
‘I feel more responsible when it's my pen and it's more obvious that it 
would be a suboptimal pharmaceutical care issue, and it was me’ 
[Interviewee 2 Band 8 Pharmacist] 
The subtheme ‘lack of knowledge of what constitutes suboptimal pharmaceutical 
care’ also included several participants’ discussions around the priority coding 
process being used (described in Chapter 1): 
‘…then it’s all subjective. One person’s high priority patient is another 
person’s slightly lower priority patient.  So, there is that inter-variability 




A number of participants highlighted that the process for prioritising patients had 
perhaps inadvertently lead to a new area for identifying suboptimal 
pharmaceutical care. Priority coding has been introduced as a tool to help 
pharmacists prioritise how they direct their skills, and manage workload by 
identifying at risk patients.  The tool has changed how pharmacists work but has 
also potentially created a feeling of poor performance, with several interviewees 
citing the inability to see priority patients as an example of suboptimal 
pharmaceutical care: 
‘If we or a professional colleague has reviewed a patient, screened a 
patient for care issues, and in their judgement, feel there are enough 
issues going on with that patient that we should check their status every 
day, check their prescription regularly, ensure that they are appropriately 
monitored… So, if we’re not doing that? It’s suboptimal’ [Interviewee 1 
Band 8 Pharmacist] 
And: 
‘If there are code 1 patients, I will try my best to do it, but some days you 
can’t.  When I don’t get to them I feel it is suboptimal pharmaceutical 
care’ [Interviewee 6 Band 7 Pharmacist] 
However, one participant was more circumspect, pointing out that, when at 
work, prioritisation is continually changing, and other tasks may become more 
important: 
If you don’t get to see them (priority 1 patients) because you’ve literally 
had so much to do that you considered to be as much a priority in your 
opinion, then no, I don’t think that it’s suboptimal. [Interviewee 7 Band 8 
Pharmacist] 
 
Lack of knowledge – expected as in training 
The second subtheme emerged where some participants reported that they 
would sometimes identify suboptimal pharmaceutical care in others, where it 
appeared to be because the other person (often a trainee) did not have 
adequate knowledge of work practices in the area: 
‘She’d not been qualified that long, and she hadn’t followed up something 
as well, and, well, I was the same, after I’d qualified’ [Interviewee 3, Band 
6 Pharmacist] 
The benefit of this informal feedback was acknowledged by a recipient: 
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‘when you’re a junior you really benefit from that informal peer review, 
sort of feedback session’ [Interviewee 7 Band 8 Pharmacist]] 
Another participant referred to a point at which you might be expected to have 
the required knowledge, and this is captured by the main theme of knowledge: 
‘probably there's a kind of middle grade where you think you should know 
things’ [Interviewee 2 Band 8 Pharmacist] 
It appears that participants felt that there was a level of experience – ‘a kind of 
middle grade’- where they would expect colleagues to have the required 
knowledge to be able to deliver optimal pharmaceutical care.  Beyond this level 
of experience, as will be indicated later in this section, ‘hierarchy’ and ‘personal 
and professional barriers’ may become more prevalent as determinants of 
behaviour that affect reporting of suboptimal pharmaceutical care. 
 
4.4.4.2 Skills domain 
 
 
There were 44 quotes identified from participants in the skills domain. The 
quotes were captured within two subthemes:  
1) skills for reporting on suboptimal pharmaceutical care 
2) skills in giving feedback 
Skills for reporting on suboptimal pharmaceutical care 
The first subtheme related to the skills involved in reporting on suboptimal 
pharmaceutical care, and participants stating that they did not have the skill set 
to report: 
‘Yeah, it’s something on reflection that we probably aren’t very good at 
and probably still aren’t very good at, in terms of reporting erm incidents’ 
[Interviewee 1 Band 8 Pharmacist] 
There was reference to the practicalities of reporting suboptimal pharmaceutical 
care being difficult, as a skill: 
‘I think the practicalities of actually doing it might be difficult’ [Interviewee 
2 Band 8 Pharmacist] (referring to reporting of suboptimal pharmaceutical 




These illustrative quotes demonstrate that there is an awareness amongst 
participants that there are occasions when suboptimal pharmaceutical care 
occurs, but is not reported.  
Skills in giving feedback 
The second subtheme identified that skills are needed to be able to give 
feedback to other pharmacists when you have observed suboptimal 
pharmaceutical care in their practice. One participant identified that they lacked 
skills in giving feedback or having ‘difficult conversations’: 
‘I suppose, lacking the skills to have difficult conversations…[Interviewee 
4 Band 8 Pharmacist] 
And another identified that they lacked the skills, felt uncomfortable crossing the 
professional barrier, and invoked an emotional reaction: 
I find it very difficult to feedback directly to my colleague, I don’t feel 
comfortable to do that, emotionally’ [Interviewee 6 Band 7 Pharmacist] 
In these two examples, participants describe an absence or lack of skills.  This is 
in contrast to an example given where the presence of skills to provide feedback 
was perceived as an enabling determinant to developing others in the team: 
‘although she’d covered quite a lot of the common policies in her training 
this one seemed to be omitted for whatever reason. So, I just caught her 
the next day, and showed her the protocol, and she said she’d not seen it 
before’ [Interviewee 5 Band 8 Pharmacist] 
Therefore, the ‘skills in giving feedback’ subtheme can be either a positive or a 
negative influence on behaviour. 
 
4.4.4.3 Social/professional roles and identity domain 
 
 
There were 75 quotes identified from participants in the social/professional roles 
and identity domain. The quotes were captured within two subthemes: 
1) personal and professional barriers 




Social/professional roles and identity 
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Personal and professional barriers 
Participants reflected on what it meant to be a pharmacist, and expressed how 
they felt pharmacists were perceived as paying attention to detail. This created a 
barrier to disclosing suboptimal pharmaceutical care,  captured by the subtheme 
‘personal and professional barriers’: 
‘It would be very difficult (to disclose suboptimal pharmaceutical care), as 
I think as pharmacists we’re known for our attention to detail’ 
[Interviewee 1 Band 8 Pharmacist] 
This related to disclosure to the wider community of the multidisciplinary team 
or to pharmacy senior management. 
Other participants described in their interviews how the pharmacy profession is 
viewed by others within the MDT, with the subtheme of ‘personal and 
professional barriers’ describing how the pharmacist may not be held 
accountable by other members of the MDT, and how other professions were 
unlikely to report on suboptimal pharmaceutical care:  
‘I feel like pharmacy is not judged as harshly as maybe the other 
professions are. Like doctors’ [Interviewee 2 Band 8 Pharmacist] 
and 
‘I don't think other professionals are very critical of us’ [Interviewee 3 
Band 6 Pharmacist] 
Participants gave examples of why they thought there were professional 
barriers, and the difficulty other professions may have in identifying whether 
care provided was suboptimal pharmaceutical care: 
 ‘I don’t think many people understand what a pharmacist truly does, I 
think that’s the key thing’ [Interviewee 6 Band 7 Pharmacist] 
These two illustrative quotes are captured within the ‘personal and professional 
barriers’ subtheme, and relate to the unlikelihood of other professions identifying 
suboptimal pharmaceutical care. 
Professional embarrassment 
A second subtheme was identified that captured discussions around feelings of 
shame as barriers to reporting: 
‘I think that it (professional embarrassment) is a barrier in lots of ways to 
reporting’ [Interviewee 4 Band 8 Pharmacist] 
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Professional embarrassment was also expressed by a participant when 
describing the disclosure of a ‘silly’ mistake: 
‘the embarrassment of admitting to the team that you've done something 
really silly’ [Interviewee 4 Band 8 Pharmacist] 
Another participant discussed their experience of disclosure, and suggested that 
if they had made an error, they would be selective about who they shared that 
with, due to professional embarrassment: 
‘you might sort of tell people you know well and trust, but you don't 
necessarily want to, won't necessarily tell everyone...’ [Interviewee 4 
Band 8 Pharmacist] 
Professional embarrassment therefore appears to create a barrier to reporting on 
suboptimal pharmaceutical care, however one participant pointed out that they 
would overcome professional embarrassment in order to fix something that may 
harm a patient, or to act on suboptimal pharmaceutical care: 
‘did I do something wrong for those patients?... and that overrides the 
embarrassment that I'm like, I'm trying to fix this’ [Interviewee 2 Band 8 
Pharmacist] 
 
4.4.4.4 Beliefs about capabilities domain 
 
 
There were 26 quotes identified within the beliefs about capabilities domain. All 
quotes were captured within beliefs about capabilities as a main theme and 
there were no subthemes.  
Participants reflected on their ability and competence to identify and to report on 
suboptimal pharmaceutical care. However, there did not appear to be a 
consensus amongst participants. Some participants felt they, and other 
pharmacists would be competent and able to identify instances of suboptimal 
pharmaceutical care: 
‘I think we all, all pharmacists, junior and senior, have the ability to 
identify suboptimal pharmaceutical care. It’s how comfortable people are 
then to report that then.’ [Interviewee 6 Band 7 Pharmacist] 
However, other participants were more reticent: 
Beliefs about capabilities 
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‘I think before we find suboptimal pharmaceutical care we have to identify 
optimal pharmaceutical care and I don't think we’ve really got that yet.’ 
[Interviewee 4 Band 8 Pharmacist] 
The quote is used here to illustrate how the lack of clarity of optimal and 
suboptimal in terms of pharmaceutical care can be a barrier to the capability of 
individuals to identify instances of suboptimal pharmaceutical care.   
Some participants were unclear on their capability of being able to report.  This 
included references to reporting by self: 
‘I suppose self-reporting is very difficult. That you have to blame yourself 
kind of’ [Interviewee 2 Band 8 Pharmacist] 
As previously described, in this situation subthemes from the social/professional 
role and identity domain, namely ‘personal and professional barriers’ and 
‘’professional embarrassment’ are determinants of whether self-reporting is 
likely. 
Other participants referred to barriers in the reporting of others: 
‘to be honest unless it was something I suppose, a near miss or 
something very serious, generally you wouldn’t feedback to the person 
who had seen the patient before you’. [Interviewee 7 Band 8 Pharmacist] 
In this situation the participant appears to be using their own criteria to 
determine whether the instance of suboptimal pharmaceutical care that they had 
observed in another’s practice should be fed back on, or just fixed, and this is 
discussed further as a subtheme (fix and forget) under the memory attention 
and decision-making domain. 
 
4.4.4.5 Optimism domain 
 
 
There were six quotes in the optimism domain, and all were contained within the 
theme of optimism, with no subthemes.  
Some participants did not feel optimistic that reporting on suboptimal 
pharmaceutical care would be carried out, with one participant describing their 




suboptimal pharmaceutical care, and with individual or collective attitude having 
an influence:  
‘I think it’s a lot to do with attitude, erm and I think we could, but I think 
some, some of them (other pharmacists) would probably have excuses’ 
[Interviewee 6 Band 7 Pharmacist] 
A further participant reflected on the unlikelihood of reporting of suboptimal 
pharmaceutical care, perceiving overload as being a barrier, with some 
suggestion of defeatism in their statement: 
‘you could report suboptimal pharmaceutical care all day ‘cause there's 
always going to be something that we're going to miss.’ [Interviewee 2 
Band 8 Pharmacist] 
The theme of optimism captured perceptions by participants that reporting on 
suboptimal pharmaceutical care was unlikely unless changes in attitude and 
behaviour took place. 
 
4.4.4.6 Beliefs about consequences domain 
 
 
There were 23 quotes identified in the beliefs about consequences domain and 
all were captured within beliefs about consequences as a main theme with no 
subthemes.   
Participants had contrasting views on whether the consequence of reporting on 
suboptimal pharmaceutical care would be negative or positive, with one 
participant being negative about the consequences for them as an individual: 
‘it would require a culture shift, or a culture change for it to be accepted, I 
suspect like everything, I mean it’s just nature isn’t it, everyone’s 
individual reaction is you know, oh I’m getting told off or I’ve done 
something wrong and you’re having to disclose and you’re airing your 
dirty laundry’ [Interviewee 1 Band 8 Pharmacist] 
In this example, the previously described subtheme of ‘professional 
embarrassment’ can be seen to be a barrier to reporting, unless there was a 
change in culture. 
However, other participants felt the consequence of reporting on suboptimal 
pharmaceutical care would be positive: 
Beliefs about consequences 
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‘I think there could be some good learning from it’ [Interviewee 2 Band 8 
Pharmacist] 
whilst another participant acknowledged that ‘personal and professional barriers’ 
could be overcome by the recognition that there would benefit overall: 
‘I think initially I’d be quite nervous about it, because then like everyone’s 
basically seeing your mistake essentially, but then in the long run it would 
be better overall’ [Interviewee 3 Band 6 Pharmacist] 
Other participants discussed how senior management might view reporting on 
suboptimal pharmaceutical care.  One participant had concerns that there may 
be criticism from senior management, and this reflected the ‘personal and 
professional barriers’ subtheme: 
‘it might just be difficult for them (senior management team) to 
understand how that could happen, a suboptimal episode of care for a 
patient. So, it might turn like a little bit too critical, when actually it’s just 
reality’ [Interviewee 8 Band 8 Pharmacist] 
whilst another participant acknowledged that information on instances of 
suboptimal pharmaceutical care should be something that senior management 
know about, but were not clear how this could be achieved: 
‘It’s quite difficult to know how to report them isn’t it though? And I think 
probably its vital that senior management do know that, because then the 
strategy, if that’s what needs changed, like the pharmacy strategy, can 
kind of be tweaked to fit better with that, so that’s what the advantages of 
senior management knowing these things are, that support can be from 
the top down’ [Interviewee 8 Band 8 Pharmacist] 
 
4.4.4.7 Reinforcement domain 
 
 
There were two quotes identified in the reinforcement domain, and both were 
captured within ‘reinforcement’ as a theme with no subthemes.  One interviewee 
described how they had used their personal experience of suboptimal 
pharmaceutical care to provide knowledge to others, as an example of 
reinforcing the learning they had received themselves: 
‘I definitely use what I have learnt to give examples to people’ 




4.4.4.8 Intentions domain 
 
 
There were eleven quotes identified in the intentions domain, and these were 
captured within the theme of ‘intentions’ with no subthemes. The TDF domain 
for intentions included those instances where the interviewee intended to see 
patients as planned, and did not or could not: 
‘I may have a plan that goes completely by the wayside of what I will be 
doing that day because of the reactive nature of the job, the bleep goes 
off, things change, patients change, discharges happen and, yes, ah ha, I 
do see that as suboptimal, if I've planned to go and see a certain patient 
and I don't see them, I'd see that as suboptimal. [Interviewee 4 Band 8 
Pharmacist]   
 
4.4.4.9 Goals domain 
 
 
There were four quotes in the goals domain, and no subthemes; it was noted 
that there was some overlap between the goals domain and the intentions 
domain.  
Participants discussed how their overall goal of seeing patients was sometimes 
impeded: 
‘I guess because I’m quite conscientious it does kind of, I do think, oh 
that’s quite annoying I didn’t get to that’ [Interviewee 5 Band 8 
Pharmacist]  
This was sometimes described as being due to distractions or other tasks taking 
priority: 
‘Where you may have a plan of erm you know the next two hours this is 
what I’m going to do, you get bleeped or called for something else’ 










4.4.4.10 Memory, attention and decision-making domain 
 
 
There were 23 quotes identified by participants in the memory, attention and 
decision-making domain. Quotes were captured within memory attention and 
decision-making as a theme, and with one subtheme: 
1) Fix and forget 
In the theme ‘memory, attention and decision-making’, participants described 
how lapses in memory or attention contributed to an episode of suboptimal 
pharmaceutical care, (in this example, not providing timely counselling on 
warfarin), which may result in additional unscheduled work for another member 
of the team: 
‘It might be things like I’ve forgotten to…say…someone needs to be 
warfarin counselled and then it’ll be a few days later and someone will 
have to do it in a mad rush.’ [Interviewee 10 Band 7 Pharmacist] 
Other participants describe how the lack of attention or remembering to go back 
and complete a task are behaviours that can create the environment in which 
suboptimal pharmaceutical care can occur: 
 ‘Sometimes there's a complete forget and you think, oh, I never ever, 
ever came back to that and you're too late now or, it doesn't, just gets 
pushed to the bottom of the list.’ [Interviewee 2 Band 8 Pharmacist]  
And one participant described how other, more urgent tasks, can take priority 
and lead to a situation where suboptimal pharmaceutical care is invoked: 
‘I am doing what is urgently needing my attention and, in doing so that 
might have slipped your mind or, you might have put at the back of your 
mind that I can deal with it later on and then that didn't happen for 
whatever reason…’ [Interviewee 9 Band 7 Pharmacist] 
Fix and forget 
A subtheme of ‘fix and forget’ emerged when discussing the process of providing 
feedback to someone else who has delivered suboptimal pharmaceutical care 
‘...feeding that back to people, there could be a time constraint of actually 
having to, you see something, you fix it and you've got to remember to go 
back to somebody.’. [Interviewee 4 Band 8 Pharmacist] 
Memory attention and decision-making 
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In this situation, the participant described memory failure as a barrier, and 
instead, acted to fix the issue.  In the subtheme of ‘fix and forget’, participants 
described how identifying suboptimal pharmaceutical care, and acting in the 
moment to fix the error were dominant behaviours, but that reporting was less 
likely where there were time constraints, and the error would then be forgotten. 
Another participant however, described that if there was a more serious error 
then they would take time to provide feedback. 
I would probably go and fix it, and then I’d just catch them whenever I 
next saw them and just kind of say, well if it was something that would 
harm the patient I would definitely highlight it to them [Interviewee 3 
Band 8 Pharmacist] 
The description of ‘fixing’ something that was observed in another’s practice was 
referred to several times, and included ‘fixing’ across multiple grades and 
experience of pharmacist. 
 
4.4.4.11 Environmental context and resources domain 
 
 
There were 33 illustrative quotes extracted from participants in the 
environmental context and resources domain.  The quotes were captured within 
the theme ‘environmental context and resources’ with three subthemes:   
1)  Time constraints 
2)  Lack of access to computers 
3)  Lack of formal mechanisms for reporting on suboptimal pharmaceutical 
care 
Time constraints 
For the first subtheme, several participants referred to ‘time constraints’ as an 
issue that may lead to suboptimal pharmaceutical care being delivered, for 
example, not following up a pharmaceutical care issue as planned and intended: 
‘suboptimal- I mean a lot of it’s about time pressure, it’s not following up 
on something that you know really you should have done, and you’re kind 
of like ach I’m sure it will be fine’ [Interviewee 1 Band 8 Pharmacist] 
Another participant described time constraints as a barrier to completing tasks: 
Environmental context and resources 
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‘Time is always an aspect and I think that would be for me, that would, 
that would be the biggest one’ [Interviewee 2 Band 8 Pharmacist] 
Time constraints were also cited as a barrier to formal reporting on suboptimal 
pharmaceutical care: 
‘I think because of time constraints I probably wouldn’t do it. I think 
documenting on DATIX is poorly done, people just think I’ll do it later, and 
never do it. So, I think something else to complete, it sounds a bit 
pessimistic, but I just don’t think it would work’ [Interviewee 6 Band 7 
Pharmacist] 
Lack of access to computers 
A second subtheme emerged, where participants cited a lack of access to 
computers as being a barrier, and described the consequences of this as being 
duplication of effort, and impact on others: 
‘in the course of the day, I’ve been really busy and I’ve done the 
discharge letter and I’m still trying to see code 1’s and I’ve not always put 
it on (TRAK), because there’s still issues or there’s no access to 
computers, and of course that has an impact on someone’s work the next 
day because they don’t know it’s been done’ [Interviewee 10 Band 7 
Pharmacist] 
Lack of formal mechanisms for reporting on suboptimal pharmaceutical 
care 
The third subtheme emerged since mechanisms for reporting are an 
organisational issue, and are not currently described. Whilst the lack of formal 
mechanisms for reporting on suboptimal pharmaceutical care was a barrier for 
some participants: 
‘I think if you do it in a more formal way, people do feel picked on, 
because pharmacists like to get everything right’ [Interviewee 7 Band 8 
Pharmacist]] 
or saw that the presence of a formal process itself could become a barrier: 
‘if you had to do it in a formal way, as a reporter you might feel less 
inclined to do it.  It’s like DATIX, oh I don’t want to get anyone into 
trouble, don’t want to be that person that’s told a tale’ [Interviewee 7 
Band 8 Pharmacist] 
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The participant here was contrasting formal means of reporting on suboptimal 
pharmaceutical care with informal means of providing feedback. There were 
multiple references to ‘feedback’ given during the interviews.  The term 
‘feedback’ has differing meanings in different contexts, but use here is 
interpreted as meaning ‘giving information about performance, as a basis for 
improvement’ (Oxford Dictionary 2020c).  As discussed previously, informal 
feedback may be given to more junior pharmacists, acknowledging that they will 
have less knowledge and experience.  
Some participants expressed concern that there were no formal processes in 
place to provide feedback to pharmacists – particularly more experienced, senior 
pharmacists: 
‘I do sometimes worry about that, that we don't get the feedback for our 
own work’ [Interviewee 2 Band 8 Pharmacist] 
Participants also discussed means of getting more formal feedback on their 
performance, with two participants referring to a method used for trainees and 
considering that it might be of benefit for senior pharmacists too:  
‘But I don't have that (feedback). I remember when we first did the mini-
CEX training thinking I should get (the tutor) to come and do mini-CEX 
with me’ [Interviewee 4 Band 8 Pharmacist] 
‘The Mini-Cex training, the way that the juniors, for want of a better word, 
the way they have to demonstrate… I think that provides a much better 
forum for discussing these types of things. I think that would have value’ 
[Interviewee 7 Band 8 Pharmacist] 
The mini-CEX (mini clinical evaluation exercise) is a type of supervised learning 
event, where an individual carries out a task whilst being observed. 
 
4.4.4.12 Social influences domain 
 
 
There were 30 illustrative quotes identified in the social influences domain.  





One participant reflected on social influences that had affected them, and how 
the interactions they had had with colleagues had influenced the way they now 
felt about giving feedback on suboptimal pharmaceutical care: 
‘I think that’s important, from when you’re a junior, having been a junior, 
not to feel like you’re being picked on, or pulled up, because it’s ok to 
make mistakes. We are all learning’. [Interviewee 7 Band 8 Pharmacist] 
This quote illustrates the role the participant felt they now had in being a 
positive social influence on a more junior member of staff, and is also reflected 
by the previously identified ‘skills in giving feedback’ subtheme. 
Two other participants described variation in, and barriers to, giving and 
receiving feedback.  The first participant indicates the positive social influence 
that giving feedback on suboptimal pharmaceutical care can have: 
‘that’s why I think it’s such an important thing that people do receive 
feedback on these things. Certain people are better at giving feedback 
than others. I can imagine that there would be some people that would 
have just come and been like….(shrugs)... or like not even have told me’ 
[Interviewee 8 Band 8 Pharmacist] 
This quote also revisits the subtheme of ‘skills in giving feedback’. However, a 
second participant identified that there were barriers involved as a determinant 
of behaviour in the reporting of suboptimal pharmaceutical care: 
‘So, then that’s subjective, and you feel, well the implications of you 
reporting a colleague, from both a professional and from a personal issue, 
that’s very difficult’ [Interviewee 7 Band 8 Pharmacist] 
This second quote also reflects how the subtheme ‘personal and professional 
barriers’ has influence.  
Hierarchy 
The subtheme of ‘hierarchy’ was created to capture a specific area of discussion 
that related to the influence of the relative grades of the pharmacists involved 
on the likelihood of giving feedback on suboptimal pharmaceutical care: 
‘I think when it comes to probably giving feedback to others, thinking 
about it, now I think I will say it will be probably easier to do that with the 
people who are junior compared to someone who has a lot more 
experience then you, because people can sometimes see it as a criticism’ 
[Interviewee 9 Band 7 Pharmacist] 
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The subtheme of ‘hierarchy’ as a barrier when providing feedback on suboptimal 
pharmaceutical care was echoed by other interviewees: 
‘Yes, I would feel more comfortable feeding back more junior colleagues 
than more senior, or my peers’ [Interviewee 6 Band 7 Pharmacist] 
Of note is that these two illustrative quotes relating to hierarchy were from 
middle grade (Band 7) pharmacists.  Interviewee 6 gave some insight into the 
reason for this behaviour: 
‘I think it might be perceived in the wrong way. They may feel I am 
judging on how they are performing their tasks’ [Interviewee 6 Band 7 
Pharmacist] 
Not wanting to provide negative feedback on suboptimal pharmaceutical care to 
a more senior colleague because of hierarchical boundaries was established as a 
barrier.  This was also reported from the recipient’s perspective, in this case a 
more senior grade pharmacist: 
‘I do find that often people are reluctant to give negative feedback, so it’s 
not always helpful.  I just think they don’t want to upset you or…yeah, it 
can be quite awkward for them’ [Interviewee 8 Band 8 Pharmacist] 
Whilst representing the subtheme of ‘hierarchy, this quote, and others above, 
also reflects the ‘skills in giving feedback’ subtheme, for both giver and recipient 
of feedback. 
 
4.4.4.13 Emotion domain 
 
 
There were 43 quotes identified from participants in the emotion domain.  
Quotes were captured within two subthemes: 
1) emotional reaction to provision of suboptimal pharmaceutical care 
2) moral distress 
Emotional reaction to provision of suboptimal pharmaceutical care 
The first subtheme emerged from several participants expressing emotion when 
disclosing episodes of suboptimal pharmaceutical care.  Emotions expressed 




‘I felt terrible, I felt...I felt like I hadn't paid enough attention to the 
patient and that could've caused them serious harm’ [Interviewee 2 Band 
8 Pharmacist] 
And similarly, feeling ‘terrified’ that there would be harm to a patient: 
‘I was terrified!  I mean oh my goodness, I made that error quite early on 
when I was prescribing [Interviewee 6 Band 7 Pharmacist] 
There were similar negative emotions of guilt and fear of wrong doing expressed 
by participants when they described instances that they perceived as being 
suboptimal. 
‘And I was like ugh, god, it just makes you feel sick’ [Interviewee 8 Band 
8 Pharmacist] 
Moral distress 
One participant expressed an emotional response of dissatisfaction, when feeling 
unable to provide optimal pharmaceutical care when resources are lacking, and a 
subtheme of ‘moral distress’ emerged, describing the inability to do the job 
properly due to organisational constraints: 
‘I find it very emotionally wearing. I find it causes a lot of dissatisfaction 
with the job because you feel like you should be doing a job properly’ 
[Interviewee 10 Band 7 Pharmacist] 
Although this was a single illustrative quote, it reflected discussions by other 
participants of how emotions influenced their behaviour, and how anxieties 
about suboptimal pharmaceutical care may be taken home with them: 
‘Yeah I’m told oh you need to leave work at work, I mean it’s getting 
better, but I do spend time thinking, oh goodness I haven’t done this’ 
[Interviewee 6 Band 7 Pharmacist] 
‘you’d go home and think oh did I do that right, and not sleep, and 
worry…’  [Interviewee 7 Band 8 Pharmacist] 
Whilst these interviewees did not express dissatisfaction, the emotions 







4.4.4.14 Behavioural regulation domain 
 
 
There were 45 quotes identified from participants in the behavioural regulation 
domain. Quotes were captured in the theme of behavioural regulation and one 
subtheme: 
1) suboptimal pharmaceutical care as a learning opportunity 
Participants referred to behavioural regulation as a means of using their personal 
experiences of suboptimal pharmaceutical care, and taking the opportunity to 
promote behavioural regulation in others: 
‘I would definitely do it from a training point of view. Definitely. I would 
see that as a priority, because if they start developing habits, not 
intentionally, but missing that sort of thing they’re never gonna learn 
unless someone picks up on it’ [Interviewee 5 Band 8 Pharmacist] 
This also reflects the previously identified subtheme ‘lack of knowledge – 
expected as in training’, with the interviewee understanding that that is a 
behaviour that is required for the development of others 
Suboptimal pharmaceutical care as a learning opportunity 
Participants described how they used their experiences of suboptimal 
pharmaceutical care to change their own practice: 
‘certainly, after that I was incredibly careful when I was checking 
[Interviewee 1 Band 8 Pharmacist] 
Or, that reflecting on suboptimal pharmaceutical care made them realise that 
internal process checks were flawed: 
‘it made me realise that maybe some of my subconscious warning 
systems were not working’ [Interviewee 4 Band 8 Pharmacist] 
The sentiments here are captured by the subtheme ‘suboptimal pharmaceutical 
care as a learning opportunity’ – and this can be an opportunity for learning as 
an individual or as an opportunity for learning for the wider community. 
The opportunity for sharing experiences within the wider community was further 
discussed in relation to suggestions for how sharing the learning from reporting 




‘and it just sort of prompts everyone to maybe be that little bit tighter in 
their care or approach to care and maybe change their practice a little bit’ 
[Interviewee 8 Band 8 Pharmacist] 
‘But it would be worthwhile, because then it would identify if everyone 
was having the exact same problem’ [Interviewee 3 Band 6 Pharmacist] 
‘I think it could have a positive impact, in terms of especially with topics, 
it might identify topics for learning’ [Interviewee 9 Band 7 Pharmacist] 
These participants were able to describe benefits to individuals and teams of 
more formal reporting and of shared learning opportunities. 
  
4.4.4.15 Summary of findings: framework analysis 
To summarise the findings from Phase 2 interviews: there was uncertainty 
amongst participants as to what, when, whether, how or why to report on 
suboptimal pharmaceutical care and Table 4.5 summarises the findings. Themes 
and subthemes (behavioural determinants) were identified from the generated 
data, and the behaviours that were demonstrated by the findings are described.
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Table 4.5 Key themes and subthemes from generated data from interviews 
TDF Domain/theme Subtheme Behaviour 
Knowledge Lack of knowledge of what 
constitutes suboptimal 
pharmaceutical care 
Not knowing what constitutes suboptimal pharmaceutical care means 
cannot report on it 
Lack of knowledge – expected 
as in training 
Fixing of suboptimal pharmaceutical care, may or may not provide 
feedback (reporting) to trainee 
Skills Skills for reporting on 
suboptimal pharmaceutical 
care 
Lack of process for reporting means can identify but not report; 
reluctance to report 
Skills in giving feedback 
 
Other determinants impact, for example hierarchy, personal and 
professional barriers. 
 
Good feedback skills ensure lessons are learned 
Social/professional role 
and identity 
Personal and professional 
barriers 
Other professions unlikely to identify and report on suboptimal 
pharmaceutical care 
Professional embarrassment Unlikely to self-report 
Beliefs about capabilities No specific subthemes – 
includes overlap with others 
Positive and negative beliefs that capable of identifying, (influenced by 
lack of knowledge of what constitutes suboptimal pharmaceutical care); 
lack of belief that capable of reporting (influenced by time constraints) 
Optimism No specific new subthemes Pessimism about reporting 
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TDF Domain/theme Subtheme Behaviour 
Beliefs about 
consequences 
No specific subthemes Positive and negative beliefs about consequences of reporting 
Reinforcement No specific subthemes Using personal experiences to reinforce learning in others 
Intentions No specific subthemes Intention hampered by organisational and environmental factors 
Goals No specific subthemes Goals hampered by organisational and environmental factors 
Memory attention and 
decision-making 
Fix and forget Likely to act on suboptimal pharmaceutical care in others but may 
forget to feedback 
Environmental context 
and resources 
Time constraints Time may be a factor in providing feedback or self-reporting  
Lack of computer access Lack of access to computers may inhibit reporting 
Lack of formal feedback 
process 
Lack of formal process inhibits reporting 
Social influences Hierarchy Unlikely to report more senior colleagues 




Distress and guilt may inhibit reporting. 
Moral distress Reflection on inability to deliver optimal pharmaceutical care due to 
organisational and environmental factors causes anxiety and distress  
Behavioural regulation Suboptimal pharmaceutical 
care as a learning opportunity 
Learning opportunity for self, on refection, or for responding to and 





4.4.5 Findings: personality tests 
The personality test data was not collected with the intention of using in primary 
data analysis, as the study sample was too small to make meaningful 
comparisons. Personality test data was however used to profile the participants, 
and understand more about their personality traits. Personality traits are linked 
to the likelihood of adoption of behaviours, and perception (the way something 
is understood or interpreted (Ferguson and Lievens 2017).  Perception will differ 
depending on the worldview of the participant, and is influenced by personality 
type. Perception and the adoption of behaviours were of interest in this study. 
The personality test results revealed that there was variation in expression of 
the five personality traits across the participants (Figures 4.5 to 4.14), and 
indicated that different personality type were represented by the findings. The 
five traits are openness, conscientiousness, extroversion, agreeableness and 
neuroticism (John and Srivastava 1999). Each personality trait is a spectrum: 
from openness to closedness, from conscientious to non-conscientious, from 
extrovert to introvert, from agreeable to antagonistic, from neurotic to 
emotionally stable. Indicative quotes revealed that personalities from opposing 
ends of the personality spectrum responded differently to a similar line of 





Table 4.6 Indicative quotes for personality traits of interviewees 
Personality trait Indicative quote Personality trait Indicative quote 
Openness ‘I think it’s a good thing, that we are 
all comfortable enough to be able to 
share with each other what we’ve 
done well and what we’ve not done so 
well’ [Interviewee 6] 
Closedness ‘I think pharmacists are quite, as a profession, 
critical of themselves and each other’ 
[Interviewee 4] 
Conscientiousness ‘I kind of know what I should be 
prioritising and I know that I’ve 
addressed the serious ones [Ph 5] 
I would definitely do it from a training 
point of view’ [Ph 5] 
Unconscientious ‘...and you’re kind of like ach I’m sure it will be 
fine’ [Interviewee 1] 
 
‘Yes, almost like making an assumption because 
it’s slightly easier to do that’ [Interviewee 8] 
Extroversion ‘I quite like feedback and I quite often 
search it out, which I don’t know that 
everybody does’ [Interviewee 8] 
Introversion ‘I think within pharmacy we’re maybe not good 
at sharing our negative experiences’ 
[Interviewee 4] 
Agreeableness ‘I am comfortable with people telling 
me I have made a mistake’ 
[Interviewee 6]  
Antagonistic ‘I’m aware of that because I can be a quite 
brusque person’ [Interviewee 10] 
 
Neuroticism ‘I suppose self-reporting is very 
difficult. That you have to blame 
yourself kind of’ [Interviewee 2] 
Emotional 
stability 
‘if you have learnt something then share that 
with the team’ [Interviewee 9] 




The discussion section will outline the key findings from the data analysis, and 
provide interpretation of the data in relation to the aims and objectives for this 
study. 
 
4.5.1 Key findings from Phase 2 interviews 
Key findings will be presented for the four different areas of suboptimal 
pharmaceutical care that participants described: identifying, responding to, 
reporting and reflecting on suboptimal pharmaceutical care. 
 
4.5.1.1 Identifying suboptimal pharmaceutical care 
Participant interviews revealed determinants of behaviour that influenced how 
individuals identified suboptimal pharmaceutical care. A subtheme emerged from 
the knowledge domain of ‘lack of knowledge of what constitutes suboptimal 
pharmaceutical care’ and this subtheme expressed how participants lacked 
clarity in what they would consistently identify as suboptimal pharmaceutical 
care in their own or in other’s practice.  In addition, participants described a lack 
of definition, and the absence of a process, or of documentation that would drive 
the process of identifying suboptimal pharmaceutical care. 
Secondly, the subtheme of ‘personal and professional barriers’ in the 
social/professional role and identity domain described how other professions 
would be unlikely to identify what was suboptimal pharmaceutical care. A reason 
given for this was that other professions were not fully aware of the role of the 
clinical pharmacist. 
There was indication that some of the participants would view the identification 
of suboptimal pharmaceutical care in junior pharmacists from a different 
perspective than they would in a colleague or more senior pharmacist. 
Participants expressed a desire to provide useful feedback (reporting) when 
identifying suboptimal practice in a trainee. However, there was not sufficient 
information from the data to assess whether these participants were actively 
providing feedback because they were in a supervisory role, or if it was a 
practice they had developed from their own experiences, and used for multiple 
216 
 
individuals.  This appears to be informal arrangement, and many episodes of 
pharmaceutical care take place without checking or review by another 
pharmacist. 
Participants recognised that there was a certain level of experience that was 
needed before you could recognise suboptimal pharmaceutical care in others.  
 
4.5.1.2 Responding to suboptimal pharmaceutical care 
Discussions on how participants would respond to suboptimal pharmaceutical 
care were focussed mainly on suboptimal pharmaceutical care as identified in 
other’s practice.  The majority of participants stated that they would ‘fix’ 
something that they identified as being suboptimal.  One barrier identified for 
responding to suboptimal pharmaceutical care was failing to remember to go 
back to address an issue that was observed earlier. This barrier was in the 
memory, attention and decision-making domain. 
Participants described how they may or may not change behaviours when 
suboptimal pharmaceutical care was identified in their practice and they were 
informed.  Some participants described how behavioural regulation meant that 
they were likely to carry out checks on their own work more carefully, if they 
were made aware of an episode of suboptimal pharmaceutical care, whilst others 
were pragmatic in stating that occasional informal feedback was unlikely to 
make them change behaviour. 
There was limited discussion that referenced to how participants acted when 
detecting suboptimal pharmaceutical care in their own practice. 
 
4.5.1.3 Reporting suboptimal pharmaceutical care 
There was more expansive discussion on the topic of reporting of suboptimal 
pharmaceutical care than other areas.  Behavioural determinants included 
themes and subthemes across several TDF domains.  Reporting is interpreted 
here as including the giving of informal feedback, as well as formal feedback 
and/or reporting. Informal feedback was mainly described as giving verbal 
feedback to an individual, or occasionally of leaving a written note.  Formal 
feedback was interpreted as reporting using the DATIX risk management 
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system.  Again, participants referred to reporting suboptimal pharmaceutical 
care in terms of their own, or in other’s practice. 
Participants identified that lack of certainty of what constitutes suboptimal 
pharmaceutical care was a barrier to reporting.  Exceptions included where 
reporting would benefit a trainee, or where there was a pharmacist prescribing 
error.  Participants also indicated that there was an absence of formal reporting 
mechanisms, and a lack of definition, and that this created a barrier to reporting. 
Although participants expressed their intention of feeding back informally to 
junior pharmacists on practice they identified as suboptimal, lack of time was 
identified as a barrier to carrying out that intention.  Other barriers that impeded 
the giving of feedback, informal or formal, to peers or more senior colleagues 
were identified as personal and professional barriers, and barriers due to 
hierarchy. 
Participants also identified that there were personal and professional barriers to 
their own reporting, with professional embarrassment being given as a reason 
why they would be reluctant to report on an error they had made.  Participants 
however expressed that if there was a risk to patient safety, they would be more 
inclined to report, and to share lessons learned.   
Participants differed in their perception of whether formal reporting of 
suboptimal pharmaceutical care would be beneficial to the organisation, with 
some interviewees feeling they could overcome professional embarrassment and 
other barriers if the culture was different, and others being less positive about 
the consequences of reporting.  Influence from senior management was deemed 
important.  The potential benefits of reporting suboptimal pharmaceutical care 
were perceived as being for the team, to build awareness of areas for 
improvement, and for the senior management team, to understand the 
challenges faced by the team. 
However, participants expressed pessimism regarding the likelihood of formal 
reporting being carried out, citing time constraints and the lack of a formal 





4.5.1.4 Reflecting on suboptimal pharmaceutical care 
Participants described how reflecting on suboptimal pharmaceutical care in their 
own practice could lead to them making improvements to their own practice.  
Participants also indicated that they considered sharing their experience with 
others. This appeared to incur less professional embarrassment once time had 
elapsed and if the episode could be used as a learning opportunity. 
However, reflecting on episodes of suboptimal pharmaceutical care was also 
described as invoking emotional reactions, and cumulatively, leading to 






Interpretation of the data will be related to the aims for this phase of the study, 
namely to explore pharmacists’ experiences of the provision of optimal and 
suboptimal pharmaceutical care, and to explore the behavioural determinants 
that relate to the provision of optimal and suboptimal pharmaceutical care. 
 
4.5.2.1 Pharmacists’ experiences of the provision of optimal and suboptimal 
pharmaceutical care 
The interviews focussed more on suboptimal pharmaceutical care, than on 
optimal pharmaceutical care, in accordance with the semi-structured interview 
schedule (Appendix 4.2). The interviews were successful in achieving their aim 
of enabling in-depth discussion on the topic of suboptimal pharmaceutical care.  
There is a paucity of literature on suboptimal pharmaceutical care, and this 
study adds to knowledge. However, the lack of comparator studies mean that 
interpretation relies on opinion and review studies, and comparison with studies 
on patient safety incident reporting and error disclosure from other healthcare 
professions. 
A key finding from the interviews was that participants were uncertain of how to 
define optimal pharmaceutical care, meaning that defining suboptimal 
pharmaceutical care was also difficult.  This particularly affected the 
identification and reporting of suboptimal pharmaceutical care   Other authors 
have described a lack of agreement and definition of which components of 
pharmaceutical care are the most important, (Onatade et al 2018) and this was 
reflected in the current study.   
Participants in this study stated that they did not know what or how to report, 
when discussing the reporting or provision of feedback on suboptimal 
pharmaceutical care. These findings are supported by the findings of a 
systematic review of the reporting of medical device adverse events, (Polisena et 
at 2015) where lack of awareness of what and how to report were cited as 
reasons for the underreporting of adverse events.  Similarly, a barrier of lack of 
knowledge of what to report was described in a study examining barriers to 
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reporting adverse drug reactions through pharmacovigilance routes (Mirbaha et 
al 2015), and was supported by the findings of the current study. 
However, despite interviewees expressing doubt at knowing what to report, and 
what constituted suboptimal pharmaceutical care, this was not borne out by 
their individual responses. During interviews, participants were able to identify 
and describe examples of suboptimal pharmaceutical care in their own and in 
other’s practice (Appendix 4.9). Thus, their perception that they lack knowledge 
of what constitutes suboptimal pharmaceutical care can be disputed, and may 
instead refer to a lack of a set of definitions, or a framework, or direction from 
the organisation on what constitutes suboptimal pharmaceutical care, rather 
than lack of individual knowledge. This finding supports those of Quirke, Coombs 
and McEldowney, who described how a lack of definition of suboptimal care in 
nursing was a barrier to understanding how and when suboptimal care arises, 
and the antecedents that may be involved (Quirke, Coombs and McEldowney 
2011). In the current study, the lack of a formal defined process for reporting 
suboptimal pharmaceutical care added to the uncertainty of what or how to 
report. 
Participants described how time constraints were a factor in not reporting 
instances of suboptimal pharmaceutical care.  This supports the findings of two 
UK studies investigating the provision of feedback to junior doctors on 
prescribing errors. In a UK study on pharmacists’ attitudes towards giving 
feedback to junior doctors, recruits to focus groups described barriers of time 
and workload as influencing the likelihood that they would provide feedback on a 
prescribing error to a doctor (Lloyd et al 2016). Other influences were the 
severity of the error, with the likelihood of providing feedback increasing with 
the perceived severity of the error, and the availability and accessibility of the 
prescriber. In another UK study, Bertels et al examined the views of both 
pharmacists and junior doctors on feedback by pharmacists on junior doctors’ 
prescribing errors, using a self-administered questionnaire.  Doctors perceived 
feedback from pharmacists as constructive but irregular.  Pharmacists 
acknowledged they were inconsistent with feedback, and cited time constraints 
and lack of availability of the prescriber as barriers (Bertels et al 2013). The 
current study did not investigate whether lack of availability of the person 
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receiving feedback was a barrier, and this would have been a useful addition to 
the interview schedule. 
Senior pharmacists acknowledged that responding to and reporting back to 
junior members of the team on instances of suboptimal pharmaceutical care was 
important for the junior pharmacist’s development.  However, senior 
pharmacists expressed that they were aware that they did not have an 
equivalent process for themselves as senior pharmacists.  Senior pharmacists 
also identified that they were aware that there were inconsistencies in the 
process of providing feedback to junior pharmacists, citing time constraints as 
leading to a ‘fix and forget’ culture.  ‘Fix and forget’ has previously been 
described (Hewitt and Chreim 2015), in relation to patient safety incident 
reporting: the qualitative case study designed research found that most of the 
doctors interviewed fixed patient safety incidents themselves, and rarely 
reported on incidents unless there was actual harm (Hewitt and Chreim 2015).  
The authors concluded that better criteria could be set to guide practitioners 
about what and how to report, and this was reflected by the findings of this 
study, with lack of knowledge of what and how to report being frequently cited 
by participants as barriers to reporting, as previously described.   
Participants in this study described that they were less likely to report back on 
instances of suboptimal pharmaceutical care to those more senior than 
themselves, although they may still act on those instances, to ‘fix’ them. This 
was described as a hierarchical barrier.  In a systematic review of barriers to 
reporting of adverse events by nurses (Vrbnjak et al 2016), personal and 
professional barriers, including the power hierarchies that exist in healthcare, for 
example between professions, or within professions, were reported as barriers to 
reporting, and is supported by the findings of this study.   
Participants in this study expressed barriers to the self-reporting of episodes or 
incidents in their own practice. Professional embarrassment was cited as a 
factor. In a study looking at barriers to the reporting of adverse events by 
doctors, embarrassment was cited as a critical barrier (Smith et al 2014).  The 
study suggested that the embarrassment barrier could be overcome by case 
reporting, regularly, in a non-threatening environment, and getting feedback. In 
the current study participants also expressed that they would disclose 
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suboptimal pharmaceutical care if there was perceived benefit, and if there was 
an established process to follow. A further study with doctors (O’Connor et al 
2010), on the disclosure of adverse events and perceived barriers, cited 
professional embarrassment, a lack of training, and the emotional impact of 
reporting as being barriers to disclosing and reporting adverse events.  
Professional embarrassment was also a barrier identified in a Scottish study 
examining the significant event analysis (SEA) process that GPs use, where GPs 
also expressed a reluctance to share events that may expose them to 
professional embarrassment (Bowie et al 2005).  There was a paucity of studies 
from within the pharmacy profession to act as comparators. The reluctance to 
share events that would expose participants was a conflicting factor in the 
current study, with contrast between those who stated that they could overcome 
embarrassment, if there was benefit to the service, and those who stated they 
were reluctant to disclose and share events. This reluctance was expressed in 
the interviews, with participants stating they would be selective about what they 
would be willing to share with colleagues.   
 
4.5.2.2 Behavioural determinants that relate to the provision of optimal and 
suboptimal pharmaceutical care 
The use of the TDF to analyse the results meant that behavioural determinants 
were identified from the interviews.  All fourteen domains of the TDF domains 
were identified as having influence on participant behaviours, with some 
domains perceived as having greater influence than others.  Awareness and 
examination of the behavioural determinants that influenced participants means 
that behavioural change interventions can be proposed. 
There are nine available behavioural changes interventions that articulate with 
the TDF: education, persuasion, incentivisation, coercion, training, restriction, 
environmental restructuring, modelling and enablement (Michie, Atkins and West 
2014). The behavioural change intervention types, and their definitions were 
described in Chapter 2, in Tables 2.12 and 2.13. 
Chapter 2 also described the link between TDF domains and behaviour change 
techniques. The behaviour change wheel and the COM-B model (Michie, Van 
Stralen and West 2011) can be used to identify behaviour change techniques to 
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address barriers which are identified when using TDF as a framework. The 
behaviour change techniques that articulate with the TDF domains were 
described in in Table 2.14 within Chapter 2.  From this, recommendations can be 
made in the form of recommended interventions that are underpinned by 
implementation science, and thus have likelihood of successful when 
implemented, and these are described in 4.6. 
 
4.5.2.3 Interpretation of personality tests  
This small study used personality tests to create profiles for interviewees 
(Figures 4.4 to 4.13), and the results demonstrated that there were a range of 
personality traits across the participant cohort. Personality traits were reflected 
in participants’ responses (Table 4.6), and will affect the behaviours they display 
at work.  For example, certain personality traits have been seen as an influence 
on performance in medical training (Doherty and Nugent 2011), with 
conscientiousness seen as a significant predictor of good performance amongst 
medical students.  Doherty and Nugent also observed a link between the 
personality trait of neuroticism and an individual’s vulnerability to stress, and to 
psycho-social tendencies associated with stress such as moral distress.  
Personality traits have also been linked to work performance (Neal et al 2011), 
with openness positively predicting adaptability to change and proactivity, and 
agreeableness predicting good team workers, as does extroversion.  
Conscientiousness was found to predict individual rather than team proficiency, 
and high levels of neuroticism found to negatively predict work performance. 
The findings from the personality test are of interest to the study when 
considering the suitability of planned interventions (requiring change and 
proactivity).  Some personality types are likely to respond well to change, whilst 
others may not, and this may be considered by the organisation, and 
interventions adjusted to reflect different personality types. In addition, 
personality traits have been demonstrated to influence behaviours in relation to 
the giving and receiving of feedback (Krasman 2010; Robison, McQuiggan and 
Lester 2010), and this may be of consideration when developing interventions 




Recommendations in the form of described interventions are detailed for each of 
the identified behavioural determinants from the findings. The behavioural 
determinants are clustered within the overarching TDF domain, and summarised 
in Table 4.7.  The recommendations include both those specific to the 
organisation, as befits a professional practice doctorate, and recommendations 
for the wider pharmacy profession.  Recommendations specific to the 




4.6.1 Lack of knowledge of what constitutes suboptimal pharmaceutical care 
Education strategies may be utilised to increase knowledge and awareness of 
what constitutes suboptimal pharmaceutical care.  There could be local and 
wider National, and professional discussions on whether there are elements of 
suboptimal pharmaceutical care that can be described and defined, and that are 
reportable. There are existing frameworks and guidance that describe reportable 
adverse events for pharmacists (Royal Pharmaceutical Society 2016a), including 
under duty of candour (General Pharmaceutical Council 2014), but currently, 
reporting on suboptimal pharmaceutical care is not included.   
Within the context of the organisation, the lack of clarity of what constitutes 
suboptimal pharmaceutical care means that the requirement to describe what 
constitutes a nonconformity, and what action should be taken is missing (British 
Standards Institute 2015), and this should be addressed. The medical profession 
has attempted to address lack of awareness of how to deal with prescribing error 
amongst junior doctors, for example, by provision of training using simulation, 
and by experiential placement learning (Klein et al 2017; Ryder et al 2019), and 
these methods may be considered.   
 
4.6.2 Lack of knowledge – expected as in training 
Education strategies may be utilised to ensure both trainer (or supervising 




pharmaceutical care should form part of the knowledge development that takes 
place during the training period.  
Education could be used in conjunction with the development of skills in giving 
feedback by trainers and supervisors (4.6.4). Within the study setting, 
awareness may be raised by incorporating guidance into local learning 
agreements, and promulgating through foundation tutor support sessions. 
Foundation training includes scope for discussion between trainer and trainee on 
trainee performance, through mini-CEX and case based discussion and these 
could be further developed; in addition, there are opportunities for the trainee to 





4.6.3 Skills for reporting on suboptimal pharmaceutical care 
A training intervention may be utilised to develop skills around reporting, but 
only once a formal feedback or reporting process has been established (4.6.16).   
 
4.6.4 Skills in giving feedback 
A training intervention may be utilised to develop skills relating to giving 
feedback.  The skills training should encompass giving feedback across 
hierarchies, in receiving feedback (for recipients) and in giving feedback to 
trainees that helps develop their knowledge (4.6.2).  Skills training may start 
with undergraduates and continue throughout professional development.  Skills 
training may improve competence and thus confidence in the provision of 
feedback (Duffy 2013).  Skills in giving feedback is included in the training of 
tutors and supervisors (NHS Education Scotland 2017), and aspects of the 
training could be shared within the organisations’ clinical pharmacy teams, to 






4.6.5 Personal and professional barriers 
An education and modelling intervention may be utilised to raise awareness of 
personal and professional barriers, using modelling to give examples of 
behaviours in overcoming personal and professional barriers where these are a 
barrier to the provision of optimal pharmaceutical care (Vrbnjak et al 2016). 
Modelling may include sharing learning from episodes of suboptimal 
pharmaceutical care by more senior clinical pharmacists; this approach has been 
described in medical teams (Millwood 2014) to help junior doctors overcome 
personal and professional barriers.  Barriers to the reporting of medication 
errors, where professional barriers have been implicated, has been widely 
described in literature and lessons may be learned from these studies (Williams 
Phipps and Ashcroft 2013; Keers et al 2013); suggestions from the studies 
include easier reporting, and addressing concerns about interprofessional 
relationships. 
 
4.6.6 Professional embarrassment 
An education, modelling and persuasion intervention may be utilised to raise 
awareness of professional embarrassment as a barrier, using persuasive 
commentary to highlight the negative effect of the barrier; education could use 
model examples or strategies for overcoming professional embarrassment. For 
example, a study by Smith et al (2014) suggested that professional 
embarrassment may be overcome by case reporting regularly, in a non-
threatening environment, and would be a means of applying the true principles 
of peer review (Al-Lamki 2009). Peer review should aim to improve the quality of 
care for patients, by allowing participants to reflect on their practice compared 
with that of others. It requires a skill set, depends on the openness and 
transparency of participants, and relies on the presentation of a case that can be 
thoroughly examined. The mitigation of professional embarrassment may also 
reduce the impact of an emotional reaction to suboptimal pharmaceutical care 
(4.7.19) (Smith et al 2014).  





4.6.7 Beliefs about capabilities 
Modelling and enablement of reporting may be an intervention that would 
increase pharmacist’s confidence in their own ability to provide feedback and 
report on suboptimal pharmaceutical care. Gaining skills in giving feedback 
(4.6.4) will increase confidence (Duffy 2013).  In addition, addressing the 
perception that time constraints (4.6.14) influence individual capability of 
providing feedback and reporting on suboptimal pharmaceutical care will 





Education and modelling interventions, demonstrating the gains from reporting, 
and using persuasion to encourage reporting are interventions that may reduce 
pessimism associated with reporting or providing feedback on suboptimal 
pharmaceutical care. Similar interventions have been used to encourage the 





 4.6.9 Beliefs about consequences 
Educational and persuasive interventions that focus on the positive outcomes 
associated with engagement with reporting or providing feedback on suboptimal 
pharmaceutical care may reduce concerns about consequences. The negative 
consequences of failing to engage with the process may also be highlighted. For 
example, the positive outcomes, e.g. shared learning, opportunities to learn 
from suboptimal pharmaceutical care (4.6.21), ensuring that others do not make 
similar errors, and targeting areas for future training may be addressed in an 
educational intervention.  Similar interventions have been made with prescribers 
Optimism 
Beliefs about consequences 
Beliefs about capabilities 
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to encourage reporting on, and sharing the learning from, prescribing errors 





Engaging strategies which enhance the positive rewards and outcomes from 
providing feedback and reporting on suboptimal pharmaceutical care, for 
example where changes in individual or team actions create a safer environment 
for patients, may be used.  Coercive techniques, using a trusted clinical 
pharmacy lead, to demonstrate as an educational intervention the advantages 
that providing feedback and reporting on suboptimal pharmaceutical care have 





The use of strategies which promote motivation to engage in reporting or 
provision of feedback on suboptimal pharmaceutical care should be encouraged. 
For example, outlining optimal methods and ensuring reporting structures exist 





Having goal and target-setting strategies may aid pharmacists in facilitating and 
maintaining a behaviour change around reporting and providing feedback on 
suboptimal pharmaceutical care (Michie, Atkins and West 2014). For example, 
pharmacy teams may be encouraged to set goals and targets to increase the 
level of reporting and providing feedback, using incentivisation and persuasion; 
in addition, modelling can be applied, through asking recipients of the feedback 
process to give their perceptions, to ensure the process of reporting is having 








4.6.13 Fix and forget 
Environmental restructuring, ensuring that pharmacists have the ability to 
provide feedback or report on suboptimal pharmaceutical care ‘in the moment’ 
may be beneficial as an intervention (Dearnley et al 2013). This may require 
additional IT access (4.6.15).  This, along with other interventions that raise 
awareness of the benefits and gains of providing feedback (Hewitt, Chreim and 
Forster 2013), and reporting on suboptimal pharmaceutical care may reduce the 
tendency towards fixing suboptimal pharmaceutical care but not reporting on, or 




4.6.14 Time constraints /lack of staff resource 
Environmental restructuring, ensuring that there is the ability to rapidly provide 
feedback or report on suboptimal pharmaceutical care ‘in the moment’ may 
ensure that time constraints do not have impact on the ability to provide optimal 
pharmaceutical care, nor on the ability to provide feedback and report on 
suboptimal pharmaceutical care (Dearnley et al 2013).  Addressing lack of staff 
resource, which is linked to perceptions of time constraints may reduce impact of 
this barrier.  In addition, training interventions that address time management 
may be beneficial.  Time constraints and low staff levels are known contributory 
factors in moral distress in nurses (Burston and Tuckett 2013), and this may be 
the case with pharmacists too (Kälvemark et al 2004). 
 
4.6.15 Lack of computer access 
Enablement, through environmental restructuring that facilitates the provision of 
improved computer access may improve the ability to self-report on suboptimal 
pharmaceutical care; provision of feedback currently is predominantly done face 
to face (although that may change) and is therefore not affected by lack of 
computer access. 
 
Environmental context and resources 
Memory attention and decision- making 
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4.6.16 Lack of formal described process for reporting/feedback 
Environmental restructuring, by ensuring a defined, process exists for formal 
reporting, for example outlining the type or nature of suboptimal pharmaceutical 
care that is reportable may be beneficial. Also, enabling reporting by provision of 
training in how reports should be made, for example, via existing systems, such 
as the DATIX risk management system. 
 
4.6.17 Conflicting priorities 
Environmental restructuring and enabling interventions may allow pharmacists 
to address conflicting priorities, and skills training in task prioritisation and time 
management may be beneficial.  Better understanding of the source of conflict is 
required, and this could be assessed through data collection. The priority coding 
process should be reviewed to ensure that priority setting is not creating an 
additional burden of distress, since conflicts in ethical decision making is a 





Enablement through skills training (4.6.4) to ensure pharmacists are comfortable 
with the provision of feedback and reporting suboptimal pharmaceutical care 
identified in more senior colleagues may be beneficial (Vrbnjak et al 2016). Also, 
ensuring through awareness and educational sessions that the advantages of 
reporting and providing feedback are understood across all grades of staff may 
be of benefit; this may require a culture change. Studies in medicine and in 
nursing have attempted to describe and address this barrier (Hooper et al 2015; 






4.6.19  Emotional reaction to suboptimal pharmaceutical care 
Modelling and educational interventions may be utilised to assure pharmacists 
that an emotional reaction to an episode of suboptimal pharmaceutical care is 
appropriate, and recognising that the emotional reaction will be different for 
different people.  Using techniques to manage emotional reaction to suboptimal 
pharmaceutical care may reduce likelihood of negative feelings becoming 
overwhelming and contributing to moral distress (4.6.20). Support mechanisms, 
such as exist for other professions when involved in medical error, could be 
utilised in an enabling intervention (Cabilan and Kynoch 2017; Klein et al 2017; 
Austin, Saylor and Finley 2017). 
 
4.6.20 Moral distress 
Modelling and persuasion interventions may be utilised to assist pharmacists 
who experience emotional reactions to an episode of suboptimal pharmaceutical 
care (4.6.19), as ‘exposure to dilemmas’ may be a contributory factor in moral 
distress (Monrouxe et al 2015).  Raising awareness of the features and 
consequences of moral distress by educational intervention may be supportive of 
this. The use of coercive techniques and persuasion by line managers may allow 
pharmacists to disclose areas of concern they have in their own ability to provide 
optimal pharmaceutical care to their patients. The negative feeling arising from 
an inability to perform work as desired is a contributory factor in moral distress 
(Jameton 1984). Studies have shown that feeling supported increases the 
likelihood of disclosure of areas of concern (Cabilan and Kynoch 2017; Sporrong 
et al 2005), and that reducing distress and anxiety can mitigate the tendency 
towards behaviours that manifest as moral distress; there is some evidence that 
moral distress affects junior staff more than senior (Wilkinson 1987; Sporrong et 
al 2005).  Recognition of the effects moral distress has on workforce should be 
recognised by the profession and requires further research (Astbury, Gallagher 








4.6.21 Suboptimal pharmaceutical care as a learning opportunity 
Educational interventions to ensure that there is awareness of suboptimal 
pharmaceutical care as a learning opportunity rather than as a threat to 
individuals or the profession may be beneficial.  Modelling by senior pharmacists, 
and templates or proformas that capture learning opportunities may enhance 
this intervention. Similar interventions have been applied to the reporting of 
medication incidents (Williams, Phipps and Ashcroft 2013) 
 
4.6.22 Summary of recommendations 
In summary, there are a number of interventions that may be implemented to 
facilitate the identification, responding to, reporting and feedback of suboptimal 
pharmaceutical care.  Interventions include educational interventions, skills 
training, modelling, enablement, restriction, persuasion, incentivisation, coercion 
and environmental restructuring as behaviour change techniques (Michie, Atkins 





Table 4.7 Suggested behaviour change technique for identified behavioural determinants 
TDF Domain/theme Subtheme Suggested Behaviour change technique 
Behavioural determinants Intervention 




Lack of knowledge – expected as in 
training 
Education 
Skills Skills for reporting on suboptimal 
pharmaceutical care 
Training 
Skills in giving feedback Training 
Social/professi
onal role and 
identity 
Personal and professional barriers Education; persuasion; modelling 
Professional embarrassment Education; persuasion; modelling 
Beliefs about 
capabilities 
No specific subthemes – includes 
overlap with others 
Education; persuasion; modelling; enablement 
Optimism No specific subthemes Education; persuasion; modelling; enablement 
Beliefs about 
consequences 
No specific subthemes Education; persuasion; modelling 
Reinforcement No specific subthemes Training; incentivisation; coercion; environmental restructuring 
Intentions No specific subthemes Education; persuasion; modelling; incentivisation; coercion 
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TDF Domain Subtheme Suggested behaviour change technique 










Time constraints Training; restriction; environmental restructuring; enablement 
Lack of computer access Training; restriction; environmental restructuring; enablement 
Lack of formal feedback process Training; restriction; environmental restructuring; enablement 
Social 
influences 
Hierarchy Restriction; environmental restructuring; modelling; enablement 
Emotion Emotional reaction to suboptimal 
pharmaceutical care 
Persuasion; incentivisation; coercion; modelling; enablement 
Moral distress Persuasion; incentivisation; coercion; modelling; enablement 
Behavioural 
regulation 
Suboptimal pharmaceutical care as a 
learning opportunity 




Although the suggested behavioural technique interventions and 
recommendations are described separately in 4.7.1 to 4.7.21, there may be 
overlapping strategies, particularly around educational interventions, and 
synergistic opportunities to combine interventions. For instance, skills training 
could focus around skills in giving feedback, both to junior staff, and to more 
senior colleagues to address skills, hierarchy and personal and professional 
barriers.  Educational interventions may address multiple behavioural 
determinants, including the advantages of feedback, overcoming professional 
barriers, awareness of, and means of overcoming professional embarrassment, 
and awareness of moral distress and antecedent behaviours.  Environmental 
restructuring may be commissioned to address IT access, staff shortages and 
the design of a process of formal reporting. 
Additionally, the design and the most appropriate mode of delivery for the 
intervention should be identified to assure impact.  For example, educational 
interventions are not limited to face to face delivery but may also include written 
material (posters, procedures etc.). The mode of delivery of interventions should 
be designed based on APEASE criteria (Michie, Atkins and West 2014) to 




E Effectiveness (including cost effectiveness) 
A Acceptability (to those delivering and receiving 
S Side effects or unintentional outcomes minimised 
E Equity 
      Figure 4.15 APEASE criteria (adapted from Michie, Atkins and West 2014) 
 
In this study, personality tests were used to profile participants, and exploration 




4.7. Strengths and limitations of Phase 2 study 
This qualitative study has addressed the paucity of literature relating to 
suboptimal pharmaceutical care.  The novel approach taken in the study ensures 
the content is unique, providing a unique exploration of pharmacists’ 
experiences of suboptimal pharmaceutical care.  In addition, the theoretical 
foundation used enhances the evidence and provides the knowledge required to 
move forward with developing interventions. 
4.7.1 Participants, recruitment and setting 
Prior to the interviews, participants had been involved in focus group discussions 
as described in Chapter 3.  This ensured participants were familiar with the 
research topic. Participants received information prior to the interview that 
summarised key findings from the focus groups (Appendix 3.10).  The examples 
used were selected by the researcher as indicative of discussions, however, a 
different researcher may had selected a different set of examples and as such 
this could have introduced bias by influencing the thought processes for 
participants in advance of the Phase 2 interviews. 
The setting for the study was a single health board in Scotland, and clinical 
pharmacy practices in other settings may vary.  In describing in detail these 
practices in Chapter 1 and throughout the thesis, the readership can consider 
whether findings will be transferable to their own setting. 
In terms of representation, the participant demographic had spread in terms of 
age, but less so in terms of grade or band of staff, nor of gender.  This may have 
been because junior staff (Band 6) were less able to commit to time away from 
their schedule, or were less inclined to be involved in research, or were not 
interested in the topic area, and this may have introduced bias (Bowling 2014), 
as may the low level of male participants in the study. However, by including 
detailed descriptions of study participants’ demographics, including personality 
profiles, the readership can consider whether the findings would be applicable 
within their own setting. The novel use of personality profiles demonstrates 




4.7.2 Study design and conduct 
The interview schedule was developed in accordance with the TDF, and is a 
strength of this study. Until recently, theoretical underpinning has been less 
common in pharmacy practice research compared to other disciplines (Stewart 
and Klein 2016). Theoretical underpinning is recognised as promoting quality 
and relevance in research (Stewart and Klein 2016). Dyson and colleagues, for 
example, compared the effectiveness of qualitative and quantitative research 
underpinned by the TDF with similar research in the absence of any theoretical 
basis. They found some overlap in effectiveness, but that TDF-informed research 
elicited more relevant information (Dyson et al 2011). The domains of the TDF 
were also used to prepare an initial coding framework for data analysis in this 
study, and this was a strength of study design.   
Identification of the mechanisms driving behaviour is important in the context of 
intervention development since behavioural determinant identification enables 
interventions to be targeted accordingly (Michie, Aktins and West 2014; Atkins 
et al 2017). It is anticipated that development of recommendations as 
interventions that relate to evidenced behavioural determinants will enhance the 
effectiveness and sustainability of behaviour change. Findings from personality 
tests could be applied to behaviour change techniques to strengthen uptake 
(Eccles et al 2005; O’Connor et al 2020), and the use of personality tests in the 
study is therefore justified. 
The coding process included mapping to all 14 TDF domains in this study, and 
analysis and recommendations were made across all domains; an alternative 
approach, where there was focus on the more influential behavioural 
determinants (Atkins et al 2017) may have strengthened the study  
The flexibility of the interviews, by using a semi-structured interview schedule 
and allowing participants to identify for themselves the aspects of suboptimal 
pharmaceutical care they wanted to discuss, means the topic area had breadth 
and depth.  The behavioural determinants were obtained from across all 
interviewees, and this is a strength of the study.  
There was emphasis in the interviews on mechanisms for reporting suboptimal 
pharmaceutical care and it is recognised that this was an area where the 
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reflexivity of the researcher was weak; the researcher should have been more 
aware of their bias on this topic, and used more open questions, and less 
focussed probing.  Given the naivety of the researcher, more interaction with the 
research team between interviews, and better reflection could have minimised 
the impact that this bias may have had, and is a lesson to be learned. 
There are known weaknesses associated with using deductive methods to 
analyse data, such as mapping to TDF.  Coding may be restrictive and there is 
considerable overlap between some of the domains in the TDF. In addition, 
individual domains may be perceived differently by coders (Cane, O’Connor and 
Michie 2012). However, efforts were made to minimise this by including an 
interrater comparison step, and by the frequent comparison of coding during the 
process. 
Research trustworthiness was assured via a number of strategies, as have been 
described earlier in this chapter. Steps were taken to promote credibility, 
transferability, dependability and confirmability. Strategies included: utilising 
methods with a favourable evidence base and deemed fit for purpose; previous 
workplace experience of the researcher, and additional training in conducting 
interviews; the detailed and accurate reporting and recording of research 
procedures, and the reflexive processes the researcher undertook to develop an 
awareness of the effect that personal beliefs have on interpretation of the data. 
In summary, the study has strengths in terms of study design and the use of a 
theoretical framework, and some limitations which include the naivety of the 
researcher and the limitations of the study setting. 
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4.8 Conclusions  
Evidence from the Phase 2 study demonstrated that the use of interviews 
allowed in-depth exploration of the experiences of hospital clinical pharmacists 
with optimal and suboptimal pharmaceutical care, and was an appropriate 
method to use in the study.  The use of a semi-structured interview schedule, 
designed around the TDF, ensured that the study was robust in design and that 
recurring themes and subthemes could be readily identified. Participants were 
able to describe their experiences of suboptimal pharmaceutical care, both in 
their own practice and in that of others.  It was identified that there were 
different areas where which barriers and facilitators could be described, and 
these were identifying, responding to, reporting on and reflecting on suboptimal 
pharmaceutical care. 
There were behavioural influences from all 14 domains of the TDF, and with 
significant influence from some domains, such as social/professional role and 
identity, behavioural regulation, skills and emotion. Subthemes were also 
identified and described.  Recommendations were made using acknowledged 
behavioural change techniques, for the behavioural determinants identified from 
the findings, using the behavioural change wheel and the COM-B model. 
Behaviour change techniques suggested that address the influential behavioural 
domains include education, skills training, modelling, enablement, persuasion, 





CHAPTER 5 DISCUSSION 
 
5.1 Introduction to Chapter 5 
The final chapter of the thesis will revisit the overall aims of the research, and 
highlight the key findings associated with each phase.  It will emphasise the 
originality of the research, and consider the strengths and limitations of the 
research study.  Areas for future research will be identified along with 
consideration of the impact of this research - for the researcher, for the work 
environment the study took place in, and for the pharmacy profession. Finally, 
the main conclusions will be outlined. 
 
5.2 Thesis review 
This research study was described by the title ‘Exploring hospital clinical 
pharmacists’ perceptions, experiences and behavioural determinants relating to 
provision of optimal and suboptimal pharmaceutical care: qualitative studies 
using the Theoretical Domains Framework’.  It took as its overarching research 
question: ‘How do hospital clinical pharmacists perceive and experience 
suboptimal pharmaceutical care?’ 
The research study was qualitative, with a phenomenological worldview, and was 
conducted in two phases, with the second phase building on the findings of the 
previous phase.  The first phase used focus group discussions, and the second 
phase used a semi-structured interview schedule to conduct in-depth interviews.  
 
5.2.1 Key findings from Phase 1 focus groups 
Findings from Phase 1 suggest that participants of focus groups were aware of 
instances of suboptimal pharmaceutical care in the services they provided.  A 
definitive definition of suboptimal pharmaceutical care was not elicited, and was 
not an aim of this phase of the study, but participants were able to describe how 
suboptimal pharmaceutical care manifested within the clinical pharmacy 
processes of medicines reconciliation and Kardex/medicines review.  Participants 
described the challenges they faced when conducting the tasks associated with 
these two processes, and cited time constraints, conflicting priorities (including 
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uncertainties over efficiency vs thoroughness) and capacity (staff resources 
available relative to patient numbers and turnover) as being barriers to the 
provision of optimal delivery of medicines reconciliation and of Kardex/medicines 
review.  For medicines reconciliation additional barriers were identified, for 
example, role uncertainty within the multidisciplinary team, and for 
Kardex/medicines review, additional barriers were identified including, for 
example, poor competency in conducting and documenting the task. 
 
5.2.2 Key findings from Phase 2 interviews 
The findings from the in-depth interviews suggested that participants were able 
to identify suboptimal pharmaceutical care in their own and in other’s practice. 
Participants described challenges in knowing how, and whether to report on 
instances of suboptimal pharmaceutical care, as well as uncertainty as to what 
would constitute ‘reportable’ suboptimal pharmaceutical care. The majority of 
participants would opt to ‘fix’ an episode of suboptimal pharmaceutical care, but 
the likelihood of going on to report or provide feedback was influenced by 
hierarchy and time constraints, with participants expressing a tendency towards 
reporting or providing feedback when the other person was at the same, or at a 
more junior level than them.  The likelihood that a participant would self-report 
instances of suboptimal pharmaceutical care identified was influenced by 
professional embarrassment, as well as time constraints, and opportunity.  
 
5.3 Interpretation of findings from Phase 1 and Phase 2 studies 
In this section, the findings from both studies will be integrated and interpreted.  
Both studies utilised TDF as a framework for analysis, and different TDF domains 
featured dominantly across the two phases. Not all TDF domains were 
represented by the findings from Phase 1 focus groups, and this was as 
expected. The focus group discussions were participant-led, whilst the interviews 
followed a semi-structured interview schedule designed around the TDF.  The 
interview schedule included questions relating to each domain (Appendix 4.2), 
hence all TDF domains were predicted to be represented by the findings from the 
interviews, and this was found to be the case.   
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The findings of Phase 1 and Phase 2, when integrated, identified a number of 
common themes that described barriers to the provision of optimal 
pharmaceutical care: time constraints and a lack of staff resource in relation to 
patient volume and turnover, conflicting priorities, a lack of IT access, and a lack 
of defined policy or guidance. The findings will be triangulated with the 
requirements of the quality management system for interpretation in the next 
section, since meeting the requirement of the quality management system was a 
driver for the research. 
In both phases of the research, time constraints were referred to as a challenge 
to providing optimal pharmaceutical care. In particular there was discussion on 
time management skills, and on finding the balance between being efficient and 
being thorough.  Participants from focus groups described a lack of agreement 
as to which approach to take, and this theme was repeated in some of the 
interviews. This dilemma has been described as the efficiency thoroughness 
trade off (ETTO), (Hollnagel 2009) and has been previously described in the 
healthcare setting (Duncan et al 2019; Hollnagel 2009; McNab et al 2016).  
McNab et al (2016) describe how when things go well, healthcare practitioners 
are judged on efficiency, but when things go wrong they are judged on 
thoroughness.  The authors conclude that there is no right or wrong approach, 
especially within organisations as complex as healthcare settings, and that 
instead, the focus should be on managing variation through protocol, rather than 
through policy (McNab et at 2016).  Provision of an efficient and effective service 
is required within the quality management system requirements of control of 
service provision, and monitoring and measuring of the delivered service (British 
Standards Institute 2015). Therefore, in the context of the study setting, 
definition of how to achieve the correct balance for the organisation should be 
described. 
Participants across both phases described a lack of policy, procedure or guidance 
as being barriers to provision of optimal pharmaceutical care. Lack of local policy 
was described for the task of medicines reconciliation, and the consequences of 
this have been described.  In addition, participants described how a lack of 
definition or guidance as to what constitutes suboptimal pharmaceutical care 
prevented reporting.  Better description of processes through policy, procedures 
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or guidance would enable the clinical pharmacy service to ensure that knowledge 
of the correct procedure, and training in the correct procedure would be part of 
training programmes, and thus enhance and assure competence.  This is in 
accordance with quality management principles where the ongoing assurance of 
competency is a requirement (British Standards Institute 2015).  
Improving the delivery of the two processes of medicines reconciliation and 
Kardex/medicines review will be beneficial to the clinical pharmacy service, and 
fulfil some requirements of the quality management system, namely: control of 
service provision and monitoring and measuring of the delivered service (British 
Standards Institute 2015).  In addition, definition of what constitutes suboptimal 
pharmaceutical care will be beneficial to the clinical pharmacy services and fulfil 
in part the quality management system requirements relating to nonconformity 
and corrective action; describing what constitutes a nonconformity within clinical 
pharmacy services is a key requirement of the organisation.  Nonconformity and 
corrective action processes have key roles within the continuous improvement 




5.4 Strengths and limitations 
This section will outline the known strengths and limitations of the research, 
highlighting the originality of the research, aspects of study design, 
trustworthiness of the research, and reflexivity of the researcher 
 
5.4.1 Originality 
As far as is known, this is the first research study to have explored suboptimal 
pharmaceutical care as a concept, and to identify barriers to the provision of 
optimal pharmaceutical care.  Suboptimal pharmaceutical care is an unexplored 
area of research, and this is, as far as is known, original research on this topic. 
The use of personality tests to provide enhanced participant profiles is unique, 
and adds to the originality of the presentation of findings, and to the description 
of participants. 
The use of an adapted focus group method in Phase 1 focus groups enabled a 
rapid assimilation of the findings, which were then used to inform the design and 
conduct of the Phase 2 in-depth interviews, and this was, as far as is known, a 
novel approach.   
These examples from the research conducted meet originality criteria: 
undertaking empirical research that has not been done before, researching 
unexplored areas in a discipline and using techniques (focus group; personality 
test results) in a new way (Edwards 2014; Phillips and Pugh 2010). 
 
5.4.2 Study design 
The phenomenological approach to this research was appropriate, given the 
overarching aim, which was to explore perceptions and experiences of study 
participants. The qualitative methodology of focus groups allowed for collective 
exploration of perceptions of optimal and suboptimal pharmaceutical care.  
Focus groups and interviews took place across a range of settings (different 
hospital sites), and across a range of participant levels of experience.  The 
qualitative methodology of interviews allowed for in-depth exploration of 
participants experiences, particularly in relation to suboptimal pharmaceutical 
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care, the interview setting facilitating openness and candour (Dejonckheere and 
Vaughn 2019; Bowling 2014).  Participants in Phase 2 were drawn from the 
population from Phase 1, and this ensured interview participants had previously 
been involved in discussions about suboptimal pharmaceutical care.  Using the 
same participants for both phases offered both strengths and limitations for the 
research: participation in focus groups had allowed those taking part in 
interviews the opportunity to reflect on the topic, and to consider aspects of 
pharmaceutical care that they considered to be suboptimal.  However, this may 
have inadvertently led to bias, and input from naïve participants may have 
provided new insight into the concept. 
The use of TDF as theoretical underpinning in the research design, and 
additionally in the development of the semi-structured interview schedule for 
Phase 2 provided a theoretically driven foundation for the research.  The use of 
theory is likely to enhance the strength of the study design (Stewart and Klein 
2016), and benefit the development of interventions (Craig et al 2008), and is a 
strength in study design. Craig et al (2008) suggest that integration of theory is 
critical in ensuring robustness in research since it permits determinants of 
behaviour to be reliably mapped, and intervention content to be tailored 
accordingly; there is however a lack of specific guidance of how to achieve this. 
As a phenomenological study, the research asked participants to reflect on their 
experiences retrospectively, and this relied on their recall of events.  This may 
be a limitation of study design, since recall bias is a known factor of influence in 
qualitative research (Bowling 2014; Robson 2011). 
 
5.4.3 Data saturation 
Phase 1 focus groups did not apply data saturation techniques but instead relied 
on recognised principles of conducting focus groups in terms of numbers of 
participants per group, and the total number of groups (Bowling 2014), as 
described in Chapter 2.  For Phase 2 interviews, data saturation techniques were 
applied and met, but representation was limited by the availability of 
participants across the range of experience, location and gender.  Wider 
participation may have allowed for additional subthemes, and may have 





Conducting the study in a single health board in Scotland is appropriate for a 
professional doctorate research study, but may limit generalisability. The rich 
detail around study design description, and around setting and participant 
details, including personality profiles, allows the readership to assess whether 
the findings from the study are applicable to another setting. 
 
5.4.5 Trustworthiness 
Reference to trustworthiness of research has been referred to throughout the 
thesis: in the methodology chapter, and in each of the studies described for 
Phase 1 and Phase 2.   
Various steps were taken to augment the trustworthiness of the research and 
are described under the four tenets of trustworthiness as described by Shenton 
et al (2004), of credibility, transferability, dependability and confirmability, and 
these are described: 
Credibility was enhanced by the use of an appropriate methodology and 
methods, a reflexive approach, knowledge of and attention to the background 
and culture of clinical pharmacy practice locally, and the involvement of relevant 
experts in the study design. 
Transferability was promoted by description in this thesis of background 
contextualising data and detailed descriptions of what was done, while at the 
same time protecting the anonymity of participants. 
Dependability was engendered by the use of overlapping methods, the use of 
two phases of study, and by inclusion of detailed descriptions within the thesis of 
setting, context and participants. 
Confirmability was incorporated by taking a reflexive and reflective approach 
during and after the research, including the consideration of limitations, and rich 
descriptions of process and procedure. 
Trustworthiness within the research is summarised by revisiting the descriptive 
table (Table 2.4) from Chapter 2, and expanding it to include the actions taken 
in this study, and the rationale behind each action (Table 5.1) 
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Table 5.1 Trustworthiness actions embedded in the current research (adapted from Shenton 2004) 
Parameter Planned action Rationale 
Credibility (whether the 
phenomena been 
accurately represented 
by the study) 
Choose appropriate research 
method - phenomenology  
The research method is consistent with similar studies exploring e.g. perception and 
understanding, as determined by evaluating research literature  
Be familiar with cohort of 
study/”natural setting” 
The researcher works within organisation where the research took place and was known to 
participants; field work was undertaken prior to data collection to become familiar with 
practices, process and terminology 
Robust sampling plan 
 
Research across multiple sites within organisation, and across different grades and levels of 
experience of staff, allowing for “multiple voices”. Data saturation techniques applied. 
Triangulation  The selection of different methods – focus group and individual interview - allowed for cross 
verification of the data; Involvement of participants from different sites with different 
specialties gave multiple perspectives.  
Integrity and honesty Researcher was independent of the clinical pharmacy service; iterative questioning used 
Reflective commentary Field notes/reflective log completed by researcher (focus groups and interviews) and 
facilitator (focus groups) and formed part of analysis 
Peer and supervisory 
support 
Peer/supervisor verification used to sense check themes emerging during focus groups and 
interviews; “member checks” obtained through adapted design of focus group 
Transferability 
(whether the study could 
be “transferred” to other 
situations) 
Full description of the study 
context 
Description of study setting; numbers and grades of participants, inclusion or exclusion 
criteria; data collection methods; number of and duration of sessions; time period over 
which data collected: These were built into the study design and reported on 
Dependability (whether 
the study could be 
repeated and get similar 
results) 
Use of overlapping methods  Use of focus groups and individual interviews; textual reference to research design from 
planning to execution, including detail of operational issues and reflective commentary and 
appraisal 
Confirmability (whether 
the study has been 
carried out as objectively 
as possible) 
Triangulation  See above under triangulation 
Reflective commentary  See above under reflective commentary 
Acknowledgment of bias of 
researcher and/or 
facilitators.  
Reflexivity summary descriptions throughout thesis 
Audit trail Records and logs kept of data and processes for duration of research project; continuous 
input of supervision team to assure objectivity 
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In addition to trustworthiness, researcher skills are required in order that 
planned research is conducted according to design requirements.  The 
researcher’s previous experience in conducting internal quality audits, and 
additional knowledge and skills gained through self-directed as well as taught 
learning (Appendix IV) ensured that the qualitative methods used were applied 




Reflexivity describes less the actions taken to ensure the robustness of the 
research, and more the cognitive, philosophical and reflective stance of the 
researcher in understanding how bias arises, and the steps taken to minimise 
those biases influencing the results (Creswell 2014). 
Known biases were identified: The researcher had long standing personal 
interest in drivers for ethical and professional development.  In addition, the 
researcher had organisational responsibilities for quality management for clinical 
pharmacy, and was invested in finding a solution to a work-related problem and 
gap in knowledge.  Actions taken to minimise the impact of personal bias have 
been described throughout the thesis, and included continual reflective practice, 
ongoing discussion with the research team and awareness of the areas where 
bias is most likely to occur. 
Bias can be introduced during the preparation of research tools and instruments 
(Robson 2011; Bowling 2014). In this study tools included a topic guide for the 
focus groups and a semi-structured interview schedule for the interviews.  The 
topics in the topic guide were reviewed within the research team for 
appropriateness in meeting the research objectives.  The semi-structured 
interview schedule was reviewed to minimise use of biasing or leading questions 
by the research team. However, the conduct of the focus groups and interviews 
relied on researcher skills, and their ability to conduct the interviews without 




In describing actions taken to minimise the impact of bias, and to enhance 
trustworthiness, the readership may draw their own conclusions on the 
effectiveness of the actions taken.
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5.5 Future research 
 
This study suggests that the concept of suboptimal pharmaceutical care can be 
used to describe events and episodes that pharmacists perceived as being less 
than the desired standard of care for patients.  More research is needed to 
identify whether the terminology is applicable in other settings.  In addition, the 
study identified that there were influences on the ability of pharmacists to 
provide optimal pharmaceutical care, and expansion beyond this small scale 
qualitative study may provide broader insight, identify other influences, and 
enable the development of interventions to support optimal pharmaceutical care 
delivery.  This would be a Scotland or UK wide study, and is described below as 
Proposal 1.  
Furthermore, the study identified that pharmacist independent prescribers may 
lack a mechanism to share the learning from prescribing errors and near misses 
that are made with their fellow independent prescribers. Research to date has 
been on determining accuracy (Latter et al 2012)) and error rate (Baqir et al 
2015; Taylor and Davies 2019; Phillips et al 2019).  Determining the nature and 
type of prescribing errors and near misses, and using the data to inform 
education and training of pharmacist independent prescribers would contribute 
to knowledge in this area. There has been no study to date comparing types of 
prescribing error between different sectors of pharmacist independent 
prescribers, meaning that no sector-specific learning is available.  This would be 
a local study, and is described below as Proposal 2. 
Finally, intervention research is proposed within the organisation to evaluate the 
implementation of recommendations made within this research, and this is 
described as Proposal 3. 
 
Proposal 1: A large scale study of behavioural determinants relating to the 
provision of optimal and suboptimal pharmaceutical care is proposed. 
The current study used TDF to study determinants of behaviour using 
interpretivist philosophy and qualitative methodology, using focus groups and in-
depth interviews to gather data.  A large scale survey would require that a 
positivist philosophy and quantitative methodology be used to generate data.  A 
cross-sectional survey of pharmacist across different sectors, hospital, general 
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practice and community could be carried out by means of an online 
questionnaire. 
Sampling could be facilitated using existing networks of pharmacists across 
Scotland and the UK. 
The aims of the research would be: 
• To determine the key behaviours that inhibit the delivery of optimal 
pharmaceutical care 
• To determine whether the same determinants influence delivery across 
the different sectors and settings 
• To investigate pharmacists’ views on whether capturing information on 
suboptimal pharmaceutical care enables quality improvement 
The research would gather data on 
• Participant demographics, including the sector they were currently 
working in 
• Participant views on and experiences of suboptimal pharmaceutical care in 
self and in others 
• Participant views on and experiences of provision of feedback and/or 
reporting on suboptimal pharmaceutical care  
A quantitative questionnaire for online administration would be developed using 
the TDF, as has been described in literature (Taylor et al 2013, Taylor, Lawton 
and Conner 2013; Huijg et al 2014). Data would be gathered using a 
combination of closed questions, Likert scale fixed choice responses and open 
questions, as is usual for quantitative online surveys.  Quantitative data from 
closed and fixed choice questions would be analysed using descriptive analysis.  
The inclusion of open questions would capture richer, qualitative data which 
would be used to expand and augment quantitative results. Qualitative data 
would be analysed using a framework approach (Ritchie et al 2006) developed 
from the literature, including this current study and literature pertaining to 
applications of TDF. Quantitative data from the online questionnaire would be 
presented using descriptive statistics. 
 
Proposal 2: Evaluation of prescribing errors and near misses made by 
pharmacist independent prescribers.  A small scale local cross-sectional mixed 
methods study across hospital, primary care and community pharmacy settings 
is proposed.   
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The aims of the research would be 
• To evaluate  prescribing errors and near misses made by pharmacist 
independent prescribers in different pharmacy settings 
• To determine whether the types of pharmacist prescribing error/near miss 
differ across the different sectors of pharmacy practice 
• To understand, using the accident causation theory (Reason 2000; 
Aronson 2009), the types of pharmacist prescribing error that occur (for 
example slips, lapses, mistakes or violations) 
Data would be collected on 
• Participant demographics, including the sector they are currently working 
in, and length of practice as a pharmacist independent prescriber 
• Participants’ perceptions and experiences of prescribing errors and near 
misses in their own and other’s practice, and how they are acted on 
• Participants’ descriptive examples of prescribing errors and near misses 
The qualitative phase would utilise focus groups in each sector, hospital, primary 
care and community pharmacy to explore perceptions and experiences of 
prescribing errors and near misses.  The quantitative phase would use the 
results of the qualitative phase to inform the development of a questionnaire 
that would collect data on error types from across the different sectors of 
practice.  The questionnaire would use Reasons’ theory of accident causation 
(Reason 2000) as a model to determine the types of prescribing error that are 
experienced within pharmacist prescribing (for example slips, lapses, mistakes 
or violations). The questionnaire would include fixed choice and open questions.  
Qualitative data would be analysed using a framework approach.  Data on types 
of errors and near misses would be analysed using Reason’s theory of accident 
causation, using an expert panel (Reason 2000; Aronson 2009). Results would 
be presented using descriptive statistics and narrative description. 
 
Proposal 3: Implementation research to address key barriers to delivery of 
optimal pharmaceutical care. 
Within the current research study, behavioural change technique 
recommendations have been made to address barriers identified from the 
qualitative data generated.  Behaviour change theories have been described as 
strengthening the effectiveness of intervention implementation, (Craig et al 
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2008). Moore et al (2015) have since outlined a framework to assist in 
implementation process evaluation using a model that incorporates fidelity 
(quality of intervention content), dose (how frequently the intervention is 
delivered) and reach (how many individuals the intervention reaches) (Moore et 
al 2015).  The evaluation of effectiveness should be underpinned by appropriate 
theory (Moore et al 2015), for example diffusion of innovation (Rogers 2003), or 
Normalisation Process Theory (McEvoy et al 2014); the behaviour change wheel 
can also be used to evaluate implementation (Michie, Atkins and West 2014).  
The proposed intervention research would be locally conducted, and would 
initially explore the optimum mode of delivery for each of the interventions 
identified using the APEASE criteria (Michie, Atkins and West 2014), described in 
Figure 4.15; this phase would use consensus methodologies, for example 
nominal group technique or the Delphi technique (Bowling 2014; Robson 2011).  
Next, the research would first determine and then apply the optimum 
underpinning theory to evaluate the implementation, and assess the 
effectiveness of the evaluation using qualitative methodology. The aims of the 
research would be: 
• To determine the optimum mode of delivery for interventions, using 
consensus methodology 
• To implement the interventions according to findings 
• To determine the optimum underpinning theory to evaluate intervention 
• To evaluate the implementation of interventions using the selected theory 
Consensus methodology results would inform the intervention implementation. 
Implementation findings would then be described in accordance with the 






5.6 Impact and reach of the research  
The impact and reach of research can be summarised under the four headings of 
knowledge, people, society and economy (Figure 5.1) (Economic and Social 
Research Council 2020). 
 
 
Figure 5.1 Impact and reach schematic for research 
 
Each aspect of impact and reach was reflected on individually in relation to the 
current research; this was done both in advance (Appendix 5.1), when designing 
the research for impact and reach, and at the conclusion, to assess whether 
impact and reach had been achieved.  Each aspect of impact and reach is 
considered here: 
Knowledge 
There were knowledge gains from this study. Firstly, the description of the novel 
concept of suboptimal pharmaceutical care adds knowledge to the field of 
pharmaceutical care research.  Secondly, the research provided a unique 
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pharmaceutical care in the researcher’s local setting.  Thirdly, the research 
developed and used a novel adaptation of focus group method that utilised a 
combination of written and verbal output. 
In considering the impact of the research knowledge, transfer of knowledge 
must be considered.  In the professional doctorate, the transfer of knowledge 
back to the organisation is important.  For this research, this was achieved 
through sharing the results with the organisation’s pharmacy senior 
management team, and with the clinical pharmacy teams (Appendix 5.1).  Wider 
transfer of gained knowledge is achieved by sharing the findings of the research 
with other pharmacists and other research teams.  For this research, knowledge 
sharing was achieved through presentations and publications, locally, nationally 
and internationally, and these are described under Research Outputs.  Future 
plans for knowledge sharing include publication of findings, and further 
presentation locally and nationally. 
People 
There were many research skills and personal skills that the researcher 
developed over the course of the research study. These skills included the 
attainment of research skills through application of qualitative research skills in 
the current study, of study design and in the conduct of focus groups and of in-
depth interviews. In addition, preparation of a thesis to describe conducted 
research requires the researcher to reflect on, and to describe alternate research 
methods, and thus broader knowledge is obtained.  The researcher also gained 
knowledge of the use of software relating to research including NVivo® , as data 
analysis software and Refworks, as a bibliography and reference database. 
Additional personal skills developed during the doctorate journey relate to time 
management and planning, writing skills, oral presentation skills, and poster and 
abstract design and development. 
The reach of these research skills is primarily through transfer to the 
organisation’s pharmacy service.  Individuals who took part in the focus groups 
and one to one interviews were exposed to qualitative research methods, and 
took an interest in qualitative research methods used.  Since the research took 





The society in the context of this research is the hospital clinical pharmacy 
community. Enhanced awareness of suboptimal pharmaceutical care will lead to 
shared learning, team work and ultimately patient safety.  Locally this has 
already happened, with discussions on changes to how nonconformities are 
captured within clinical pharmacy services. Wider impact on the clinical 
pharmacy community has taken place through knowledge sharing at 
conferences, and will be developed with future research, and with publication 
and knowledge sharing. 
Economy 
Wealth creation and new company creation were not intended targets of this 
research. Changes to product and procedures, where product is the clinical 
pharmacy service were impacted with quality management principles becoming 
aligned with the clinical pharmacy service.  In addition, there can be said to be 
inward investment of the existing and future workforce.  The research had 
intention to bring efficiencies to current processes with shared learning, and the 




This study aimed to answer the research question: ‘How do hospital clinical 
pharmacists perceive and experience suboptimal pharmaceutical care?’  
Participants in this study were hospital clinical pharmacists, delivering 
pharmaceutical care for a range of patients in secondary care.  Using a 
theoretically informed approach, and qualitative methodologies of focus groups 
and interviews, the study has enabled the understanding of meanings, 
perceptions, experiences and behavioural determinants of suboptimal 
pharmaceutical care from the perspectives of hospital clinical pharmacist 
participants.   
The study design, with the theoretical underpinning of the TDF, allowed an in-
depth, rigorous and trustworthy exploration of the perceptions and experiences 
of hospital clinical pharmacists with optimal and suboptimal pharmaceutical care. 
The research has allowed the researcher insight into barriers that have to date 
prevented identification and reporting of suboptimal pharmaceutical care within 
the study setting. The key barriers described were time factors, lack of guidance 
or definition of what constitutes suboptimal pharmaceutical care, conflicting 
priorities, lack of knowledge (of trainees), and personal and professional barriers 
and enablers, including hierarchy, and professional embarrassment.   
Further, use of the TDF to underpin the research enabled behaviour change 
techniques to be mapped to the key influencing domains, such as 
social/professional role and identity, environmental context and resources, 
knowledge, skills and emotion.  The articulating behavioural change techniques 
include educational interventions, skills training, modelling, enablement, 
persuasion and coercion and environmental restructuring. 
It is advised that, going forward, intervention development is underpinned by 
behaviour change theory to ensure the effectiveness of the intervention, and 
that effectiveness of implementation is adequately assessed. 
The exploration of the concept of suboptimal pharmaceutical care has enabled 
hospital clinical pharmacists within the organisation to reflect on their current 
practice, and to consider areas for improvement.  Aspects of the research 
findings will be applied within the quality management system for clinical 
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pharmacy to improve compliance with requirements of the quality management 
standard, including criteria on what and how to report in terms of suboptimal 
pharmaceutical care.   
It is acknowledged that behaviour change, in itself, is not a strong intervention 
(Fan and Trbovich 2020; Hollnagel et al 2015), and that systems changes are 
more likely to produce lasting and effective results (McNab et al 2016; McNab et 
al 2020; Hollnagel et al 2015), and these will be addressed within the  
environmental restructuring components of recommendations. However, in the 
context of this phenomenological research study, the behaviours of the clinical 
pharmacists involved, and the potential barriers to them engaging with 
initiatives to enhance reporting on suboptimal pharmaceutical care was the 
interest and focus, and highlighted a number of interesting results.  These 
results, articulated as recommendations, will be considered by the organisation 
in the future development of clinical pharmacy services. 
Across the wider pharmacy profession, the research identified gaps in 
professional guidance for pharmacists.  Current guidance for pharmacists on 
adverse event and error reporting remains focussed on dispensing errors, and 
should be widened to ensure adverse events from within clinical pharmacy 
services are captured, shared and learned from. Additionally, pharmacist 
independent prescribers are required to report prescribing errors, but 
methodology to achieve this requirement has not yet been described.  
It is hoped that this research exploring suboptimal pharmaceutical care will allow 
for wider conversations amongst clinical pharmacists about the opportunities for 
improvement, and for quality assurance, that can arise from open and candid 
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Appendix 1.1    Priority Coding Tool  
Phar: 1 Review Daily Patients may fulfill criteria in more than one of the prioritisation criteria - in this situation, 
Phar: 2 Review Every 3rd day (range 2 - 4 days) allocate to the highest level of code. 
Phar: 3 Review Weekly (range 5-9 days) In the absence of specific examples relevant to each individual patient, 
Phar: 4 Review at 14 days or re-referral Phar: D Reviewed 
for Discharge 
allocate based on clinical judgement. 
Phar 1 Criteria : Phar 2 Criteria : 
High risk medicine / medicine requiring TDM High risk medicine / medicine requiring TDM 
e.g. SACTs, cytotoxics, digoxin, lithium, phenytoin, theophylline, vancomycin, warfarin,  e.g. SACTs, cytotoxics digoxin, lithium, phenytoin, theophylline, vancomycin, warfarin, etc. 
valproate in women of childbearing potential etc.  NB Considered Phar 2 if no indication of toxic or subtheraputic effect. 
NB Considered Phar 1 if some indication of toxic or subtheraputic effect 
Severe chronic renal impairment (Est. CrCl ≤ 30ml/min) Severe chronic renal impairment (Est. CrCl ≤ 30ml/min) 
NB Considered Phar 1 if on medications requiring close adjustment. NB Considered Phar 2 if  not on medications requiring dose adjustment. 
Acute kidney injury (urea ≥ 10, creat ≥ 30 from baseline) Acute kidney injury (urea ≥ 10, creat ≥ 30 from baseline) 
NB Considered Phar 1 if on potentially nephrotoxic medcines. NB Considered Phar 2 if no potentially nephrotoxic medicines. 
Severe hepatic impairment (LFT's  ≥ 3x upper limit of normal) Moderate hepatic impairment (LFT's > ULN but < 3X ULN) 
Polypharmacy  ≥ 10 regular medications Polypharmacy  ≥ 10 regular medications 
NB Considered Phar 1 if complex regimen e.g. drug-drug or drug-disease interactions, NB Considered Phar 2 if polypharmacy in absence of complex regimen and 
non-compliance with evidence based guidelines. compliant with evidence based guidelines. 
Nil by mouth/ swallowing difficulties Nil by mouth/ swallowing difficulties 
NB Considered Phar 1 if essential medicine or medical condition must be treated. NB Considered Phar 2 if no essential medicine or medical condition to be treated. 
Short term use of antipsychotics/ benzodiazepines in delirium/ agitation Short term use of antipsychotics/ benzodiazepines in delirium/ agitation 
NB Considered Phar 1 for patients with contra-indication/ cautions for use of NB Considered Phar 2 for patients with no obvious contra-indication to  
antipsychotics e.g. Parkinsons, Lewy body dementia etc. pharmacological management. 
Significant drug interaction Significant drug interaction 
NB Considered Phar 1 if indication of toxic/ subtherapuetic effect resulting from interaction NB Considered Phar 2 if no indication of toxic/ subtherapuetic effect resulting from interaction 
Significant adverse drug reaction (ADR) Significant adverse drug reaction 
NB Considered Phar 1 if noted ADR e.g. recent fall or prolonged QTc >500ms NB Considered Phar 2 if no current indication of ADR e.g. history of falls or prolonged QTcmonitor for any changes to 
medication 
Unresolved medicines reconcilliation or supply issue e.g. non-formulary and ULM use 
Multiple new medications for new/ acute medical condition requiring 
Patient with daily aseptic need e.g. on Total Parenteral Nutrition, antibiotic infusion 
Discharge issue resolution by next working day e.g. counselling, MCD, MAR 
monitoring/ education 
Phar 3 Criteria :    Patient stable with no acute issues but requires weekly review 
Phar 4 Criteria : Patient stable with no acute issues - review at 14 days or at re-referral 
Phar D Criteria:                                                               Patient assessed as suitable for discharge with professionally checked Immediate Discharge Letter (IDL) 
Written approved for use by the clinical pharmacist operations group. 
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Re.: Exploring hospital clinical pharmacists' perceptions experiences and 
behavioural determinants relating to provision of optimal and suboptimal 
pharmaceutical care: qualitative studies using the Theoretical Domains Framework 
 
The School Research Ethics Committee has assessed your application and the 
overall decision is that there are no ethical issues with your project.  
 
I can now confirm that you are able to proceed with your research and any 
further ethics applications.  
 
Should there be any amendments to this project during the research we would 
advise you to consult with the convener of the ethics committee as to whether a 
further ethical review would be required.  
 
 














SCHOOL OF PHARMACY & LIFE SCIENCES 
Robert Gordon University 









Appendix 2.2 South East Scotland Research Ethics Approval (ethics not required) 
 
 





MPhil MFRPSII  MRPharmS  
GPhC Registered 
Specialist QA Pharmacist 
NHS Scotland Organisation  






Your Ref:  




Direct Line: 0131 465 5679 
Email:  
 
Dear Dr McLean, 
Project Title:  
 
Exploring hospital clinical pharmacists’ perceptions, experiences and 
behavioural determinants relating to provision of optimal and suboptimal 
pharmaceutical care 
You have sought advice from the South East Scotland Research Ethics Service on the 
above project.  This has been considered by the Scientific Officer and you are advised that, 
based on the submitted documentation (email correspondence), it does not need NHS 
ethical review under the terms of the Governance Arrangements for Research Ethics 
Committees (A Harmonised Edition).   
The advice is based on the following: 
• The potential participants are neither patients (identified from, or because of, their past or 
present use of NHS services) nor relatives or carers of patients (recruited for this reason) 
• The project is a survey seeking the views of NHS staff on service delivery 







If the project is considered to be health-related research you will require a sponsor 
and ethical approval as outlined in The Research Governance Framework for Health 
and Community Care.  You may wish to contact your employer or professional body 
to arrange this.  You may also require NHS management permission (R&D approval).  
You should contact the relevant NHS R&D departments to organise this. 
 
For projects that are not research and will be conducted within the NHS you should 
contact the relevant local clinical governance team who will inform you of the relevant 
governance procedures required before the project commences. 
 
This letter should not be interpreted as giving a form of ethical approval or any endorsement 
of the project, but it may be provided to a journal or other body as evidence that NHS ethical 
approval is not required.  However, if you, your sponsor/funder feel that the project requires 
ethical review by an NHS REC, please write setting out your reasons and we will be pleased 
to consider further.  You should retain a copy of this letter with your project file as evidence 















Appendix 2.3 NHS Scotland Organisation Pharmacy Quality Improvement Team 
Approval 
       
 
Date: 16th March 2017 
Dear Amanda  
  
Project Title:  Exploring hospital clinical pharmacists’ perceptions, experiences and 
behavioural determinants relating to provision of optimal and suboptimal 
pharmaceutical care: qualitative studies using the Theoretical Domains Framework  
  
I am pleased to inform you that the Pharmacy Quality Improvement Team has approved 
your project titled ‘Exploring hospital clinical pharmacists’ perceptions, experiences and 
behavioural determinants relating to provision of optimal and suboptimal 
pharmaceutical care: qualitative studies using the Theoretical Domains Framework’  
  
Can I remind you that your project must conform to governance requirements as 
described in the audit and evaluation workbook.   The Pharmacy ERD Administrator will 
contact you periodically for a report on your progress, to be logged in pharmacy records.  
At the end of the study please return the project completion form in the audit and 
evaluation workbook to the Pharmacy ERD Administrator and include plans for 
subsequent conference or publication submissions as detailed in the attached Pharmacy 
Project Guidance.  
  
Yours sincerely  
  
  
Moira Kinnear  
Head of Education, Research & Development  
 
On behalf of Pharmacy QIT  
Amanda McLean  
Ref: QIT83 







Appendix 3.1 Participant information pack 
                                                    
 
 
Participant Information Pack 
Hospital clinical pharmacists’ perceptions on the provision of optimal and suboptimal 
pharmaceutical care 
You are invited to take part in a research study. Thank you for taking the time to read the 
following information carefully.  It is important that you understand why the research is being 
done and what it will involve.  Please ask if there is anything that is not clear or if you would like 
more information.  Take your time to decide whether or not you wish to rake part. 
 
The research study. 
This study is being undertaken for my Doctorate in Professional Practice.  This qualitative research will be 
in 2 phases. Phase I will seek to gain understanding and scope the meaning of optimal and suboptimal 
pharmaceutical care from the perspectives of clinical pharmacists. Phase II will further explore the 
experiences of clinical pharmacists in the provision of optimal and suboptimal pharmaceutical care in 
NHS Scotland Organisation.  You are invited to participate in Phase I only or in Phase I and II. 
Phase I will involve you taking part in a focus group at your site with 4 to 9 others, lasting up to 60 
minutes.  Each session will be audio recorded to enable analysis of the data. Phase II will consist of 
individual face to face in-depth interviews between you and me.  Each interview will take 30-45 minutes 
and will be at a time and place most convenient for you.  The interviews will be audio recorded and 
transcribed to enable analysis of the data. 
Why take part?   
You will help in the understanding of what barriers and enablers are at play when delivering individual 
pharmaceutical care.  Participation in research can be recorded for portfolio development at foundation 
level:  Personal Practice: Research and Evaluation competencies: actively supports research and enquiry in 
the workplace and in Management and Organisation competencies: improves the quality of the services 
offered.  Advanced practitioners will be able to reflect on their own practice, and identify gaps in 
research, quality improvement or innovation.  The results may contribute to the development of the 
clinical pharmacy service in NHS Scotland Organisation. 
What next? 
If you wish to take part on the study, please complete the Consent Form and Demographic Data 
Collection Form attached to the email and return to Amanda McLean by email or in internal mail by 
(date) 
Researcher information:   
The team supporting this research consists of Moira Kinnear, Head of ERDS, Caroline Souter, Principal 
Pharmacist ERDS, Professor Derek Stewart, Robert Gordon University and Dr Vibhu Paudyal, University of 
Birmingham. 
I can be contacted with any queries relating to the research at a.p.mclean@rgu.ac.uk , 
amanda.mclean@nhslothian.scot.nhs.uk or on 0131 537 2325. 
Amanda McLean.  Quality Risk and Governance Pharmacist, NHS Scotland Organisation & 
Doctorate of Professional Practice Student, Robert Gordon University.
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Appendix 3.2 Consent form for participants 
                            
Consent form for Participants 
Project title:  Exploring hospital clinical pharmacists’ perceptions, experiences and behavioural 
determinants relating to the provision of optimal and suboptimal pharmaceutical care: qualitative 
studies using the Theoretical Domains Framework 
1. I confirm that I have read the information pack dated  March 17 for the above named study.  
I have had the opportunity to consider the information and ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw from the 
study at any time, without giving any reason, without this having any adverse outcome. 
 
3. I understand that, for Phase II, I can also withdraw after my participation if I change my mind 
within 14 days of the interview, by contacting the researcher to request this. 
 
4. I understand that the data collected during the study will be used for research purposes 
including publication of anonymised findings and quotations.  I grant permission to use these 
on the understanding that my confidentiality will be protected. 
 
5. I agree to audio recording of my input.   I understand that the audio recordings will be 
destroyed at the end of the study 
 
6. I understand that any event where patient safety may have been compromised will be 
followed up following normal governance procedures for adverse event reporting. 
 
7. I agree to take part in the study.  I agree to take part in: (please tick one) 
 
 
Phase I only      Phase I & II     
 
Name of participant        Date   Signature 
   
   
 
 





Appendix 3.3 Demographic data collection                                                    
Demographic Data Collection 
Project title:  Exploring hospital clinical pharmacists’ perceptions, experiences and behavioural 
determinants relating to the provision of optimal and suboptimal pharmaceutical care: qualitative 
studies using the Theoretical Domains Framework 
 
Please answer the following questions and return with the consent form.  
                            
Are you:   
Age (tick one)  
Less than 25  25-35  35-45  45-55  Over 55  
Years qualified (tick one) 
Less than 5  5-15  15-25  25-35  over 35  
Current level of work:  (tick one) 
Rotational 
Band 6 
 Rotational  
Band 7 
 Specialist 
Band  7 
 Specialist 
Band  8 
 Team Lead 
Band 8  
 
Are you prescribing?     
Yes  No  

















Previous areas of work (tick as many as apply) 
Other  NHS 
Lothian 
hospital 









What day/time of the week suits you best for FOCUS GROUP DISCUSSION at your site? 
(tick as many as apply) 
MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY 
AM  AM  AM  AM  AM  
PM  PM  PM  PM  PM  
Twilight*   Twilight  Twilight  Twilight  Twilight  
*5.30-6.30pm 






Data collection form processed by:   (researcher)   Date: 
Female  Male  
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Appendix 3.4 Supplementary information pack for Focus group participants 
                            
 
Supplementary Information Pack for Focus Group Participants 
Following some questions from potential recruits for my research, I am going to include some 
background information in this email.   
Question 1  What are the project objectives?   
The study is qualitative research from a phenomenological perspective  (i.e from the viewpoint of 
hospital clinical pharmacists in NHS Scotland Organisation) with the objectives 
• To explore perceptions and scope of the terms ‘optimal’ and ‘suboptimal pharmaceutical 
care’ in relation to practice. 
• To explore their experiences of the provision of optimal and suboptimal pharmaceutical care 
within their practice. 
• To explore the behavioural determinants relating to the provision of optimal and suboptimal 
pharmaceutical care using the Theoretical Domains Framework 
Question 2   What is suboptimal pharmaceutical care? 
This is the phenomena I am exploring with this study:  The concept exists in healthcare – suboptimal 
healthcare delivery/suboptimal prescribing for example. I want to explore what it means within 
pharmaceutical care.  I have depicted it by seeing pharmaceutical care as a continuum: 
 
I am interested in exploring what factors have affect in this continuum, and how that helps us define 
what is suboptimal pharmaceutical care. 
Examples of factors may be:  lack of information/time/resource/access/training/planning…..  I also 
want to look at what factors may impact e.g. different patient types? Different medicine types? 
Different clinical scenarios?  I will explore these ideas in focus groups held at each site across NHS 
Scotland Organisation. 
Question 3  Will my input be anonymous?  YES – this is qualitative research and the results will be 




Appendix 3.5 Focus Group Rules 
Focus group house rules The rules were presented and clarified during the 
introduction.  
Be respectful no criticism of others’ ideas or comments. You don’t need to 
agree 
Be courteous give everyone a chance to input, speak, and express themselves. 
Be focussed keep to the topic, keep to time 
Be considerate minimise impact of any interruptions 
Be mindful of the meaning of consent; treat anything you hear or that is 







Appendix 3.6  Reflective field notes template 
Reflective Field notes: 
Location: 








(check consent in place for all) 
 
Audio recording – recorder used: 
 





Interactions between participants (describe) 
 
 
Key points described: 
 
 









Appendix 3.7 Operating procedure for Focus group discussions 
Operating Procedure: The purpose of this procedure is to ensure consistency of 
approach and clarity of responsibilities. 
In advance: 
Liaise with facilitator(s). 
Contact all pharmacist across NHS Scotland Organisation, outlining research and asking 
for notes of interest. 
Where interest noted, send information pack with demographic data collection, preferred 
day/time, and consent forms. 
Arrange dates for sessions. Book room at sites. 
Once confirmed, send out advance notice of date and collect responses to ensure 
sufficient numbers. 
On day: 
Arrive in advance to set up room: 3 flip charts. Post-it notes. Pens. Flip chart pens. 
Water.  Sweets/fruit. 
Check participants have given consent, and get signatory of participation. 
Introduce self and facilitator(s). 
Introduce focus group topic and method of recording data; take questions before 
starting the discussion. 
During: 
Maintain focus and keep to time. 
Note any observations about group working, distractions. 
Give warning of time minus 5 minutes. 
Sum up /clarify information provided on flipchart/post-it notes. 
Immediately after: 
Write reflective journal and encourage facilitator(s) to do same. 
Afterwards: 
Thank participants via email 
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Appendix 3.8 Focus group on the day checklist 
Purpose: a checklist to follow on the day of the focus group, and a summary of 
the procedure for operating the digital recorder. 
Refer to Focus Group Standard Operating Procedure  
 
Collect together items for Focus Group: 
 
Digital recorder, charger cable, manual 
 
Flipchart with “suboptimal” overlay 
 
Post its (green orange pink); pens, paperclips 
 
Snacks for participants 
 




Equipment check: Digital recorder – check battery > 2 bars.  
 
 Equipment operation: Digital recorder  
 
1. Power on (slide switch) 
2. Create new file by pressing NEW 
3. Press REC to start recorder – verify by observing REC light illuminated 
4. Press STOP to stop recorder 








Appendix 3.9 Standard introduction to focus groups discussions 
 
‘In the session, you will be asked about what suboptimal pharmaceutical care 
looks like in different situations.  For this piece of research, the focus is on 
whether suboptimal pharmaceutical care is a description that can be understood, 
and that can be usefully applied.  The definition of pharmaceutical care being 
used is:  Pharmaceutical Care is the pharmacist’s contribution to the care of 
individuals in order to optimise medicines use and improve health outcomes. 
(PCNE -Pharmaceutical Care Network Europe 2013)] 
The session will be in two parts, the first looking at medicines reconciliation, and 
the second focussing on Kardex/medicines review.  
Medicines reconciliation is the process by which the medicines that the patient is 
taking on admission or discharge are verified against documented records. 
 Kardex/Medicines review is the process by which the suitability of medicine and 






Appendix 3.10 Information for Phase 2 interview participants  
The following are themes extracted from Phase I focus groups where the topics were optimal and 
suboptimal pharmaceutical care with medicines reconciliation, and with Kardex/medicines review.  
This list is not exhaustive and represents discussions held within the focus groups. It is important to 
understand that these are given as examples, and that the interview will be looking to discuss your 
personal account of what suboptimal pharmaceutical care looks and feels like within your own 
experience. 
Theoretical Domain mapped to 
Environment context/resource 
Being unable to follow up care issue due to other tasks 
Not following up with Doctor due to lack of time 
Not documenting actions on TRAK due to lack of time/lack of PC issues 
Plan to see patient and then don’t due to other pressures/constraints on time 
Failing to check if complies with formulary because don’t have time 
Memory attention and decision-making: 
Missing changes to prescription at transcription – saw what expected to see 
Forgetting to follow up a care issue 
Skills 
Not actually seeing patient – didn’t realise had nasogastric tube and this affected care issues 
Intentions 
Not following up in appropriate timescale –e.g. code 1 patient not seen for 48 hours 
Social/professional role and identity 
Not checking blood results because assumed someone else would 
Knowledge 
Lacking specialist knowledge for xx medicine and not acting on it, either by own learning or by 
contacting appropriate specialist 
Beliefs about capabilities 





Appendix 3.11 Extracts from field notes for focus groups 
 
Focus Group 1:  Field notes from the researcher and facilitator indicated that 
participation was inclusive, wlth all participants contributing, and the discussion 
was wide ranging.  There was a short delay whilst waiting for a participant who 
did not turn up.  There were three interruptions (bleep). As this was the first 
session, researcher and facilitator discussed afterwards how to improve for next 
time, including using clearer instructions at outset to get discussion on the 
negative and positiive influencing factors. 
 
Focus Group 2:  Field notes from the researcher and facilitator indicated that 
the discussion was wide ranging, with good participantion, however the most 
junior member of staff needed to be prompted; was not reluctant but needed 
drawn in first. There were three interruptions (bleep, same person). 
 
Focus Group 3: Field notes from researcher only, no facilitator at this session. 
Participation was dominated by two individuals and other participants needed to 
be prompted to input; sometimes they were talked over by dominant, more 
senior colleagues, and this was managed by researcher.  There were no 
interruptions. 
 
Focus Group 4: Field notes from the researcher and facilitator indicated that 
participation was inclusive with all participants contributing; although less input 
from the most junior member of staff, who needed to be prompted. There was 
one interruption (bleep). 
 
Focus Group 5: Field notes from the researcher and facilitator indicated that 
participation was inclusive although with less input from the most junior member 
of staff, and there were two interruptions (bleep) and one participant arrived 




Appendix 3.12 Transcripts of post-it notes and illustrative quotes 
Written statements were transcribed, and are presented. Where necessary, the 
example of suboptimal pharmaceutical care is expanded to give contextual 
understanding [in square brackets].  The use of colour in the tables reflects the 
different colours of post-it notes for: example of suboptimal pharmaceutical care 
(green), negative influencing factor or barrier (orange) and positive influencing 
factor or enabler (pink).Illustrative quotes extracted from the audio files are 
included. Tables are presented for medicines reconciliation and 
Kardex/medicines review separately for each focus group, as per study design. 
 
Focus group 1: Written statement/illustrative quotes transcript: medicines reconciliation.  
Example of suboptimal pharmaceutical care  Illustrative quote 
 Lack of shared ownership/responsibility [for 
medicines reconciliation] 
‘Technically the pharmacist’s role should be a 
verification process, but it’s not.’ 
 Not seeing as a dynamic process [i.e. process 
that needs to be updated during patient stay] 
 
 
Using inappropriate sources – GP print; old IDL, 
incomplete or wrong ECS;  
‘There’s not a policy that says which sources, it 
just says two sources’ 
 Medicines reconciliation not carried out at all  
 Inability to complete medicines reconciliation – 
patient absent, distractions, bleeped/called away 
from ward 
 
 No clear area to document medicines 
reconciliation 
 
‘I mean, where do you keep a med rec?- 




 Loose paper being lost Agreed location and 
format 
 Incomplete medicines reconciliation – 
• Specialist area focus only 
• not using 2 sources 
• incomplete documentation 
‘maybe they don’t feel as confident when it’s 
general medical things or maybe they are 
happy doing their specialist area but can’t be 





Lack of motivation/time 
Only focussing on area 




Using ECS as primary 
source 





Focus group 2: Written statement/illustrative quotes transcript: medicines reconciliation. 
Example of suboptimal pharmaceutical care  Illustrative quote 
Too many resources to access – ECS, renal vital data, GP 
letter, patient [increases time taken to do medicines 
reconciliation thoroughly] 
‘sometimes when there are too many sources of 
information it can be difficult to get to the point 





Out of date ECS 
Lack of time 
Patient volume 
Clinical technician referral 
tool/input 
Location of documentation [not easy to find]  
Health care professionals and patients not recognising 
medicines as medicines – e.g. patch, pill, inhaler, ointment 
‘the patient forgot to mention one that wasn’t 
listed, -and it was specialist prescribed SACT!’ 
(systemic anti cancer therapy) 
Over reliance on one source [best practice suggests two 
sources of information] 
 
Over emphasis on medicines reconciliation  [impeding 
other aspects of pharmaceutical care] 
‘sometimes I think med rec has become such a 
focus; pharmaceutical care equals med rec, 
whereas to me it’s only part of it’ 
‘I must have all this documented before he goes to 
the next ward otherwise that pharmacist will think 
I’m terrible’ 
Lack of available resources e.g. ECS [up to date ECS not 
always available] 
 
Time issues – more patients less intensely or less patients 
done well 
‘I always think it’s better to see less patients and 
try and finish what you’re doing with each patient’ 
Patient unable to provide information [on their medicines]  
Revisiting an incomplete episode duplicating effort [due to 
poor documentation] 
 
Traceability of documentation – who has 
completed/seen/added [for purpose of follow up] 
‘TRAK is set up different on different sites so we 
don’t always know where stuff is’ 
Asking closed questions of patient [to obtain information 
required for thorough medicines reconciliation] 
‘a patient may give their whole life story but not 
give you relevant information’ 
 
‘I think it’s just the way we’re trained –
pharmacists may focus on medicines too much’ 
 
‘I need to think about how I’m going to speak to 
this patient, how I introduce myself so they know 






Overemphasis on medicines 
and not seeing other factors 
e.g. medical history 
Time consuming task 
Health literacy 
Holistic approach 






Focus group 3: Written statement/illustrative quotes transcript: medicines reconciliation. 
Example of suboptimal pharmaceutical care  Illustrative quote 
Lack of understanding of medicines reconciliation 
and why doing it within multidisciplinary team 
 
Pharmacy staffing – priorities [competing priorities 
on time] 
‘so, you don’t actually finish the process, not 
through lack of following the process, or lack 
of skill, but because of other priorities pulling 
you away’ 
 
‘I may have covered it for me, but it still 
feels suboptimal for the patient’ 
 
Timeliness [completing within appropriate 
timescale] 
 
Patient factors – capacity/cognition [and impact on 
ability to carry out medicines reconciliation] 
‘sometimes – it’s not an ideal scenario – but 
for that patient, that is the best 
(pharmaceutical) care that’s going to be 
available 
IT access on wards limited ‘you can’t record in real time due to lack of 
access’ 
‘I can’t sit there and do that like for every 
patient and hog the computer’ 
Not following process [for carrying out and 
documenting medicines reconciliation] 
 
Lack of access to relevant information [relating to 
patient’s medicines] 
‘good TRAK training would help; everything I 
find on TRAK that has been useful has been 
shown to me by someone else, not through 










Prescribing split into specialties with no transfer of 
information; (primary/secondary/specialist) 
complex care for vulnerable p patients  [relates to 
lack of single system to access information relating 
patient’s medicines] 
‘you may feel you’ve done med rec, may or 
may not have spoken to the patient, but you 





Focus group 4: Written statement/illustrative quotes transcript: medicines reconciliation. 
Example of suboptimal pharmaceutical care written 
statement) 
Illustrative quote 
Availability of sources for med rec e.g. ECS not 
available/not up to date [impacts on ability to perform 
medicines reconciliation] 
 
Reassignment of staff/priorities whilst carrying out task 
[referencing that task is not always possible due to service 
pressures] 
 
Patient cognition/language barrier/willingness to engage; 
patients’ expectation 
‘sometimes a frustrated patient just wants to vent’ 
Distractions on ward ‘you can be half way through a task and then 
another priority comes up and you’re called away, 
and not handed over’ 
Patient not present e.g. away for scan/x-ray  
Kardex/ECS/Med rec don’t match [requiring time to 
establish accurate list of current medicines] 
‘the patient was clearly on an inhaler, it was right 
by them, but it wasn’t recorded anywhere’ 
Communication/handover between staff e.g. Dr to Dr, 
pharmacist to Dr. pharmacist to pharmacist/pharmacy 
staff 
‘The nurse said -I don’t know why you’re reviewing 





Differences across different 
sites yet all sites access 
TRAK. 
Lack of understanding of 
pharmacy/pharmacy staff 
role by doctors and nurses 
– e.g. sometimes seen as 
policing role 
Robust system in place with 
same terminology 
Clear documentation on 
what has been done/still to 
do 
Medicines reconciliation issues not followed up ‘some doctors do a great job and others just don’t 
seem to think it’s important and then, you know, 
you’ll have to put in more effort and time’ 
 
‘nursing staff are maybe not as involved with it, 











Staff time constraint 
Complexity of patient; poor 
documentation – unable to 
identify and understand 
issues like stopped/withheld 
Culture and attitude 
Training (pharmacist and 
doctor); clear processes 
(standardisation) One 
national single computer 
system through NHS 





Focus group 5: Written statement/illustrative quotes transcript: medicines reconciliation. 
Example of suboptimal pharmaceutical care written 
statement) 
Illustrative quote 
Not seen by specialists (boarders) ) [refers to 
patients outwith the speciality and the additional 
burden this brings] 
 
Incomplete (e.g. hospital only supply not on ECS- 
emergency care summary) [medicine reconciliation 
not being fully completed, using all sources, and 
documented appropriately] 
‘the focus can be on what they get from the 
GP rather than everything’ 
 
‘the process might have happened but it’s 
not clear that it has’ 
Decision process not clearly documented 
(stop/continue/withhold) 
‘sometimes med rec is seen in isolation as a 
task rather than as part of an ongoing 
process’ 
Review of doses as appropriate for patient – 
age/weight, renal function 
 
Non-stock medicines – omitted doses or incorrect 
alternatives 
‘patients may come back in with different 
things that we don’t have and that can cause 
continuity issues that we can get caught up 
in’ 
 
‘it doesn’t take a pharmacist to say 













Technician support e.g. 
with non-stock 
medicines 
Omission of OTC medicines on list  
Incorrect formulation/unmeasurable doses 
prescribed; targeted training for nurses 
 
Not completed  
Not being documented adequately ‘there is a lack of access to PC’s on the ward, 
and now you need longer on the computer to 
find everything’ 
 
‘Yesterday I saw a 2 day admission and there 





Access to computer 
Electronic case notes 
difficult to navigate 
Writing notes straight 







Focus group 1: Written statement/illustrative quotes transcript: Kardex/medicines review 
Example of suboptimal pharmaceutical care  Illustrative quote 
Not following up in appropriate timescale [according 
to local priority coding process] 
‘suboptimal is not reviewing the patient 
in the timescale that you think is right’ 
Locating appropriate resources to answer questions 
– ed Dr, nurse, pod keys, drug cupboard keys, 
order books 
‘I can spend a lot of time trying to find 
the doctor, trying to find the notes, trying 
to find the kardex, the nurse, the keys, 
trying to get into the pods, the cupboard, 
finding the order book’ 
No medicine reconciliation done on admission 
(example where patient not referred for review until 
3 weeks later) 
‘as a pharmacist I find it very difficult not 
to get bogged down in the first kardex’ 
 
‘maybe sometimes I am trying to go into 
too much depth; I’ve got too much 
knowledge and not enough time’ 
 
‘band 6’s are much better trained now, 
but it’s almost like they don’t know what 
to do with their knowledge, and I don’t 
think there’s a lot of advice out there on 
that’ 
 
‘I was told – you saw this patient and you 
missed this – and it might have been for 
a million different reasons and I found 





Too many new patients 
to see to achieve proper 
medicines reconciliation 
Trying to do ‘swoop’ of 
kardexes to identify high 
risks but getting stuck 







Not checking blood results where appropriate[for 
medicines the patient is on] 
 
Not checking route of administration is appropriate  
Not actually seeing patient to assess risk factors 
e.g. NG tube, weight (high or low), IV cannula. 
[where review carried out remotely] 
 
Overreliance on notes and not speaking to staff or 
patient[to ascertain or confirm details of medicines 






Focus group 2: Written statement/illustrative quotes transcript: Kardex/medicines review 
Example of suboptimal pharmaceutical care  Illustrative quote 
Review of Kardex without patient having medicines 
reconciliation completed [contrary to best practice] 
 
Not prioritising high risk patients [for Kardex review 
practice according to priority coding process] 
‘I’d ask nurses or doctors whether any patients 
are on high risk medicines, or I would have to 
check myself, before deciding who to kardex 
review’ 
 
‘suboptimal would be if you didn’t flag those 
patients for follow up’ 
Conflicting priorities ‘depends on whether you think it is 
suboptimal. Say you’ve got half an hour to 
whip round, what is better use of your time – 
to med rec 2 patients or to nip round 16 
kardexes and make sure there are no 
overdoses, drug interactions, anything that is 
going to cause harm’ 
 
‘due to patient turnover in xx, it’s maybe more 
risk reduction: look at kardex, everything’s 
fine, move on’ 
Signature in pharmacy box – what does it mean? [lack of 
clarity and variation in practice as not defined] 
‘I might not be inclined to sign off a kardex in 
a situation where I have 20 minutes to see 20 
patients…like as a communication tool – I 
haven’t signed off because I haven’t been able 
to do all the checks I want to do.  But this is 
just something I have set up for myself’ 
Pharmacy/clinical team’s expectations ‘expectations are different in each area and 
staffing is different in each area; some areas 
have clinical technicians and some have none’ 
 
‘when I started in xx I kind of just had to go, 
had to decide what were the priorities’ 
 
‘there is an assumption made that you will 







Mixed messages within one 
team 
Rotation packs for team 
Clear criteria for pharmacy 
as a whole 
Team specific induction to 
make expectations clear  











Focus group 3: Written statement/illustrative quotes transcript: Kardex/medicines review 
Example of suboptimal pharmaceutical care  Illustrative quote 
Familiarity with patient care/case [can be barrier or 
enabler] 
‘so, you know the patient really well, and you 
look at a kardex and you see what you expect 
to see, and you miss the glaringly obvious 
transcription error ‘ 
Only see what expect to see [confirmation bias, and 
related to familiarity] 
 
Access to Kardex [to carry out review]  





 Skills mix 
Use of technician referral 
tool 
Missing changes to medicines since admission due to 
infrequent visits to ward/not checking back 
‘you base the coding on what the patient is on 
at the start, but a few days later they could 
have been started on a high-risk medicine’ 
Lack of specialist knowledge and training [to be able to 
provide adequate medicine review in a specialist role] 
‘there’s not adequate time to train yourself 
before you need to use that knowledge, you 
kind of wait until something has happened and 
go, I need to learn about that’ 
 
‘to prepare for a journal club we would need 
time and there isn’t any, and we don’t 
necessarily have the appraisal skills either’ 
 
‘we may be better at voicing our thoughts and 
our knowledge with the multidisciplinary team 
but we maybe don’t have the level of expert 





Online only access to 
journals limits reading 
Regular MI updates and 
training 
Critical appraisal skills 
Protected learning time and 
resource 
Journal club 
Ability to pass on issues to other pharmacists in team 
[handover of ongoing and unresolved pharmaceutical care 
issues] 
‘sometimes a doctor will call to get an answer, 
and you really don’t know what the other 
person has already said or what to do next’ 
Multiple roles of pharmacists, may be off site. [as a barrier 
to conducting adequate and timely medicine review] 
‘sometimes you are communicating without 
being able to know whether the action has 
been done or not’ 






Focus group 4: Written statement/illustrative quotes transcript: Kardex/medicines review 
Example of suboptimal pharmaceutical care Illustrative quote 
Issues with medicine availability and access ‘sorting out unlicensed medicines and 
non-formulary- that all takes time’ 
Decision making ‘sometimes you’re waiting for a decision 
to be made, you’ve flagged up issues but 
they haven’t been acted on and there’s 
no one around’ 
Access to computers (especially when paperlite) ‘I can’t get access to a computer and I 
think, I’ll do it later, and maybe don’t, or 
I think I’ll do it tomorrow, or half 
complete and then not go back’ 
Timely review – staff availability, competing 
priorities 
‘suddenly that patient that should have 
been seen, won’t get seen’ 
‘the frustration is I know where I should 
be focussing my time but I still don’t 
have enough time’ 
 
‘it’s so time-consuming putting things on 






Lack of documentation 
to support review 
Lack of pharmacist 
resource; lack of doctors 
to follow up 
Incomplete TRAK notes, 
time added unknown 
More staff would help, 
variety of grades and 
clinical technicians 
Experience of pharmacists to know what should be 
followed up-competence/experience/training. 
 
‘there are issues you’d be able to sort out 




Focus group 5: Written statement/illustrative quotes transcript: Kardex/medicines review 
Example of suboptimal pharmaceutical care  Illustrative quote 
Capacity ‘we have quite a tight schedule so we 
only really see discharges’ 
‘I may plan to see a patient but then 
don’t’ 
‘I aim to see every kardex every day and 
then kind of prioritise with my own 
internal system’ 
‘we often just work to demand, and 
there’s still another whole workload, with 
no slack built in’ 
‘I spend a lot of time going between the 
doctor and the nurse-nurses contact me 
first and I’m the conduit’ 
Negative influencing 
factor 
Positive influencing factor 
Get drawn into technical 
issues 
Review of skill mix, use 
of pharmacy 
technicians/upskilling 
Defined role within 
multidisciplinary team 
Clinical pharmacy service 
aims clarified 
Team working – learning 
from each other and 
supporting each other  
Formulary adherence ‘don’t have time to check, like say non-
formulary prescribing, there’s just not 
time, you have to just make sure it’s 
safe 
Medicines stewardship  
Priority review vs comprehensive ‘sometimes I don’t have enough time to 
access the information I need to be able 
to prescribe’ 
‘there’s a huge emphasis on discharge, 
rather than carrying out pharmaceutical 
care’ 
Standalone computer prescribing system  
Time pressures  
Communication  
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Appendix 4.1 Template for field notes – interviews 
 






Room booking details: 
Consent confirmed: Y/N 
 
Digital recorder used: 
 
File reference for audio recording 
Participant engagement: e.g. 
full/distracted 
 
Duration of interview 
 
 






























Prepared by A McLean        Jan 2018 
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Appendix 4.2 Semi-structured interview schedule designed around Theoretical 





 Domain Sample questions 
1 Knowledge What would you describe as suboptimal pharmaceutical care? Do you 
know how to identify report or act on suboptimal pharmaceutical 
care in context of your own practice? What does it mean to you? 
2 Skills What skills, attributes or information do you think you need to be 
able to identify or report suboptimal pharmaceutical care? Have you 
been trained in any of these skills?  
3 Social/professional roles and 
identity 
Who do you think would be best at identifying suboptimal 
pharmaceutical care? Who should report, and who should develop 
actions to take? 
4 Belief about capabilities How would your ability to identify suboptimal pharmaceutical care be 
affected by external factors? e.g. time, access to patient data. How 
confident are you that you can overcome the barriers? 
5 Optimism With regard to identifying, reporting or acting on suboptimal 
pharmaceutical care, are you optimistic about the task?  
6 Belief about consequences Will there be any disadvantage to you if identifying, reporting or 
acting on suboptimal pharmaceutical care? (treat as 3 questions) 
7 Reinforcement Do you think there will be recognition from within Pharmacy or 
within the multidisciplinary team if you identify report or act on 
suboptimal pharmaceutical care? Would that be positive? Negative? 
8 Intentions Have you intended to report or escalate an episode where   
suboptimal pharmaceutical care has been a concern, in yourself or in 
another? How strong was the intention?  Were there barriers? What 
would you expect outcome to be? 
9 Goals When thinking about identifying reporting or acting on suboptimal 
pharmaceutical care, how often is something else higher on your 
agenda? 
10 Memory, attention and 
decision-making 
How often do you forget to complete a task, or lack the focus that is 
needed to complete a task? 
11 Environment context and 
resource 
Would resources or a different work environment make a difference 
to your likelihood to identify report or act on   suboptimal 
pharmaceutical care? Time? Computer access? Other team members 
availability? 
12 Social influences Who would benefit from pharmacists identifying reporting or acting 
on suboptimal pharmaceutical care?  Who would influence or affect 
the reporting? 
13 Emotion Are there instances when your reflection on an example of 
suboptimal pharmaceutical care has caused anxiety? Or where 
optimal pharmaceutical care has led to feeling of satisfaction? 
14 Behavioural regulation How do you reflect personally on your delivery of pharmaceutical 
care? How do you track your personal progress in the delivery of 




Appendix 4.3 The Big 5 Inventory personality test 
 
The Big Five Inventory (BFI – dimensions of personality) 
Here are a number of characteristics that may or may not apply to you.  
Please write a number next to each statement to indicate the extent to which you agree or 




a little  
Neither agree  
nor disagree  
Agree  
a little  
Agree  
Strongly  
1 2 3 4 5 
I see myself as someone who... 
 Score  Score 
Is talkative  Tends to be last  
Tends to find fault with others  Is emotionally stable, not easily 
upset 
 
Does a thorough job  Is inventive  
Is depressed, blue  Has an assertive personality  
Is original, comes up with new ideas  Can be cold and aloof  
Is reserved  Perseveres until the task is finished  
Is helpful and unselfish with others   Can be moody  
Can be somewhat careless   Values artistic, aesthetic 
experiences 
 
Is relaxed, handles stress well   Is sometimes shy, inhibited  
Is curious about many different 
things 
 Is considerate and kind to others  
Is full of energy  Does things efficiently  
Starts quarrels with others  Remains calm in tense situations  
Is a reliable worker   Prefers work that is routine  
Can be tense  Is outgoing, sociable  
Is ingenious, a deep thinker  Is sometimes rude to others  
Generates a lot of enthusiasm  Makes plans and follows through 
with them 
 
Has a forgiving nature  Gets nervous easily  
Tends to be disorganized  Like to reflect, play with ideas  
Worries a lot  Has few artistic interests  
Has an active imagination  Likes to cooperate with others  
Tends to be quiet  Is easily distracted  
Is generally trusting  Is sophisticated in art, music or 
literature 
 
Amanda McLean.  Quality Risk and Governance Pharmacist, NHS Scotland Organisation & 




Appendix 4.4 Standard Operating Procedure for Interviews 
 
Standard Operating Procedure  
Phase II interviews with hospital clinical pharmacists in NHS Scotland Organisation, to explore 
their experiences of ‘optimal’ and ‘suboptimal’ pharmaceutical care. 
 
The purpose of this procedure is to ensure the interviews function effectively, to ensure consistency 
of approach and clarity of responsibilities. 
 
In advance: 
Contact pharmacists from Focus Groups, outlining research and asking for recruits. 
Where interest noted, assess preferred day/time. 
Arrange dates for sessions. Book room at sites. 
Once confirmed, send out advance notice of date/time 
On day: 
Arrive in advance to set up room : 2 chairs, table  with digital recorder. 
Check participants have given consent, and get signatory of participation. 
Introduce self, ask participant to complete Big 5 inventory personality test (3-4 minutes) 
Introduce interview topic and method of recording data; take questions before starting the 
discussion. 
During: 
Maintain focus and keep to time. Aim for unstructured interview but refer to Interview Guide for 
prompts and probes if necessary. 
Make notes, including emerging themes relating to TDF 
Give warning of time minus 5 minutes.   
Close the interview. Thank participant. 
Immediately after: 
Write reflective journal  
Afterwards: 




Appendix 4.5  Standardised one to one interview introduction 
 
Reminder of Project title: Experiences and behaviours of hospital clinical 
pharmacists relating to the identification, reporting and responding to 
suboptimal pharmaceutical care (SOPC).* 
 
The purpose of this interview is to expand on discussions from focus group 
where suboptimal pharmaceutical care was discussed.  You will now have an 
opportunity to expand those discussions individually.  I will be looking for 
themes which will be matched to the theoretical domains framework which is a 
psycho-social tool for analysing qualitative data such as that that comes from 
focus groups and interviews.  It has been chosen because the domains can be 
matched to intervention types. 
As this is a research interview, it will be audio recorded. As an interviewer, I 
may appear more formal than you thought and may ask probing or seemingly 
intrusive questions.  The data will be anonymous and cannot be traced to an 
individual.  You were sent some information on themes that were assimilated 
following the focus groups (share Appendix 3.10) 
During the interview you will be asked to think about suboptimal pharmaceutical 
care particularly in your own experience and practice. When you signed the 
consent form you were asked that you understood that any event disclosed 
where patient safety may have been compromised would be followed up 
following normal governance procedures for adverse event reporting.  Your 
consent form is here, (show to participant), and you are asked to confirm that it 
is your signature on it 
We will be discussing how you can identify and/or act on and/or report 
suboptimal pharmaceutical care, and also about your feelings related to this.  As 
an ice breaker you are now asked to complete a personality profile called the Big 
5 inventory.  This looks at the following as dimensions of personality: 
extroversion, agreeableness, conscientiousness, neuroticism and openness. 





Appendix 4.6 Big Five Inventory scale scoring 




a little  
Neither agree  
nor disagree  
Agree  
a little  
Agree  
Strongly  
1 2 3 4 5 
I see myself as someone who... 
E = extroversion; A=Agreeableness C=conscientiousness N=neuroticism O=openness 
Is talkative E Tends to be lazy C(R) 
Tends to find fault with others A(R) Is emotionally stable, not easily 
upset 
N (R) 
Does a thorough job C Is inventive O 
Is depressed, blue N Has an assertive personality E 
Is original, comes up with new 
ideas 
O Can be cold and aloof A(R) 
Is reserved E (R) Perseveres until the task is 
finished 
C 
Is helpful and unselfish with 
others  
A Can be moody N 
Can be somewhat careless  C (R) Values artistic, aesthetic 
experiences 
O 
Is relaxed, handles stress well  N (R) Is sometimes shy, inhibited E(R) 
Is curious about many different 
things 
O Is considerate and kind to almost 
everyone 
A 
Is full of energy E Does things efficiently C 
Starts quarrels with others A(R) Remains calm in tense situations N (R) 
Is a reliable worker  C Prefers work that is routine O (R) 
Can be tense N Is outgoing, sociable E 
Is ingenious, a deep thinker O Is sometimes rude to others A(R) 
Generates a lot of enthusiasm E Makes plans and follows through 
with them 
C 
Has a forgiving nature A Gets nervous easily N 
Tends to be disorganized C (R) Like to reflect, play with ideas O 
Worries a lot N Has few artistic interests O(R) 
Has an active imagination  Likes to cooperate with others A 
Tends to be quiet E(R) Is easily distracted C (R) 
Is generally trusting A Is sophisticated in art, music or 
literature 
O 
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Appendix 4.7 Report template for personality scores for participants 
BIG FIVE INVENTORY OF PERSONALITY TRAITS 
The five traits are said to be EXTROVERSION, AGREEABLENESS 
CONSCIENTIOUSNESS, NEUROTICISM AND OPENNESS, 
 average max min Your 
score 
Extroversion 29.3 38 21  
Agreeableness 37.7 43 31  
Conscientiousness 33.4 43 24  
Neuroticism 23 33 13  
Openness 34.2 45 24  
Extroversion has two familiar ends of the spectrum: extroversion and introversion. It concerns where an 
individual draws their energy and how they interact with others. In general, extroverts draw energy or 
“recharge” from interacting with others, while introverts get tired from interacting with others and replenish 
their energy from solitude. 
People high in extroversion tend to seek out opportunities for social interaction, where they are often the “life of 
the party.” They are comfortable with others, gregarious, and prone to action rather than contemplation. People 
low in extroversion are more likely to be people “of few words,” people who are quiet, introspective, reserved, 
and thoughtful. 
Agreeableness concerns how well people get along with others. While extroversion concerns sources of energy 
and the pursuit of interactions with others, agreeableness concerns your orientation to others. It is a construct 
that rests on how you generally interact with others.  
People high in agreeableness tend to be well-liked, respected, and sensitive to the needs of others. They likely 
have few enemies, are sympathetic, and affectionate to their friends and loved ones, as well as sympathetic to 
the plights of strangers. People on the low end of the agreeableness spectrum are less likely to be trusted and 
liked by others. They tend to be callous, blunt, rude, ill-tempered, antagonistic, and sarcastic. Although not all 
people who are low in agreeableness are cruel or abrasive, they are not likely to leave others with a warm fuzzy 
feeling. 
Conscientiousness is a trait that can be described as the tendency to control impulses and act in socially 
acceptable ways, behaviours that facilitate goal-directed behaviour.  Conscientious people excel in their ability 
to delay gratification, work within the rules, and plan and organize effectively. 
Someone who is high in conscientiousness is likely to be successful in school and in their career, to excel in 
leadership positions and to doggedly pursue their goals with determination and forethought. A person who is 
low in conscientiousness is much more likely to procrastinate, to be flighty, impetuous, and impulsive. 
Neuroticism is not a factor of meanness or incompetence, but one of confidence and being comfortable in one’s 
own skin. It encompasses one’s emotional stability and general temper 
Those high in neuroticism are generally given to anxiety, sadness, worry, and low self-esteem. They may be 
temperamental or easily angered, and they tend to be self-conscious and unsure of themselves. Individuals who 
score on the low end of neuroticism are more likely to feel confident, sure of themselves, and adventurous. They 
may also be brave and unencumbered by worry or self-doubt. 
Openness to experience has been described as the depth and complexity of an individual’s mental life and 
experiences. It is also sometimes called intellect or imagination. Openness to experience concerns an 
individual’s willingness to try to new things, to be vulnerable, and the ability to think outside the box. 
An individual who is high in openness to experience is likely someone who has a love of learning, enjoys the 
arts, engages in a creative career or hobby, and likes meeting new people. An individual who is low in openness 






Appendix 4.8 Extracts from field notes for interviews 
Interviewee Reflective field note (extract) 
1 • Fixing not solving  
• Poor self-reporting/responsibility/ownership  
• Age and experience as factor 
• Prioritisation 
• Highlighting gaps. 
2 • Self-blame    
• Competing priorities  
• Failing to follow up 
• Hierarchy 
• Fixing 
• Embarrassment and self esteem 
3 • Time pressures  
• Fixing  
• Failing to share learning 
• Only feeding back serious issues 
• Hierarchy 
4 • Time pressures 
• Lack of feedback from MDT  
• Fixing not feedback 
• Informal peer review  
• Embarrassment as barrier 
5 • Feedback -giving and receiving  
• Fixing not solving  
• Attitude and culture 
• Reluctance (professional embarrassment) 
• Dissatisfaction 
6 • Fixing 
• Time as barrier 
• Feedback  
• Difference in opinion/variation across profession 
• Barriers to sharing learning  
• Hierarchy as barrier 
7 • Junior staff support via informal peer review 
• Blame culture 
• Professional embarrassment 
• Attitude and culture  
• PC access 
8 • Making assumptions 
• Failure to feedback to colleague 
• Own poor experience of feedback 
• Informal peer review/sharing 
9 • Developing experience 
• Time pressures and prioritisation  
• Informal peer review 
• Hierarchy barrier  
10 • Time pressure 
• Dissatisfaction  
• Lack of timely access to PC 
• Self-esteem 



















Error missed when chart rewritten – 
drug prescribed twice a day instead 






Wrong advice given about reduction 




Mixing two patients vancomycin 







Error missed when chart rewritten – 





Interaction missed, not known about 




Error on discharge prescription 
missed at clinical check 
LAPSE 
 
SELF SELF Failed to get round all patients had 
planned to see in a session, unknown 





Failed to detect omission on 
prescription – did not have 
knowledge of protocol. 
MISTAKE 
SELF SELF Missed satisfactorily reviewing 
patient due to lack of time (fixed by 
completing next day) 
LATENT 
SELF SELF Not communicating discharge to 
community pharmacy (fixed by 







Prescribed insulin at wrong 
frequency when transcribing 





Did not flag a patient for warfarin 
counselling resulting in it needing to 




10 fold error in prescription for 
patients own meds (pharmacist 
independent prescriber)during 
medicines reconciliation. 2 doses 
administered 
SLIP (violation if 
approved process not 
followed) 
Reportable error 
SELF SELF Not documenting on discharge letter 
that has been clinically checked, 
creating additional work 
LAPSE 
SELF OTHER Colleague pointed out a missed 
interaction between medicines that 








Appendix 5.1 Creating local impact for the research 
As this was professional practice research, taking place within the researcher’s 
base in NHS Scotland Organisation (NHSSO) pharmacy department, prior 
approval was sought from the senior management team. During planning of the 
study, a power/interest impact diagram was constructed to ensure all 
stakeholders were identified, and to understand the relationship between them 





Different methods were used to seek approval and to raise awareness of the 
proposed research in advance.  Oral and written presentations were made to 
senior management teams asking for support in the research project, 
particularly in terms of allowing and enabling staff to be released to take part in 
the research study.  There was support for the project from all Site Leads and 
the Director and  Associate Directors of Pharmacy, and this was recorded in 
meeting minutes.   
KEEP SATISFIED
NHSSO Director of 
Pharmacy

























Support from clinical pharmacists was gained by presenting the research 
proposal as a short oral presentation at an open-invite R & D session, and by 
presenting to the clinical pharmacy operations group. 
Stakeholder approval for research project. 
Key players or stakeholder Method 
NHSSO Director of Pharmacy 
(Keep satisfied) 
Oral presentation of outline proposal 
and request for NES funding approval 
RGU Supervisors 
(Keep informed)  
Research approval, through university 
procedures; annual update 
NHSSO Associate Directors of 
Pharmacy 
(Keep satisfied) 
Pharmacy Operations Group – 
presentation at meeting 
NHSSO Site Leads  
(Nurture) 
Pharmacy Operations Group – 
presentation at meeting 
NHSSO Pharmacy Education 
Research and Development Team 
(Keep informed) 
Pharmacy Operations Group – 
presentation at meeting 
Presented proposal at NHS Scotland 
Organisation R&D Session 
Lead also at presentation of outline 
proposal and request for NES funding 
approval 
NHSSO Clinical pharmacists 
(Keep informed & Nurture) 
Presented proposal at NHS Scotland 
Organisation R&D Session, and at the 
clinical pharmacy operations group 
(Lead clinical pharmacists also attend 
Pharmacy Operations Group) 




Lead also at presentation of outline 
proposal and request for NES funding 
approval 
NHSSO = NHS Scotland Organisation where research took place. 
As the study progressed, steps were taken to keep stakeholders informed. An 




was used for communication both to university supervisors (academic) and to 
the NHS Scotland Organisation Education Research and Development team 
(workplace).   
Interim findings were presented at a further NHS Scotland Organisation open-
invite R & D session, and oral and poster presentations (as described in the 
research outputs section of this thesis) were made available on the NHS 
Scotland Organisation pharmacy Education Research and Development intranet 
site and included in newsletters.  The reach of these sessions was to all 
pharmacy staff and included clinical pharmacists. 
In addition to these formal means, there were interim informal meetings with 
academic and workplace supervisors, the education and research team, lead 
directorate pharmacists and the quality risk and governance team.  In addition 
to being beneficial for impact building, the informal meetings formed an integral 
part of the research project, on reflexivity, and on continued governance.  
Specific parts of this process of reflexivity and reflection are referenced in the 
thesis, but the ongoing interaction with others who are stakeholders, to ensure 
the project remained focussed, was an important component of the research 























Appendix IV Formal training and learning 
 
Formal training undertaken during professional doctorate: 
 
Doctor of Professional Practice Modules 2014-2016; Robert Gordon University 
 1.Skills for research 
 2. Applied research methods 
 3. Creating impact in professional practice 
 4. Research process and critical evaluation 
 
Questionnaire design – May 2015; Wellcome Trust Clinical Research Facility 
Edinburgh  
NVivo training. June 2016 University of Edinburgh Summer School for Scottish 
Graduate School of Social Science  
The art of qualitative interviewing.  November 2016; Social Research 
Association. Edinburgh 
Health Sciences Research and Pharmacy Practice May 2017; Reading, UK. (as 
delegate, to observe and learn about research presentation as posters and oral 
presentation) 
Tougher Minds for research students. September 2019; The Burn, Edzell, c/o 
Robert Gordon University, Aberdeen. 
Be a better writer (academic writing workshop) October 2019; Robert Gordon 
University, Aberdeen. 
 
